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1 Introduction
Antimicrobial research is driven by the contributions of many different
disciplines such as medicine, chemistry, biochemistry, microbiology, bacteriology,
and pharmaceutical chemistry. Arguably only few areas of research have had such a
profound influence upon human society as the introduction of antibiotics into clinical
practice. At present, the vast majority of known microbial infections are amenable to
antibiotic therapy and around 250 different antibacterial compounds, plus an
increasing number of antimycobacterial, antiviral, antiretroviral, antifungal,
antiprotozoal, and anthelmintic agents are available for their treatment.[1]
Notwithstanding the tremendous success of past and present antimicrobial
chemotherapy, factors such as the increase of widespread bacterial resistance, the
emergence of new pathogens, or the increase in human life expectancy, together with
increased susceptibility of the elderly to infectious diseases, lead to the continued
demand for developing future antimicrobial agents.
1.1 Antibiotics and chemotherapy
The notion of antibiotic action (antibiosis) was first introduced by Vuillemin,
a pupil of Pasteur, in 1889 to describe an antagonism between micro-organisms:
“principe actif d'un organisme vivant qui détruit la vie des autres pour protéger sa
propre vie”.[2] Already in the previous decade of the same century - and over fifty
years before the discovery of penicillin by Fleming in 1928[3] - Pasteur and Joubert
described an antagonism involving the anthrax bacterium[4] and Tyndall noted the
retarding effect of a mould on bacterial growth.[5] It is noteworthy in this respect that
the first commercially available antibiotic to find therapeutic use was an extract of
Pseudomonas aeruginosa, called pyocyanase.[6] In 1942 the term antibiotic was
redefined by Waksman to denote substances produced by micro-organisms
antagonistic to the growth or life of other micro-organisms in high dilution.[7]
Antimicrobial chemotherapy is generally defined as the administration of a
compound with systemic action, meaning that the compound reaches the infected area
via the bloodstream.[1] Traditional remedies which are capable of systemic action
include quinine from cinchona bark and emetine from the ipecacuanha root.[8] The
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concept of chemotherapy was coined by Paul Ehrlich at the beginning of the twentieth
century, founded on his belief that infectious diseases could be treated with synthetic
chemicals.[9] Other concepts introduced by Ehrlich into the field of antimicrobial
research include (a) that antimicrobial agents should be toxic compounds which bind
to micro-organisms - by means of chemical receptors - and that the binding of the
micro-organism relative to the host determines the effectiveness of the compound, (b)
the use of screening processes to aid in drug discovery, (c) the chemical modification
of existing compounds to improve their pharmacological properties, and (d) the notion
that drugs can be activated by metabolism in the host organism. Furthermore, Ehrlich
proposed that bacteriostatic action of a compound, that is the inhibition of bacterial
growth instead of direct killing, can be sufficient for the immune system of the host to
cope with the infectious disease.[10]
The beginning of modern chemotherapy was marked by the introduction of the
sulfa drugs, and their forerunner prontosil rubrum, by Domagk in 1935,[11] followed
by the antibiotic revolution set off by the re-evaluation of penicillin through Chain
and Florey in 1940.[12] Inspired by their tremendous success, the screening of
microbial cultures lead to the discovery of most of the classes of antibiotics that are in
current use, such as the aminoglycoside, macrolide or glycopeptide antibiotics.
Following a period of extensive screening programmes, both the synthetic- and
discovery-based approaches have converged by introducing chemical variations into
the scaffolds of established antibiotics, as exemplified by the development of four
generations of semi-synthetic cephalosporins.[13]
1.2 Bacterial targets of antimicrobial action
As already noted by Ehrlich, the fundamental basis of antimicrobial
chemotherapy is the selective toxicity of antibiotics towards micro-organisms.
Fortunately, there exist sufficient differences in the structure and organisation of
microbial and mammalian cells to allow for selective drug action.[14] Probably the
most prominent example of this principle is manifested in the bacterial cell-wall,
which is absent from higher organisms and thus a natural target of several antibiotics
in current use. Other important processes that are targeted by antibiotics include
bacterial protein synthesis, replication and transcription of DNA, or folate synthesis.
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Table 1.1 Site of antibacterial action and primary targets of antibiotics frequently used for the
systemic treatment of infectious diseases.
Site of action (Class of) Antimicrobial agent Primary Target(s)
Cell wall β-Lactams and cephalosporins Transpeptidases / transglycosylases (PBPs)a
Glycopeptides D-Alanyl-D-alanine of peptidoglycan / lipid II
Cycloserine Alanine racemase / D-alanine synthetase
Fosfomycin Pyruvyl transferase
Protein synthesis Chloramphenicol Peptidyl transferase
Aminoglycosides Initiation complex / translation
Tetracyclines Ribosomal A-site
Macrolides Translocation
Oxazolidinones Formation of 70S initiation complex
Cell membrane Colistimethate sodiumb Bacterial phospholipids
Folate synthesis Sulfonamides Pteroate synthetase
DNA replication Quinolones DNA gyrase
Novobiocin DNA gyrase
RNA synthesis Rifampicin RNA polymerase
a PBPs ≡ penicillin binding proteins; b colistimethate consists of poly-sulfomethylated polymyxins.
Figure 1.1: Structural diversity of various antibiotics in current clinical use. Polymyxins are
generally confined to topical applications.
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A summary of currently used antibiotics and their bacterial targets is given in Table
1.1 and the structural diversity of some of these compounds is indicated in Figure 1.1.
1.3 Bacterial resistance and the need for new antibiotics
Antibiotic resistance is an increasing problem associated with, and endangering the
use of, clinically relevant antibiotics as frequently accentuated in the literature.[15]
Several mechanisms exist by which micro-organisms evade the action of antibiotics
and the most common of these are:
 Enzymatic inactivation of drugs (e.g. through β-lactamases, chloramphenicol
acetyl transferase, aminoglycoside inactivating enzymes).
 Modification of the bacterial cell envelope (e.g. alterations in membrane
composition or the expression of porin proteins).
 Drug removal from the microbial cell (e.g. multidrug efflux pumps).
 Modification of the antibiotic target (e.g. mutations in penicillin binding
proteins or RNA polymerase).
 Metabolic bypass (e.g. replacement of the D-alanyl-D-alanine terminus in
enterococci).
Resistance is due to the genetic flexibility of micro-organisms in combination
with the large populations encountered in typical infections, and their short generation
times.[14] Three important genetic bases exist for the development of bacterial
resistance. Firstly, bacteria such as P. aeruginosa show a high degree of intrinsic
resistance which is caused by a combination of decreased antibiotic uptake and the
prevalence of multidrug efflux systems.[16] These free-living soil organisms have
evolved under exposure to antibiotics in the environment for aeons and were probably
already resistant to many antibiotics when they became available for treatment.
Secondly, spontaneous mutations affecting genes – especially those encoding target
sites of antimicrobial drug action - can lead to resistance. While spontaneous
mutation is an important mechanism for the development of resistance in bacterial
populations it is thought to be the main mechanism in viral populations since the
DNA replication machinery of these pathogens lacks sophisticated proof-reading
abilities. In contrast, for bacteria, the most important origin of drug resistance is
horizontal gene transfer via conjugation, transduction, or transformation.[17] A well-
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studied mechanism for the spreading of resistance genes in Gram-negative bacteria
consists of cellular conjugation mediated by so-called R-plasmids.[18]
Several approaches exist to preserve the usefulness of existing antibiotics and
to minimise the effects of bacterial resistance. Foremost amongst these are the
rational use of antibiotics and improved efficiency in treating microbial infections by
the right choice of drugs or combinations thereof. For decades, resistance was
successfully fought by introducing chemical modifications into semi-synthetic
derivatives but the increased pressure of resistance leads to increased effort to find
drugs with new targets and/or belonging to new chemical classes. Different strategies
exist for antimicrobial drug discovery such as target-based high throughput
screening.[19] In addition to phenotypic screening and due to the availability of more
than 300 microbial genome sequences (September 2006), functional genomic
approaches play an increasing role in various aspects of antimicrobial research.[20]
For instance, the comparison of human and pathogen genome sequences can be used
for the selection and validation of antibacterial targets, and transcriptome and
proteome expression profiling can help in elucidating antimicrobial modes of
action.[21] Nevertheless, it has to be mentioned that targets identified by such methods
are not necessarily viable for drug development, since the screening conditions
generally ignore important aspects such as cell permeability.[22]
1.4 Antimicrobial peptides (AMPs)
One class of compounds that shows considerable promise for development
into novel antimicrobial agents and which has therefore recently received an increased
amount of interest are the so-called antimicrobial peptides (AMPs). These are short
peptides of typically less than 50 amino acids found widespread throughout all
kingdoms of life; representatives have been isolated from such diverse sources as
mammals, fish, molluscs, amphibians, insects, and plants. AMPs typically show
broad spectra of activity against Gram-positive as well as Gram-negative organisms
and they also frequently display antifungal, antiprotozoal, and antiviral properties.[23]
AMPs are thought to be part of the innate immune system,[24] and although they show
large structural diversity in primary sequences as well as with respect to their
secondary structures, they share common physico-chemical parameters. Most
prominently, due to the high abundance of lysine and arginine residues, virtually all
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AMPs bear multiple positive charges at physiological pH; hence they are sometimes
collectively referred to as cationic AMPs. Furthermore, most of them are able to form
amphipathic structures, at least after interaction with membranous systems. It has to
be mentioned that some negatively charged AMPs such as dermcidin from human
sweat glands have been described,[25] but their antimicrobial activity is often only
modest.
The main mechanism of action for the vast majority of these compounds is
thought to be the disturbance and/or disintegration of membrane structures. A
detailed discussion of these and alternative mechanisms of AMP action will be
deferred until Chapter 2, but it is indicated at this point to emphasise that the
targeting of the microbial membrane is far from being unprecedented in either
research or clinical applications. For example, polymyxin B (1) and colistin, two
peptide antibiotics, are often included in topical applications and colistimethate
sodium, a polymyxin derivative, finds systemic use in combination therapies directed
against P. aeruginosa (c.f. Table 1.1).[26] However, it is in the field of AMPs that
such agents reach a level of discrimination between mammalian and microbial
membranes that is sufficient for conceivable systemic use on a broader therapeutic
scale.
Figure 1.2 An overview of major classes of antimicrobial compounds that contain peptide bonds
(peptide antimicrobial agents). The grey box highlights similarity in the presumed and/or proven
membrane-active mechanisms of the contained (classes of) compounds.
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Because there is occasionally some confusion in the literature, it is desirable to
give a more rigorous definition of the term AMP and of the way it will be used
throughout this work. A superficial definition of a peptidic compound with
antimicrobial activity will not do, since this does not differentiate them from
compounds of such paramount clinical importance as the glycopeptide antibiotics.[27]
These and other antibiotics, such as the already mentioned polymyxins, are generally
referred to in the literature as peptide antibiotics.[28, 29] A natural way of
distinguishing AMPs from these compounds is provided by their biosynthetic origins
(Figure 1.2). All peptidic antibiotics (peptide antimicrobial agents) that are in current
clinical use are of non-ribosomal origin, and this holds also for -lactams and
cephalosporins, although they are not generally termed peptide antibiotics. In
addition to the principal classes of peptide antibiotics depicted on the left side of
Figure 1.2, various compounds that share features of more than one class have been
described. Well-studied examples of such composite peptide antibiotics comprise
teicoplanin (lipoglycopeptide), daptomycin (lipodepsipeptide), or ramoplanin
(lipoglycodepsipeptide).[30]
In contrast to these peptide antibiotics, AMPs are exclusively of ribosomal
origin. They are gene-encoded, i.e. one gene encodes for one peptide and they are
synthesised as prepropeptides containing an N-terminal signal sequence, a highly
conserved pro-region, and a highly variable C-terminal cationic peptide region.[31]
After the signal sequence is removed by signal peptidases,[32] the release of the AMP
in its active form depends on further proteolytic processing.[33] Different proteases are
involved in different species to cleave off the propeptide region. Additionally, the C-
terminus of the AMP is frequently amidated by the action by peptidylglycine -
amidating monooxygenase (PAM).[34] The majority of ribosomally synthesised
peptides with antimicrobial activities is of eukaryotic origin but three classes of
peptides are produced by prokaryotes, namely the class I and II bacteriocins from
Gram-positive and the microcins from Gram-negative species. Extensive post-
translational modifications occur in the biosynthesis of class I bacteriocins (often
better known as lantibiotics) and microcins; for example, the nisin gene cluster
consists of 11 distinct gene products.[35] Therefore it seems justifiable to exclude
them from a classification as AMPs. Class II bacteriocins, on the other hand, are
unmodified polypeptides consisting of 20 to 60 amino acids and thus will be treated as
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AMPs, although the gene clusters of these peptides are more complex than those of
their eukaryotic counterparts.[36]
Extensive post-translational modifications are not confined to micro-
organisms.  Primate θ-defensin (RTD-1) is initially processed like a normal defensin,
but is subsequently backbone-cyclised.[37] Moreover, two distinct genes are
responsible for the amino acid sequence of the mature peptide. Other backbone-cyclic
peptides such as the plant cyclotides,[38] have been described to display antimicrobial
activity, and as in the case of RTD-1 little is known about the mechanisms of their
cyclisation.[39] Analogously to the lantibiotics and microcins, these compounds will
therefore not be regarded as genuine AMPs.
Finally, anionic AMPs and several cationic AMPs such as buforin or
lactoferricin B are products of the proteolytic processing of larger peptides/proteins
that have a distinct function in the cell apart from the independent antimicrobial
activity of their processing products. It is noteworthy that the parental proteins might
even display antimicrobial activity on their own, as is the case for lysozyme. These
fragments were first proposed to constitute a distinct subclass of AMPs by Boman.[40]
In the following discussions, the term AMPs will be used to describe those
ribosomally derived polypeptides from eukaryotic organisms and the class II
bacteriocins that are capable of exerting their antimicrobial action without distinct
post-translational modifications, i.e. modifications that require the presence of
tailoring enzymes whose function(s) are only associated with the synthesis of the
(class of) antimicrobial agent (c.f. Figure 1.3).
1.4.1 Classification of AMPs
At present, more than 1000 different AMPs have been isolated from natural
sources, not to mention the large number of derivatives synthesised in order to
optimise their biological properties. Several comprehensive online databases of
AMPs are available, which can be searched according to primary sequences,
secondary structures or reported activity spectra.*
* See for example: http://www.bbcm.units.it/~tossi/pag1.htm, http://research.i2r.astar.edu.sg/Templar/
DB/ANTIMIC/, and http://aps.unmc.edu/AP/main.php.
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Figure 1.3 Classification of ribosomally synthesised peptide antimicrobial agents apart from
antimicrobial proteins (c.f. Figure 1.2). Compounds treated as genuine AMPs in this work are
indicated by the broken line (see text). Note that the compounds in the shaded area fulfil all
requirements of Waksman’s antibiotic definition.
Due to the large number of AMPs it is desirable to classify them further.
Various classification schemes exist, for instance they can be grouped according to
which organism or class of organisms they originate from, which kind of tissue they
are expressed in, or on the basis of their antimicrobial spectra. However by far the
most common approach adopted in the literature for organising the multitude of
AMPs consists of classifying them according to their (secondary) structural features.
As mentioned, most AMPs are able to adopt a defined secondary structure, at least
upon interaction with membranous systems, and they are accordingly grouped into
four different structural classes.[41] The two largest classes are comprised of linear α-
helical and β-sheet/β-hairpin AMPs. Among the latter, subclasses are often
introduced, for example according to how many disulfide bonds are involved in
constraining the peptide conformation; compounds containing between two and five
disulfide bonds have been described. The third important class of AMPs consists of
peptides enriched in certain amino acids such as the Trp-rich, His-rich or Pro/Arg-rich
AMPs. Only limited structural data for this class of AMPs is available, although
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those peptides with an unusually high proportion of proline in their sequence are
sometimes described to possess a type II poly-L-proline helix, based on CD and FTIR
spectroscopic data.[42] They are therefore sometimes alternatively denoted extended
helical peptides.[41] The fourth class, which contains only a small number of AMPs, is
made up of compounds containing loop structures, such as thanatin or bactenecin.
Looped structures are often defined as possessing only one disulfide bridge,[43]
although this criterion might seem rather arbitrary and especially thanatin could also
be classified as a β-sheet/β-hairpin peptide. Due to the large number of AMPs
described in the literature no attempt can or will be made here to digress into an
exhaustive description of the different classes, sequences, structures, sources, and
activities of these substances. Rather Table 1.2 and Figure 1.4 serve to hint at these
aspects of AMPs. A multitude of review articles focusing on all aspects of AMP
chemistry and biology is available (for recent reviews, see [23, 44-47]).
Figure 1.4: Structural diversity of antimicrobial peptides. (A) HBD-2 [PDB code 1FD3];[48] (B)
EAFP-2 [PDB code 1P9Z];[49] (C) protegrin-1 (11) [PDB code 1PG1];[50] (D) pleurocidin [PDB code
1Z64];[51] (E) thanatin [PDB code 8TFV];[52] (F) HNP-2 variant [PDB code 1ZMH];[53] (G) leucocin A
[PDB code 1CW6];[54] (H) indolicidin [PDB code 1G89].[55] The illustrations have been prepared with
the VMD software package;[56] disulfide bonds are indicated in yellow.
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Table 1.2: Sources, sequences and activity spectra of selected AMPs, grouped according to
classes described in the text.
AMP Source Primary sequencea Spectrumb Ref.c
-helical
LL-37 Human H-LLGDFFRKSKEKIGKEFKRIVQRIKDFLR…
...NLVPRTES-OH
G-, G+, F,
V
[57-59]
Magainin-2 Amphibian H-GIGKFLHSAKKFGKAFVGEIMNS-OH G-, G+, F, P [60]
Dermaseptin Amphibian H-ALWKTMLKKLGTMALHAGKAALGAAA…
…DTISQGTQ-OH
G-, G+, F, P [61, 62]
Pleurocidin Fish H-GWGSFFKKAAHVGKHVGKAALTHYL-OH G-, G+ [63]
β-sheet / β-hairpin
Protegrin-1 Pig H-RGGRLC1YC2RRRFC2VC1VGR-NH2 G-, G+, F,
V
[64-66]
Androctonin Scorpion H-RSVC1RQIKIC2RRRGGC2YYKC1TNRPY-OH G-, G+, F [67]
Tachy-
plesin-1
Crab H-KWC1FRVC2YRGIC2YRKC1R-NH2 G-, G+, F,
V
[68, 69]
Poly-
phemusin
Crab H-RRWC1FRVC2YRGFC2YRKC1R-NH2 G-, G+, F,
V, P
[69-71]
α-defensin
(HNP-1)
Human H-AC1YC2RIPAC3IAGERRYGTC2IYQGR…
…LWAFC3C1-OH
G-, G+, F,
V, P
[72-75]
β-defensin
(HBD-2)
Human H-GIGDPVTC1LKSGAIC2HPVFC3PRRYKQIGTC2G…
…LPGTKCC3KKP-OH
G-, G+, F,
V, P
[76-79]
θ-defensin
(RTD-1)
Monkey GFC1RC2LC3RRGVC3RC2IC1TRd
└────────────────────┘
G-, G+, F,
V
[37, 80]
MGD-1 Mussel H-GFGC1PNNYQC2HRHC3KSIPGRC4GGYC1GGW…
…HRLRC2TC3YRC4G-OH
G-, G+ [81]
Ee-CBP Bark H-QQC1GRQAGNRRC2ANNLC3C1SQYGYC2GRTN…
…EYC3C4TSQGC5QSQC5RRC6G-OH
F [82]
Enriched in certain amino acids
PR-39 Pig H-RRRPRPPYLPRPRPPPFFPPRLPPRIPPG…
…FPPRFPPRFP-NH2
G-, G+ [83]
Pyrr-
hocoricin
Insect H-VDKGSYLPRPTePPRPIYNRN-OH G-, G+, F [84, 85]
Drosocin Insect H-GKPRPYSPRPTfSHPRPIRV-OH G-, G+, F [86, 87]
Apidaecin Insect H-GNNRPVYIPQPRPPHPRI-OH G-, G+ [88]
Histatin 5 Human H-DSHAKRHHGYKRKFHEKHHSHRGY-OH G-, G+, F [89]
Indolicidin Bovine H-ILPWKWPWWPWRR-NH2 G-, G+, F,
V
[90-92]
Looped structures
Thanatin Insect H-GSKKPVPIIYC1NRRTGKC1QRM-OH G-, G+, F [93]
Bactenecin Bovine H-RLC1RIVVIRVC1R-OH G-, G+, F [94, 95]
Derived from larger precursor molecules
Buforin Frog H-AGRGKQGGKVRAKAKTRSSRAGLQFPVGR...
...VHRLLRKGNY-OH
G-, G+, F [96]
Lacto-
fericin B
Bovine H-FKC1RRWQWRMKKLGAPSITC1VRRAF-OH G-, G+, F,
V, P
[97-
100]
a To emphasise the charged nature of AMPs, basic residues are depicted in boldface and acidic residues
are underlined; the positive charge of the free N-termini is indicated by H and the negative charge of
the free C-termini by OH; The disulfide bonding patterns are indicated by subscripts; b G- ≡ active
against Gram-negative species; G+ ≡ active against Gram-positive species; F ≡ antifungal activity; V ≡
antiviral activity; P ≡ antiprotozoal activity; c References; d backbone-cyclisation of RTD-1 is indicated
by a solid line; e the threonine residue of pyrrhocoricin is glycosylated with N-acetyl--D-
galactosamine; f the threonine residue of drosocin is glycosylated with -D-galactopyranosyl-(1 → 3)-
-N-acetyl-D-galactosamine.
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1.4.2 Selectivity of AMPs
As mentioned already, selective toxicity towards microbial cells is crucial for
any antibiotic compound to be of therapeutic use. Compounds such as the
polymyxins suffer from poor selectivity and it is this property that greatly hampers
their utility in systemic applications. One of the main reasons for the microbial
selectivity of AMPs is thought to lie in the different make-up of various cell
membranes.[24] In contrast to mammalian membranes, for instance, the outer layer of
the bacterial plasma membrane contains a high density of negatively charged
phospholipids such as phosphatidylglycerol (PG) and cardiolipin (CL).[101]
Additionally, the outer membranes of Gram-negative organisms are composed of
negatively charged lipopolysaccharides (LPS) which are thought to interact
electrostatically with the positively charged AMPs.[102] However, electrostatic forces
on their own are unlikely to be the sole parameter of selectivity since on the one hand
mammalian cells are also decorated with macromolecules bearing negative
charges,[103] and on the other hand anionic polypeptides are also able to insert into
negatively charged phospholipid bilayers.[104] The interactions of several AMPs with
model membranes of different compositions have been studied and it is generally
found that they selectively bind to or permeabilise negatively charged membrane
systems. AMPs for which such selectivity has been demonstrated include magainin-
2,[105] tachyplesin-I,[106] peptide G15 from granulysin,[107] or PGLa.[108] In contrast,
closely related peptide venoms (often also referred to as AMPs) such as melittin and
mastoparan, which display a more hydrophobic character, are able to permeabilise
both zwitterionic and anionic model membranes.[105] It has been reported that
supplementary membrane compounds such as cholesterol can confer additional
protection from attack by AMPs, at least when introduced into zwitterionic model
membranes.[105] However, a recent publication ascribes only a secondary role to
cholesterol in influencing the interaction of cationic AMPs with anionic model
membranes.[109]
1.4.3 AMPs and bacterial resistance
It has been proposed that AMPs are less prone to generate bacterial resistance
than currently used antibiotics. An argument in favour of this notion is the fact that
these compounds are still active despite their evolutionary ancient lineage.[24]
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Mechanisms of resistance to AMPs do exist however, comprising expression of
proteases, secretion of proteins that bind AMPs, extrusion of AMPs by multidrug
efflux systems and especially the reduction of the net anionic charge of the microbial
cell walls and/or membranes.
Several factors have been described to account for the putative ability of
AMPs to counteract these measures.[110] Firstly, many AMPs lack unique epitopes for
recognition by bacterial proteases. Secondly, the ability of bacteria to lower the
negative charge at their surfaces seems to be limited and thirdly, a reduced anionic
nature of the microbial surface might be counterbalanced by the introduction of higher
positive charge into the peptide scaffolds. Additionally, it has been argued that AMPs
might act by multi-hit mechanisms (c.f. Section 2.2);[111] the simultaneous interaction
with diverse targets would of course greatly diminish the possible emergence of
resistance. Moreover, bacteria are expected to encounter a wide array of different
AMPs at the source of infection, which could further explain a decreased propensity
to generate bacterial resistance. This effect may be even increased by the fact that
AMPs are released at high concentrations directly at the site of infections, contrary to
the low concentrations typically encountered in antibiotic chemotherapy. They have
therefore been described as ‘dirty’ antibiotics that, by virtue of their antimicrobial
mechanisms, are able to affect a wide range of antimicrobial pathogens
simultaneously.[112] Noteworthy, more recently, so-called ‘dirty’ drugs, i.e. drugs
acting by multiple mechanisms, and/or addressing possessing multiple targets, are
receiving increased attention for various therapeutical applications.[113]
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1.5 Antimicrobial peptide mimetics (AMPMs)
As outlined in the previous section, AMPs show considerable potential as
candidates for development into new therapeutically useful antimicrobial agents. The
increased interest in this class of compounds originates mainly from their hitherto
possibly underappreciated main mechanism of action, which is associated with
differential features of prevailing cell membranes (c.f. Chapter 2).[24] Two factors
which are intricately related to this mechanistic aspect account largely for the appeal
of AMPs as prospective drugs. Firstly, membrane-active mechanisms of action are
associated with the broad spectrum of antimicrobial activities of AMPs and secondly,
these mechanisms could account for the presumably low potential of AMPs to
generate bacterial resistance. Notably, AMPs often show good activities against
multidrug resistant pathogens such as multidrug (methicillin) resistant S. aureus
(MRSA) and P. aeruginosa. Dichotomously, membrane-active mechanisms also
account for one of the major drawbacks of naturally occurring AMPs, undermining
their therapeutic potential. That is, they frequently display high toxicity, as
exemplified, for instance, in an ability to lyse red blood cells. Thus, an important pre-
requisite for their further development, at least for systemic applications, is an
increase of their selectivity towards micro-organisms.
Several approaches for uncoupling the toxic and antimicrobial properties of
AMPs, thereby increasing this selectivity, have been described in the literature. A
commonly employed strategy consists of taking naturally occurring AMPs as
scaffolds for the construction of novel derivatives, typically by incorporation of
alternative amino acid residues into the molecular framework. Yet another virtue of
AMPs lies in their amenability to combinatorial chemistry based approaches, due to
the modular principle of peptides in general. Not surprisingly, extensive structure-
activity relationship (SAR) studies aimed at improving their biological activity have
been carried out on a variety of AMP scaffolds. The parameters generally varied in
these studies comprise overall size, primary sequence, secondary structure,
hydrophobicity, amphipathicity, and charge.[114] The result of such an approach is
illustrated by the development of IB-367, a protegrin analogue with improved
antimicrobial activity, albeit with undiminished haemolytic activity.[115]
An extension to this approach of modifying the peptide sequence consists of
the deletion or addition of residues, or in the truncation of the naturally occurring
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peptide sequence. For example, an N-terminally shortened derivative of dermaseptin
shows improved activity compared to its parent compound, and a C-terminal fragment
of LL- 37 was found to display cytotoxic activity towards both microbial and cancer
cells.[116, 117] This truncation of AMPs can not only provide an insight into minimal
structural motifs necessary for biological activity, but also leads to shorter peptide
fragments that are more attractive for possible large scale synthesis.
Furthermore, AMPs have been designed de novo either by methods
relying on general structural requirements such as the presence of amphipathicity and
α-helical structure,[118] or by template-assisted methods. In template-assisted
methods, patterns of different amino acids in connection with their physico-chemical
parameters such as charge or hydrophobicity are assembled into sequence-templates
which can then be used for the designed synthesis of AMP(M)s.[119] Moreover,
template-assisted methods are not confined to the above mentioned sequence-
templates. Additionally, structural templates can be used to constrain linear peptides
into defined conformations such as β-hairpins or α-helices. For example, Tam et al.
introduced additional cystine or backbone cyclisation constraints into the framework
of tachyplesin and Andreu and co-workers likewise used a cystine link to induce an
amphipathic α-helical conformation in short linear peptide fragments derived from
thionin.[120, 121]
1.5.1 D-Pro-L-Pro as a structural template
The approach employed by our group for the development of antimicrobial
peptide mimetics with improved biological activities is based on the introduction of
organic templates into a peptidic backbone in order to stabilise β-hairpin
conformations.[122] Several organic templates have been developed for achieving such
stabilisation, but of particular interest for this work is the D-Pro-L-Pro template (10)
depicted in Figure 1.5. It has been demonstrated that the heterochiral 10 promotes
the formation of regular hairpin conformations,[123, 124] and this has been exploited by
our group in the synthesis of β-turn mimetics that are obtained by grafting the
sequences of naturally occurring β-hairpin folds onto the template. This methodology
has been successfully applied to the design of inhibitors of the p53-HDM2
interaction,[125] trypsin inhibitors,[126] human antibody Fc-binding
peptidomimetics,[127] and ligands that bind to viral TAR RNA regulatory elements.[128]
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Figure 1.5 The D-Pro-L-Pro template (10); attachment points to the peptide backbone are
indicated by wavy lines.
1.5.2 AMPMs derived from naturally occurring -hairpin AMPs
There exist a variety of naturally occurring AMPs with β-hairpin folds which
present auspicious starting points for AMPMs based on the D-Pro-L-Pro template (10).
A selection of these compounds is depicted in Figure 1.6 along with schematic
drawings emphasising their β-hairpin folds. As can be seen, the β-hairpin of naturally
occurring AMPs is typically constrained by disulfide bonds. An additional constraint
of backbone-cyclisation can be found in RTD-1, a mammalian AMP isolated from a
monkey species.[37] While other AMPs, especially the α-helical subclass, often adopt
their secondary structure only upon interaction with membranous systems, -hairpin
AMPs generally already display their secondary structure in an aqueous environment.
These compounds were isolated from a variety of sources and they have been studied
extensively because of their interesting antimicrobial activities, and as model
compounds for mechanistic studies. The extensive SAR studies on protegrin-1 (11),
resulting in the development of IB-367, have been mentioned already. Additionally,
this peptide has been used frequently as a model compound for solid-state NMR and
computational studies directed towards understanding its interaction with
membranous systems. Further interest in -hairpin AMPs originates from the
antiviral properties that some of these compounds display. Most notably amongst
those are the tachyplesins and polyphemusins, which have been isolated from various
crab species.[129, 130]
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Figure 1.6 NMR structures of naturally occurring -hairpin AMPs together with schematic
drawings emphasizing their -hairpin folds. Disulfide bonds are depicted in yellow, or as broken lines,
and the clustering of polar (red) and apolar residues (blue) is indicated. From top: Protegrin-1 (11)
[PDB code 1PG1],[50] tachyplesin-1 (12) [PDB code 1WO0], polyphemusin-1 (13) [PDB code
1RKK],[131] and gomesin (14) [PDB code 1KFP].[132] The illustrations have been prepared with the
VMD software package.[56]
A further incentive for the use of this class of molecules as sequence templates
in the design of AMPMs derives from findings that underline the importance of the
well-defined β-hairpin conformation in naturally occurring AMPs for their
antimicrobial activity. For example, it has been shown that linear derivatives of
protegrin-1 displayed diminished antimicrobial as well as membrane-lytic
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properties,[133] and similar results have also been reported for tachyplesins and
polyphemusins.[131, 134] Furthermore, disulfide constrained peptide-mimetics of the -
hairpin region of mammalian and mussel defensins retain antimicrobial activity, once
again highlighting the importance of this structural motif.[135, 136]
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Figure 1.7 Grafting of sequences of naturally occurring antimicrobial -hairpin peptides (11 =
protegrin-1; 12 = tachyplesin-1; 13 = polyphemusin-1) onto the D-Pro-L-Pro template (10).
Motivated by these findings, several series of AMPMs based on the above
mentioned naturally occurring β-hairpin structures and the D-Pro-L-Pro dipeptide (10),
as well as other organic templates, have been synthesised by our group.[137-140] The
AMPMs were designed by grafting the sequences onto the organic template as
indicated in Figure 1.7. Since this work is only concerned with experiments directed
at AMPMs employing the D-Pro-L-Pro (10) template, I will focus solely on
compounds containing this template. An additional possible advantage of the organic
template approach lies in the fact that the hairpin inducing template relaxes the
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requirement for the cystine bridges, thereby creating free slots for additional amino
acid side-chains.
1.5.3 Project outline
The biological activities of selected representatives of four generations of
AMPMs are reproduced in Table 1.3. It is evident from this table that the first library
of -hairpin mimetics, of which mimetics 15 and 16 are shown in Table 1.3, was
successful in separating the antimicrobial and haemolytic activities of the parent
AMP(s). While mimetic-15 still showed an appreciable amount of haemolytic
activity towards human red blood cells (hRBC), compound 16 retained good
antimicrobial activity against Gram-positive as well as Gram-negative organisms but
almost completely lost the haemolytic properties.
Extensive SAR studies have been conducted with the scaffold of mimetic-16,
the most attractive compound of the first library with respect to its low haemolytic
activity,[138] which demonstrated that the antimicrobial activity is tolerant to a large
number of the over 100 single site substitutions tested. Several other AMPMs based
on 16 have been developed in our laboratory and in cooperation with Polyphor Ltd.†
Of particular interest was the discovery of mimetic 17, which in addition to non-
detectable haemolytic properties under standard assay conditions (with a peptide
concentration of 100 g/mL), displayed an increased selectivity towards the Gram-
negative organism P. aeruginosa. Remarkably, the haemolytic activity of 17
amounted to only 1% at a peptide concentration of as high as 1 mg/mL. Subsequent
modifications in two further rounds of optimisation lead to the AMPMs 18 and 19
with a concomitant increase in activity and selectivity towards P. aeruginosa (c.f.
Table 1.3). During the course of development of these newer generations of
AMPMs, several clues such as differences in their killing kinetics and the remarkable
selectivity towards P. aeruginosa, accumulated, indicating that some representatives
might exert their antibacterial action by a mechanism that differs fundamentally from
the membrane-active models generally proposed for the naturally occurring -hairpin
AMPs from which they were ultimately derived.
† Polyphor Ltd. Gewerbestrasse 14, CH-4123 Allschwil
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Table 1.3 Antimicrobial and haemolytic activities of AMPMs derived from protegrin-1. The
values for mimetics 15 and 16 and for 11 are taken from [137]; other values are taken from [139].
IDa sequenceb MICc [g/mL] %Hd
E. coli P. aeruginosa S. aureus C. albicans hRBCe
25922f 27853f PAO1f 25923f 29213f
15 LRLQYRRFQYRVpP 6 12 n.d.g 12 n.d. 6 27
16 LRLKKRRWKYRVpP 12 6 n.d. 12 n.d. 12 1
17 RWLKKQRWKYYRpP 16 0.25 n.d. > 64 > 64 n.d. 0
18 TWLKKRRWKKVKpP 64 0.03 0.06 32 >64 n.d. 0
19 TWLKKRRWKKAKpP 64 0.015 0.004 >64 >64 n.d. 0
11 Protegrin-1h 3 3 n.d. 6 n.d. 6 37
a Substance identifier; b peptides are cyclised by a peptide bond between the terminal residues; c
minimal inhibitory concentration (for a definition, refer to Section 3.3) d % Haemolysis at a peptide
concentration of 100 g/mL; e hRBC ≡ human red blood cells; f strain or ATCC number; g n.d. ≡ not
determined; h the sequence of 11 is shown in Figure 1.7.
Therefore, it was decided to investigate the possible modes of action of these
compounds. To this end, a variety of biophysical, bacteriological and biochemical
methods were employed and these experiments will be described in subsequent
sections following a review of mechanistic aspects of AMP(M)s.
Finally, it should be mentioned that the mechanistic studies and the
development of new AMPMs progressed to a large extent in parallel. Therefore,
certain experiments have not been conducted with all mimetics of Table 1.3.
Nonetheless, all experiments always include at least a representative of those
mimetics that show the characteristic selectivity towards P. aeruginosa, and which are
therefore assumed to share the same underlying mechanistic behaviour.
2 Modes and mechanisms of AMP action
Since the preliminary studies on AMPMs derived from protegrin-1 (11) led to
the presumption that some of these compounds might exert their antibacterial activity
by mechanisms differing from the ones commonly associated with AMPs, it seems
desirable at this point to summarise what is currently known about the modes and
mechanisms of AMP action. Both expressions “mode of action” and “mechanism of
action” are generally used interchangeably in the literature, but for the purpose of this
work they will be associated with different concepts. The term mode of action will be
used in a phenomenological sense, which is independent from the underlying
mechanism(s) that will be denoted as mechanisms of action. For example, the mode
of action of chloramphenicol is the inhibition of protein biosynthesis; mechanistically
it does so by binding to the 50S subunit of the bacterial ribosome.
With increased research efforts directed towards the in vivo antimicrobial
action of AMPs it becomes increasingly evident that this action can be divided into
two different modes. Firstly, AMPs might act by directly killing or inhibiting the
growth of micro-organisms. These direct effects are the defining feature of AMPs as
implied by their name, and are used for the isolation of AMPs from natural sources.
Antimicrobial activity is typically assessed by in vitro assays (c.f. Section 3.3), and in
an in vitro setting any antimicrobial effect has necessarily to be mediated directly
through the AMP. These considerations hold even for the conceivable case where the
active principle might be derived from the AMP by metabolic processing through the
target organism.
In contrast, the antimicrobial action of an AMP, or that of any antimicrobial
agent in general, in an in vivo setting cannot per se be attributed to a direct effect on
the microbial cells. Complications arise due to the inevitably increased complexity of
the system and therefore a second mode of antimicrobial action, functioning by
exerting immuno-modulatory effects on the host, as opposed to the abovementioned
direct mode of action, is well conceivable. The proposed contribution of such
immuno-modulatory effects to the antimicrobial action of AMPs has led to the
coining of the term host defence peptides (HDPs) as an alternative to the commonly
used term AMPs. Although AMPs are increasingly referred to as HDPs by some
authors,[141, 142] I will continue to use the former term, since this work is concerned
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with AMPMs of distinct antibacterial activity in vitro, which thus evidently display a
direct mode of antibacterial action.
Notwithstanding the accumulating evidence for immuno-modulatory effects of
AMPs on the host immune system, the vast majority of AMPs is thought to act
mainly, if not exclusively, by a direct mode of action. For these AMPs, another
distinction with respect to the underlying mechanisms of the antimicrobial action can
be made. On the one hand, a large majority of AMPs that have been studied with
mechanistic aspects in mind are thought to, or have been shown to act by targeting
and impairing the function of the microbial cell membrane and/or cell wall. The
importance of such mechanisms in motivating AMP research was pointed out in the
introduction. On the other hand, there is an increasing number of AMPs for which
mechanisms of direct antimicrobial action have been suggested which would not
primarily depend on fundamental features of membranous systems. To emphasise the
unusual behaviour of such AMPs, they are often described as possessing an
“alternative”, or “different” mechanism of action.
Figure 2.1 Modes and mechanisms of antimicrobial action displayed by AMPs. Note that
several compounds might act by a combination of different modes of action. Some examples of well-
studied AMPMs are given.
Direct antimicrobial mode of action
membrane-active
mechanisms
(independent form stereo-
specific interactions)
DEFENSINS, CATHELICIDINS,
CECROPINS, ETC.
Immuno-modulatory mode of action
“alternative” mechanisms
(dependent on stereospecific
interaction with microbial cells)
PRO/ARG-RICH PEPTIDES
receptor-based mechanisms
(dependent on stereospecific
interaction with host cells)
TACHYPLESIN
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A graphical representation of the different modes and mechanisms of AMP
action is shown in Figure 2.1. The following discussion is based on this division into
different modes as well as mechanisms of action, and special emphasis will be given
to AMPs with alternative mechanisms of direct antimicrobial action, due to the
experimental behaviour of our AMPMs.
2.1 Direct modes of action
Regardless of the concrete models that are used to rationalise the direct action
of AMPs, several steps must occur in order to bring about bacterial killing. These
steps comprise: (1) attraction of the AMP to the microbial species (possibly mediated
by electrostatic interactions); (2) attachment to the microbial plasma membrane which
might, in the case of bacteria, be preceded by permeation of the cell wall (outer
membrane and/or peptidoglycan layer); (3) permeabilisation of the target plasma
membrane and/or translocation across it; resulting in (4) the bacterial killing,
mediated by various effects which might include action on intra-cellular targets.
First of all, AMPs must be attracted to the microbial membrane, or to the
bacterial cell wall. The latter is composed largely of a peptidoglycan layer (Gram-
positive species), or of the outer membrane (OM) together with a smaller
peptidoglycan layer (Gram-negative species). Attraction of AMPs to the surface of
microbial targets is intimately related to the issue of selectivity (c.f. Section 1.4.2),
and a major role in this first step is generally attributed to electrostatic interactions,
especially with LPS,[143] or with other negatively charged components of bacterial cell
walls.[144] Following attraction to the bacterial targets, the peptides have to pass
through the outer membrane in Gram-negative species. HNP-1, for instance, was
shown to effectively disrupt the OM, as demonstrated by the release of a periplasmic
β-lactamase.[145] The release of this enzyme is thought to be brought about by
destabilisation of the OM via displacement of divalent cations during the binding of
peptide to LPS.[146] In the case of Gram-positive bacteria, the bacterial cell-wall
generally represents no barrier for AMPs as suggested, for example, by the size
exclusion limit of 30 to 57 kDa for polysaccharides.[147] The preference of AMPs to
attach to microbial membranes is thought to originate mainly from the differing
phospholipid compositions of host and target plasma membranes (vide supra).
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After penetration of the cell wall and attachment to the membrane, several
events have been suggested to be responsible for killing the target organism. Such
events have been proposed to include dissipation of trans-membrane potential and the
pH gradient,[148, 149] caused, for example, by formation of ion-channels,[150]
disturbance of the osmotic regulation,[151] efflux of metabolites, and the uncoupling of
respiration,[152] although various AMPs vary considerably in their ability to depolarise
cytoplasmic membranes with respect to a membrane sensitive dye.[43] Additionally,
the interaction with intra-cellular targets or the inhibition of enzymatic processes of
the target cells have been suggested. The latter effects touch on the border between
membrane-active and alternative mechanisms of action, but first we will be concerned
with membrane-active mechanisms, in which the killing events are solely dependent
on disruption of membrane integrity and function.
2.1.1 Membrane-active mechanisms
It seems appropriate to begin a mechanistic discussion with this category for
several reasons. Firstly, in spite of increasing reports of AMPs to which other
mechanisms of action are attributed, the vast majority of AMP(M)s described to date
is still thought to belong in this category. Also, historically the various hypotheses,
theories, and models explaining the antimicrobial action and selectivity of these
compounds were originally concerned with membrane-active mechanisms, which
might be partially attributable to the fact that early mechanistic research in this field
was stimulated by peptide venoms that had long been expected to disrupt cellular
membranes. Most importantly, though, it has to be kept in mind that an important
question for any antibiotic substance is concerned with its uptake into the target
organism, unless it is acting on extracellular or surface compounds alone. Therefore,
even if AMPs employ alternative mechanisms in the killing or the growth-inhibition
of micro-organisms the models derived for a more direct action on the membrane
remain an important aspect of AMP action.
Several indications point to a membrane-active mechanism being best suited
to account for the antimicrobial action of the majority of AMP(M)s. Firstly, these
compounds usually possess similar activity ranges, typically in the low micromolar
range. They also display broad-spectrum antimicrobial activity towards Gram-
negative, Gram-positive, and fungal species. The similar activities and activity
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patterns of AMPs, despite large differences in their structures and sequences, can be
satisfactorily explained by membrane-active mechanisms. These are able to provide
an underlying mechanistic framework which, in accordance with the observations, is
insensitive to variations in the peptide structures as long as certain physico-chemical
parameters are adhered to (vide infra). The same holds true for the rapidity with
which many of these compounds exert their (mostly bactericidal) action. Often a
decrease in the viable cell count of several orders of magnitude is observed within
minutes of induction with the AMP (c.f. Section 3.3), and such rapid action would be
expected from an impairment of membrane function.
Of paramount importance, and one of the main arguments for the development
of the different models of cell permeabilisation, is the identical behaviour of various
enantiomeric pairs of AMP(M)s (c.f. Section 3.4), which strongly suggests
mechanisms that are not dependent on topological recognition of chiral entities such
as protein or nucleic acid receptors. Indeed, these findings rather point to an
involvement of peptide/lipid interactions in the mode of action of these peptides.
Furthermore, morphological studies on the effects of AMPs on bacterial cells,
typically employing scanning and/or transmission electron microscopy, often show
the formation of compromised membrane structures, such as the formation of blebs on
the membrane surface,[153] or the swelling of the bacterial cell concomitant with
detachment of the outer membrane in E. coli.[154] It has to be mentioned though, that
such morphological changes have also been interpreted as secondary effects that occur
only after the cells have been damaged irreversibly.
2.1.1.1 Parameters of membrane-active mechanisms
Several interdependent structural determinants have been examined for their
influence on antimicrobial action according to membrane-active modes of action.[155]
For example, the overall charge of the AMP might be important in the initial
electrostatic interaction with the cell wall, and contribute to the selectivity for certain
phospholipids. Indeed, most AMPs are positively charged, and several studies
emphasise a relationship between increased cationic charge and increased
antimicrobial activity.[156, 157] Other important parameters that have been studied
systematically include the hydrophobic moment H,[158] which is used as a measure
for the amphipathicity, especially in α-helical AMPs.[159] It has been found that a
26 Chapter 2
modification of the hydrophobicity can increase the selectivity of AMPM gramicidin
S derivatives towards micro-organisms.[160] Related to the hydrophobic moment is the
peptide hydrophobicity, which is defined as the percentage of hydrophobic residues in
the peptide. Hydrophobicity seems to be necessary for insertion of the peptides into
the membrane, and it is thus not surprising that AMPs possess a hydrophobicity of
around 50%. Additionally, it has been shown that increasing hydrophobicity can lead
to an increase in haemolytic activity.[159] Another important parameter for -helical
peptides is the polar angle (Θ), which describes the relative angles subtended for the
polar and the apolar faces, as best demonstrated in a helical wheel projection.[161] A
smaller polar angle has been linked to an increased capacity for pore formation and
membrane permeabilisation.[162] It has to be emphasised that all these parameters are
interconnected, and subtle variations in one of them can lead to quite drastic changes
in the activity and selectivity of the AMP.[155]
2.1.1.2 Models of pore-formation and membrane permeabilisation
As mentioned above, killing events caused by membrane-active peptides are
associated with permeabilising effects on the cytoplasmic target membrane. Several
models have been devised for this process; a graphical representation of the three
most common models is shown in Figure 2.2. These models have been proposed
based on biophysical experiments with artificial and natural membranes,
computational studies, and bacteriological data (e.g. activity spectra).
An important factor in all models is the orientation of the peptide molecules
with respect to the bilayer surface. It has been found that the most important variable
for this orientation is the peptide concentration, generally expressed as the peptide to
lipid ratio [P]/[L]. According to OCD (orientated circular dichroism), AMPs are
typically bound parallel to the lipid bilayer if this ratio remains below a certain
threshold concentration [P]/[L]*, above which increasing amounts of the peptide are
found perpendicular to the lipid bilayer. The threshold concentration has been found
to depend essentially on membrane composition and temperature.[163]
The state of an AMP in which it is bound parallel to the membrane surface is
commonly referred to as the S state, while the inserted peptide is denoted as being in
the I-state. Generally, peptides in the S-state lead to a thinning of the membrane, as
found for example by X-ray diffraction studies.[164] This thinning effect is also
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thought to facilitate pore-formation, and originates in the expansion of the membrane
surface by the insertion of the peptides between the headgroups of the
phospholipids.[165, 166]
Figure 2.2 Three common models of membrane-permeabilisation by AMP(M)s. (A) barrel-
stave model; (B) carpet-model; (C) toroidal-pore model. Note the different diameters of the membrane
pores predicted by the barrel-stave or the toroidal-pore model shown in the insets, and the orientation
of the peptides with respect to the bilayer normal in the different models. The amphipathic nature of
the peptide molecules and the adoption of secondary structure upon interaction with the membrane is
indicated.
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BARREL-STAVE MODEL The barrel-stave model (Figure 2.2A) postulates
the formation of discrete pores in the phospholipid bilayer and was in its essentials
first proposed by Baumann and Mueller in 1974.[167] In this model, amphipathic
compounds first bind to the surface of the membrane, possibly with concomitant
adoption of secondary structure. Subsequently, they self-assemble on the surface and
insert into the bilayer, thus creating the pore structure(s). The multimerisation of
monomers before the insertion into the membrane is necessary because it would be
energetically unfavourable for a single amphipathic molecule to insert into the apolar
region of the membrane, due to the unfavourable interactions between the apolar
interior of the phospholipid bilayer and the polar face of the amphipathic
molecule.[168] Recruitment of additional peptide monomers could then successively
increase the pore size until a stable configuration was achieved. For amphipathic
peptides, the inside of the pore is lined with their hydrophilic faces, whilst their
hydrophobic faces are in contact with the membrane interior.[169] Therefore,
compounds for which a barrel-stave mechanism seems plausible are thought to be
generally more hydrophobic than the majority of AMPs.[170]
The geometrical layout of the pores is such that the long axis of the inserted
molecules is parallel to the normal of the bilayer at all times. This gives the pore the
appearance of a barrel whose shape is lined with peptidic staves. Notably, in the
barrel-stave model, the molecules are not always entirely in contact with the
phospholipid head groups,[163] and this is a major criterion that differentiates it from
the other models of pore-formation. An additional feature of the barrel-stave model is
illustrated by the fact that peptides need a certain length to span the membrane in its
entirety. In the case of AMPs, those belonging to the -helical subclass are most-
likely to fulfil this requirement, although they need a minimum of at least 20 amino
acids to achieve the necessary length.[171]
One of the few peptide antimicrobial agents for which the applicability of the
barrel-stave model seems secure, is the peptaibol alamethicin. This wide acceptance
is based on experimental evidence, such as the reproducible discrete states of single-
channel ion conduction,[172] indicating the presence of discrete aggregates of
alamethicin monomers in the pore, and neutron in-plane scattering experiments. The
scattering experiments suggest a pore-size of 4 nm outside diameter and 1.8 nm inside
diameter, giving a calculated diameter of 1.1 nm for the lining peptides.[173] This is in
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good agreement with the diameter of the alamethicin helix found in crystal structures,
and indicates that the pores are composed of 8 peptide monomers.[174] A membrane
pore composed of 8 peptidic monomers, that is reminiscent of alamethicin pores, has
also been described for the lantibiotic nisin (vide infra).
A relatively recent example of a genuine AMP (according to the definitions
given in the introduction) is ceratotoxin A, a 36 residue α-helical insect AMP that has
been reported to form voltage-dependent ion channels in lipid bilayers, and which is
thought to form pores consisting of five to six peptide monomers according to the
barrel-stave mechanism.[175]
CARPET MODEL In the carpet model, the target cell membrane is thought
to become covered by AMPs in a carpet-like fashion (Figure 2.2B).[176] The peptides
orient themselves in such a way that their hydrophilic face is in contact with the polar
head groups of the phospholipids, while their hydrophobic face is in contact with, or
respectively inserts into, the apolar environment of the membrane. After reaching a
certain threshold concentration, the peptides are believed to impair the membrane
integrity, for example by influencing the bilayer curvature.[168, 170] For example, the
expansion of the hydrophilic head group region by AMPs leads to perturbation of the
membrane integrity by introduction of positive membrane curvature strain; these
effects can be studied by differential scanning calorimetry (DSC) which measures the
effect of AMPs on the phase transition temperature of the change from the lamellar to
the hexagonal phase.[177] Examples of peptides that are reported to introduce positive
membrane curvature strain include the AMP magainin-2 and the wasp venom
mastoparan.[178, 179] Generally, vesicle lysis, i.e. the complete breakdown of the
membrane, accompanied by formation of micellar structures, is associated with a
classical carpet model. Therefore, this model is closely associated with the concept of
detergent-like action and these effects have also been aptly described as membrane
solubilisation. An important feature of the carpet model is that the AMPs are in
constant contact with the hydrophilic head groups of the phospholipids, instead of
inserting parallel to the bilayer normal as is the case for the barrel-stave model.
Important experimental support for this geometry comes from solid state NMR
experiments determining the orientation of peptides in the lipid bilayer. For example,
piscidins, AMPs from fish,[180] or cecropin A[181] are found to be oriented
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perpendicular to the bilayer normal in solid-state NMR experiments throughout the
process of membrane permeabilisation.
The carpet model is attractive for rationalising the action of a variety of
AMPs, including those that are too short to span the lipid bilayer in its entirety. This
model is also in agreement with the broad activity spectra of AMPs; the MIC values
of these compounds are usually in a range that is well explicable with the need to
reach a certain threshold concentration such as is necessary in the carpet model. It
was first proposed by Shai and co-workers for the 34 residue AMP dermaseptin,[182]
based on biophysical experiments employing fluorescently labelled AMPs, that
indicated that dermaseptin and other peptides, such as magainin, only achieved very
shallow penetration into the membrane bilayer. It has since been used to account for
the action of a variety of AMPs other than the ones noted above, such as
androctonin,[183] diastereomeric AMPs derived from naturally occurring AMPs,[184, 185]
LL-37,[186] and mastoparan X,[187] to mention but a few.
TOROIDAL PORE MODEL This model is also synonymously known as the
wormhole model, and in analogy to the carpet model, one of its major features is that
the molecules remain associated with the polar headgroups throughout the
permeabilisation process.[188] In contrast to the carpet model, it postulates the
transient formation of the eponymous pores, instead of the disintegration of the
membrane bilayer. The toroidal pores are lined with both peptides and phospholipid
headgroups, resulting in a high curvature of the phospholipid bilayer (c.f. Figure
2.2C). The curvature of the membrane results in a thinning of the headgroups at the
surface of the pore, and the peptide molecules also act by filling this space. The
toroidal pore model can also account for the phenomenon of lipid flip-flop, i.e. the
redistribution of phospholipids between the outer and inner layers of a membrane.[189]
AMPs can reduce the half-life time for lipid flip-flop from days to minutes, and
additionally, lipid flip-flop has been found, in dye-leakage experiments, to be
correlated with membrane permeabilisation, suggesting an interrelation with pore-
formation.[190] Since the pores are thought to be only of temporary existence, the
same principle of redistribution between inside and outside layers of the membrane is
also conceivable for the AMPs themselves. Accordingly, the toroidal pore model can
also lend itself to account for the translocation of AMPs across target membranes.
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Another distinction from the barrel-stave model, apart from the orientation of
the peptides, can be found in the overall pore size in this model. The toroidal pores
are expected to be larger than the typically penta- to octameric pores of the barrel-
stave model. Estimates of pore-sizes can be obtained via dye-leakage experiments
and indeed, pores formed by AMPs such magainin-2 are found to be significantly
larger than those formed by alamethicin.[191] Additionally, the characteristics of ion-
channel formation, for instance voltage independence, have been reported to favour a
toroidal pore mechanism.[192]
MISCELLANEOUS MODELS Apart from the three common models depicted
in Figure 2.2, others have been described occasionally. For example, Miteva et al.
proposed, based on calculations of the electrostatic potential of the AMP NK-lysine
bound to the membrane surface, that the formation of pores could be due to molecular
electroporation, i.e. the formation of pores due to the presence of an electrical field
caused by the AMPs surrounding the target membrane.[193]
A sinking-raft model was proposed by Pokorny et al. for the pore forming
action of δ-lysine, in which α-helical peptides form trimers on the membrane surface
that sink through the membrane, whereby they keep their hydrophilic faces in contact,
and allow pore formation when the trimer is half-way across the bilayer.[194]
Figure 2.3 The in-plane diffusion model of membrane permeabilisation. The amphipathic
character of the permeabilising compound is indicated.
Yet another model is the in-plane diffusion model, which postulates that the
insertion of peptides into the surface induces curvature strain into the membrane
within a diameter of about 100 Å around the peptide (Figure 2.3). These disturbances
are suggested to diffuse in the plane of the membrane and allow for the formation of
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transient pores in overlapping areas. The in-plane diffusion model has been suggested
to explain the findings that the membrane-association of many AMPs is not
cooperative.[195]
2.1.1.3 Final remarks concerning membrane-active mechanism(s)
The models of membrane permeabilisation have been developed to rationalise
the killing of micro-organisms mediated by effects on the integrity of their membrane
structures. On the one hand, such effects can be brought about by pore-formation,
independent of whether the pores are only of transient existence, as in the toroidal-
pore or in-plane diffusion models, or of a more stable nature, as is the case for the
barrel-stave model. On the other hand, membrane-active killing of microbes might be
associated with complete disintegration of the target membrane, which is, for
example, suggested for the carpet model. It should be noted though, that a major
difference between the carpet and toroidal pore models only exists for the final stages
of membrane permeabilisation.
The classical carpet model is associated with a detergent-like action and an
important experimental methodology that can be used to distinguish it from the
toroidal pore model is the use of oriented lipid bilayers in 31P-NMR.[196] In such
experiments, the presence of isotropic peaks indicates the presence of smaller bilayer,
or respectively micellar fragments. Additionally, the β-hairpin AMP protegrin-1 (11)
has been proposed to disrupt membranes under the formation of small, disk-shaped
fragments, instead of micellar aggregates.[197] The formation of micelles has been
found to occur for certain peptides such as melittin,[198] or mastoparan,[199] two insect
venoms that have often been described to possess detergent-like properties and whose
mechanisms of action are in full agreement with the carpet model. Accordingly,
Ladokhin and White showed that melittin induced the release of fluorescently labelled
markers of different sizes from model membrane systems in an unselective, i.e.
detergent-like, fashion.[200] In contrast to these peptides, micellisation has not been
found for LL-37,[196] which has been traditionally associated with the carpet model
(vide supra). Another experimental result in favour of a toroidal pore model consists
of the findings that there is often no complete dissipation of membrane potential at
concentrations below the MIC.
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It has been suggested that the carpet model could be an extreme case of the
toroidal pore model, viz. it is well conceivable that the simultaneous formation of too
many transient pores leads to the disintegration of the target membrane. A decisive
factor concerning which of both models is more adequate in a given situation could
therefore consist of the overall peptide-to-lipid ratio. Consequently, the term Shai-
Matsuzaki-Huang model (SMH model) is sometimes used to unite both models.[24]
Like the toroidal pore model, the SMH model is also attractive to account for the
translocation of AMPs across microbial membranes in such mechanisms as propose
interaction with intra-cellular targets.[111]
2.1.2 Alternative mechanisms of direct antimicrobial action
The postulation of alternative mechanisms of AMPM action originates from
experimental findings that are difficult to account for within the mechanistic
framework of membrane-activity. Foremost, on investigation of the biological
activities of some enantiomeric pairs of AMPs, a diminished activity was displayed
for the unnatural all-D forms. This is a very powerful argument for the involvement
of stereospecific receptors in the corresponding mechanism (c.f. Section 3.4).
Additionally, some AMPs show antimicrobial activities at concentrations that are
much lower than necessary for the killing of microbes according to a carpet
mechanism, and they often display a concomitant selectivity for certain microbial
species (c.f. Section 3.3).
Not surprisingly, the border between alternative and membrane-active
mechanisms is not clear-cut. For instance, mechanisms that depend on stereospecific
binding to a receptor molecule on the membrane surface before exerting a principally
unspecific permeabilising effect are conceivable. Indeed, lantibiotics such as nisin
and mersacidin have been shown to bind to a so-called docking molecule in the
bacterial membrane. This docking molecule has been identified as lipid-II, a
precursor of peptidoglycan biosynthesis.[201] But whereas mersacidin is thought to
directly inhibit the cell-wall biosynthesis,[202] nisin forms pores in the lipid bilayer in a
targeted fashion, involving a pore complex of eight nisin molecules and four lipid-II
moieties.[203] It is thought that after binding to lipid-II on the membrane surface, a
part of the molecule is inserted into the membrane to achieve pore-formation similar
to the barrel-stave model.[204] This notion is further supported by findings that nisin
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displays membrane-permeabilising properties even in model systems lacking lipid-II,
but only at higher concentrations, which are comparable to those typically
encountered for membrane-active AMPs.
Conversely, unspecific binding of peptides to membranes could induce
secondary structure that might be necessary for stereospecific interaction with a
membrane-bound receptor molecule. Alternatively, the membrane-active properties
of an AMP might enable it to translocate efficiently through the membrane and
interact stereospecifically with an intra-cellular target. In addition to the lantibiotics,
the microcins from Gram-negative bacteria also show interesting mechanistic
features.[205] For example, microcin B17 impairs the function of bacterial DNA
gyrase,[206] and microcin J25 is suggested to interact with the β-subunit of bacterial
RNA polymerase, thus affecting RNA synthesis.[207]
The following discussion will focus on AMPs as defined in the introduction,
and special emphasis will be given to two well-studied cases. This serves not only as
a background for comparison with our AMPMs but also to review the experimental
methodology used in the delineation of alternative mechanisms of antimicrobial
action. Despite increased effort directed towards the study of alternative mechanisms,
it is fair to mention that unambiguous examples are rare. Not surprisingly, most
studies have been directed at AMPs that show promise for future clinical applications,
such as the human AMP histatin 5.[185]
2.1.2.1 Interaction with discrete macromolecules
HISTATIN-5 Histatins are relatively small, (3-4 kDa) cationic histidine-rich
peptides, found as components of human saliva. They possess bactericidal and
fungicidal properties, although their antibacterial activities are only modest.[208, 209]
Histatins play an important role in the control of fungal infections of the oral cavity
via the innate immune system. Histatin-5, which is formed by processing of its
histatin-3 precursor, displays the most potent antifungal activity of all histatins. In
addition to their antimicrobial activity, they have been described to possess other
biological activities, such as binding to tannins, hydroxyapatite, or metal ions, and the
inhibition of cytokine induction, of certain proteases involved in periodontal disease,
or of leukotoxin activity. For more information about these activities, the reader is
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referred to a recent review by de Smet and Contreras.[44] Apart from these effects, the
direct fungicidal activity of histatin-5 in an in vitro setting has been studied
extensively, and the fungicidal mechanism of this compound has been suggested to
involve binding to a receptor on the cell surface, followed by cell cycle arrest, efflux
of ATP, inhibition of respiration, and production of reactive oxygen species (ROS).[44,
210] Due to the large body of publications directed towards it, histatin-5 serves as an
excellent case-study for the elucidation of alternative mechanisms of AMP action.
The story of histatin-5 as an AMP with an alternative mode of action began in
1998 with a report from Edgerton and co-workers, who described saturable binding of
125I-histatin 5 to C. albicans cells.[211] This binding could be competed with histatins-
3 and -4, and was not detected for spheroblasts created from the same organism, the
latter of which are also less susceptible to histatin-5. The latter result is somewhat
contradictory to the report of Driscoll et al, who described that C. albicans
spheroblasts are as susceptible to histatins as the wild type cells.[212] In addition, it
was observed that dye-release from calcein loaded C. albicans was not correlated with
microbial killing, suggesting that the loss of cell integrity is a secondary effect,
occurring after cell death, rather than the primary source of the antifungal action. Blot
overlays and chemical cross-linking experiments with 125I-histatin 5 led to the
isolation of a proteinaceous compound of around 70 kDa in the cell lysate and in
crude membrane preparations.[211] This putative receptor was later identified by
MALDI mass spectrometric analysis as either Ssa1p or Ssa2p, both heat-shock
proteins from C. albicans.[213] Ssa1p/2p are conserved members of the yeast HSP70
heat-shock protein family and are major immunogens of the fungal cell-wall in C.
albicans. Fungicidal studies with SSA1/SSA2 mutants showed a reduced activity of
histatin-5 and suggest a function of Ssa1p/Ssa2p as binding receptors for histatins that
could be involved in their translocation across the membrane.[213] Recently, this
functional role was attributed to Ssap2 alone.[214]
Fluorescently-labelled histatin-5 is taken up into the cell, as has been shown
by fluorescence microscopy, and the uptake was correlated to the metabolic state of
the cell. C. albicans cells treated with sodium azide showed diminished uptake, and
they were found to be less susceptible to histatins in a candidacidal assay. The
labelled compound co-localised with mitochondria and was proposed to dissipate the
trans-membrane potential of the mitochondrion, based on dye-efflux experiments.
Interestingly, the uptake of labelled histatin-5, as well as the killing of the fungal cells,
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is reduced under high ionic strength conditions,[215] especially under high calcium
conditions,[216] and translocation of the peptide is accompanied with influx of
propidium iodide. Both findings suggest an involvement of membrane-
permeabilisation during the uptake of histatin-5, contrary to the above mentioned dye-
leakage experiments. It has also been shown that the release of histatins can be
brought about intracellularly, i.e. by expressing histatins inside C. albicans cells.[217]
Based on these results, energized mitochondria were proposed to be the cellular target
of histatin-5, for example via perturbation of the mitochondrial membrane.[215] That
the metabolic state of C. albicans cells has an influence on the killing by histatin 5
was also reported by Gyurko et al. who found that mutants of C. albicans that are
incapable of respiration are also less susceptible to histatins than wild-type cells. The
same reduced susceptibility has been found for cells treated with the respiratory
inhibitor sodium azide or with the proton gradient uncoupler CCCP,[218, 219] and the
accumulation of the peptide in the cytosol and subsequent killing was correlated with
the inhibition of mitochondrial ATP synthesis.[218]
This notion is corroborated by the finding that S. cerevisiae, grown under
conditions at which they perform fermentation, are less susceptible towards histatin
5.[220] Koshlukova et al. reported on the loss of intracellular ATP induced by histatin-
5 via a proposed non-lytic mechanism,[219] and they suggested that extra-cellular ATP
can activate putative purinergic P2 receptors on the surface of C. albicans, that could
lead to cell death via alteration of the membrane permeability,[221] or by lysis.[222] It
has been shown that ATP efflux alone is not sufficient to cause cell death, and that the
incubation of C. albicans cells with ATP analogues increased the killing, while
removal of extra-cellular ATP decreased it.[223] Interestingly, anaerobically grown
cells were not susceptible to extra-cellularly added ATP.
Also seemingly related to this loss of intra-cellular ATP could be the
disruption of the C. albicans cell cycle by halting the cells in the G1 phase, which is
also a marker of cell apoptosis. This is thought to be caused by a decrease in cell
volume mediated by histatin-5, which causes rapid efflux of potassium and
magnesium ions leading to parallel movement of water out of the cell. It is
noteworthy that the increase of the cell size is thought to be critical for progression
through the cell cycle.[224] A recent publication from Baev et al. suggests that the
potassium transporter TRK1 is involved in the release of ATP and potassium by
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histatin-5,[225] and the uptake of propidium iodide into the cells caused by histatin-5
has also been associated with the presence of Trk1p.[77]
Helmerhorst et al. on the other hand, correlated the formation of intracellular
reactive oxygen species (ROS), by means of the oxygen radical sensitive probe
dihydroethidium, with cell death and proposed that ROS formation, resulting from an
impaired mitochondrial function, is the key event in the killing of fungal cells
mediated by histatin-5.[226] Contrary to this proposal, recent publications claim that
ROS formation is only a secondary effect of histatin-5 action. These experiments are
based on the use of a cell-permeant ROS scavenger and on the lack of certain markers
of apoptosis such as protein carbonyl formation, cytochrome c release or
chromosomal fragmentation.[227, 228]
Despite increased experimental effort, it still remains unclear by which
mechanisms a non-lytic efflux of ATP and other metabolites from the cell occurs. Of
special interest is the study by Den Hertog et al, who investigated the binding to, and
the peptide-induced leakage of trypsin from PC/PS liposomal systems, caused by
histatin-5 and two derivatives. These authors suggest that peptide translocation
occurs via peptide-phospholipid interactions and they found the translocation rate of
histatin-5 in these artificial systems was much slower than observed for C. albicans,
suggesting that other components of the fungal cell membrane might be involved in
the process.[229] The candidacidal effects of LL-37 and histatin-5 were compared, and
although effects were less pronounced for histatin-5, efflux of nucleotides such as
ATP or NAD could be observed.[230]
To conclude, the mechanism of candidacidal action of histatin-5 is still a
matter of debate. The currently proposed mechanism consists of binding to a specific
receptor, presumably Ssa1p (Hsp 70), followed by translocation into the cytoplasm
and targeting of mitochondria. Further events might comprise non-lytic release of
ATP leading to cell death via activation of purinergic receptors, or the formation of
reactive oxygen species (ROS) due to histatin-5 mediated out-of-sequence electron
transfer from a carrier in the respiratory chain to molecular oxygen, which could lead
to damage of macromolecular cell components, and ultimately to cell death.
To complicate matters, P113, a synthetic linear peptide containing a sequence
of 12 of the 24 amino acids of histatin-5, possesses good antibacterial activity against
P. aeruginosa, S. aureus, and H. influenza.[231] Of special interest are the findings that
P113D, the enantiomer of P113, is as active against C. albicans as the parent
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compound.[232] P113 has been demonstrated to be taken up into C. albicans cells and
the activity of both P113 and P113D is abolished by pre-incubation with sodium
azide, exactly as is the case for histatin-5.[233] This is an experimental result which is
difficult to bring into accordance with the proposed specific binding events proposed
for histatin-5, even if P113 is only a shortened derivative. It could nevertheless point
to the fact, that the interaction of histatin-5 with Ssa2p might either not be
stereospecific, or not primarily involved in the killing events caused by histatin-5.
Intriguingly, the undiminished activity of P113D is not mentioned in any studies on
histatin-5, and there has been no attempt to test fungicidal activity of an enantiomeric
histatin-5, although the synthesis of a linear 24-mer consisting only of standard amino
acids poses no conceptual difficulties. Indeed, all-D histatin-5 has been synthesised
and was reported to be a selective inhibitor of the pro-protein convertases furin and
PC7, but no data for the antimicrobial activity of all-D histatin-5 or histatin-5 was
given.[234]
PRO/ARG-RICH PEPTIDES The class of short Pro/Arg-rich insect AMPs
contains to-date the best characterised examples of AMPs with evidence for an
alternative mechanism of action. Strong indications thereof originated again in the
findings that the enantiomer of apidaecin proved to be practically inactive towards
several strains of E. coli.[235] This turned out to parallel the behaviour of other
proline-rich AMPs from invertebrates, namely drosocin and pyrrhocoricin, further
highlighting their close relationship and attractiveness from a mechanistic point of
view.[87, 236]
Other clues pointing to an alternative mechanism were reported, for instance
the ability of formaecin to affect only growing cells.[237] Such behaviour is often
taken as an indication that active metabolism is required for the antimicrobial action,
but on the other hand it has been argued that membrane-active peptides might need a
sufficiently high trans-membrane potential for translocation and active metabolism is
required to generate such a potential. Additionally, the action of Pro/Arg-rich
peptides is associated with being independent from lysis of the target cells. Indeed,
apidaecin Ib and drosocin have been shown to possess no ability to induce dye-
leakage from artificial liposomes containing lipid A analogues, and they have not
been found to adopt amphipathic structures.[238]
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The incorporation of radioactively labelled D- and L-apidaecin into eukaryotic
cells has been studied, and it was found that the uptake is stereospecific and energy-
driven, suggesting translocation of apidaecin through a transporter-, or permease-
mediated mechanism.[239] It has been remarked that the data could also be interpreted
in a way that both enantiomers transverse the outer membrane non-specifically, whilst
during the washing process employed in the experiment, only the L-form is
specifically retained, for example by a putative intra-cellular target. It was also
concluded, that another target might be involved in the mechanism of action of
apidaecin, based on the fact that some radioactively labelled peptides with modified
sequences which were taken up into the bacterial cell, failed to kill them.
Experiments on the incorporation of radioactively labelled biosynthetic precursors
suggested that inhibition of bacterial protein synthesis is a likely mode of action for
apidaecins.[239]
Further studies on the mechanism of action of Pro/Arg-rich AMPs were
carried out by Otvos and co-workers, mostly with pyrrhocoricin. Based on the fact
that a biotinylated pyrrhocoricin analogue only lost one order of magnitude in activity
towards E. coli D22,[236] an affinity chromatography approach employing anti-biotin
monoclonal antibodies coupled to agarose for the immobilisation of the biotinylated
probe molecule, was developed. Eluates from affinity chromatography experiments
carried out with E. coli cell lysates were subjected to SDS-PAGE analysis and led to
the discovery of two protein bands corresponding to 60 and 70 kDa respectively.[240]
A modified Western-blot protocol using biotinylated pyrrhocoricin instead of a
primary antibody, and horseradish peroxidase conjugated to streptavidin, led to strong
labelling of these bands, confirming an interaction between the labelled probe
molecule and the two proteinaceous compounds. Additionally, two low molecular
weight bands were detected, which did not respond to protein-selective staining
methods. One of these bands was found to arise from unspecific labelling when
checked with a biotinylated negatively charged control peptide. Tryptic digestion of
the two proteinaceous compounds, followed by MS/MS analysis, led to their
identification as DnaK and GroEL. Interestingly, LPS preparations from E. coli and
S. typhimurium could not be detected with this modified Western blot, and
biotinylated all-D pyrrhocoricin showed significantly lower binding to DnaK in the
Western blot assay, suggesting a correlation of antimicrobial activity and binding to
DnaK. In a further set of experiments, the authors studied the binding of fluorescently
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labelled pyrrhocoricin, as well as drosocin and apidaecin, to heat shock proteins and
LPS via fluorescence polarization assays.[240] In these experiments, the fluorescently
labelled pyrrhocoricin was found to bind to DnaK as well as to GroEL. The fact that
GroEL did not bind biotinylated pyrrhocoricin under Western blot conditions might
originate from elimination of GroEL-ligand interaction during the denaturing
conditions of the SDS page or during binding to the blotting membrane. The binding
of the biotinylated probe molecule to DnaK under these conditions was explained by
the authors as possibly originating from a mechanism that does not depend on the
native global fold of the protein, or from partial re-naturation on the blotting
membrane. Additionally, it was found that LPS bound strongly to all employed
fluorescently labelled peptides. From the fact that a negative control peptide also
bound to GroEL, it was concluded that this interaction was unspecific. Further
competition binding assays, using unlabelled pyrrhocoricin as the competitor together
with either DnaK or GroEL, were conducted. These experiments led the authors to
propose that the interaction with DnaK involves two independent fragments of DnaK,
in contrast to GroEL.
In a subsequent study by the same group, it was found that pyrrhocoricin
inhibited the ATPase activity of recombinant DnaK in contrast to all-D pyrrhocoricin
and the control peptides magainin-2 and cecropin A.[241] To study the effect of
pyrrhocoricin on the re-folding of proteins (a biological function of DnaK), the group
assayed the activity of two bacterial enzymes, namely alkaline phosphatase and β-
galactosidase in vivo, and similar results were obtained. Based on dot-blot and
fluorescence polarisation assays it was suggested that pyrrhocoricin binds in the hinge
region of DnaK, forming a multi-helical lid over the peptide binding region of DnaK.
The inhibition of ATPase activity was located in the N-terminal residues 2-10 of
pyrrhocoricin whilst the C-terminal half of the molecule was described to be involved
in its ability to translocate across cellular membranes as studied by confocal laser
microscopy using fluorescently labelled analogues.[85] It should be mentioned though,
that Chesnokova et al. reported that L-pyrrhocoricin binds to DnaK like a
conventional peptide substrate, and does not inhibit DnaK mediated ATP
hydrolysis.[242] It is also noteworthy that pyrrhocoricin showed similar effects on the
ATPase activity of a wild type as well as a lidless mutant of DnaK.
Based on these experimental data, the following model for the action of
pyrrhocoricin, apidaecin and drosocin is currently accepted as most likely: (1) The
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peptides interact unspecifically with an outer-membrane component of Gram-negative
bacteria, presumably LPS; (2) after accessing the periplasmic space they bind to a
docking molecule, for example a component of a permease-type transporter system
and are translocated into the cell; (3A) final targeting of an intracellular component,
presumably DnaK and inhibition of its ATPase and/or other functions in refolding
proteins. Alternatively (3B), the peptides might bind to macromolecular compounds
corresponding to a molecular weight of around 15 kDa or to bacterial DNA, which
were both found in the blot-overlay experiments.
2.1.2.2 Inhibition of macromolecular biosynthesis
In contrast to the reported binding to proteinaceous compounds by Pro/Arg-
and His-rich peptides, a variety of AMPs are also suggested to exert their
antimicrobial action through another type of binding to macromolecules, which might
be independent from the exact sequence of the constituent monomeric units. In these
cases, an interaction would rather be associated with recurring structural motifs, such
as the DNA double helix.
In particular, there are several AMPs for which an alternative mechanism of
action has been proposed to comprise the inhibition of the target organisms’
macromolecular biosynthetic machinery. Typically, such mechanisms are inferred
from the effects of AMPs on the patterns of incorporation of radioactively labelled
precursor molecules into the micro-organismal macromolecular fractions (c.f. Section
3.6). Additionally, these data are often correlated with studies on the membrane-
permeabilising properties of the AMPs in liposomal model systems, and with kinetic
data of their antimicrobial action.
PR-39 In 1993, Boman et al. reported on the mechanism of antibacterial
action of PR-39, a Pro-/Arg-rich antimicrobial peptide isolated from the small
intestine of the pig.[243] These authors described an 8 minute lag phase in the killing
of E. coli D21 which they attributed to a barrier in the outer membrane since, this lag
phase was absent in a strain with a defective OM barrier. Furthermore, it was
concluded from measurements of the time course of the optical density of PR-39
treated cell suspensions, that no lysis occurred during PR-39 mediated killing of E.
coli D21, because there was no apparent drop in the optical density of the bacterial
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suspension. Kinetic studies of the antibacterial action, which were carried out in
parallel, showed that after the short lag phase an immediate drop of more than three
orders of magnitude in the viable cell counts occurred, pointing to a rapid bactericidal
action of PR-39.
Experiments with radioactively labelled precursor molecules of
macromolecular biosynthesis, namely [3H]-thymidine and [3H]-leucine showed that
their incorporation ceased within three to nine minutes after addition of PR-39,
followed by degradation of cellular protein and DNA. Based on this data it was
suggested that PR-39 kills bacteria by a non-lytic mechanism which selectively arrests
DNA and protein biosynthesis, and leads to degradation of these macromolecules.
From my point of view it is important to comment on this report, because PR-
39 is cited in virtually every review article that touches on modes and mechanisms of
AMP action, and it is typically taken as a prototype for an AMP that acts by an
alternative mechanism. Judging from the experimental data given in the original
publication and outlined above, this seems rather astonishing. The observed rapid
killing, coupled with rapid cessation of incorporation of biosynthetic precursor
molecules, bears all the hallmarks of a membrane-active mode of action.
Additionally, effects on the biosynthesis of other macromolecules, especially RNA
were not studied, thus the statement that PR-39 kills bacteria through a mechanism
that stops selectively DNA and protein biosynthesis lacks any firm experimental
foundation. Furthermore, Merrifield and co-workers synthesized all-D PR-39 and
found that this compound is comparable in activity to the natural all-L form with
respect to E. coli (which was employed in the experiments described by Boman et al.)
and B. subtilis, leading them to propose that both isomers lyse the bacteria by a
mechanism other than the one proposed by Boman and colleagues.[244] Ironically, the
all-D form was reported in this study to be significantly more active towards P.
aeruginosa and S. aureus, the latter of which is 1000-fold more susceptible towards
the all-D PR-39, as judged by determination of lethal concentrations (LC).
P-DER This peptide is a synthetic hybrid of the AMPs pleurocidin and
dermaseptin and has been shown to translocate across membranous systems at sub-
MIC concentrations, without inducing concomitant dye-leakage. Based on the
incorporation of radioactively labelled precursor molecules it was suggested that this
peptide exerts a selective inhibitory effect on RNA biosynthesis around its MIC,[245]
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although this interpretation of the experimental data might seem rather bold at closer
inspection. Additionally, at concentrations above the MIC, P-Der clearly showed
behaviour in accordance with a membrane-active mechanism. Interestingly, these
findings for P-Der were interpreted by Brogden in his review article as indications
that pleurocidin and dermaseptin act by inhibiting bacterial macromolecular
biosynthesis.[47]
INDOLICIDIN This short AMP isolated from bovine neutrophils contains an
unusually high amount of tryptophan residues. The incorporation of radioactively
labelled precursors of macromolecular synthesis showed inhibition of DNA and RNA
at concentrations at which protein synthesis was not affected.[246] E. coli cells treated
with indolicidin showed filamentation, and this has been compared to the inhibition of
DNA synthesis by other antibiotics, such as nalidixic acid,[247] further supporting the
notion that inhibition of DNA synthesis might be involved in the antibacterial
mechanism of indolicidin.
CAP10A CAP10A is a synthetic indolicidin derivative, in which all
proline residues are replaced by alanines. This peptide was suggested to impair
protein, RNA, and DNA biosynthesis in S. aureus without killing the bacterial cells
when treated with twofold MIC concentrations of peptide.[248] Nevertheless,
incorporation of radio-labelled precursors for all studied classes of macromolecules
stops simultaneously, a fact that is generally assumed to be best explained by a
membrane-active mechanism.
BUFORIN-2 Buforin-2 is a condensed variant of a naturally occurring
amphibian AMP which was reported to cross membranes following a toroidal pore
model in which the pores are postulated to possess such a short lifetime that no
significant impairment of membrane functions occurs. This has been inferred from
dye-leakage experiments and the absence of lipid flip-flop, i.e. the scrambling of
phospholipids between the inner and outer layers of the plasma membrane.[249]
Buforin-II has been suggested to kill by binding to DNA and RNA, mostly based on
gel-retardation experiments.[96]
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TACHYPLESIN-I This β-hairpin AMP from the horseshoe crab has been
reported to bind to the minor groove of the DNA duplex helix, based on DNA
footprinting analysis.[250] Anti-parallel β-sheets have been identified as DNA binding
motifs,[251] and the reduction of the disulfide bonds in tachyplesin-I or their
replacement with alanines in an analogue indeed leads to a strongly reduced
interaction. Therefore, the binding to DNA has been suggested to be involved in the
antibacterial mechanism of tachyplesin-I. Interestingly, several compounds that bind
to the DNA minor groove, such as pyrrole tetramides, show potent antimicrobial
activity.[252]
2.1.2.3 Final remarks concerning alternative mechanisms
To summarise, it can be noted that although a variety of AMPs have been
suggested to act by an alternative mechanism of antimicrobial action, these claims
often do not withstand closer inspection, as has been argued for PR-39. The
experimental data does suggest interaction with nucleic acids for some AMPs but it is
questionable as to how specific these interactions might be, not least because no
reports on enantiomeric forms of these peptides (except for PR-39) are available. Not
surprisingly, the binding of buforin-II to nucleic acids is referred to as unspecific in
recent publications, the same might very well apply to indolicidin and its congener
Cap10A. Moreover, and this is an important aspect that distinguishes these
compounds from the Pro/Arg-rich peptides, all of them have been demonstrated to be
capable of interacting with, or permeabilising, membrane structures. Thus, it is
conceivable that these effects are mediated by unspecific, for example electrostatic,
interactions between the cationic AMPs and components of the biosynthetic
machinery, notably with negatively charged molecules such as ribosomes, nucleic
acids in general, or proteins which are negatively charged at physiological conditions.
Support for such a notion comes, for example, from the finding that indolicidin-
derived AMPs inhibit aminoglycoside acyltransferase and phosphotransferase,
enzymes that show stretches of high negative charge at physiological pH. A variety
of structurally different AMPs can inhibit these enzymes, indicating the lack of
specificity for this inhibition.[253] Unspecific interaction can lead to an additive or
synergistic effect caused by the impairment of several processes inside the target cell.
It is very likely that such combined effects are operative, and this is sometimes
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referred to as a multi-hit mechanism.[23] Another hypothesis in this respect is that a
given AMP might act preferentially on one or more intracellular targets, also
depending on the bacterial species and the exact nature of the AMP.[254]
It is therefore important for a mechanistic classification of AMPs to consider
whether an unspecific interaction with intracellular components represents a primary
or rather a secondary effect leading to the death of the target organism. Yet, even if
an AMP primarily kills or inhibits the growth of micro-organisms by unspecific
interaction with intracellular targets, it can do so only by translocating into the target
cell. The requirement of reaching a putative intracellular target has been commented
on before.[24] However, if the uptake depends on membrane-active properties of the
AMP, I suggest that these should be regarded as membrane-active peptides, instead of
ascribing alternative mechanisms to them. The ability to interact with and to
translocate across target membranes is the underlying mechanistic feature of such
AMPs. Without this ability, no antimicrobial activity could be observed.
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2.2 Indirect (immuno-modulatory) modes of action
The second main mode of AMP action is concerned with their immuno-
modulatory properties (c.f. Figure 2.1). The existence of such a mode of action for
certain AMPs, which is at least partially independent from the direct killing of micro-
organisms, has been suggested by experimental observations that link their in vitro
and in vivo activities. Many AMPs, especially defensins and cathelicidins are thought
not to be capable of directly killing micro-organisms either at concentrations
corresponding to their natural abundance in the host, or with respect to the
physiological conditions that they are likely to encounter at the sites of infection, i.e.
the high salt concentrations, especially of the divalent cations of magnesium and
calcium.[255] For example, LL-37 displays MIC values in the range of 1-30 g/mL
under routine assay conditions (low ionic strength), whereas in the presence of tissue
culture medium it is completely inactive against S. aureus and S. typhimurium at
concentrations up to 100 g/mL.[256] Nevertheless, there is strong evidence that
AMPs play an important role in host immunity. For instance, the expression of AMPs
in cells of the immune system is induced by inflammatory stimulants such as LPS,[257]
and in vivo studies involving transgenic or knockout animal models have shown that
defensins significantly contribute to the clearing of bacterial infections.[258-260]
Accumulating evidence points to the fact that many of these peptides might exert their
beneficial action through activation and modulation of cells of the host immune
defence. Indeed, a variety of AMPs have been demonstrated to confer beneficial
effects on the host organism other than the direct killing of invading micro-organisms.
2.2.1 Immuno-modulatory effects displayed by AMPs
The immuno-modulatory effects of AMPs can be grouped into three classes,
namely immune activation, immune suppression, and enhancement of the immune
response. Studies on the immuno-modulatory effects of AMPs have largely been
carried out with α- and β-defensins or with cathelicidins, and an overview of their
properties is given here.
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IMMUNE ACTIVATION Several AMPs have been described to be involved in the
recruitment of cells of both the innate and the adaptive immune system to areas of
infection. This attraction might take place either directly by a chemotactic activity of
these compounds, which has been demonstrated for a variety of AMPs, (Table 2.1) or
indirectly, via the induction of chemokines such as IL-8, or by stimulating the release
of other mediators of inflammation such as the degranulation of histamine from mast
cells (c.f. Table 2.2). It is noteworthy though, that no correlation between
antimicrobial activity and histamine releasing potency has been found for several
defensins.[261] Other effects of defensins involved in the inflammatory response
comprise the modulation of neutrophil activity, for example by the up-regulated
expression of adhesion molecules, the enhancement of phagocytosis,[262, 263]
modulation of the classical pathway of complement activation, [264, 265] and induction
of the production of reactive oxygen species (ROS) which might aid in the killing of
micro-organisms.[266] Interestingly, an activating function on the complement
pathway was also reported for the β-hairpin peptide tachyplesin-I.[267]
Table 2.1 Chemotactic effects on various cells of the immune system associated with AMP
action.
Cell type AMP Reference(s)
monocytes/macrophages human neutrophil peptides 1 & 2 (HNP-1/-2) [268]
human β-defensins 3 & 4 (HBD-3/-4) [269, 270]
proBac7 [271]
Bac2A [256]
LL-37 [272]
CRAMP [273]
T-lymphocytes (and subsets) human neutrophil peptides 1 & 2 (HNP-1/-2) [274, 275]
CAP37 [274]
human β-defensin 2 (HBD-2) [276]
LL-37 [272, 277]
immature DCsa human neutrophil peptide 2 (HNP-2) [275]
human β-defensin 2 (HBD2) [276]
murine β-defensins 2 & 3 (MBD-2/-3) [278]
mast cells human β-defensin 2 (HBD-2) [279]
LL37 [280]
neutrophils PR-39 [281]
LL-37 [272]
CRAMP [273]
PMLb LL-37 [277]
a DC ≡ dendritic cells; b PML ≡ polymorphonuclear leukocytes
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IMMUNE SUPPRESSION A variety of AMPs have been shown to protect
animals from the severe effects of septic shock which are associated with the killing
of Gram-negative micro-organisms and the release of LPS. Septic shock can also be
caused by the induction of high levels of pro-inflammatory cytokines such as TNF-α,
IL-1β, and IL-6. Indeed, it has been found that LL-37 inhibits macrophage
stimulation by LPS with concomitant up-regulation of several cytokines, but not the
pro-inflammatory TNF-.[282] An analogous inhibition of the release of TNF-α was
found for LL-37 in human monocytes challenged with LPS, [283] or for PR-39 in a
murine model.[284] Other AMPs have been found to neutralise the detrimental effects
of LPS in vitro as well as in various animal models, for example CAP18,[285]
indolicidin,[256] and synthetic LALF31–52.[286] Additional effects of AMPs that could
help to attenuate the negative effects accompanying inflammatory response on the
host have been found to include the enhancement of angiogenesis, an important aspect
of wound repair, by PR-39 and by LL-37.[287, 288]
Table 2.2 Differential expression and release of mediators of inflammation induced by AMPs.
Effect(s)a AMPs Reference(s)
various rabbit, guinea pig, and human
defensins
[261]
human β-defensin 2 (HBD-2) [289]
histamine release from mast cells
LL-37 [289]
induction of PGD2 human β-defensin 2 (HBD-2) [289]
induction of IL-6 human neutrophil peptides 1 – 3 (HNP-1/-2/-
3)
[290, 291]
human neutrophil peptides 1 – 3 (HNP-1/-2/-
3)
[290, 291]
LL-37 [256, 292,
293]
induction of IL-8 synthesis
indolicidin [256]
up-regulated expression of TNF-α
and IL-1β
human neutrophil peptides 1 - 2 (HNP-1/-2/-3) [294]
down-regulation of IL-10 human neutrophil peptides 1 - 2 (HNP-1/-2/-3) [294]
up-regulation of IL-8 and several
chemokine receptors
LL-37 [282]
induction of IFN-, IFN-,
IL-2, and IL-13
LALF31-52 [295]
LL-37 [296]induction of TNF-
murine β-defensin 2 (MBD-2) [297]
induction of IL-1β murine β-defensin 2 (MBD-2) [297]
a IL ≡ interleukin; PGD2 ≡ prostaglandin D2; IFN ≡ interferon; TNF ≡ tumour necrosis factor.
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Furthermore, defensins have been reported to promote proliferation of
epithelial cells and fibroblasts,[298, 299] indicating a role in wound healing.[300] Finally,
the AMP precursor proBac5 has been reported to inhibit cathepsin L, a protease that is
present in inflammatory cells and might contribute to damage of the host tissue.[271]
ENHANCEMENT OF ADAPTIVE IMMUNITY AMPs can bridge the innate and
adaptive immune systems by chemo-attracting iDC (to take up antigens) and by
influencing the differentiation of DCs. For example, LL-37 enhances the
phagocytotic properties of iDCs, which can increase the density of antigen
presentation and thus subsequently the T-cell stimulation.[296] Likewise, murine β-
defensin 2 has been found to stimulate the maturation of DCs via the Toll-like
receptor 4 (TLR4).[297] Defensins can enhance the systemic antibody response,[301, 302]
and have been shown to induce anti-tumour immunity in mice when fused to a non-
immunogenic tumour antigen.[278] Analogously, LL-37 showed adjuvant effects in a
genetically fused vaccine.[303]
2.2.2 Mechanisms of immuno-modulatory effects in vivo
Inasmuch as it is of interest to understand how the direct antimicrobial action
of AMPs is mediated on the molecular level, it is also of interest to elucidate how
AMPs exert their immuno-modulatory functions. Generally, the interaction of AMPs
with immune cells has been related to the involvement of specific receptors. For
example, human β-defensins have been proposed to interact with CC chemokine
receptors, based on the fact that HEK293 cell lines transfected to express this receptor
were chemo-attracted by HDB-2.[276] Additionally, chemotactic effects of HDB-2
could be inhibited by pertussis toxin, which is generally regarded as indicating the
involvement of a receptor coupled to Gi protein.[276] Other receptors that have been
suggested to be involved in the action of AMPs include formyl peptide receptor-like 1
(FPRL1),[272, 273] epidermal growth-factor receptor (EGFR),[304] or the P2X(7)
receptor.[305] Further, -defensins have been reported to bind to fibronectin, thus
affecting endothelial cell adhesion and angiogenesis,[300] and LL-37 has been
documented to induce phosphorylation and activation of extracellular kinases such as
p38 and the mitogen activated protein kinase (MAPK).[306]
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The effect of AMPs on modulating the immune response towards LPS is
thought to be mediated by binding of the AMP to the LPS, which in turn could abolish
the binding of LPS to LPS binding protein (LBP).[307] Strong evidence for such a
mechanism comes from the fact that certain AMPs such as HNP-1 and HBD-2/-3
show an additive behaviour with indolicidin or LL-37 with respect to the anti-
endotoxin properties.[256] On the other hand, the combination of LL-37 and
indolicidin displays a synergistic effect in anti-endotoxin activity,[256] and the AMP
Bac2a is less effective at inhibiting LPS mediated release of TNF- than indolicidin,
despite its stronger binding to LPS,[307] thus suggesting the involvement of other
mechanisms in these activities.
It is interesting to note in this context that the diverse effects elicited by -
defensins have been classified into two groups according to the required dose of the
AMP. Disruption or permeabilisation of cell membranes (vide supra), inhibition of
NADPH activation,[308] and modulation of the complement system all require higher
concentrations of -defensins (in the micromolar range), [264, 265] whereas chemotactic
activities of these peptides are detectable at nanomolar concentrations.[275] Thus, it
might seem tempting to associate a membrane-active mechanism with the interactions
depending on a high peptide concentration, especially if one considers that the
membrane-activity of defensins in this concentration range has been well documented.
Along these lines, it has been found that the classical pathway of complement
activation was induced by -defensins in their native state, as well as when their
disulfide bonds were reduced, and even when the corresponding cysteine residues
were acetylated. In contrast, activities at low nanomolar concentrations are often
associated with receptors, especially with G-protein coupled receptors.
However, of particular importance in this respect is a report by Braff et al, in
which immuno-modulatory effects of LL-37 and its enantiomer D-LL-37 were
studied.[293] The authors found that the stimulating effect of D-LL-37 on the induction
of IL-8 in keratinocytes was even greater than for naturally occurring LL-37, and this
was attributed to increased proteolytic stability of D-LL-37. The induction of IL-8 by
both antipodes could be inhibited by pertussis toxin, indeed suggesting an
involvement of G-protein coupled receptors in the process, but it has to be concluded
that these receptors are not (stereo)specifically inhibited by LL-37. It has been
speculated that LL-37 might activate membrane-receptors by inducing conformational
2.2 Indirect (immuno-modulatory) modes of action 51
changes associated with its interaction with the plasma-membrane. The example of
LL-37 serves as a vivid illustration of the problems in assigning receptors to the
immuno-modulatory function of AMPs. In fact, many of these effects could be
mediated by the underlying membrane-activity of AMPs. It would therefore be of
great interest to examine the immuno-modulatory effects of other enantiomeric pairs
of AMPs, or of chemokines in general.
Finally, arguments brought forward in favour of a membrane-active direct
mode of action, like the tolerance to large variations in sequences and structures of
AMPs of diverse origins, increasingly apply to immuno-modulatory functions as well
(inasmuch as more different AMPs are studied). The fact that all of these substances
have been shown to be capable of displaying membrane-active properties has been
mentioned already. Interestingly, there are several reports on the antibacterial activity
of several chemokines, and these activities are in the same concentration range as
found for defensins.[309] These findings could lead to the notion of a possibly similar
underlying mechanism for both the immuno-modulatory and the antimicrobial actions
of these compounds, and a membrane-active mechanism poses the no conceptual
difficulties to accommodate both functions. A mechanism of bacterial killing
displayed by the chemokines, apart from a membrane-active mechanism is only
difficult to imagine, especially at the observed concentration regime.
2.3 Final remarks on modes and mechanisms of AMP action
As has been elaborated, mechanistic aspects of a variety of AMPs have been
studied, and they are usually distinguished in the literature as following either a
membrane-active or alternative mechanism, in a sense that these are mutually
exclusive. Arguments have been presented in this section that this distinction is (a)
often not unambiguous and that (b) the membrane-active principle of AMPs can serve
as a unifying theme for almost all AMPs described to date.
More precisely, the described activities of various peptides are likely to be
ultimately dependent on membrane-interactions of these compounds, and it is also
likely that many of the immuno-modulatory effects described for AMPs are no
exception. The possibility that compounds impair the function of membrane-
receptors mechanosensitively, i.e. by disturbing their function via alteration of
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membrane properties of the embedding membrane, has been mentioned (vide supra,
c.f. also Section 3.4).
To conclude, it has been pointed out that the permeabilising activity of AMPs
might be overestimated due to the facts that (a) studies on model membranes cannot
lead to the detection of alternative mechanisms, (b) these studies are often carried out
under conditions that are not physiologically relevant, and (c) amphipathic peptides
will disturb any membranous system, if their concentration is high enough (i.e. not
necessarily reflecting the MIC).[23] On the other hand, it could also be remarked that
reports on the action of AMPs by an alternative mechanism are overemphasised
because of the attractiveness of discovering unusual mechanisms, and because the
term alternative mode of action is often (mis-)interpreted in a sense that equates
membrane-activity with a detergent-like action.
3 Mechanistic studies on AMPMs
3.1 Synthesis of AMP(M)s
All antimicrobial peptide mimetics (AMPMs) used in this work were
synthesised according to a mixed solid-phase solution-phase strategy developed in our
group (Scheme 1).[124] Briefly, the first amino acid was coupled to freshly activated,
acid-labile 2-chlorotrityl chloride resin (20) with 4 equivalents DIEA in DCM.
Generally, Fmoc-L-Pro-OH was chosen as the first amino acid to be attached to the
resin, since this allowed for the synthesis of larger batches of preloaded resin (21) that
could be used for the synthesis of all AMPM(s). The linear, fully side-chain protected
precursors (22) were synthesised employing standard SPPS Fmoc-chemistry on an
Applied Biosystems model 433A peptide synthesizer on a 0.25 mmol scale.[310]
Generally, 4 equivalents of the appropriately side-chain protected N-Fmoc amino
acids are activated with HBTU, HOBt and DIEA in DMF. Fmoc-deprotection was
achieved with 20% piperidine in NMP.
Linear, fully side-chain protected precursors (22) were cleaved from the resin
with 0.6 to 0.8% TFA in DCM and the excess of acid was neutralized with an
appropriate amount of 10% pyridine in MeOH. Linear peptide solutions were
concentrated to 5% of the original volume under vacuum, and precipitated with water,
followed by washing with NaHCO3 and NaHSO4 solutions. Crude 22 was dried
overnight in a vacuum desiccator over KOH. Cyclisation reactions were carried out
in freshly distilled DMF at room temperature at peptide concentrations ranging from 1
to 2.5 mg/mL of crude 22.
The C-termini of the linear peptides was activated with 1.25 equivalents of
both HATU and HOAt and with 2.5 equivalents of DIEA based on the crude yield of
22, and the progress of the cyclisation reactions was monitored by LC/MS via the
disappearance of the peak corresponding to the starting material, and was typically
completed after 30 minutes. Deprotection reactions were run until LC/MS analysis
showed the absence of any by-products containing residual protecting groups.
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3.1 Synthesis of AMP(M)s 55
The crude, cyclic and fully side-chain protected peptides (23) were evaporated
to dryness followed by deprotection with TFA/H2O/TIS (95:2.5:25 v/v/v) as an
odourless deprotection cocktail. Typically, all deprotection reactions were finished
after 2 to 3 hours. The crude cyclic peptides (24) were precipitated with ice-cold
diethyl ether, centrifuged and washed three times with ether. After air-drying, the
crude peptide products were purified by preparative reversed phase HPLC using
H2O/aetonitrile with added 0.1% of TFA as solvent system. The purified AMPMs
were characterised by LC/MS, MS, analytical HPLC and 1H NMR (c.f. Appendix 2).
3.3.1 Chromatographic behaviour and purification of mimetic 17
Mimetic 17 displays an unusual, characteristic two-peak pattern when
analysed by HPLC chromatography; a representative chromatogram illustrating this
pattern is shown in Figure 3.1. Identical patterns were also obtained for other
AMPMs developed in our group, most notably, when position-12 of the amino acid
sequence (N-terminal to the D-Pro-L-Pro template) is occupied by an arginine residue.
Direct evidence for the influence of this position on the chromatographic pattern of
the AMPMs is given by the fact that replacement of Arg-12 by Val-12 in an otherwise
unchanged sequence leads to the recurrence of a normal single peak pattern.[139]
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Figure 3.1 Characteristic two-peak pattern of purified mimetic-17. Conditions: Vydac218TP54
C18 analytical column; 5 to 100% acetonitrile in water (+0.1% TFA) in 7 column volumes; flow 1
ml/min; blue trace=226 nm; red trace=278nm.
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Due to this peak pattern, a two-step purification protocol was needed to obtain
pure 17. Typically, three fractions (F1 to F3) as depicted in Figure 3.2 were collected
and re-subjected to a second round of purification. Pure 17 was obtained by
collecting fraction F1(2nd purification) of re-injected fraction F3 and vice versa.
Fortunately, both AMPMs 18 and 19 showed normal single peak patterns, greatly
simplifying their purification protocols.
F1 F3F2A C
B D
Figure 3.2 HPLC patterns in the two-step purification of mimetic 17. (A) crude 17, fractions F1
to F3 were collected as indicated; (B) re-purification of fraction F1; (C) re-purification of fraction F2;
(D) re-purification of fraction F3. Pure 17 was obtained by collecting fractions F1(2nd) and F3(2nd).
Purification conditions: Vydac218TP1022 C18 preparative column; 10 to 50% acetonitrile in water
(+0.1% TFA) in 30 minutes; 15 ml/min; blue trace=226 nm; red trace=278nm.
3.3.2 Synthesis of protegrin-1
As a control AMP possessing a well-studied mechanism of action, protegrin-1
(11) has been synthesised, using standard Fmoc-SPPS methodology. Briefly, crude,
linear protegrin-1 was assembled on a rink amide MBHA resin, which allows for the
routine synthesis of C-terminal amides. The automated peptide synthesis was carried
out analogously to the protocol described for the AMPMs, followed by simultaneous
F1 (2nd)
F3 (2nd)
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cleavage from the resin and deprotection of the side-chain protecting groups with
TFA/phenol/thioanisole/ethanedithiol 82.5:5:5:2.5 (v/v/v/v), to yield a fully
deprotected linear precursor.
The oxidation of the linear precursor was carried out as air oxidation in 0.1M
NH4/HCO3 solution at a crude peptide concentration of 0.1 mg/mL until LC/MS
analysis showed complete consumption of the linear precursor. The absence of free
thiols was checked by an Ellman test, and crude 11 was purified by preparative
HPLC. The identity of the final product could be confirmed by comparison of the 1H
NMR spectrum with a published literature example,[311] and additionally, the
antimicrobial activity of pure 11 was in excellent agreement with reported values.[312]
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3.2 NMR experiments
NMR studies with mimetic 16 in aqueous solution and bound to perdeuterated
dodecylphosphocholine (DPC-d38) micelles have been described previously.[137] It
was found that this compound was largely unstructured in aqueous solution, as
indicated by 3JHN scalar coupling constants around 7 Hz and the absence of a
significant number of cross-strand NOEs in NOESY spectra (Figure 3.3A). In the
presence of DPC-d38 micelles, however, 16 adopted a regular hairpin structure;
containing a type-II’ -turn at the tip of the hairpin (Figure 3.3B). Such behaviour,
namely the induction of secondary structure upon transition from an aqueous to a
more apolar environment, is frequently encountered with many amphipathic AMPs,
especially those belonging to the -helical subclass.[155] Additionally, solvent
mixtures such TFE/water or HFIP/water are often used as membrane mimicking
environments as an alternative to micellar systems.[313]
Figure 3.3 (A) Superimposition of 13 low energy average solution structures over the backbone
heavy atoms of the D-Pro-L-Pro template (calculated for mimetic 16 in water at pH 2.3). (B)
Superimposition of 18 low energy average solution structures over the backbone heavy atoms
(calculated for 16 in the presence of DPC-d38 micelles). Taken from ref [137].
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3.2.1 NMR structures of 17 and 18 bound to DPC-d38 micelles
1D 1H-NMR spectra of 17 as well as 1D and 2D 1H-NMR spectra of 18 were
recorded at 600 MHz in aqueous solution (H2O/D2O 9:1, pH 5, 300K) at a typical
peptide concentration of approximately 10 mg/mL. The narrow range of the chemical
shifts of the amide proton resonances of these compounds, suggested that neither
mimetic 17 nor mimetic 18 adopted any preferred conformations in aqueous solution
(Figure 3.4).
Figure 3.4 Expansions of the amide proton regions of the 600 MHz 1H-NMR spectra of mimetic
17 (top) and mimetic 18 (bottom); recorded at peptide concentrations of 10 mg/mL in H2O/D2O (9:1) at
pH 5 and 300K.
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In addition, the number of observed amide proton resonances suggests that
both mimetics contain at least two molecular species, at ratios of approximately 3:1,
which interconvert slowly on the NMR timescale. This parallels the situation found
for mimetic 16, where NMR analysis also showed the presence of different molecular
species in aqueous solution. Although signal overlap in the NMR spectra of mimetic
16 in aqueous solution precluded the assignment of two of the minor conformational
isomers, it was suggested that at least one of these isomers arose through cis-trans
isomerism of the peptide bond between Val-12 and D-Pro-13.[137] In contrast to all
other naturally occurring amino acids, only proline has a significant propensity to
form Xaa-Pro (Xaa = arbitrary amino acid) cis peptide bonds, and these bonds are
often found in turn regions of water-soluble proteins.[314]
It is of interest to note, in this respect, that a derivative of mimetic 16 into
which the additional constraint of a disulfide bridge had been introduced, formed an
unusual loop structure containing a cis amide bond N-terminal to the D-Pro-L-Pro
template, as well as a short 310-helical stretch.[137] Furthermore, the presence of an
Xaa-D-Pro bond in other -hairpin mimetics based on the D-Pro-L-Pro template, such
as a Fc-binding peptide mimetic, has been reported.[127] It is also of interest to recall
the peculiar HPLC profile observed for mimetic 17 (c.f. Section 3.1); a plausible
explanation of such a profile is offered by the presence of cis-trans peptide bond
isomers of this compound.
To study the AMPMs in a membrane mimetic environment, spectra were
recorded in 300 mM DPC-d38 in H2O/D2O 9:1 at pH 5 and 300K, and at a peptide
concentration of 2 mM (approximately 4 mg/mL). From the 1D 1H-NMR spectra
(Figure 3.5, Appendix 4) it could be seen that the amide proton resonances
corresponding to both 17 and 18 covered a wider range of chemical shift values than
in the spectra measured in aqueous solution. This finding was indicative of the
adoption of preferred conformations upon interaction with the perdeuterated micellar
system.
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Figure 3.5 Expansions of the amide proton regions of the 600 MHz 1H-NMR spectra of 17 (top)
and 18 (bottom); recorded at peptide concentrations of 4 mg/mL in 300 mM solutions of DPC-d38 in
H2O/D2O (9:1) at pH 5 and 300K. The amide resonances, as determined from 2D TOCSY
experiments, are indicated (c.f. Appendix 4). For mimetic 18, the resonances corresponding to the cis-
or the trans-isomer are depicted in black and red, respectively. The numbering for the cis-isomer is
derived from the normal numbering system by the addition of the value 20. * denote artefacts from the
DPC-d38 preparation (c.f. reference [315]).
62 Chapter 3
The spectral assignment of DQF-COSY and TOCSY spectra of 17 and 18
bound to DPC-d38 micelles was performed according to standard methods.[316]
Distance restraints were obtained from NOESY spectra with a mixing time of 120 ms,
and the large number of observed NOEs made structure calculations possible (c.f.
Appendix 4), by applying a simulated annealing (SA) protocol implemented in the
DYANA software package.[317] These calculations were carried out by Dr. K. Möhle.
MIMETIC-17 In addition to the network of sequential NOE connectivities, a
variety of medium- and long-range NOEs were observed, indicating a defined
structure of 17 in the presence of DPC-d38 micelles; these connectivities are depicted
in Figure 3.6. In particular, many side-chain to side-chain and backbone to side-
chain contacts were found between Leu-3/Trp-8, Leu-3/Tyr-11, and Trp-8/Tyr-11,
illustrating that 17 is furnished with a hydrophobic core.
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Figure 3.6 Medium- and long-range NOE connectivities observed for mimetic 17 bound to
DPC-d38 micelles. The sequential NOE indicating the presence of a cis-amide bond is included and
highlighted in red.
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An interesting structural feature of mimetic 17, which is indicated by the dN(i,
i+2) NOE connectivity between Gln-6/Trp-8, as well as by the dN(i, i+3) NOE
connectivity between Lys-9/Trp-12, is the formation of a 310-helical stretch N-
terminal to the template. Moreover, the presence of a cis-amide bond N-terminal to
the D-Pro-L-Pro template was deduced from a strong NOE between the H protons of
Arg-12 and D-Pro-13 (c.f. also Figure 3.6A), confirming again the involvement of
cis/trans isomerism. It should, however, be noted that in the case of 17, the cis-
isomer is the only molecular species found to be present in DPC-d38 micellar solution.
The ensemble of structures calculated by the SA protocol converged to a well-
defined amphipathic structure with a pairwise rmsd of 1.03 Å for all backbone atoms
(Table 3.1). A superimposition of the 20 calculated structures of mimetic 17 with the
lowest target energy function, emphasising the amphipathic nature of these molecules
in the presence of micelles, is given in Figure 3.7.
Table 3.1 Input of conformational constraints and statistics of the structure calculation for
mimetics 17 and 18 with the Program DYANA
Mimetic 17 18
NOE upper-distance limits Total 153 155
Intra-residue 63 65
Sequential 54 46
Medium- and long-range 36 44
Residual target function value [Å2] 0.62 ± 0.08 0.97 ± 0.08
Mean rmsd values [Å] All backbone atoms 1.03 ± 0.37 0.81 ± 0.22
All heavy atoms 2.47 ± 0.65 2.10 ± 0.56
Residual NOE violation Number > 0.2 Å 21 23
Maximum (Å) 0.34 0.30
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Figure 3.7 Comparison of the average solution NMR structures of the major (or exclusive)
conformational isomers of mimetics 17 (A), 18 (B), and 19 (C) bound to DPC-d38 micelles. On the
left, superimpositions of the 20 average solution structures with the lowest energy target functions over
the backbone heavy atoms are shown (18 for mimetic 17). Polar residues, apolar residues and the D-
Pro-L-Pro template are depicted in orange, blue, and green respectively. On the right, ribbon
representations of the corresponding average solution structures with the lowest energy target function
are given, shown with the amino acid side-chains.
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MIMETIC 18 In contrast to 17, two conformational isomers were observed
for 18 in micellar solution, at a ratio of approximately 5:3. The spectral assignment
made it possible to identify the major and the minor isomer as containing a Lys-
12/pro-13 cis- or trans-amide bond, respectively. Since the minor trans-isomer was
characterised by the absence of medium- and long range NOE contacts, it was not
surprising that the resulting low-energy structures showed little convergence to a
defined three-dimensional conformation (Figure 3.8, c.f. also the narrow range of
amide resonances in Figure 3.5).
Figure 3.8 (A) Superimposition of 20 average solution structures with the lowest energy target
function over the backbone atoms of the D-Pro-L-Pro template (calculated for mimetic 18 in 300 mM
solution of DPC-d38 at pH 5).
For the major isomer, however, the presence of a network of sequential NOE
connectivities, as well as a variety of observed medium- and long-range NOEs (c.f.
Appendix 4) pointed to the adoption of a preferred three-dimensional structure in the
presence of DPC-d38 micelles. The obtained medium- and long-range NOEs are
depicted in Figure 3.9. In particular, a variety of side-chain to side-chain contacts
were found between Leu-3/Trp-8, and Trp-8/Val-11, indicating a hydrophobic core
for 18, comparable to that of mimetic 17. Another similarity to 17 is the presence of a
310 helical stretch N-terminal to the D-Pro-L-Pro template, as deduced from the
presence of dN(i, i+2) NOE connectivities between Trp-8/Lys-10, Lys-9/Val-11, and
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Lys-10/Lys-12. The cis-configuration of the Lys-12/pro-13 amide bond was deduced
from a strong NOE between their H protons (c.f. also Figure 3.11).
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The ensemble of structures calculated by the SA protocol converged to a well-
defined amphipathic structure with a pairwise rmsd of 0.81 Å for all backbone atoms
(Table 3.1). A superimposition of the 20 calculated structures of mimetic 18 with the
lowest target energy function, emphasising the amphipathic nature of these molecules
in the presence of micelles, is given in Figure 3.7.
COMPARISON OF 16, 17 AND 18 An amphipathic distribution of the amino
acid side-chains is found for all three compounds, but it can be seen from Figure 3.7
that the structures employed to accommodate this distribution differ fundamentally
between 16 on the one hand, and 17 and 18 on the other. Whereas in mimetic 16 a
regular -hairpin fold is able to spatially separate residues of different polarity,
despite the introduction of a charged residue on the apolar face of the idealised hairpin
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structure, both 17 and 18 are characterised by the formation of 310-helical stretches
and the presence of a cis-amide bond N-terminal to the D-Pro-L-Pro template.
The formation of these unusual structural elements might be necessary in order
to accommodate hydrophobic interactions between Leu-3, Trp-8, and Tyr-11 in 17, or
between Leu-3, Trp-8, and Val-11 in 18, thus generating the hydrophobic cores of
these molecules. The calculated average solution structures of 17 and 18 with the
lowest energy target functions are superimposed in Figure 3.10 so as to emphasise
their close structural relationship.
Figure 3.10 (A) Superimposition of the 20 average solution structures with the lowest energy
target function of mimetic 18 over the backbone heavy atoms of the D-Pro-L-Pro template (calculated
in the presence of DPC-d38 micelles). (B) Superimposition of the two calculated structures with the
lowest energy target function of 17 (green) and 18 (red), calculated in the presence of DPC-d38
micelles.
As can be seen from the bundle of 20 superimposed average solution
structures with the lowest energy target function (Figure 3.10), as well as from the
network of medium- and long-range NOE connectivities (c.f. Figure 3.6 and Figure
3.9), the structure of 18 is more ambiguous in the polar region of the molecule,
opposite to the D-Pro-L-Pro template comprising residues Lys-4 to Arg-7, when
compared to 17. In particular, several long-range NOEs observed in this region for 17
(Leu-3H/Lys-5NH, Glu-6H/Trp-8NH, and Lys-5NH/Trp-8NH) had no counterparts in the
spectra of mimetic 18.
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With respect to the cis/trans isomerism, it is noteworthy that, starting from a
cis/trans ratio of approximately 1:3 in aqueous solution for both 17 and 18, the
introduction of micelles leads to an exclusive population of the cis-isomer in the case
of 17, whereas for mimetic 18 the ratio is only shifted to approximately 5:3 in favour
of the cis-isomer (Figure 3.11).
Figure 3.11 Sections of NOESY spectra of mimetic 17 (left) and mimetic 18 (right) in the
presence of DPC-d38 micelles. Cross peaks indicating the presence of a Xaa-D-Pro cis peptide bond
(red), or a Xaa-D-Pro trans-peptide bond (blue) are highlighted.
3.2.3 Conclusions
It was found that 16, 17 and 18 adopt amphipathic structures in the presence of
DPC-d38 micelles, albeit with different secondary structures. The formation of
secondary structure upon interaction with membranous systems is often regarded as a
general property of many AMPs, and most notably, the commonly employed
classification scheme of AMPs is built upon such secondary structural features. It
should be borne in mind, however, that such behaviour does not necessarily imply
bacterial killing via a membrane-active mechanism. Nevertheless, it has to be
concluded from the NMR experiments that 16, 17 and 18 show the ability to form
amphipathic structures upon interaction with a model membrane system, and thus
these AMPMs become at least potentially membrane-active. It is further noted that
the formation of amphipathic structures in a micellar environment does not implicitly
indicate an involvement in the binding of the AMPM to a putative receptor, or that the
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AMP is able to (efficiently) permeabilise membrane systems. Last but not least, it
should be remembered that the use of micellar systems in the NMR experiments will
possibly select for the formation of amphipathic structures.
Recently, proline residues have received attention as molecular switches. For
instance, cis/trans isomerism of a Xaa-Pro bond has been reported to be responsible
for opening and closing a neurotransmitter-gated ion-channel,[318] or to be involved in
the regulation of lysine methylation in histone H3.[319] Interestingly, the antimicrobial
activity of a histone H1 fragment was also described as being dependent on the
configuration of the Xaa-Pro bond(s).[320]
It is, therefore, also conceivable that two different conformational isomers of
an AMPM might be involved in its antimicrobial mechanism(s). For example, one
conformer could permit membrane interaction (e.g. to translocate across the
membrane) whereas a different conformer could be involved in the interaction with
other (specific) targets (e.g. DNA, c.f. -hairpins as DNA minor groove binding
motifs). Along these lines, indolicidin has recently been proposed to exert its
antimicrobial action via a combination of different conformations that are formed
when the peptide is bound either to membranes, or to DNA.[321]
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3.3 Biological Activities and Selectivities
As mentioned in Section 1.5, the evaluation of the biological activities of
AMPMs derived from protegrin-1 (11) pointed towards the involvement of alternative
mechanisms of antibacterial action for several members of this class of mimetics. A
variety of bacteriological experiments have been carried out on the AMP(M)s that
have been synthesised in this work (11; mimetics 16 to 19;) in order to (a) verify the
notion of alternative antibacterial action and (b) gain further insights into the basis of
the putative alternative mode of action. Therefore, in the following discussion of the
experiments, special emphasis will be given to those aspects that can aid in the
inference of mechanistic features, as well as to the comparison of the results obtained
with the behaviour of AMPs described the literature.
3.3.1 Minimal inhibitory concentrations and haemolytic activities
The primary criterion for the evaluation of the AMPMs is their activity against
micro-organisms. Several methods exist for the quantification of this activity in vitro,
which is generally referred to as susceptibility testing. Such tests are routinely
performed on isolated micro-organisms, in order to predict the in vivo success of
antibiotic chemotherapy, and three different approaches are commonly used. In
broth- or agar dilution methods, serial dilutions of the test compounds are prepared in
the corresponding medium and inoculated with a defined quantity of test
organisms.[322] The amount of test compound that inhibits bacterial growth after a
defined incubation period, typically taken to be between 16 and 20 hours, is defined
as the minimal inhibitory concentration (MIC). The MIC is used as a direct measure
of the in vitro susceptibility of the test organism towards the test compound. The
second most commonly used method is the so-called disc diffusion test (Kirby-Bauer
disc diffusion), in which filter discs impregnated with test compounds are placed on
agar plates which have been inoculated to give confluent growth of the test organism,
and the size of the zone of growth inhibition after overnight incubation is used as a
measure for the bacterial susceptibility.[323] Finally, the E-test is a diffusion method
based on a pre-formed gradient of the antibacterial agent on a plastic strip; the MIC
value is obtained from the intersection of the growth inhibition zone with the gradient
strip.[324]
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Routine testing of the antibacterial activity of the AMPMs, via determination
of their MIC values, was implemented as a broth micro-dilution method in 96 well-
plates, according to published guidelines. Since it has been shown that the MIC
values obtained for cationic AMPs can depend drastically on adsorption effects, the
protocol of Steinberg et al. was adapted, in which bovine serum albumin (BSA) is
added at a final concentration of 0.01% in order to counteract these effects.[312]
Briefly, two-fold serial concentrations of the AMPM were prepared in Mueller-Hinton
(MH) broth and inoculated with a final concentration of approximately 5×105
CFU/mL of the appropriate test organism. The MIC values were recorded as those
dilutions of test compound that completely inhibited bacterial growth after an
incubation period of 20 hours, as judged by visual inspection.
A second important criterion for the AMPMs, with respect to their potential
usefulness as therapeutic agents, consists of their haemolytic activity, i.e. their ability
to lyse red blood cells. Such activity is often used as an indicator for the toxicity of
AMPs towards (mammalian) host cells, and a low extent of haemolysis is naturally a
pre-requisite for any systemic applications. The haemolytic activity of our AMPMs
was determined by their ability to lyse human red blood cells (hRBC), typically at a
peptide concentration of 100 g/mL. The results of these experiments are expressed
as % haemolysis relative to 0.1% Triton-X 100™, which is taken as reference
corresponding to complete lysis of the blood cells. Table 3.2 summarises the MIC
values obtained for a panel of five test organisms, as well as the haemolytic activities
of the AMPMs that have been synthesised in this work for studying their modes and
mechanisms of action. For comparison, protegrin-1 (11), the prototypal AMP of our
AMPMs, polymyxin B (1, c.f. Figure 1.1), a structurally related bactericidal agent,
and tobramycin (25, c.f. Figure 3.31) an aminoglycoside displaying good activity
against Pseudomonas spp. are also included.
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Table 3.2 MIC values and haemolytic activity of AMPMs (16-19) and control antimicrobial
agents (1, 11, 25).
IDa MICb [g/mL] % Hc
E. coli
ATCC 25922
P. aeruginosa
ATCC 27853
P. aeruginosa
PAO1
S. aureus
ATCC 25923
S. aureus
ATCC 29213
hRBCd
16 4 2 2 16 16 1
17 16 0.25 1 16 > 64 0
18 32 0.03 0.03 4 > 64 0
19 64 0.008 0.015 > 64 > 64 0
1 < 0.06 < 0.06 0.125 4 32 4.4
11 0.25 0.5 0.5 0.25 1 37
25 1 0.5 0.5 0.06 0.125 n.d.e
a substance identifier; b minimal inhibitory concentration; c % haemolysis at a peptide concentration of
100 g/mL; d human red blood cells; e not determined.
3.3.2 Selectivity and activity spectra of AMPMs
An interesting trend that can be extracted from Table 3.2 is the increased
selectivity of the later generations of AMPMs, most notably of mimetic 19, towards
the two strains of Pseudomonas aeruginosa. The selective growth inhibition of this
Gram-negative, opportunistic pathogen by 19 is highlighted in Table 3.3, and is to be
contrasted with the absence of comparable selectivity for 16, a member of the first
generation of AMPMs, and for protegrin-1 (11), one of the -hairpin AMPs from
which these mimetics were ultimately derived.
The absence of selectivity, i.e. a broad-spectrum of antimicrobial action is
generally regarded as one of the hallmarks of AMPs. The lack of selectivity
encountered in most AMPs is readily explicable in mechanistic terms, on the basis of
a membrane-active mode of action. It is evident that AMPs which follow a
membrane-active mechanism also depend on characteristic features of membranes to
display any kind of selectivity. Variations in membrane composition, for instance, are
intimately related to the selectivity of AMPs towards bacterial membranes (c.f.
Section 1.4.2). Although it has been shown that variations in the membrane
composition can also provide at least a rudimentary explanation of the selectivity of
some AMPs towards different bacteria,[150] the reported selectivities are orders of
magnitude less pronounced than observed for mimetic 19.
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Table 3.3 Selectivity of antimicrobial peptides towards P. aeruginosa strains PAO1 and ATCC
27853. The selectivity is expressed as the ratio of the corresponding MIC values taken from Table 2.5
Substance Selectivity Ratios
E. coli ATCC 25922 vs. S. aureusa vs.
P. aeruginosa
ATCC 27853
P. aeruginosa
PAO1
P. aeruginosa
ATCC 27853
P. aeruginosa
PAO1
16 2 2 4 4
17 64 16 128 32
18 1100 1100 2100 > 2100
19 4300 8000 > 4300 > 8000
11 0.5 0.5 1.5 1.5
a values averaged for strains ATCC 25923 and ATCC 29213.
In addition to the remarkable degree of selectivity demonstrated by mimetic 19
(three to four orders of magnitude higher activity towards P. aeruginosa as compared
to both E. coli and S. aureus), further aspects suggest that the selectivity of our AMPs
may have a more fundamental origin than mere discrimination between different
bacterial membranes. To begin with, it is especially instructive to consider the pair of
Gram-negative test organisms, which show a comparable composition of
phospholipids in their plasma membranes.[325] Moreover, protegrin-1 (11),[312] as well
as other β-hairpin AMPs, such as polyphemusin-1 (13),[326] tachyplesins,[327] RTD-
1,[327] or a cyclic 18 residue peptide mimetic of the β-hairpin region of HNP-2[135], all
display broad-spectrum activity against E. coli, P. aeruginosa, and S. aureus, despite
several structural differences between them. Both findings suggest that the change in
selectivity from 16 to 17, and the later generation mimetics 18 and 19, is caused by
something more than a subtle alteration of structural parameters such as
hydrophobicity, amphipathicity, and charge. It is noteworthy in this respect, that the
estimated positive charge of the AMPMs at physiological pH remains constant for
mimetics 16, 18, and 19 and is even reduced from +7 to +6 for mimetic-17.
A comparable high selectivity towards certain bacterial species has been found
for leucocin A, a type IIa bacteriocin produced by lactic acid bacteria, which has been
shown to depend on a stereo-specific interaction for its antibacterial activity (c.f.
Section 3.4).[328] The involvement of a stereospecific receptor has been proposed to
account for the potency, as well as for the narrow activity spectrum of this compound.
Accordingly, large differences in the activity spectra of other type IIa bacteriocins
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have been described, despite their high sequence homology and have been attributed
to differences in their modes of action.[329, 330]
It is important to note that the increase in selectivity for mimetics 17-19
derives both from an improvement in the activity towards P. aeruginosa and from a
loss of activity against other bacterial species. This loss of activity could originate
from an associated loss of a membrane-active mechanism pathway, which could
operate for the complete panel of test organisms. The improvement in activity
towards P. aeruginosa in this scheme would then be mediated by (specific) interaction
with a target absent from both E. coli and S. aureus.
Finally, it should be emphasised that although the AMPMs lose their broad-
spectrum of activity, this does not diminish their potential as therapeutically useful
antibacterial agents. Foremost, mimetic-19 possesses a very potent activity against P.
aeruginosa, which is both an important opportunistic pathogen of humans and a plant
pathogen. As a nosocomial pathogen, it causes infections of the urinary tract and the
respiratory system as well as bacteraemia and a variety of systemic infections,
especially in immuno-compromised patients such as burns victims. Additionally, P.
aeruginosa plays an important role as a pathogen in cystic fibrosis patients. To
further capitalise on this selectivity, the MIC values of 16, 18, and 19 for a variety of
species belonging to the genus Pseudomonas, as well as against Burkholderia
cepacia, a related Gram-negative bacterium, were determined; the results are shown
in Table 3.4. It can be seen from this table that all tested mimetics, as well as
protegrin-1 (11), displayed satisfactory activity against most tested species, except P.
chlororaphis and B. cepacia. The latter finding is not surprising, since this species is
notorious for its resistance towards antibacterial agents.[331] It is also noteworthy that
the later generation mimetics 18 and 19 generally possess higher activity towards the
susceptible Pseudomonas species, when compared to 16 and 11, thus further
underlining their potential as anti-pseudomonal agents.
Furthermore, highly selective antibiotics are attractive since they are less
prone to disrupt the natural flora of the host, which plays an important part in host
immunity by preventing colonization by pathogens,[332] and they can help to decrease
the selective pressure on non-targeted bacteria, thereby decreasing the development of
resistance by horizontal gene transfer.[333] Therefore, it is not surprising that attempts
are being made to develop highly selective antibacterial compounds, for example by
including a Pseudomonas-specific target sequence into an antimicrobial peptide,[334]
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by fusing antibiotics to monoclonal antibodies specific for certain bacteria,[335] or by
fusing a bacterial pheromone to the antibacterial domain of colicin Ia.[336]
Nevertheless, further advances in rapid aetiological diagnosis and determination of the
susceptibility patterns of the pathogen to be treated might be needed in order to
increase the applicability of narrow spectrum antibiotics.[337]
Table 3.4 MIC values of mimetics 16, 18, 19 as well as 11 towards Pseudomonas spp. and B.
cepacia.
Species MICa [g/mL]
mimetic-16 mimetic-18 mimetic-19 protegrin-1 (11)
P. aeruginosab 2 0.03 0.015 0.5
P. aeruginosac 2 0.03 0.008 0.5
P. putida 0.25 0.13 ≤ 0.008 0.25
P. aureofaciens 1 0.06 0.015 0.25
P. syringae 0.13 ≤ 0.03 ≤ 0.008 ≤ 0.03
P. fluorescenced 16 4 0.06 0.125
P. fluorescence 2 0.5 0.06 0.125
P. chlororaphis > 64 > 64 > 64 32
B. cepacia > 64 > 64 > 64 > 64
a minimal inhibitory concentration; b PAO1; c ATCC 27853; d strain III.
3.3.3 Bactericidal effects of the AMPMs
In principle, there are two fundamentally different ways by which
antimicrobial substances can exert their biological activity. Bactericidal agents do so
by directly killing their bacterial target, whereas bacteriostatic agents only inhibit the
growth of bacterial cells. Examples of both types are widespread and well
documented. For instance, linezolid, an oxazolidinone antibiotic that inhibits the
initiation of protein synthesis in susceptible bacteria, is a bacteriostatic agent with a
broad-spectrum activity,[338] whereas β-lactam antibiotics such as the penicillins are
well known for their bactericidal action.[339] Nevertheless, the distinction is not
always clear-cut, and bacteriostatic agents can become bactericidal at higher
concentrations.[340] For example, antibiotics such as the macrolides, which are
generally considered bacteriostatic, also show bactericidal activity against some
Gram-positive species.[341] It should be emphasised that bacteriostatic action of an
antibacterial agent does not impair its usefulness in antimicrobial chemotherapy, since
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the uncompromised immune system can generally cope with an infection that is
prevented from getting out of control.[342] Also, for many infections by Gram-
negative pathogens, a rapid lysis of bacteria, with the concomitant release of LPS, can
lead to serious complications, namely septic shock, and these conditions can be
attenuated by the use of bacteriostatic agents.[343] An important parameter used to
discriminate between bactericidal and bacteriostatic action is the minimum
bactericidal concentration (MBC) (or minimum lethal concentration, if other
organisms such as fungi are to be included). The definition of the MBC is not as
unambiguous as for the MIC, and varies according to the source. Generally, the MBC
is taken to be the minimum concentration of a test compound that results in a
reduction of at least 3log10 (99.9%) in the viable cell count - as compared to the
inoculum - after incubation for 24 hours.[344] Comparable to the MIC, the inoculum is
typically chosen to have a value of around 5×105 CFU/mL and can greatly influence
the results obtained (vide infra). The MBCs for 16 and 18 have been determined in
parallel to their MICs and are shown in Table 3.5. The MBC values obtained show
that both mimetics display a bactericidal action against P. aeruginosa PAO1 at
concentrations that are comparable, respectively identical, to their MIC values. It
must therefore be concluded that these two AMPMs exert a bactericidal action
towards P. aeruginosa PAO1.
Table 3.5 Comparison of the MBC and MIC values obtained for 16 and 18 with respect to P.
aeruginosa PAO1. Values obtained from two independent experiments are shown.
substance MBC [g/mL] MIC [g/mL]
mimetic-16 8 / 8 4 / 4
mimetic-18 0.125 / 0.25 0.06 / 0.06
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3.3.4 Kinetics of bacterial killing
Whereas the determination of the MBC value allows for discrimination
between bacteriostatic and bactericidal action, its usefulness is limited by the fact that
it is only concerned with effects that manifest themselves during the 24 hours
incubation period. More interesting from a mechanistic point of view, however, is the
recording of so-called killing curves (time-kill analysis), which permit the analysis of
the kinetics of antibacterial action. Killing curves are an extension to the MBC
concept inasmuch as the decrease of viable cells is sampled more frequently during a
time-period of interest, instead of relying solely on one endpoint. Therefore, multiple
subcultures of the samples are evaluated for their viable cell count in order to study
the rate of bactericidal action. For the following experiments, a spread-plate method
on MH-agar plates was used to determine the number of viable cells. The bacterial
samples were serially diluted in MH-broth to achieve a count range between 30 and
300 colonies; the number of required dilutions was typically determined by
preliminary experiments.
One of the indications that mimetic 17 might act by an alternative mode of
action, mentioned above, came from the recording of killing curves, which was
carried out by Polyphor Ltd.‡ with 17. The results of the time-kill analysis of P.
aeruginosa with mimetic 17 and with protegrin-1 (11), which was used as a control,
are shown in Figures 3.12 and 3.13. From these experiments it was evident that
although 16 and 11 were bactericidal at or above their MIC values, 16 showed a
significantly slower onset of the antibacterial action than the naturally occurring,
reportedly membrane-active AMP, 11. For example, bacterial suspensions induced
with 11 at 1×, 4×, and 8× the MIC showed a reduction of 3log10 or higher in the viable
cell count during the first 30 minute incubation period, whereas the same reduction
for 4× and 8× the MIC of mimetic-17 occurred only after 3 to 4 hours. The re-growth
of the P. aeruginosa induced with 1×MIC of 17 after crossing the 3log10 threshold is
probably caused by the uncertainty in the determination of the MIC values, which can
typically vary about a factor of two and was probably not reached in this experiment.
Prompted by these results, the kinetics of antibacterial action of AMPMs were
studied, with special emphasis on the effects caused in the first two hours after
induction.
‡ See footnote †, page 19
78 Chapter 3
1.E+00
1.E+02
1.E+04
1.E+06
1.E+08
1.E+10
0 4 8 12 16 20 24
time [h]
C
FU
/m
L
Figure 3.12 Time-kill analysis of P. aeruginosa ATCC 27853 with mimetic-17; (●): control; (○): 
0.5×MIC; (□): 1×MIC; (◊): 4×MIC; (×): 8×MIC.
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Figure 3.13 Time-kill analysis of P. aeruginosa ATCC 27853 with protegrin-1 (11); (●): control; 
(○): 0.5×MIC; (□): 1×MIC; (◊): 4×MIC; (×): 8×MIC.
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3.3.4.1 Experimental considerations
To ensure maximum reproducibility, time-kill experiments were performed
during the exponential growth-phase of P. aeruginosa PAO1; this strain was chosen
because of the availability of its fully sequenced genome. For comparison with later
experiments, such as those concerned with the incorporation of radioactively labelled
precursor molecules into PAO1 cells, the assay was modified to accommodate a
higher cell-density of about 1×108 CFU/mL, at the time of adding test peptide. A
representative growth curve obtained for P. aeruginosa PAO1 is shown in Figure
3.14. It can be seen from this curve that the bacteria grow exponentially between
about 60 and 180 minutes, when incubated at 200 rpm and 37 °C in an orbital shaker.
For all experiments, pre-warmed (37 °C) MH-broth was inoculated ~1:100
with an overnight culture of PAO1 cells grown under identical incubation conditions,
to give a starting OD600nm of ~0.05. Typically, under these conditions, an OD600nm of
0.2 is reached 90 minutes after inoculation, which corresponds to the desired ~1×108
CFU/mL. Unless otherwise indicated, all further experiments were conducted with
bacteria in the two hour time frame of exponential growth.
0
0.5
1
1.5
2
2.5
3
3.5
0 50 100 150 200 250 300
time [min]
O
D
60
0
nm
Figure 3.14 Growth curve of P. aeruginosa PAO1 incubated at 200 rpm and 37° C in MH-broth,
and inoculated to a starting OD600nm of 0.05; the generation time is estimated to be ~28 minutes.
Since it has been described that the amount of the inoculum can have profound
effects on the obtained MIC values for certain antibiotics, such as macrolide
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antibiotics and β-lactams,[345, 346] and even more so for AMPs and other peptide
antibiotics,[347, 348] the MICs for the AMPM were re-determined for a higher inoculum
of 1×108 CFU/mL. It was found that the size of the inoculum also had a significant
effect on the AMPMs, as can be seen from Table 3.6, which compares the MIC
values for P. aeruginosa PAO1 obtained according to the standard protocol (5×105
CFU/mL) with those obtained for the higher inoculum. Influences of the inoculum
size are less pronounced for other classes of antibiotics, such as quinolones and
fluoroquinolones,[349] and such behaviour was indeed found for ciprofloxacin (7) and
tobramycin (25), which are included in Table 3.6.
Table 3.6 Comparison of the MIC values obtained with different sizes of inoculum for AMPMs
and some control antibiotics against P. aeruginosa PAO1.
substance MICa [g/mL] MIC ratio
standard inoculumb high inoculumc high/standard
mimetic-16 2 8 4
mimetic-17 1 4 4
mimetic-18 0.03 0.25 8
polymyxin B (1) 0.125 1 8
ciprofloxacin (7) 0.06 0.06 1
protegrin-1 (11) 0.5 16 32
tobramycin (25) 0.5 0.5 1
a minimal inhibitory concentration; b 5×105 CFU/mL; c 1×108 CFU/mL.
The MIC values for the peptide antimicrobial agents typically increased 4- to
8-fold when the higher inoculum was used. An exception is the 32-fold increase of
the MIC value for protegrin-1 (11) and this might originate either in a mechanistic
requirement for a certain threshold concentration of the AMP (e.g. in a carpet model),
or it could reflect a higher instability towards proteolytic degradation; 11 is the only
peptide from Table 3.6, which is not backbone-cyclic. Unless otherwise indicated,
the MIC values used for all following experiments are those determined with the high
inoculum.
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3.3.4.2 Experiments with mimetics 17 and 18
To study the kinetics of killing of P. aeruginosa PAO1, time kill analyses
were carried out with mimetics 17 and 18. A representative experiment with mimetic-
18 at 1×MIC and 5×MIC is depicted in Figure 3.15.
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Figure 3.15 Time-kill analysis of mimetic 18 with P. aeruginosa PAO1; (●): control; (□): 
2×MIC; (◊): 10×MIC.
As can be seen from Figure 3.15, mimetic 18 displays an essentially
bacteriostatic effect with respect to the PAO1 cells during the first two hours after
induction. The observed decrease in the viable cell count does not fulfil the 3log10
criterion of bactericidal action for either concentration. On the contrary, the number
of viable cells stays on a level comparable to the amount present in the inoculum for
up to 40 minutes after induction with 18. After this time period, the viable cell count
decreases slowly for both concentrations, the effect for the higher concentration being
somewhat larger. The time course of the viable cell count can be followed more
clearly if the percentage of surviving (viable) cells relative to the viable cell count at
the time point of addition of the test compounds is plotted against time, as
demonstrated in Figure 3.16. Mimetic 17, as well as protegrin-1 (11) and the
aminoglycoside antibiotic tobramycin (25) are included therein for comparison.
Under these conditions, mimetic-17 displays a similar bacteriostatic effect at 1×MIC.
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Interestingly, at 5×MIC of 17, there was a more rapid drop in the viable cell count
during the first hour following induction, after which time the viable cell count
remained on a comparable level throughout the rest of the experiment.
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Figure 3.16 Survival of P. aeruginosa PAO1 after induction with (●): 1×MIC mimetic-18; (○): 
5×MIC mimetic-18; (■): 1×MIC mimetic-17; (□): 5×MIC mimetic-17; (♦):2×MIC protegrin-1 (11);
(◊): 1×MIC tobramycin (25).
It could be possible that this behaviour is a manifestation of the above
mentioned putative residual membrane-lytic activity of the AMPMs. For example,
5×MIC of mimetic 17, under high inoculum conditions, correspond to a concentration
of 20 g/mL, a value well within the MIC range of 17 displayed against E. coli and S.
aureus ATCC 25923 (albeit determined for a lower inoculum). The aminoglycoside
antibiotic tobramycin (25) shows a slower onset of its bactericidal action as compared
to protegrin-1 (11), which exhibits a minimum decrease of 5log10 in the viable cell
count 10 minutes after induction. Such rapid bactericidal action is expected for an
AMP that acts by a membrane-lytic mode of action. Identical results have been
described for protegrin-1,[312] and other AMPs that are thought to operate by
membrane-active mechanisms, in the literature.[350, 351] Additional time-kill analyses
were performed with mimetic 18 at higher concentrations, inter alia to determine
concentrations for which the onset of the putative residual lytic activity might occur.
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From Figure 3.17 it can be seen that 18 displays a concentration-dependent
bactericidal action during the 2 hours incubation period of the experiment, i.e.
increasing concentrations of the mimetic lead to an increased drop in the viable cell
count.
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Figure 3.17 Concentration-dependent bactericidal action of mimetic 18 against P. aeruginosa
PAO1; (●): 2×MIC; (♦): 10×MIC; (○): 128×MIC; (◊): 256×MIC; (□): 512×MIC.
It is remarkable, however, that the bactericidal action is not pronouncedly
rapid even at the highest concentration of 18, corresponding to 128 g/mL. At this
concentration the 3log10 threshold is reached only 40 minutes after induction,
suggesting that even for such a high concentration, a typically membrane-lytic mode
of action is not in operation for mimetic 18, at least not with respect to P. aeruginosa
PAO1.
3.3.4.3 Post-antibiotic effect of mimetic 18
The post antibiotic effect (PAE) describes a delay of re-growth of bacteria
after short exposure to a test antibiotic, and is described by the formula PAE = T – C
where T is the time in hours required for the culture induced with the test substance to
increase its viable cell count by about 1×log10 after removal of the drug, as compared
to the control, as denoted by C. The degree of an observed PAE can be related to the
amount and degree of damage inflicted upon the bacterial culture. The PAE effect of
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18 on P. aeruginosa PAO1 was studied by a drug-removal procedure involving
centrifugation and washing steps. Briefly, bacterial suspensions were grown and
induced with 18 according to the standard protocol (vide supra) and after two hours of
incubation, one sample was washed and centrifuged twice with pre-warmed fresh
MH-broth while the control samples were handled identically, but without
replacement of the medium. Experiments were carried out at 5×MIC of 18 and a
representative example is shown in Figure 3.18.
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Figure 3.18 Effect of removing mimetic-18 from the incubation medium (PAE) on the survival of
P. aeruginosa PAO1; (●): control without added 18; (◊): control with 5×MIC 18; (□):5×MIC 18.
Interestingly, 18 exerts a remarkable PAE; in fact the decrease in the viable
cell count is even higher for the sample that has been washed than for the control
sample which contains an identical amount of 18. Post-antibiotic effects are common
for many antibiotics such as ciprofloxacin (7)[352] or tobramycin (25).[353] It is
especially noteworthy that two synthetic magainin derivatives, as well as the AMP
lactoferricin B, all of which are thought to act by a lytic mode of action, showed no
PAE.[347, 354]
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3.4 Enantiomers of AMP(M)s
An versatile approach for studying modes and mechanisms of action of an
AMP(M) consists of the synthesis of both its enantiomers and the evaluation of their
biological and/or antimicrobial activities. The attractiveness of this methodology has
several origins, for example the ease of preparation of both enantiomeric forms, given
the fact that most AMPs are relatively small polypeptides easily accessible via SPPS.
Due to the wide availability of L- and D-amino acid building blocks for SPPS
employing either Boc- or Fmoc-based chemistry, the synthesis and purification of the
enantiomer of an AMP(M) is not more difficult or time-consuming than the synthesis
of its parent compound; the synthetic protocols necessarily have to be identical.
Additionally, as will be described in this section, a considerable amount of data has
already been collected, with which newly obtained results can be compared. Most
importantly, however, the biological activities of enantiomers of AMP(M) can give
invaluable clues as to possible mechanisms of action for this class of compounds.
Biological membranes are chiral entities not only by virtue of imbedded or
attached chiral macromolecules, but also due to the phospholipid bilayer which is
composed of optically active phospholipids, along with other chiral lipids such as
steroids. The same holds true for additional components of fungal or bacterial cell
walls such as chitin, peptidoglycan, teichoic acids, or lipopolysaccharides (LPS).
Despite this inherent chirality of microbial cell walls it has been hypothesised that
peptides that can alter properties of the phospholipid surface, for example toxins and
venoms, might exert their action without involvement of specific receptors.[355] This
hypothesis was extended to include AMPs by Merrifield and co-workers, based on
biophysical experiments and the activity patterns of compounds such as magainin,
cecropin, and melittin.[356] As exemplified by melittin, the distinction between AMPs
and venoms is not always clear. Generally, the toxicity towards erythrocytes is used
as a parameter, although the classification of a certain peptide into either class might
vary from author to author.
The aforementioned hypotheses are in stark contrast to the situation
encountered with peptide hormones such as oxytocin,[357] bradykinin,[358] and
gastrin,[359] whose enantiomers are devoid of the biological activity of the naturally
occurring all-L forms. It is generally assumed that the interaction of a ligand with its
receptor, or more precisely, with its recognition site (which is part of the receptor),
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depends on the involvement of complementary surfaces and thus on the topology of
the ligand. In this context it seems appropriate to state the definition of a receptor
molecule as given by the NC-IUPHAR (The International Committee of
Pharmacology Committee on Receptor Nomenclature):[360]
“A cellular macromolecule, or an assembly of macromolecules, that is concerned directly and
specifically in chemical signaling between and within cells. Combination of a hormone,
neurotransmitter, drug, or intracellular messenger with its receptor(s) initiates a change in cell
function.”
The complementary interaction of ligand and receptor as epitomised by
Fischer’s lock-and-key hypothesis[361] is well established, and examples such as the
different odours produced by enantiomeric terpenes have become commonplace in
chemical education.
3.4.1 Enantiomers of AMPs described in the literature
To test the hypothesis of antimicrobial action independent from chiral
recognition for AMPs, Merrifield and colleagues[362] as well as Bessalle et al.[363]
independently synthesised the first enantiomers of naturally occurring AMPs in 1990.
The biological activities recorded for these compounds, all belonging to the α-helical
subclass of AMPs (respectively venoms), were comparable to those of the naturally
occurring all-L forms, thus supporting the original hypothesis and corroborating
mechanistic frameworks in favour of a membrane-lytic action of AMPs. On the other
hand, in 1994, Casteels et al. reported for the first time an AMP whose all-D form was
significantly less active than its naturally occurring optical antipode, apidaecin[235].
It is noteworthy, not only from a historical point of view, that in 1967,
Shemyakin et al. already described the first example of a peptidic compound that
showed equivalent antimicrobial activity for both its enantiomers towards a variety of
micro-organisms.[364] This at the time exceptionally unusual behaviour of enniatin-B,
a cyclic non-ribosomally synthesised depsipeptide, was explained by the authors via a
topological similarity of both enantiomers, sufficient to account for identical
interaction with a receptor molecule.[365] From today’s point of view, however, it
seems likely that the activity of both enantiomers can be explained by the identical
ability to transport potassium ions through bacterial target membranes. Indeed,
Shemyakin et al. noted that enniatins preferably bound potassium ions, and that this
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binding only occurred when the peptides were in contact with membranes. Notably,
such crown-ether like binding of potassium ions would be expected to be identical for
both enantiomers.
Since these first syntheses of enantiomeric pairs of AMPs, around 50 of them
have been prepared and studied with respect to their biological activity towards
various micro-organisms including fungi and protozoa. The D/L activity ratios of
enantiomeric pairs of AMPs of various origins are summarised in Table 3.7. In this
table, the differential activity of the enantiomers is quantified by the ratio of the
antimicrobial activity of the naturally occurring or synthetically derived all-L form
over the activity of its corresponding enantiomer. Therefore, D/L activity ratios larger
than unity indicate a higher antimicrobial activity of the all-L§ compound, indicating
the involvement of a stereospecific interaction in its mechanism of action with respect
to the tested micro-organism.
There are some additional reports on enantiomeric pairs of AMPs, which
could not be fitted into Table 3.7, for instance because of the methods used for the
determination, or quantification of the antimicrobial activity. Pelligrini et al.
described that the all-D form of a modified 9 residue fragment of chicken egg white
lysozyme showed significantly less bactericidal activity towards several
Staphylococcus strains as well as towards Serratia marcescens and Micrococcus
luteus in an assay based on determination of viable counts after a 2 hour incubation
period than its all-L counterpart.[366] Another interesting report is concerned with
leucocin A, a type IIa bacteriocin from lactic acid bacteria that contains an α-helical
as well as a β-sheet element, and whose enantiomer was reported to show no
antibacterial activity against several species of the genera Carnobacterium,
Leuconostoc, and Listeria.[328]
§ The term all-L form also includes compounds that contain a minor amount of D-amino acids and vice
versa.
Table 3.7 D/L Activity ratios for enantiomeric pairs of AMPs reported in the literature (polymyxin B nonapeptide is included for comparison). The activity ratios are
calculated as described in the text. Ratios that arise from a difference of 8 fold or higher in the biological activities between the all-L and all-D form are highlighted in
boldface. Numbers in parentheses indicate the number of different species tested; names of species are given for those with unusual large differences
substance sequencea class range of activity ratios (number of
tested species)
activity
criterionb
reference
androctonin H-RSVC1RQIKIC2RRRGGC2YYKC1TNRPY-OH β-sheet 0.3 to 2 (3) MIC [183]
CG117-136 H-RPGTLCTVAGWGRVSMRRGT-OH β-sheet 0.9 and 1 (2) ED90 [367]
IB-625 H-RGGLC1YC2RGRFC2VC1VGR-NH2 β-hairpin 2 and 4 (2) MIC [115]
IB-739 H-OGGOLC1YC2OOOFC2VC1VGO-NH2 β-hairpin 0.1 and 1.8 (2) MIC [115]
IB-513 H-WLC1YC2OOOFC2VC1V-NH2 β-hairpin 0.5 and 0.7 (2) MIC [115]
Ib-AMP1 H-EWGRRC1C2GWGPGRRYC1VRWC2-OH β-turn 0.1 and 1.6 (2) IC50 [368]
Ib-AMP4 H-EWGRRC1C2GWGPGRRYC1RRWC2-OH β-turn 0.2 and 1.3 (2) IC50 [368]
Lfcin B(17-31) H-FKC1RRWQWRMKKLGAPSITC1VRRAF-OH β-sheet 0.4 and 0.5 (2) MIC [369]
polymyxin B nona-
peptide
H-T(Dab)(Dab)(Dab)fL(Dab)(Dab)T
└CH2─CH2─NH─CO┘
β-turn and/or
γ-turn
1 and 1 (2)
> 128 (P. aeruginosa)
MIC [370]
protegrin-1 H-RGGRLC1YC2YRRRFC2VC1VGR-NH2 β-hairpin 0.7 and 0.9 (2) MIC/IC50 [66, 371]
thanatin H-GSKKPVPIIYC1NRRTGKC1QRM-OH β-hairpin 0.2 to 4 (17)
8 (B. subtilis)
> 67 (E. coli)
> 33 (K. pneumoniae)
> 33 (S. typhimurium)
MIC [93]
((RLA)2R)2 H-RLARLARRLARLAR-OH α-helical <0.3 (1) MIC [372]
CA-(1-13)-M-(1-13)-
COOH
H-KWKLFKKIEKVGQGIGAVLKVLTTGL-COOH α-helical 0.2 to 1.1 (5) LC [373]
CA-(1-13)-M-(1-13)-
NH2
H-KWKLFKKIEKVGQGIGAVLKVLTTGL-NH2 α-helical 0.4 to 4 (5) LC [362, 373, 374]
CA-(1-7)-M-(1-18)-
NH2
H-KWKLFKKGIGAVLKV-NH2 α-helical 0.5 to 5.7 (5) LC [375]
CA(1-7)M(2-9)-
COOH
H-KWKLFKKIGAVLKVL-COOH α-helical 0.2 to 1.5 (4)
0.07 (P. aeruginosa)
LC [373]
CA-(1-7)-M-(2-9)-
NH2
H-KWKLFKKIGAVLKVL-NH2 α-helical 0.2 to 0.8 (5) LC [374, 375]
CA-(1-7)-M-(3-10)-
NH2
H-KWKLFKKGAVLKVLT-NH2 α-helical 0.3 to 2.3 (4) LC [375]
CA(1-7)M(4-11)NH2 H-KWKLFKKAVLKVLTT-NH2 α-helical 0.5 to 1.7 (5) LC [375]
CA(1-7)M(5-12)NH2 H-KWKLFKKVLKVLTTG-NH2 α-helical 0.5 to 2 (5) LC [375]
Table 3.7 (continued)
CA-(1-7)-M-(6-13)-
NH2
H-KWKLFKKLKVLTTGL-NH2 α-helical 0.8 to 2 (5) LC [375]
CA-(1-8)-M-(1-18)-
NH2
H-KWKLFKKIGIGAVLKVLTTGLPALIS-NH2 α-helical 0.5 to 1 (5) LC [362]
CA-(1-8)-M-(1-18)-
NH2
H-KWKLFKKIGIGAVLKVLTTGLPALIS-NH2 α-helical 0.3 (1) LD50 [376]
cecropin A H-KWKLFKKIEKVGQNIRDGIIKAGPAVAVVG
QATQIAK-NH2
α-helical 0.8-2 (5) LC [362]
cecropin B H-KWKVFKKIEKMGRNIRNGIVKAGPAIAV
LGEAKAL-NH2
α-helical 2 (E. coli)
0.8 (P. aeruginosa)
LC [377]
cecropin-P1 H-SWLSKTAKKLENSAKKRISEGIAIAIQGGPR-OH α-helical 0.4 to 4 (2)
> 23 (P. aeruginosa)
< 0.1 (S. aureus)
0.07 (S. pyogenes)
LC [244]
KL peptide H-KLKLLLLLKLK-NH2 α-helical 0.5 (1) MIC [378]
KSLK H-KKVVFKVKFKK-NH2 α-helical 1 (5) MIC [379]
maculatin 1.1 H-GLFVGLAKVAAHVVPAIAEHF-NH2 α-helical 0.5 to 2 (10) MIC [380]
magainin-2 H-GIGKFLHSAKKFGKAFVGEIMNS-OH α-helical 0.5 to 2 (5) MIC [363]
magainin-2 amide H-GIGKFLHSAKKFGKAFVGEIMNS-NH2 α-helical 0.3 to 1 (5) LC [362]
mastoparan-M H-INLKAIAALAKKLL-NH2 α-helical 0.5 (3) MIC [381]
melittin H-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 α-helical 0.5 to 2 (5) LC [362]
P113 H-AKRHHGYKRKFH-NH2 α-helical 0.5 to 1 (2) MIC/LD50 [231, 232]
PBP10 RhB-QRLFQVKGRR-OH α-helical 1 (1) LC [382]
plantaricin A H-KSSAYSLQMGATAIKQVKKLFKKWGW-OH α-helical 0.8 to 1.7 (2) MIC [383]
PlnA22 H-YSLQMGATAIKQVKKLFKKWGW-OH α-helical 1 to 2 (3) MIC [384]
TAL L512 H-FLPLLGRVLSGLL-NH2 α-helical 0.7 (1) MIC [385]
temporin A H-FLPLIGRVLSGIL-NH2 α-helical 0.5 to 1.2 (3) MIC [386]
V13A Ac-KWKSFLKTFKSAAKTVLHTALKAISS-NH2 α-helical 0.3 to 2 (6) MIC [387]
V13K Ac-KWKSFLKTFKSAKKTVLHTALKAISS-NH2 α-helical 0.3 to 2 (6) MIC [387]
V681 Ac-KWKSFLKTFKSAVKTVLHTALKAISS-NH2 α-helical 0.3 to 2 (6) MIC [387]
apidaecin H-GNNRPVYIPQPRPPHPRL-OH Pro/Arg-rich up to >1600 (E. coli) MIC [235]
drosocin H-GKPRPYSPRPTHSPRPIRV-OH Pro/Arg-rich 51-143 (E. coli)
50 (M. luteus)
MIC [87]
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PR-39 H-RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPP
RFPPRFP-NH2
Pro/Arg-rich 1 to 2 (3)
0.02 (P. aeruginosa)
< 0.001 (S. aureus)
LC [244]
pyrrhocoricin H-VDKGSYLPRPTPPRPIYNRN-OH Pro/Arg–rich 4 (1)
> 1067 (A. tumefaciens)
> 16 (B. subtilis)
> 1067 (E. coli)
> 133 (S. typhimurium)
IC50 [236]
IIGGR H-IIGGR-OH n.d.c 1 (2) LD90 [388]
p-EM2 H-KKWRWWLKALAKK-OH n.d. 1 (2) MMC [389]
Lfcin (4-12)-NH2 H-RRWQWRMKK-NH2 n.d. 0.2 to 1 (5) MIC [390]
Lfcin acyl-10-(4-12)-
NH2
decanoyl-RRWQWRMKK-NH2 n.d. 0.5 to 1 (5) MIC [390]
a the pattern of the disulfide bonds are indicated by subscripts, Dab = L-1,4-diaminobutyric acid; Rhb = rhodamine B; b MIC = minimal inhibitory concentration; ED90 =
concentration of the test compound required to reduce the number of viable cells by 1×log10; IC50 = peptide concentration required to inhibit 50 % of microbial growth; LC =
lethal concentration; LDx = lethal dose leading to killing of x % of the micro-organisms; MMC = minimum microbicidal concentration; c n.d. = not determined.
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In addition to the determination of their in vitro activities, some enantiomeric
pairs of AMPs have also been studied in vivo. For example, Darveau et al. showed
that C18X, the enantiomer of a 13 residue peptide corresponding to the C-terminal
end of human platelet factor IV, possessed comparable antimicrobial activity in a
neutropenic murine model of infection[391]. They also reported on similar activities of
both enantiomers in vitro, although no quantitative data was given. Similar results
were found in another murine model of infection for a synthetic, α-helical
undecapeptide, although the authors proposed that this chemotherapeutic in vivo effect
was mediated by the activation of neutrophils rather than by direct interaction of the
peptides with the bacterial cells.[392]
The D/L activity ratios of the enantiomeric pairs from Table 3.7 are
summarised in Table 3.8 together with their classification into secondary structures
and according to differences in these ratios. It can be seen that the majority of AMPs
that have been studied show behaviour that is to be expected for substances acting by
a membrane-active mechanism, i.e. they possess a D/L activity ratio of around unity.
However, there are several examples of AMPs with ratios significantly deviating from
unity, and these examples typically belong to the Pro/Arg-rich class of AMPs. Only
few examples exist of a D/L activity ratio corresponding to a difference of more than 2
orders of magnitude in favour of the naturally occurring all-L form, the most
prominent being the insect peptide apidaecin, again a representative of the Pro/Arg-
rich class of AMPs. Other naturally occurring AMPs belonging to different classes of
secondary structure, and with activity ratios significantly exceeding unity are
thanatin,[93] a 21 residue AMP from insects which adopts a β-hairpin conformation,
and cecropin-P1,[244] an α-helical AMP originally isolated from pig small intestine but
subsequently found to originate from the nematode Ascaris suum.[393] To conclude, it
is noteworthy that cecropin-P1 and most notably PR-39, yet another Pro/Arg-rich
AMP, show activity ratios significantly lower than unity towards some microbial
species. For PR-39, the all-D form is about three orders of magnitude more active
than the naturally occurring isomer, and the unusually low activity ratio has been
proposed to arise from increased proteolytic stability of the all-D form.[244] It should
be noted, however, that an increase in the activity of all-D peptides, if observed, is
generally around a factor of two (cf. Table 3.7).
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Table 3.8 Summary of activity ratios of enantiomeric pairs of AMPs described in the literature
and correlation with their secondary structural elements.
secondary
structure
D/L activity ratios from Table 3.7 total from
Table 3.7
higher activity for the
all-L form
higher activity for the
all-D form
> 0.13 and
< 8
≥ 8 and
< 1000
≥ 1000 ≤ 0.13 and
> 0.001
≤ 0.001
β-sheet or β-turn 9 1 - - - 10
α-helical 29 1 - 1 - 31
Pro/Arg-rich - 1 2 - 1 4
not determined 4 - - - - 4
total from
Table 3.7
42 3 2 1 1 49
3.4.2 Enantiomers of related compounds
In addition to AMPs, enantiomeric pairs of related peptidic compounds have
been synthesised. For example, Raguse et al. reported that both enantiomers of a 9
residue β-peptide showed identical antimicrobial activity against E. coli, S. aureus, E.
faecium, and B. subtilis.[394] Furthermore, a variety of cell penetrating peptides (CPP),
which are of interest because of their potential as drug-delivery systems, were studied
in more detail. Notably, most CPPs bear an overall positive charge, usually due to
arginine side-chains, emphasising the similarity between CPPs and AMPs. The
ability of several enantiomeric pairs of these compounds to translocate across cell
membranes has been assessed by confocal fluorescence microscopy with fluorescin-
labelled derivatives, and, for example, no differences in the uptake of pVEC, an 18
residue peptide derived from murine endothelial cadherin,[395] or of a 16 residue
hydrophobic peptide derived from a human fibroblast growth factor,[396] into
eukaryotic cell lines were detected. Similarly, Derossi et al. reported that both
enantiomers of a 16 residue helical peptide derived from a DNA binding domain are
translocated with equal efficiency into cell cultures.[397] The same holds true for KLA
peptide, a de novo designed amphipathic α-helical model compound, with respect to
the ability of both enantiomers to translocate across the plasma membrane of rat
peritoneal mast cells.[398]
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3.4.3 Other activities of AMPs
In addition to their antimicrobial activity, other more discrete biological
activities of AMPs have been examined for the involvement of stereospecific
interactions. For instance, another motivation for the synthesis of all-D peptides lies
in their predicted proteolytic stability (vide supra). It is generally assumed that
peptides containing D-amino acids are more stable towards enzymatic degradation
than their natural counterparts, and indeed several of the above mentioned
enantiomeric pairs have been used to demonstrate this fact; for an illustrative example
see the work of Besalle et al.[363] This proteolytic stability has been suggested to
allow for the use of these compounds as therapeutics with potentially increased
bioavailability.
In addition to its antimicrobial activity ratio of around unity (cf. Table 3.7),
magainin-2, a broad-spectrum membrane-lytic AMP, showed no differences in the
toxicity of both enantiomers towards several tumour cell lines, as studied by flow
cytometry.[399] Also, the promotion of cell adhesion and tumour growth by two short
peptides derived from type IV collagen and from laminin was studied, once again
showing no involvement of stereospecific components.[400-402] Furthermore, the
interaction of both enantiomers of polymyxin B nonapeptide,[370] as well as of
pEM2,[389] a short peptide derived from myotoxin II, with bacterial LPS, have been
studied. It was found that there was no difference in LPS binding for both
enantiomers of polymyxin B nonapeptide, as judged by a polymyxin displacement
assay, whereas a slightly higher LPS neutralising property was found for all-L pEM2.
An interesting case is the α-helical plant pheromone plantaricin A which, in
addition to its antimicrobial activity that is independent of its stereochemistry, also
displays activity as a pheromone, but only the all-L form is capable of inducing the
production of bacteriocins.[384] It has been suggested that non-specific interaction of
plantaricin A with the membrane - presumably connected to the intrinsic antibacterial
properties of this molecule - induces secondary structure which is involved in the
stereospecific pheromone activity[383].
3.4.4 Synthesis of enantiomeric AMPMs
To gain insights into the antimicrobial mechanism(s) of our AMPMs, the
enantiomers of mimetics 16, 17, and 18 were prepared. The synthesis of these
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compounds was carried out analogously to that of the parent compounds (as described
in Section 3.1), and as was to be expected, no differences or difficulties other than
those mentioned earlier were encountered. The only difference in the synthesis of
ent-17 was the use of a trityl protecting group for D-Gln in place of methyltrityl,
which was routinely used as protecting group for L-Gln, and this minor modification
had no apparent effect on the synthesis of the protected precursor molecule. A
comparison of the HPLC chromatograms of the enantiomeric pairs of our AMPMs is
given in Figures 3.19-3.21.
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Figure 3.19 HPLC chromatograms of 16 (blue) and ent-16 (red). Vydac218TP54 C18 analytical
column; 5 to 100% acetonitrile in water (+0.1% TFA) in 7 column volumes; flow 1 ml/min.
0.00
100.00
200.00
300.00
400.00
500.00
5.00 7.00 9.00 11.00 13.00 15.00 17.00 19.00 21.00 23.00 25.00
time [min]
m
A
U
Figure 3.20 HPLC chromatograms of 17 (blue) and ent-17 (red). Vydac218TP54 C18 analytical
column; 5 to 100% acetonitrile in water (+0.1% TFA) in 7 column volumes; flow 1 ml/min.
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Figure 3.21 HPLC chromatograms of 18 (blue) and ent-18 (red). Vydac218TP54 C18 analytical
column; 5 to 100% acetonitrile in water (+0.1% TFA) in 7 column volumes; flow 1 ml/min.
3.4.5 D/L activity ratios of the AMPMs
The MIC values of the enantiomeric pairs of our AMPMs were determined
against the standard panel of micro-organisms, and according to our routine protocol
(cf. Section 3.3.1), employing a standard inoculum of ~5×105 CFU/mL. The results
are summarised in Table 3.9 together with the resulting D/L activity ratios for each
tested species, respectively strain.
Table 3.9 MIC values and corresponding D/L activity ratios for the enantiomeric pairs of
AMPMs derived from protegrin-1; results from at least three experiments were averaged.
peptide MICa [g/mL]
E. coli
ATCC 25922
S. aureus
ATCC 25923
S. aureus
ATCC 29213
P. aeruginosa
ATCC 27853
P. aeruginosa
PAO1
16 6.0 6.2 17 2.3 2.0
ent-16 2.0 4.3 12 0.75 1.5
D/L ratio 0.33 0.69 0.71 0.33 0.75
17 14 21 > 64 0.29 2.4
ent-17 16 32 > 64 43 > 64
D/L ratio 1.1 1.5 n.a.b 150 > 27
18 32 41 > 64 0.02 0.03
ent-18 16 49 > 64 28 20
D/L ratio 0.5 1.2 n.a. 1400 670
a minimal inhibitory concentration; b not applicable
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As can be seen from Table 3.9, the enantiomer of mimetic 16 is more active
against all tested micro-organisms than the parent compound. The activity ratio for
16 is between 0.33 and 0.75, thus indicating that ent-16 is about twice as potent as 16.
Such an activity ratio is in accordance with a membrane-active mechanism, as is also
reflected by many compounds from Table 3.8 that are believed to follow such
mechanisms. In contrast, 17 shows an activity ratio favouring the all-L form by about
one order of magnitude for P. aeruginosa. This trend is even more pronounced for
18, which achieves an activity ratio of up to 1400 for P. aeruginosa ATCC 27853.
Notably, both mimetics display ratios between 0.5 and 2 for the other bacterial
species; an activity ratio could not be calculated for S. aureus ATCC 29213 because
both mimetics were inactive against this strain up to the highest assay concentration.
3.4.6 Remarks and Conclusions
As outlined in Chapter 2, the presence or absence of a stereospecific
component in the killing or the bacteriostatic action of an AMP as described by the
D/L activity ratio is a very powerful indicator for the possible involvement of
alternative mechanisms of action. Aspects that are related to the attractiveness of this
parameter are the simplicity and reliability of its determination. The simplicity is not
only manifested in the accessible synthesis of the enantiomeric compounds, but also
in the various protocols employed for the quantification of antimicrobial action.
Moreover, since the effects of the test compounds are studied on whole organisms
rather than on isolated biochemical systems, an irrevocable result can be obtained.
Unfortunately, this global nature of the D/L activity ratio is accompanied by
the loss of any information that could be obtained about the mechanism itself.
Activity ratios around unity or smaller strongly suggest a mechanism that is primarily
dependent on the interaction of the AMP(M) with membranous systems, but no more
can be learned about the exact nature of this interaction; the same limitations
obviously apply to the case of unusually high activity ratios. However, the
synthesised enantiomers can also serve as invaluable control compounds in any
experiment that is concerned with an isolated biochemical system.
Although the association of activity ratios around unity with a membrane-
active mechanism is generally accepted, there could be exceptions. For example,
whereas a slightly higher activity of the unnatural all-D enantiomer is easily explicable
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by an increased proteolytic stability, the unusually low activity ratio, observed for
example for PR-39 towards some micro-organisms, poses a conceptual problem. If an
unusually low activity ratio, of less than 0.001 (c.f. Table 3.7), indeed originates from
an increased stability of the all-D form, than it is justified to ask whether such an
effect exists for other AMPs as well (especially since PR-39 is a linear peptide
consisting of only natural amino acids). Hence, it would be conceivable that
stereospecific preferences for antimicrobial killing exerted by all-L forms are not
detected, because their increased activity could be masked by an increased rate of
proteolysis. Along these lines, it would then also be possible that observed D/L
activity ratios underestimate the value that would be obtained in the absence of
enzymatic degradation.
Of course, with respect to unusually low activity ratios, it is also imaginable
that some peptides are much more prone to enzymatic degradation than others, for
example by virtue of their structure, or if the micro-organism possesses enzymes that
are especially well suited for the degradation of a given AMP. Additionally, it can
also not be excluded that an unnatural all-D form might interact specifically with a
target.
Shai and co-workers reported on the specific association of an all-D
glycophorin A (GPA) trans-membrane helical domain with its enantiomeric trans-
membrane helical domain,[403] as well as on the inhibition of dimerisation of a trans-
membrane domain of an E. coli aspartate receptor involved in chemotaxis, by both
enantiomers of a peptide derived from the corresponding trans-membrane helix of the
receptor.[404] Based on these findings, the authors suggest that helix-helix recognition
in a membranous environment - at least in these two cases - does not depend on the
chirality of the helices involved and is governed mainly by side-chain interactions of
the enantiomeric peptides rather than by a geometrical fit of their respective
conformations. With respect to the interpretation of enantiomeric activity ratios, this
would imply that an activity ratio of unity does not necessarily preclude the
involvement of a specific target in the antibacterial mechanism.
On the other hand, Suchyna et al. reported on the inhibition of stretch-
activated cation-channels (SAC) by GsMTx4, a peptide isolated from tarantula
venom.[405] It was found that both enantiomers of GsMTx4 inhibit SACs, and this
was demonstrated to originate from altered bilayer properties in the local environment
of the ion-channel. SACs belong to the so-called mechanosensitive channels, a class
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of proteins that responds to mechanical stress; other examples of this class comprise
phospholipase A and G proteins.[406, 407] The authors suggested that mechanosensitive
proteins, especially those sensitive towards the bilayer tension, could be regarded as
receptors for amphipathic messenger compounds. In view of this suggestion, an
activity ratio of around unity is once again placed firmly into the domain of
membrane-activity as defined in Section 2.1.1.
Finally, it has to be emphasised, that the absence of a chirality-dependent
component in antimicrobial action does not imply that the AMP under consideration
is completely devoid of such a component. Naturally, conclusions can only be drawn
for the panel of tested micro-organisms. This is evident from several cases shown in
Table 3.7. Moreover, mimetic-18 is a prime example of this behaviour, showing a
very high D/L activity ratio concomitant with a high selectivity towards P. aeruginosa
strains but not towards E. coli or S. aureus.
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3.5 Dye-leakage experiments
Dye leakage experiments are frequently used as a means of investigating the
ability of AMPs to induce permeabilisation of membrane structures. Typically,
liposome vesicles are used as model membranes, although studies involving more
complex systems are known. For example, Edgerton et al. studied calcein release
from intact C. albicans cells treated with the Pro/Arg-rich AMP histatin-5 (c.f.
Section 2.2).[211]
Vesicles of various compositions are used to emulate the differential makeup
of microbial versus mammalian membranes. Frequently, binary systems employing
zwitterionic and negatively charged phospholipids are used, and amongst these the
most common system is composed of varying ratios of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC, 26) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (POPG, 27) (Figure 3.22).
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Figure 3.22 Zwitterionic POPC (18) and negatively charged POPG (19), two phospholipids
frequently used in dye-leakage experiments.
In such binary systems, liposomes prepared only of zwitterionic phospholipids
are taken to represent eukaryotic membranes, which in contrast to their bacterial
counterparts carry less negatively charged phospholipids on their surface. The
relationship between dye-leakage from POPC vesicles and the haemolytic activity of
several AMPs, or peptide venoms, has been studied and found to be well
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correlated.[105] Analogously, vesicles composed of increasing amounts of negatively
charged POPG lipids are used to mimic prokaryotic membranes.[408]
POPC/POPG systems containing varying ratios of these two phospholipids
have been used inter alia in dye-leakage experiments with the AMPs polyphemusin-
1,[111] indolicidin,[111] KLAL peptides,[118] tritrpticin,[409] cathelicidins,[410] tachyplesin-
1,[106] P-Der,[245] magainin-2,[411] or the peptide antibiotic gramicidin S.[111] Other
phospholipid systems such as POPE/POPG or POPS/POPC were used to study
androctonin[183] and dermaseptin.[182] Finally, DOPC/DOPG systems containing a
dioleoyl moiety have been described for the AMPs pleurocidin,[412] and several
magainins.[413]
Naturally, binary systems can only be a simplified model of a real membrane
environment and accordingly, more complex systems have been described. For
instance, systems including additional lipid compounds such as cholesterol are
occasionally taken to mimic mammalian membranes,[414] and vesicles containing lipid
A analogues have been used to mimic the outer membrane of Gram-negative
organisms,.[238] Another more complex system consisting of egg-PE/egg-
PG/LPS/cardiolipin, chosen to resemble Gram-negative membranes, was used by
Waring et al. to study the behaviour of protegrin-1 (11) in model membranes.[415]
3.5.1 Principle of the Assay
The principle of the dye leakage assay is based on the observation that certain
fluorophores like calcein (28) and carboxyfluorescein (29) quench their own
fluorescence at higher concentrations (Figure 3.23).[416] Both 20 and 21 have been
used for experiments with AMPs, although calcein is employed much more
frequently.
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Figure 3.23 Calcein (28) and carboxyfluorescein (29), two self-quenching fluorescent dyes
employed in dye-leakage experiments.
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Therefore, the use of calcein in dye-leakage experiments will be implied unless noted
otherwise; for an example with carboxyfluorescein as self-quenching dye, c.f.
reference [417]. Concentrated solutions of a self-quenching fluorophore experience a
strong increase in fluorescence intensity upon dilution (Figure 3.24). The
fluorescence intensity of calcein is found to be approximately linear in a concentration
range between 30 and 3 M, thus allowing for quantification of the results (Figure
3.24B).
Figure 3.24 (A) Increase in fluorescence intensity of a self-quenching dye upon dilution; adapted
from ref [418]. (B) Concentration dependence of fluorescence intensity (arbitrary units) for calcein.
In practice, higher concentrations of the self-quenching dye (30 to 70 mM) are
encapsulated into liposomes of the desired phospholipid composition. Addition of
membrane permeabilising compounds, or detergents, then leads to dilution of the
fluorophore into the surrounding medium, with a concomitant strong increase in
fluorescence intensity (c.f. Figure 3.24B). The calcein fluorescence is measured with
an excitation wavelength between 430 and 470 nm, chosen to achieve a maximal
dynamic range for the fluorescence signal, and an emission wavelength of 520 nm.[419]
Appropriate amounts of the permeabilising compound are added, and the
increase in fluorescence intensity is monitored over time. At the end of each
experiment a detergent such as a 10 % (w/v) solution of Triton X-100™ is added, in
order to determine the maximal fluorescence signal, i.e. the value corresponding to the
total disruption of the calcein-entrapped vesicles (Figure 3.25).
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Figure 3.25 Time course of fluorescence intensity in a dye-leakage experiment carried out with
20 M of mimetic 16 as permeabilising compound and 30 M of POPC/POPG (80:20) LUVs.
The dye-leakage data can be plotted in a dose-dependent fashion according to
equation 3.1, which describes the fraction of calcein released into the surrounding
medium. Calcein release is calculated from Ft, the fluorescence at a specified time t
(e.g. 5 minutes), F0, the background fluorescence before addition of the
permeabilising compound, and Fmax, the maximal fluorescence after addition of the
detergent, taken to represent complete lysis of the liposomes.
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3.5.2 Preparation of liposomes
The vesicles used in the dye-leakage experiments were prepared according to a
liposome extrusion method.[418] Briefly, POPC and POPG phospholipids in the
appropriate ratios were dissolved in an organic solvent or solvent mixture such as
chloroform or methanol/DCM in a round-bottom flask. The solvent was evaporated
to dryness on a rotary evaporator to afford an evenly distributed lipid film on the wall
F0
Fmax
Ft
Addition of test compound
Addition of TX-100
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of the vessel. Lipid vesicles are formed when such a lipid film is hydrated with an
aqueous solution. During this process, hydrated lipid sheets become detached from
the lipid film and form large, multi-lamellar vesicles (MLVs) which possess an onion-
like makeup of multiple phospholipid bilayers. In the case of the preparation of
calcein entrapped vesicles, the hydration solution contained the appropriate amount of
the fluorophore, i.e. a concentration in the self-quenching range. Typically, a 10 mM
Tris-buffer containing 50 mM calcein, 10 mM NaCl and 0.1 mM EDTA, pH 7.4 was
used. Once MLVs have been formed, energy input is required to reduce their size and
to break up their multi-lamellar structures. This energy is generally provided either
by sonication or in mechanical form, via extrusion.
The extrusion technique employed in the preparation of the calcein entrapped
vesicles is based on forcing the MLV suspension repeatedly through polycarbonate
membranes of defined pore size, resulting in the formation of large unilamellar
vesicles (LUVs) with a mean particle size in the range of the membrane pore
diameter. Prior to the extrusion process, calcein encapsulated MLVs were subjected
to six freeze-thaw cycles with liquid nitrogen, which is thought to improve the
homogeneity of the resultant LUVs. For the preparation of LUVs, thirteen extractions
through 100 nm membranes were carried out, and the size distribution and
homogeneity of the liposome preparations was confirmed by dynamic light scattering.
Due to the phase transition temperatures of POPC and POPG, which both have a
value of TC = -2°C, all manipulations were carried out at room temperature, and the
prepared liposomes could conveniently be stored at 4°C.
Subsequent to the preparation of calcein entrapped vesicles, unencapsulated
dye had to be removed from the preparations. Therefore, the obtained liposomes were
subjected to gel filtration through a Sephadex G-25 column (1 × 25 cm) with standard
buffer (10 mM Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4) as eluent. Care has to be
taken that the calcein-entrapped vesicles are treated with a buffer system that has a
comparable osmolarity to the buffer used to hydrate the liposomes, in order to avoid
efflux of dye due to an osmotic gradient.[420] The phospholipid concentration of the
liposome preparations was then determined using a colorimetric phosphorous assay
(Bartlett assay),[421] with minor modifications.[422]
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3.5.3 Dye-leakage experiments with AMP(M)s
To study the membrane permeabilising properties of the antimicrobial peptide
mimetics 16 and 17, as well as of the positive control AMP, protegrin-1 (11), dye
leakage experiments were carried out with the POPC/POPG liposomal system at four
different phospholipid ratios. A summary of the results of these experiments,
employing a total liposome concentration of 30 M in each experiment is given in
Figures 3.26-3.28.
It can be seen from the results that protegrin-1 (11) causes substantial leakage
of calcein from POPC/POPG vesicles at all tested ratios. In contrast, the AMPMs 16
and 17 only showed a significant ability to induce dye-leakage from the highly
negatively charged vesicles composed solely of POPG phospholipids, and a
comparison of the induced dye-leakage from pure POPG vesicles by all three
compounds is shown in Figure 3.29. It is evident from this figure that there are no
fundamental differences between the three peptides. The ability of protegrin-1 (11) to
disrupt the purely zwitterionic POPC vesicles is in agreement with its pronounced
haemolytic activity (c.f. Section 1.5) and with the notion that liposomes composed of
POPC can act as models of erythrocytic membranes.[105]
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Figure 3.26 Calcein release from POPC (○), POPC/POPG 80:20 (□), POPC/POPG 70:30 (◊) and 
POPG (●) LUVs induced by protegrin-1 (11). [L] = 30 M.
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Figure 3.27 Calcein release from POPC (○), POPC/POPG 80:20 (□), POPC/POPG 70:30 (◊) and 
POPG (●) LUVs induced by mimetic 16. [L] = 30 M.
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Figure 3.28 Calcein release from POPC (○), POPC/POPG 80:20 (□), POPC/POPG 70:30 (◊) and 
POPG (●) LUVs induced by mimetic 17. [L] = 30 M.
Dye-leakage experiments with 11 and derivatives, employing LUVs composed
of either egg-PC,[133] POPC/POPG (70:30),[423] or more complex phospholipid
mixtures,[415] have been described. In agreement with our experiments, these studies
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attributed a pronounced lytic behaviour to protegrin-1 (11) and a derivative in which
the phenylalanine residue has been replaced with tryptophan to render the molecule
amenable to fluorescence spectroscopy. It has to be mentioned, however, that the
reported dye-leakage ability of 11 is generally slightly higher than observed in our
experiments. For instance, Waring et al. observed an Rf value of around 0.3 for a
peptide to lipid ratio of 0.01, compared to Rf ≈ 0.05 at a lipid to peptide ratio of 0.02
for the various phospholipid compositions used in our experiments. It was also found
that derivatives of 11 with reduced disulfide bonds, or with cysteine residues mutated
to alanine, were significantly less prone to induce dye-leakage from the corresponding
liposome systems, thus highlighting the importance of secondary structural elements
in the peptide/lipid interactions of the compound. It is also of interest to consider -
hairpin AMPs other than 11, for which dye-leakage experiments have been described.
Both tachyplesin-1[106] and polyphemusin-1[111] show a comparable tendency to
induce dye-leakage from at least partially negatively charged model systems.
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Figure 3.29 Comparison of the calcein release (Rf) from POPG LUVs induced by mimetic-16 (●), 
mimetic-17 (□), and protegrin-1 (11, ◊).  [L] = 30 M.
Unlike the dye-leakage induced by 11, which was largely independent of the
phospholipid composition of the vesicles, both 16 and 17 only caused a background
level of fluorescence intensity for the mixed POPC/POPG and the pure POPC
systems, which was slightly larger for mimetic 16 than for mimetic 17. The influence
of introducing zwitterionic phospholipids into the model systems has been
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documented in several studies. For instance, it has been reported that defensins
display a reduced ability to fuse membranes composed largely of zwitterionic
phospholipids,[424] and that dye-leakage caused by defensins is diminished upon
introduction of zwitterionic phospholipids into POPG LUVs.[425] Comparable
behaviour has been demonstrated for the cathelicidin PMAP-23,[410] and for magainin-
1.[426]
3.5.4 Conclusions of the dye-leakage experiments
It has been shown that neither mimetic 16 nor mimetic 17 were able to induce
significant dye-leakage except from the most negatively charged model system,
composed of POPG alone. Nevertheless, both AMPMs were able to interact with and
to permeabilise this model system to an extent that allowed the efflux of the
fluorescent probe molecule. Thus, it has to be concluded that both compounds
possess, in principle, membrane-active properties. Additionally, with respect to the
POPG system, these properties are manifested at peptide to lipid ratios that are in
good agreement with the ratios reported in the literature for other AMPs such as
tachyplesins,[106] polyphemusins,[111] or indolicidin.[111]
With respect to the question of antimicrobial mechanisms of action, however,
it has to be emphasised that in the test liposomal systems more reminiscent of
bacterial membranes, there were pronounced differences in the peptide to lipid ratios
necessary to effect significant dye efflux, as compared to other AMPs such as
protegrin-1 (11). On the basis that peptide to lipid ratios sufficient to induce dye-
leakage can become quite high for some AMPs, it has been argued that these ratios
are too high to render most AMPs unusually membrane-active compounds.[111]
However, it must be mentioned that peptide to lipid ratios usually encountered at the
onset of dye-leakage are found to be between 0.005 and 0.01, i.e. well within the span
of one order of magnitude. Moreover, such ratios are found for notorious examples of
membrane-lytic or pore-forming compounds such as the peptide venom melittin,[427]
or the peptide antibiotic gramicidin S.[414] The authors of the aforementioned study do
not clearly define at which point a peptide to lipid ratio should be considered too high
to point to a membrane-active mechanism. However, in the case of 16 and 17, there is
no appreciable dye efflux in liposomes containing zwitterionic phospholipids up to
ratios larger than unity, and this can safely be equated with an absence of membrane
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permeabilisation, at least with respect to a pore size and/or lifetime of the pores that
would allow for efflux of the fluorescent probe molecule. For example, the absence
of dye leakage at concentrations where lipid flip-flop occurs was correlated with the
transient character of the putative pores according to a toroidal pore mechanism, and
with the variable size that these pores have in the said model.[111]
Therefore, if we accept, for the time being, the mixed liposomal systems as an
adequate first order approximation to bacterial membranes, the results obtained with
16 and 17 are only very difficult to account for with a classical carpet model that
postulates complete lysis of the bacterial membrane, and which would require a
complete efflux of the fluorescent marker at concentrations comparable to the MIC.
This incompatibility becomes more drastic for the behaviour of mimetic-17 towards
P. aeruginosa because of the decrease in the corresponding MIC value, and it might
be anticipated that this could be even more the case for the later AMPMs 18 and 19.
However, since the possibility, in principle, of membrane activity with 16 and
17 has been proved, it is possible that the AMPMs either directly kill microbial
organisms according to the definitions of membrane-active mechanisms, or according
to a SMH model (c.f. Section 2.1.2), with involvement of intracellular targets.
Finally, the absence of dye-leakage in POPC systems is in good agreement with the
low haemolytic properties of 16 and 17.
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3.6 Macromolecular biosynthesis
A powerful approach towards elucidating possible modes of action of an
antibacterial substance consists of studying the incorporation kinetics of radio-labelled
precursor molecules for the biosynthesis of bacterial macromolecules such as protein,
DNA, RNA, and peptidoglycan. A classical example of this methodology is given by
the studies directed towards chloramphenicol, a broad-spectrum antibiotic first
isolated from Streptomyces venezuelae in 1947.[428-430] Gale and Folks as well as
Wisseman et al. observed inhibition of protein synthesis by chloramphenicol in S.
aureus and in E. coli, respectively during the course of studying the incorporation of
radioactively labelled amino acids into the trichloroacetic acid (TCA) insoluble
fractions of these bacterial species.[429, 431]
Changes in the efficiency of incorporating labelled precursor molecules into
bacterial macromolecules can thus allow for the identification of, or give hints
towards the primary site of action of the substance under consideration. This is
especially the case if on the one hand the effect is selective towards the incorporation
of a particular precursor, and on the other hand, it occurs rapidly after addition of the
antimicrobial compound. These limitations arise inter alia because of the close
interconnection between protein and nucleic acid biosynthesis in cells. For instance,
DNA biosynthesis requires protein biosynthesis for the initiation of new rounds of
replication, furthermore, an inhibition of RNA synthesis eventually leads to a halt in
protein synthesis, inasmuch as the supply of mRNA diminishes. Such indirect effects
are usually characterised by a later onset than the direct inhibition that is observed for
the case of inhibition of protein biosynthesis by chloramphenicol.[432] With respect to
the selectivity of the inhibitory action, it should be mentioned that antimicrobial
modes of action that interfere with the cellular membrane integrity, or with processes
involved in energy generation and/or utilization, can also show rapid kinetics of
inhibition, but these are typically characterised by the simultaneous cessation of all
macromolecular synthetic activity. Examples of this pattern pertain especially to the
field of AMPs, and will be discussed in the following sub-sections.
Since all experiments conducted with mimeticsv17 and 18 described in the
previous sections corroborated the notion of an alternative antibacterial mechanism of
action, their influence on the incorporation of radioactively labelled precursors of
macromolecular biosynthesis into P. aeruginosa PAO1 has been studied.
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3.6.1 Incorporation experiments with AMPMs
The radioactively labelled precursors that have been used for these
experiments are summarized in Figure 3.30, they were: L-[4,5-3H]-leucine (30) for
protein biosynthesis, [5,6-3H]-uridine (31) for RNA biosynthesis, [methyl-3H]-
thymidine (32) and [8-3H]-adenine (33) for DNA biosynthesis, and N-acetyl-D-[1-3H]-
glucosamine (34) for peptidoglycan biosynthesis.
H2N OH
O
H3C
CH2T
T
N
N NH
N
NH2
T
O
HO HN
HO
OH
T
HO
O
OHHO
N
H
NHO
O
O
T
T
OHHO
N
H
NHO
O
O
CT3
30 31 32
33 34
Figure 3.30 Tritiated precursors of macromolecular biosynthesis employed in the incorporation
studies directed towards possible modes of action for AMPMs derived from protegrin-1 (11).
As mentioned, experiments studying the incorporation of a labelled nutrient
into a bacterial macromolecular fraction should not be interpreted in isolation from
the biosynthesis of other classes of macromolecules, or from other bacteriological
data such as the kinetics of bacterial killing. Another indispensable aid in the
interpretation of the results obtained consists of the use of positive control antibiotics,
which exert their antibacterial action by an already known mechanism, and against
which the experimental data can be compared. These positive controls also allow for
the validation of the applicability of the chosen experimental setup to the presented
problem. The control antibiotics employed for this purpose are shown in Figure 3.31,
and they were chosen based on their known mode of action, in combination with their
reported activities against Pseudomonas strains.[1] As positive control for the
inhibition of protein biosynthesis, tobramycin (25), a semi-synthetic aminoglycoside,
has been chosen. It acts by binding to the A-site decoding region of the bacterial 16S
rRNA subunit.[433] Tobramycin shows good activity in the micromolar range against
several P. aeruginosa strains that are resistant towards other aminoglycosides, such as
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gentamicin.[434] Ciprofloxacin (7), a synthetic fluoroquinolone, inhibits DNA
synthesis by binding to bacterial DNA gyrase[435] and is one of the most effective
fluoroquinolones acting on P. aeruginosa.[436]
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Figure 3.31 Clinically used antibiotics employed as controls in the incorporation of radioactively
labelled precursor uptake experiments.
As control inhibitor of RNA biosynthesis, a semi-synthetic rifamycin, rifampicin (2)
was used. It has been shown to act by inhibiting DNA-dependent RNA
polymerase[437] and although intrinsically inactive against P. aeruginosa,[438] the in
vitro activity was sufficient for its use as a positive control (vide infra). Finally, as a
positive control for the inhibition of peptidoglycan biosynthesis, aztreonam (35), a
monobactam from Chromobacterium violaceum was chosen. 35 acts by inhibiting
peptidoglycan cross-linking via binding to PBP-3 (penicillin binding protein-3), and
shows good activity against P. aeruginosa.[439, 440]
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3.6.2 Experimental considerations
In principle, two different approaches exist for studying the uptake of
radioactively labelled precursors into bacterial cells. In the continuous labelling
approach, bacteria are first grown in the presence of the labelled nutrient, but without
test compound. After addition of the test compound to the labelled medium, samples
are taken at regular time intervals and processed as described below. In the second
approach, bacterial cultures are pulse-labelled (pulsed) with the radioactive building
block, i.e. samples of a bacterial suspension grown under standard conditions are
taken at regular time intervals and treated with the labelled compound for a short
period of time, typically two to ten minutes. For the incorporation experiments with
AMPMs, both of these methods have been used, although it was not possible to use
both methods for all classes of macromolecules.
It is instructive at this point to consider briefly the general experimental setup
of both approaches, in order to aid in the interpretation of the reported results. Firstly,
the assessment of the incorporation of labelled precursors relies on enumerating the
radioactivity retained in macromolecular components of the bacterial cell, and this
was achieved by a precipitation step with ice-cold 10% trichloroacetic acid (TCA),
which is commonly employed to precipitate protein, RNA, and DNA for analytical
purposes.[441] The acid-insoluble material is collected on glass-fibre filters and
washed extensively to remove unincorporated, radioactively labelled building blocks
as well as other non-macromolecular radioactive contaminants that might have arisen
during metabolism of the label. After drying, radioactivity is quantified in a liquid
scintillation counter, with a scintillation cocktail designed for organic samples that
does not dissolve the precipitate.[442, 443] That this was indeed the case has been
verified by repeating the scintillation measurements on consecutive days, which
always led to identical count rates.
For both the continuous labelling, as well as pulse-labelling approach, P.
aeruginosa PAO1 cultures were grown to an optical density (OD600 nm) of 0.2, which
corresponded to ~1x108 CFU/mL as determined by viable cell counts, to ensure
exponential growth throughout the experiments (c.f. Section 3.3). In continuous
labelling experiments, radioactive label was added to give a final activity of 37
kBq/mL (1 Ci/mL) and the bacterial suspension was grown for a further 15 to 20
minutes before being split into aliquots to which the test compounds were added; this
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was done to ensure bacterial cultures with identical activity. At regular time intervals,
samples were withdrawn, precipitated and quantified as described above. For pulse-
labelling experiments, the starting culture was split into cultures to which test
compounds were added, and from these cultures samples were taken at regular time
intervals and added to medium containing 37 kBq/mL (1 Ci/mL) of the radio-
labelled precursor. Additionally, this medium contained an appropriate concentration
of the test compound. After incubation at standard conditions for four to ten minutes,
the samples were processed as described above.
Experiments were carried out at and above the MIC of the test compounds,
and the MICs were those determined for the higher inoculum (c.f. Section 2.5). The
use of a higher inoculum in the incorporation experiments was required to achieve
reasonable count rates, especially for the experiments directed towards protein
biosynthesis. Due to the experimental error in determining the exact MIC value, most
experiments were carried out above the MIC, typically at 5×MIC. This value was
chosen to minimise potential membrane-lytic activities of the AMPMs that might
occur at higher concentrations (vide supra).
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Figure 3.32 Exponential growth of P. aeruginosa PAO1 in the time interval during which
incorporation experiments were carried out. (●): Incorporation of L-[4,5-3H]-leucine (30) via
continuous labelling; (○): incorporation of [5,6-3H]-uridine (31) via pulse-labelling.
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For comparison with other experiments, such as the killing kinetics of our
AMPM, it was important to ensure that the bacterial cultures were in an exponential
growth phase (vide supra). An example of the exponential growth under the
experimental conditions of the incorporation experiments and representative examples
of both continuous and pulse-labelling are shown in Figure 3.32. From these
examples, the calculated generation time is about 30 minutes ± 3 minutes, which is in
good agreement with the value obtained by other methods such as turbidimetry (30
minutes).
3.6.3 Protein Biosynthesis
Protein biosynthesis in P. aeruginosa PAO1 was studied with L-[4,5-3H]-
leucine (30) by the continuous labelling approach. 30 is often chosen for studying
protein biosynthesis, because it does not serve as a precursor for the synthesis of other
macromolecular building blocks such as aspartic acid. Pulse-labelling with 30 could
not be carried out, since under the experimental conditions, the achievable count rate
was too low to give meaningful results. An experiment on the effect of mimetic-17
on protein biosynthesis is reproduced in Figure 3.33. As can be seen, the
incorporation of 30 into the acid-insoluble fraction of P. aeruginosa PAO1 stopped
markedly slower than for the positive control tobramycin (25).
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Figure 3.33 Incorporation of L-[4,5-3H]-leucine (26) into the acid-insoluble fraction of P.
aeruginosa PAO1; (●): control, (◊): 5×MIC mimetic 17, (□): 5×MIC tobramycin (25)
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Inhibition of incorporation of 30 by tobramycin set in immediately, whereas a
comparable effect for mimetic-17 is visible only about 40 minutes after its addition.
This time delay corresponds roughly to a typical generation time of P. aeruginosa
PAO1 under the experimental conditions of the incorporation assay (vide supra). As
shown in Figure 3.34, an analogous result was obtained for mimetic 18.
Analogously, the reduction of incorporated radioactivity only set in significantly
about 40 minutes after induction with 18. The results of several experiments on
protein biosynthesis are summarized in Figure 3.35, in which CPM obtained relative
to the control, i.e. the labelled bacterial suspension without added antimicrobial
compound, are plotted against time, to allow comparison of the data from different
experiments.
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Figure 3.34 Incorporation of L-[4,5-3H]leucine into the acid-insoluble fraction of P. aeruginosa
PAO1; (●): control, no added compound; (◊): 5×MIC mimetic 18; (□):5×MIC tobramycin (25)
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Figure 3.35 Summary of the Incorporation of L-[4,5-3H]-leucine into the acid-insoluble fraction
of P. aeruginosa PAO1 induced with various antimicrobial agents; (○): 5×MIC tobramycin; (◊): 
5×MIC protegrin-1 (11); (□): 5×MIC mimetic-16; (♦): 5×MIC mimetic 18; (■): 5×MIC mimetic 17.
Clearly, fundamental differences are visible from examination of Figure 3.35,
and the test compounds can be divided into two different classes. Protegrin-1 (11)
and tobramycin (25), as well as mimetic 16, show a faster onset of their inhibitory
action on the incorporation of the radio-labelled leucine compared to both mimetics
17 and 18. The time difference between these two couples, i.e. where the CPM
relative to the control drop markedly below the 100 % level, is found to be about 30
minutes, which correlates well with the observed generation time under the
experimental setup. It is noteworthy that 16 shows behaviour analogous to 11 and 25.
The fast inhibition of protein biosynthesis by tobramycin (25) is explicable by its
mode of action, and attests its utility as a positive control for studying protein
biosynthesis. Accordingly, the fast inhibition of incorporation of radio-labelled 30 by
the AMP protegrin-1 (11) is also explicable by its mode of action. This agent has
been repeatedly shown to rapidly kill susceptible organisms by a membrane-lytic
mechanism, which implies immediate cessation of macromolecular biosynthesis. In
view of these considerations, the results for mimetics-17 and -18 do not point towards
a mode of action primarily affecting protein biosynthesis.
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3.6.4 RNA biosynthesis
The effects of mimetic-18 on RNA biosynthesis were studied using both
continuous labelling and pulse-labelling approaches with [5,6-3H]-uridine (31) as the
labelled precursor molecule. Because of its unique occurrence in RNA, 31 is the
precursor of choice for the study of RNA biosynthesis. The results of an experiment
employing 18 and several control antibiotics are shown in Figure 3.36. As can be
seen, the incorporation of the labelled precursor stops immediately after addition of
the positive test antibiotic, rifampicin (2). In contrast, no inhibitory effect is seen
upon addition of 18, indeed there was even an apparent increase in the incorporation
of the radioactive label. As was to be expected, the two other control antibiotics
included in Figure 3.36 showed a significantly later effect on the incorporation of 31
as compared to rifampicin (2). That is, a significant reduction in the incorporation of
radioactivity becomes apparent only about one hour after the addition of these
antibiotics. Such behaviour is not surprising, since after two generation times a
substantial reduction of the viable cell count, compared to the control sample, is to be
expected, thus leading to a concomitant decrease in incorporated radioactivity.
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Figure 3.36 Incorporation of [5,6-3H]-uridine into the acid-insoluble fraction of P. aeruginosa
PAO1; (●): control; (◊): 5×MIC mimetic 18; (□): 5×MIC rifampicin (2); (■):5×MIC ciprofloxacin (7);
(♦):5×MIC tobramycin (25).
118 Chapter 3
0
1000
2000
3000
4000
-30 20 70 120 170
time [min]
C
PM
Figure 3.37 Pulse-labelling of P. aeruginosa PAO1 with [5,6-3H]-uridine; (●): control; (◊): 
5×MIC mimetic-18; (□): 5×MIC rifampicin (2).
The results of a pulse-labelling experiment with mimetic-18 at 5×MIC and
rifampicin (2) are shown in Figure 3.37. As can be seen, the incorporation of the
labelled precursor is halted immediately by 2 as to be expected from its mode of
action. In contrast, inhibition by 18 is slower, and the reduction in radioactive counts
does not approach background level, as was the case for rifampicin (2). For mimetic
18, the amount of incorporated radioactivity decreases to about half its original value
within 30 minutes after addition of the AMPM and stays at about this level throughout
the rest of the experiment. This reduction in labelling parallels the reduction in the
viable cell count, and indicates that RNA biosynthesis continues without significant
inhibition in the fraction of viable bacterial cells. Therefore, inhibition of RNA
biosynthesis in P. aeruginosa PAO1 is unlikely to be the cause of the activity of our
AMPMs.
3.6.5 DNA biosynthesis
The first approach towards studying DNA biosynthesis in P. aeruginosa
PAO1 induced with AMPMs consisted of incorporation experiments with [methyl-
3H]-thymidine (32) as the radioactive precursor by continuous labelling. In fact, 32 is
commonly used in incorporation experiments directed towards DNA synthesis
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because of the absence of thymidine from RNA. Although there is literature
precedence for the use of a radio-labelled thymidine in studying the synthesis of DNA
in a Pseudomonas species, experiments employing 32 as labelled precursor were
unsuccessful. In such experiments, only very low count rates, below 100 CPM, with
no discernible patterns were observed.
This inability to follow incorporation of 32 into the acid-insoluble fraction of
P. aeruginosa might be explicable in the light of the study by Gottfreddson et al, who
reported on the inability of P. aeruginosa to incorporate labelled thymidine.[444] The
reason for this was argued to stem from the absence of a salvation pathway in P.
aeruginosa for the synthesis of TTP. Therefore, DNA biosynthesis was studied by the
incorporation of [8-3H]-adenine (33) into the acid-insoluble fraction. Because of the
occurrence of adenine in both RNA and DNA, the general protocol had to be
modified. A digestion step was introduced before the TCA precipitation, in which the
sample is treated overnight with 0.3M NaOH and 0.1% EDTA.[444] Continuous
labelling of bacterial DNA was not possible since the uptake of the labelled precursor
was too efficient under the experimental setup. Typically, all of the radiolabel had
already been incorporated before the addition of the test compound(s), and no further
increase in CPM after this 15 to 20 minutes period was observed.
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Figure 3.38 Pulse-labelling of P. aeruginosa PAO1 with [8-3H]-adenine; (●): control; (◊): 5×MIC 
mimetic 18; (□): 5×MIC ciprofloxacin (7).
120 Chapter 3
Therefore, the biosynthesis of DNA in P. aeruginosa PAO1 was studied by
the pulse-labelling approach. An example of a pulse-labelling experiment with
mimetic 18 and the control antibiotic ciprofloxacin (7) is shown in Figure 3.38. As to
be expected from its mode of action, ciprofloxacin (7) immediately stopped the
incorporation of the labelled precursor into the acid-insoluble fraction of P.
aeruginosa. Already at the first time point, the detectable amount of radioactivity was
reduced to less than 500 CPM, at which value it remained throughout the experiment.
In contrast, the incorporation of the label following addition of mimetic-18 increased
slightly from the level observed at the addition of 18. The incorporation of
radioactive marker starts to decrease slowly around 40 minutes after addition of 18
and stays above the level observed for the positive control throughout the experiment.
Again, the pattern of the slow decrease in measured radioactivity incorporated into the
acid-insoluble fraction is explicable by the bacteriostatic effect of 18 alone, and does
not point towards a direct influence of 18 on pseudomonal DNA synthesis. That this
statement is justified can be seen from Figure 3.39 which illustrates an experiment
conducted with tobramycin (25) and protegrin-1 (11). Analogously to 18, the
reduction of incorporated radioactivity by tobramycin (25) shows a slow onset, as to
be expected from its primary action on protein biosynthesis. The stronger inhibition
after 40 minutes is also in agreement with the beginning of dose-dependent
bactericidal behaviour, which is often encountered for aminoglycosides.[445]
The immediate effect of protegrin-1 (11) on DNA synthesis is apparent from
Figure 3.39 and is once again another manifestation of its membrane-lytic behaviour.
A comparison of several pulse-labelling experiments is shown in Figure 3.40 wherein
the obtained CPMs relative to the untreated control of each experiment are plotted
against time.
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Figure 3.39 Pulse-labelling of P. aeruginosa PAO1 with [8-3H]-adenine; (●): control; (◊): 5×MIC 
tobramycin (25); (□): 5×MIC protegrin-1 (11).
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Figure 3.40 Comparison of various pulse-labelling experiments with [8-3H]-adenine on P.
aeruginosa PAO1; (●): 5×MIC ciprofloxacin (7); (○): 5×MIC protegrin-1 (11); (■):5×MIC tobramycin
(25); (□): 5×MIC rifampicin (2); (♦): 5×MIC mimetic 18; (◊): 5×MIC mimetic 17.
Apparently, the tested compounds can be grouped into two different classes.
The first class is formed by the positive control (7) and the membrane-lytic protegrin-
1 (11), whereas the second class is made up of control antibiotics, which possess
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modes of action that do not directly inhibit DNA biosynthesis (2 and 25), and the two
AMPMs 17 and 18. It is instructive to compare the effects of 17 and 18 directly. The
reduction in the observed CPM after 40 minutes is more pronounced for 17 (c.f.
Figure 3.40), but that this is in agreement with the reduction of viable cells still
capable of DNA synthesis can be seen from the correlation of the trends in the
kinetics of bacterial killing with the incorporation of radioactive label, as shown in
Figure 3.41.
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Figure 3.41 Comparison of the decrease in CPM and the decrease in viable cell count [CFU/mL]
relative to the control for 17 and 18; (●): 5×MIC mimetic-17, CPM; (■): 5×MIC mimetic-17, CFU;
(○): 5×MIC mimetic-18, CPM; (□): 5×MIC mimetic 18, CFU.
3.6.6 Peptidoglycan Biosynthesis
Attempts were made to study the biosynthesis of pseudomonal peptidoglycan
with acetyl-D-[1-3H]-glucosamine (34) as radioactively labelled precursor and
aztreonam (35) as positive control antibiotic. Although comparable approaches have
been used, for example, in studying peptidoglycan synthesis in B. licheniformis,[446] or
the mode of action of pesticin, a bacteriocin produce by Y. pestis, in E. coli,[447]
preliminary incorporation experiments were unsuccessful. Incorporation of
radioactivity was unaffected by either mimetic 18 or the positive control antibiotic 35.
Additionally, low count rates were observed, which might have been caused by
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metabolism of the labelled nutrient. Since experiments in media with added
alternative carbon sources such as glycerol and D-glucose were also unsuccessful, the
experiments on peptidoglycan biosynthesis were discontinued.
3.6.7 Conclusions
Summarizing the experimental data, it can be concluded that neither mimetic
17 nor mimetic 18 primarily interfere with protein, RNA, or DNA biosynthesis in P.
aeruginosa PAO1. Clear differences between the behaviour of these AMPMs and the
positive control antibiotics employed were always observed. An inhibitory effect for
the AMPMs only became pronounced after about 40 minutes subsequent to their
addition, thus correlating with their bacteriostatic effects on P. aeruginosa during the
experiments. The incorporation experiments further support the notion of a mode of
action for this class of AMPMs that is not membrane-lytic, and that does not depend
on impairment of membrane functions necessary for macromolecular biosynthesis.
This becomes evident if one considers that the expected outcome of such mechanisms
is the immediate and simultaneous cessation of macromolecular biosynthesis, of
which examples can be found in the literature. AMPs for which such behaviour has
been demonstrated include bactenecins,[448] HNP-1,[145] and PR-39[243] (in my opinion,
c.f. Section 2.2). This also parallels the behaviour of membrane-lytic lantibiotics,
such as pep-5[449] and aureocin A53.[450]
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3.7 Interaction of AMPMs with lipopolysaccharides
The interactions of several AMPs with bacterial lipopolysaccharides (LPS)
have been studied regarding their effect on the direct antimicrobial activity and on the
immuno-modulatory functions of this class of compounds.[451] With respect to the
direct antimicrobial activity of AMP(M)s, lipopolysaccharides are mostly thought to
be involved in selectivity issues (differentiation between mammalian and bacterial
organisms as well as between different bacterial organisms/species), and to confer
bacterial resistance against AMPs via alteration in their structures. Both of these
aspects are linked to the major function of LPS as a permeability barrier in Gram-
negative bacteria. The role of LPS in the immuno-modulatory properties of AMPs, on
the other hand, is related to the recognition of LPS by the host innate immune system;
a process which could be impaired by AMP(M)s via their direct binding to LPS, by
their competition with LPS for its innate immune system receptor(-complex), or by
their affecting the aggregation state of LPS oligomers.[451] Irrespective of which mode
of action dominates in a given case (i.e. either direct antimicrobial or immuno-
modulatory), or even if they both operate simultaneously, the interaction of AMP(M)s
with bacterial LPS is an important aspect of their antimicrobial activity towards
Gram-negative organisms.
Therefore, this peptide-LPS interaction was studied for our AMPMs,
employing a dansyl-polymyxin B displacement assay developed by Hancock et al.[452]
Additionally, three hairpin mimetics derived from a naturally occurring LPS binding
motif, and based on the D-Pro-L-Pro template, were synthesised and tested for their
ability to bind to LPS. With respect to our AMPMs it was also of special interest to
determine whether the remarkable selectivity towards P. aeruginosa could be
correlated with their interaction with LPS.
3.7.1 Structure and function of bacterial lipopolysaccharides
Lipopolysaccharides are an essential component of the outer membrane of
virtually all Gram-negative bacterial organisms.[453] As depicted in Figure 3.42, LPS
is generally thought to be localized asymmetrically to the outer membrane’s outer
leaflet,[454] and this renders LPS the major surface component of Gram-negative
bacterial cell envelopes. It should be noted, however, that at least for Vibrio cholerae,
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phospholipids have been shown to be present in the outer leaflet, and this has been
associated with the increased sensitivity of this organism towards hydrophobic
compounds. [455] Lipopolysaccharides are amphipathic molecules that are
evolutionarily conserved components of Gram-negative organisms, but nevertheless
different bacterial genera, species, and even strains can display large variations in
their structure. The general architecture of LPS comprises three distinct subunits: the
hydrophobic lipid A domain, a core oligosaccharide, and an O-antigen polysaccharide
repeat region (Figure 3.37).
Figure 3.42 Schematic representation of the Gram-negative cell wall of E. coli K-12. Kdo = (3-
deoxy-D-manno-oct-2-ulosonic acid); PPEtN = pyrophosphorylethanolamine; MDO = membrane-
derived oligosaccharides. Note that in this case the outer leaflet on the bacterial surface is solely
composed of LPS.
Lipid A (endotoxin) consists of a phosphorylated N-acetylglucosamine (NAG)
dimer to which saturated fatty acids are attached (Figure 3.43), and functions as a
lipophilic anchor for attachment of LPS to the bacterial surface. The innate immune
system’s response towards a bacterial infection depends upon the recognition of
evolutionarily conserved patterns that are unique to the certain classes of
pathogens,[456] and lipid A functions as such a pattern, which is recognised by the
TLR-4 receptor (toll like receptor) during infection in higher organisms. Therefore,
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lipopolysaccharides are powerful modulators of the immune system in an infected
host; uncontrolled or prolonged exposure to LPS can lead to the severe pathological
condition of endotoxic (septic) shock, which is associated with a high mortality rate.
Despite the role of lipid A as a conserved recognition pattern of the innate immune
defence, large structural variations exist between different organisms in the amount,
length, and structure of attached fatty acid chains (Figure 3.43), and this can have a
profound influence on the recognition of these molecules by the TLR-4 receptor
complex.[457]
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Figure 3.43 Structural diversity of lipid A from three different Gram-negative organisms. (A) E.
coli; (B) P. aeruginosa; (C) H. pylori.
The core polysaccharide (also called core antigen) contains a short chain of
hexose and heptose sugars (Figure 3.44). There are only minor variations of the core
polysaccharide within a genus, but different species can show pronounced
differences.[453] The core oligosaccharides are generally divided into an inner core
region (close to lipid A) and an outer core region (close to the O-antigen) (c.f. Figure
3.42). A particular feature of the inner core region is the presence of L-glycero-D-
mannoheptose (2-keto-3-deoxyoctonic acid; KDO) residues which are extended by
heptose residues, the latter of which can be either phosphorylated, or modified with
phosphoethanolamine or pyrophosphoethanolamine (PPEtn) substituents.
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Figure 3.44 Structure of the core oligosaccharide of P. aeruginosa O5. The attachment points of
lipid A and the O-polysaccharide are indicated. Rha = rhamnose; Hep = glycero-mannoheptose. The
sugar moieties marked in red and the O-polysaccharide chain are missing in R-type LPS.
Finally, the O-polysaccharide (also called O-antigen) consists of repeating
oligosaccharide (3 to 5 sugars) subunits. An individual chain can consist of up to 40
repeat units and these chains are the dominant surface antigens of LPS.[453] Because
of the large amount of available monomeric units (over 60 different sugar moieties
and more than 30 different non-sugar building blocks), this structure shows
remarkable diversity and determines the serological specificity in an organism.[458]
3.7.2 LPS-binding mimetics
Mimetics that are able to bind to bacterial LPS are attractive from at least two
different points of view. Firstly, binding to LPS might protect from severe
complications related to Gram-negative bacterial infections, such as endotoxic shock
(vide supra) and secondly, such mimetics could be useful antimicrobial compounds in
their own right, especially against Gram-negative organisms.
Several proteins are known to interact with LPS, and amongst these the most
well characterised are the lipopolysaccharide binding protein (LBP),[459] the
bactericidal/permeability increasing protein (BPI),[460] and the Limulus anti-LPS factor
(LALF).[461] Binding of these macromolecules to LPS can have different outcomes,
that is, BPI and LALF exert a detoxifying effect on LPS, whereas LBP, which is a
lipid transfer protein, can enhance LPS activity by facilitating binding of LPS to
CD14 in the TLR-4 receptor complex.[462] Additionally, AMPs such as CAP-18,[463]
LL-37,[464] buforin-2,[465] and indolicidin,[465] have been documented to bind to LPS
128 Chapter 3
and to neutralise its biological effects. Therefore, AMP(M)s have been proposed to
represent a promising starting point for the development of anti-LPS agents.[327]
Originating from experiments with domain exchanged hybrid proteins, it has
been proposed that despite their partially different activities, LBP, BPI, and LALF
share a similar LPS binding motif, in the form of a solvent-exposed loop structure.[466]
Constrained peptides of this binding motif have been described as LPS-neutralising
compounds,[467-470] and as Gram-negative selective AMPs.[327]
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Figure 3.45 Schematic representation of LPS-binding hairpin mimetics of BPI (36), LBP (37),
and LALF (38). The D-Pro-L-Pro template is indicated.
Based on the structure of the putative LPS binding loop of
BPI/LBP/LALF,[461] three hairpin mimetics, incorporating the D-Pro-L-Pro structural
template (10), were prepared in order to test the applicability of the peptidomimetic
approach for the development of LPS-binding mimetics. The three mimetics, whose
structures are depicted schematically in Figure 3.45, were synthesised according to
our standard mixed solid phase/solution phase protocol (c.f. Section 3.1). All three
mimetics proved to be inactive against our panel of microbial test organisms (c.f.
Section 3.3) up to concentrations of 64 g/mL.
3.7.2 Principle of the dansyl-polymyxin B displacement assay
The dansyl polymyxin displacement assay is based on the fact that the peptide
antibiotic polymyxin B (1) and its mono-dansylated derivatives, bind to LPS.[471]
Dansylated-polymyxin B fluoresces only weakly when excited at a wavelength of
ex=335 nm in aqueous solution. Upon binding to LPS, the fluorescence of dansyl-
polymyxin is greatly enhanced,[471] and the emission maximum is shifted from
em(max)=520 nm to em(max)=485 nm (Figure 3.46). The relative LPS-binding
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affinity of a given test compound can then be evaluated on the basis of its ability to
competitively displace dansyl polymyxin B from LPS.
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Figure 3.46 Enhancement of the fluorescence intensity of dansyl-polymyxin B upon binding to
LPS. Red curve: 0.2 g/mL dansyl-polymyxin B in 5 mM HEPES buffer, pH 7.2; ex=335 nm. Blue
curve: 0.2 g/mL dansyl-polymyxin B together with 0.6 g/mL of E. coli LPS in 5 mM HEPES buffer,
pH 7.2; ex=335 nm.
For the preparation of dansylated polymyxin B, polymyxin B sulfate was
reacted with dansyl chloride, according to a published procedure.[472] As was to be
expected, a mixture of mono-dansylated polymyxins, together with minor amounts of
multiply substituted compounds was obtained. The crude mixture of dansylated
regioisomers was purified by HPLC chromatography, but no attempts were made to
isolate individual monosubstituted compounds. Therefore, the term dansyl-
polymyxin B will be used to denote the mixture of monosubstituted polymyxins, and
all experiments were carried out with dansyl-polymyxin B obtained from a single
dansylation reaction. The concentration of dansyl-polymyxin B stock solutions was
determined by a dinitrophenylation assay, as described in the literature.[473]
The dansyl-polymyxin B displacement assay was chosen because of its robust
experimental setup, the availability of data on antimicrobial agents studied with this
method,[160, 471, 474-476] and its potential for being implemented as a high throughput
assay. Other methods for the study of LPS-binding interactions include the
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chromogenic Limulus amoebocyte lysate (LAL) assay,[477] and the rabbit pyrogen
test,[477] or surface plasmon resonance spectroscopy.[478]
3.7.3 Displacement assays with AMPMs and LPS-binding mimetics
To assess the LPS binding affinities of the three LPS-binding mimetics (36-
38) as well as of the AMPMs 16, 17, 18, 39 and 40, dansyl-polymyxin B displacement
assays were carried out with LPS from E. coli O111:B4 (Table 3.10) and P.
aeruginosa Serotype 10 (Table 3.11).
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Figure 3.47 Mimetics 39 and 40, derived from 17 by replacement of Arg-12 with Val-12 in 39,
and by replacement of Arg-1 with Leu-1 in 40.
As controls, the AMP protegrin-1 (11), and the commercially available
antibiotics polymyxin B (1) and gentamicin (9) were used (Figure 3.48).
Additionally, Mg2+ ions were tested for their ability to displace the fluorescently
labelled polymyxin from LPS, since cationic compounds have been suggested to
permeabilise the outer membrane via displacement of these cations from LPS.[479]
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Figure 3.48 Polymyxin B (1) and gentamicin (9), two clinically used antibiotics employed as
control compounds in the polymyxin B displacement assays. Note that both compounds are positively
charged at physiological pH.
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Figure 3.49 Representative example of a dansyl-polymyxin displacement experiment with 3
g/mL of E. coli 055:B5 LPS and 2 M dansyl polymyxin B in 5 mM HEPES buffer, pH 7.2; ex=335
nm. For this experiment, increasing amounts of polymyxin B (9) were titrated to give concentrations of
0, 1, 3.5, 8.4, 15.7, 25.4, 39.8, 58.9, and 82.7 M.
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Figure 3.50 Decrease in the relative fluorescence intensity of dansylated polymyxin B for the
experiment from Figure 3.48.
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For the quantification of the LPS-binding affinities, the test compounds were
titrated into cuvettes containing 3 g/mL LPS and 2M of dansyl polymyxin B
(Figures 3.49 and 3.50). The maximum displacement (Imax) of dansylated polymyxin
by a given test compound is calculated from the extrapolated ordinate intercept of a
plot of the reciprocal of % inhibition as a function of the reciprocal of the inhibitor
concentration (Figure 3.51). The I50 value (i.e. 50% displacement of labelled
polymyxin at the LPS and dansyl-polymyxin concentrations used) is obtained from
the extrapolated intercept of the double reciprocal plot with the abscissa, which
furnishes the value for –1/I50.
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Figure 3.51 Double reciprocal plot of the inverse of relative inhibition vs. the inverse of
concentration for the displacement experiment from Figure 3.48. The intercept of the extrapolated plot
with the abscissa gives the value for -1/I50.
As can be seen from Table 3.10, the tested compounds can be broadly
categorized into two groups. Firstly, the controls gentamicin and magnesium show
high IC50 values, concomitant with only about 50% of maximal displacement. The
second group, which contains the synthesised LPS-binding mimetics as well as the
AMP(M)s and polymyxin B all possess comparable I50 values in the low micromolar
range, albeit with variations in their maximal displacement values. It can also be
-1/I50
1/Imax
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observed that for the peptidic compounds, the I50 values correlate well with the overall
positive charge of these molecules (estimated at physiological pH). Compounds with
a charge of +5, for instance, display I50 values between 1.2 and 7.1 M. The value of
1.2 M for polymyxin B sulphate (9) is somewhat lower than for the
peptidomimetics, but it has to be borne in mind that this compound is structurally
different from the mimetics in that it carries a hydrophobic lipid moiety. Indeed, it
has been found that polymyxin B nonapeptide possesses a lower ability to displace
dansyl-polymyxin B than its parent compound.[471, 476] More precisely, Tsubery et al.
determined I50 values of 2.5-3.0 M for polymyxin B nonapeptide as compared to 0.5
M for the parent compound. It is noteworthy that the I50 values reported in the
literature for 1 of 0.5 M,[476] and 2.2 M,[471] are in good agreement with our
obtained I50 values of 1.2 M (E. coli LPS) and 1.8 M (P. aeruginosa LPS).
Table 3.11 I50 and Imax values for LPS from E. coli 055:B5 obtained for MgCl2, control
antibiotics (1 and 9), LPS-binding mimetics (36-38), and AMP(M)s (11, 16, 17, 39, and 41).
Substance I50 [µM] Imax [%] Chargea
MgCl2 660 50 +2
9 240 49 +4
1 1.2 85 +5
36 7.1 91 +5
37 3.8 54 +5
39 3.8 54 +5
40 3.7 69 +5
ent-17 2.6 60 +6
17 2.4 81 +6
38 2.0 47 +6
16 0.5 74 +7
11 0.3 85 +7
a estimated for physiological pH
Table 3.11 I50 and Imax values for LPS from P. aeruginosa 10 obtained for AMP(M)s and for 1.
Substance I50 [µM] Imax [%]
1 1.8 93
17 2.2 56
ent-17 2.5 68
18 1.1 75
134 Chapter 3
From Table 3.11 it can be seen that there were only marginal changes in the
obtained I50 values for mimetics 17, 18 and ent-17, as well as for polymyxin B (1),
when testing LPS from P. aeruginosa. Most importantly, there was no significant
difference in the displacement of labelled polymyxin by either mimetic 17 or its
(antimicrobially) inactive enantiomer ent-17. AMPM 18 displayed the lowest I50
value of all compounds tested with pseudomonal LPS and again, this could be easily
explicable by its increased charge of +7.
3.7.4 Conclusions
It has been argued that the interaction of AMPs with bacterial LPS is an
important aspect of their selectivity towards these organisms.[451] On the other hand,
the majority of AMPs are also active against Gram-positive bacteria (broad-spectrum
activity), and from this point of view it seems likely that AMP-LPS interactions are
not a particularly fundamental feature of AMP action. Gram-positive organisms
display teichoic acids in their cell wall which, analogously to LPS, are recognised by
the innate immune system. Of course, such molecules could play a role comparable
to that of LPS in conferring selectivity of AMPs towards bacterial micro-organisms,
but the question of how specific these interactions are on the molecular level is then
immediately raised. That is, if interaction with negatively charged molecules on the
surface of micro-organisms is conferring selectivity to the AMP action, then for
broad-spectrum AMPs these interactions would have to involve structurally quite
diverse molecules. Therefore, this rather points to an unspecific interaction that could
for example be driven by electrostatic interactions between cationic AMPs and LPS,
or teichoic acids, which could also be assisted by the eventual amphipathic properties
of the AMPs. It has been mentioned already that the membranes of higher organisms
also display a multitude of negatively charged molecules on their surface (c.f. Section
1.4.2), another aspect that disfavours LPS as the sole cause for AMP selectivity.
Along these lines, it has been found, for both our LPS-binding mimetics and
our AMPMs, as well as for all tested compounds in general, that their ability to
displace labelled polymyxin B from LPS is correlated well with the amount of
positive charge that these molecules carry at physiological pH. The antimicrobial
activity of protegrin-1 (11) has been suggested to be correlated with its ability to bind
to the lipid A moiety of LPS.[480] It can be seen from our experiments, that although
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11 possesses a low I50 value, this value is not unusually low as compared to the
peptidomimetics, since 11 carries seven positive charges at physiological pH.
Of special importance is the affinity of 17 and ent-17 towards pseudomonal
LPS, since it has been found that this mimetic (and its later generation congeners) is
especially active against a variety of pseudomonal species (c.f. Section 3.3).
Therefore, it seems highly unlikely that interaction with LPS is a cause for the
remarkable selectivity towards this organism. This notion is further corroborated by
the findings that there are no significant differences in the affinities of mimetic-17
towards both types of LPS, despite its antimicrobial selectivity towards P. aeruginosa.
Interestingly, both polymyxin B nonapeptide and its enantiomer were reported to
show identical I50 values in their interaction with LPS and, as with our AMPMs, these
compounds showed a high D/L activity ratio for P. aeruginosa.[370]
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3.8 Fluorescently labelled AMPMs
Fluorescent labelling of proteins is an important methodology in modern
biochemical and biophysical studies. In particular, fluorescent labelling of proteins
allows for their visualisation, tracking, or quantification in living cellular systems.[481]
Additionally, fluorescently labelled proteins can be used to obtain direct physical
information about the structure of a ligand-binding site, about protein-membrane
interactions, or about the folding of proteins into their native state.[482] Analogously,
fluorescently labelled peptides are versatile tools, which allow probing of their
structure and biological function. Instead of labelling peptides with a (synthetic)
fluorophore, the intrinsic fluorescent properties originating from aromatic amino
acids, most notably from tryptophan, are frequently employed in bio-physical
studies.[483]
3.8.1 Fluorescence spectra of mimetics 16 and 17
Tryptophan is an environmentally sensitive probe,[483] which means that both
its fluorescence maximum and its fluorescence intensity depend on the molecular
environment of the fluorophore. Typically, a blue-shift (i.e. towards lower
wavelengths) of the emission maximum, as well as an increase in the fluorescence
intensity upon change from an aqueous to a more apolar environment is observed for
environmentally sensitive fluorophores. The dependence of the spectroscopic
characteristics of such fluorophores on the polarity of their molecular environment
apparently renders them suitable for studying peptide-membrane interactions.[484]
To provide an illustrative example, the fluorescence spectra of 2 M solutions
of the AMPMs 16 and 17 were recorded in the presence or absence of 25 mM SDS
and are depicted in Figures 3.52 and 3.53. In such experiments, the micellar
structures formed by the anionic detergent SDS are commonly employed as a
membrane-mimicking environment. Interestingly, although the fluorescence
spectrum of mimetic-17 shows the expected blue shift in the presence of SDS
micelles, the fluorescence intensity decreases.
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Figure 3.52 Intrinsic tryptophan fluorescence of 2 M mimetic 16 in the presence (red) and
absence (blue) of 25 mM SDS (10 mM Tris, 10 mM NaCl, pH 7, ex=280 nm).
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Figure 3.53 Intrinsic tryptophan fluorescence of 2 M mimetic 17 in the presence (red) and
absence (blue) of 25 mM SDS (10 mM Tris, 10 mM NaCl, pH 7, ex=280 nm).
138 Chapter 3
Although the use of intrinsic tryptophan fluorescence in biophysical studies is
straightforward, there are several problems associated with it. The most severe
limitations restricting its broader applicability are the ubiquitous abundance of
tryptophan residues in proteins and the generally unfavourable spectroscopic
characteristics of tryptophan (i.e. low excitation and emission wavelengths in the UV
region).
One way to overcome the inherent problems of tryptophan fluorescence
consists of labelling peptides with fluorophores that possess superior spectroscopic
characteristics. The use of longer excitation and emission wavelengths, for example,
avoids interference from the ubiquitous tryptophan residues of peptides and proteins,
and opens up the possibility of studying labelled compounds in complex systems. In
particular, it allows for the use of methods such as fluorescence spectroscopy in live
cellular systems, which would otherwise not be possible due to auto-fluorescent
interference of the studied cells.
Apart from being a necessary prerequisite for studies on peptide interactions
with complex systems, fluorescent labelling also offers additional advantages for the
study of smaller model systems. For instance, the interaction of peptides with model
membrane systems is often investigated by fluorescent methodologies, and although
such studies often use tryptophan as the fluorescent probe, the advantage of
fluorophores with longer excitation and emission wavelengths in applications with
model membrane systems lies in an reduced amount of scattering brought about by
liposomes or micelles, since this phenomenon decreases with increasing
wavelength.[483]
Additionally, even for the relatively small cyclic peptides in which we are
interested, the presence of multiple tryptophan and tyrosine residues can become a
complicating factor. For example, these multiple fluorescent residues may experience
different molecular environments even within the same molecule, and this can render
it impossible to specifically probe a distinct position in the molecule under
investigation.
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3.8.2 Fluorescence labelling
There exist two conceptually different approaches to the incorporation of
fluorophores into (proteinaceous) target molecules. Firstly, the fluorophore(s) can be
introduced either during the (bio-)synthetic elaboration of the target molecule, or
secondly it (they) can be introduced after the target molecule has been synthesised.
Traditionally, the most frequently used approach to the fluorescent labelling of
proteins consists of derivatisation with a reactive fluorophore, following synthesis
and/or purification. This is commonly achieved at the free N-terminus or at
nucleophilic amino and thiol side-chain functionalities. Naturally, the simultaneous
presence of several reactive sites in the vast majority of protein/peptide substrates
precludes a global procedure for site-specific labelling of these molecules.
Due to the aforementioned, and still growing, importance of fluorescent
methodologies, a variety of novel approaches have been developed to achieve more
specific labelling of target proteins with a variety of fluorophores (or other
functionalities such as photo-labels, biotin, etc.). Frequently, genetically encoded
fluorescent labels such as GFP can be fused to a target protein, which also allows the
labelling of proteins in live cellular systems.[485] Another genetic approach consists of
fusing the target protein with either a receptor domain or a peptide sequence that can
be selectively modified by a fluorescent labelling reagent. For example, the
biarsenical compound 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluorescein (FlAsH) can be
used to covalently label a tetra-cysteine motif,[486] and biotin ligase (BirA) permits the
attachment of biotin to a 15-amino acid consensus sequence.[487]
Another way of incorporating novel functionality into target macromolecules
is represented by the bio-orthogonal chemical reporter strategy. Therein chemical
reporters, which can later be reacted with the fluorescent probe molecules of
appropriate functionality, are incorporated into the proteins by the biosynthetic
machinery of the target cell. Bio-orthogonal amino acids, containing azide or alkyne
functionalities, for example, can be incorporated site-specifically into proteins by
using the nonsense suppression technique.[488] Examples of the highly selective
reactions used in bio-orthogonal approaches to attach the probe molecules comprise
Staudinger ligation, [3+2] cycloadditions with azides and alkynes, or strain-promoted
cycloadditions.[489]
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An important requirement for the applicability of labelled molecules is that the
structural change due to the incorporation of the fluorophore should be kept as small
as possible. This structural confinement can be of paramount importance for
maintaining the biological activity of the labelled compound, and thus for its
usefulness as a tool for studying the physico-chemical properties of the parent
compound. Not surprisingly, perturbation of structure and/or function can be a severe
problem for proteins labelled via genetic fusion to GFP and similar fluorophores. In
comparison, one of the advantages of labelling with bio-orthogonal amino acids is that
the structural perturbations can be kept to a minimum.
Due to their smaller molecular mass, such factors naturally affect peptides to a
greater extent than proteins. In comparison to peptides, fluorescence labelling of
proteins usually poses less stringent criteria for the introduction of the fluorophore
due to their larger size and domain architecture. Frequently, a variety of residues are
available on the surface of the protein that are not directly involved in the
activity/function of the protein, and lend themselves to modification by a fluorophore.
With respect to AMPs, the incorporation of larger sequences is obviously not
desirable; additionally the modification of the abundant positively charged lysine
residues could lead to undesirable changes in physico-chemical parameters such as
amphipathicity, hydrophobicity and charge that might adversely affect their biological
activity.
3.8.3 Labelling with fluorescent amino acids
The second approach, which was employed here to fluorescently label
AMPMs, consists of incorporating a fluorescent amino acid during the synthesis of
the target molecule. An apparent advantage lies in the fact that the incorporation of
the fluorophore can be achieved selectively in the desired position during the SPPS of
the peptide chain. Alternatively, fluorescent amino acids can be introduced
biosynthetically using nonsense suppression.[490]
Compared to the more traditional approach of labelling proteins with
fluorophores containing reactive moieties, another advantage of the direct
incorporation of the fluorophore lies in the fact that it is not restricted to the labelling
of positions in the primary sequence that carry particular functional groups, that is,
any chosen residue can be replaced by the fluorophore.
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Several fluorescent amino acids have been reported in the literature, and a
selection of amino acids with different fluorophores that have been used in SPPS is
given in Figure 3.54. Fluorophores that have been incorporated into amino acids
include the DANA system (41),[490, 491] coumarin-based dyes (42),[492] the 8-
hydroxyquinoline system (43),[493] fluorescein derivatives (44),[494] the anthraniloyl
group (45),[495] and the NBD system (46).[496]
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Figure 3.54 A selection of synthetic fluorescent amino acids that have been used in SPPS for
labelling peptides and proteins.
For the synthesis of fluorescently labelled AMPMs, we chose the so-called
DANA (6-(2-dimethylaminonaphthoyl)alanine; Aladan; 41) system, developed
independently by Imperiali and Cohen.[490, 491] The fluorescent amino acid 41 is
derived from the well-studied PRODAN fluorophore, pioneered by Weber, that has
been extensively used for bio-physical studies of peptides and proteins.[497]
Like PRODAN, DANA (41) is an environmentally sensitive fluorophore that
can be used to study peptide-membrane interactions, and it has been used to probe
protein electrostatics. However, no applications of 41 for studying peptide-membrane
interactions, especially in the field of antimicrobial peptides, have been reported so
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far. Fmoc-protected DANA (52) is fully compatible with standard SPPS protocols,
and could be used in the syntheses of various fluorescently labelled peptide mimetics,
according to the general mixed solid-phase/solution chemistry strategy used in our
laboratory (c.f. Section 3.1).
3.8.3.1 Synthesis of the fluorophore
Our synthetic approach to Fmoc-DANA essentially follows that developed
independently by Imperiali and by Cohen,[490, 491] and is outlined in Scheme 2.
Briefly, commercially available 2-acetyl-6-methoxynaphthalene (47) was reacted with
lithium dimethylamide in HMPA to give acedan (48) in 70 % yield after
recrystallisation from ethanol. Compound 48 was deprotonated using lithium bis-
hexamethyldisilazide as a sterically hindered, non-nucleophilic base, in THF at –78
C, followed by iodination in THF to afford crude iodo-acedan (49) as an orange solid
in 95 % yield. NMR analysis of the crude reaction product showed complete
consumption of the starting material, and formation of a small amount of bis-iodinated
side-product. Compound 49 has been found to be prone to rapid degradation at room
temperature and under light, especially in chlorinated solvents. Nevertheless, pure 49,
as well as its bis-iodinated side product could be isolated by column chromatography
using ethyl acetate as eluent. However, the crude reaction product of the iodination
reaction was used without further purification in the following reaction.
The key step in the synthesis of 52 consists of an asymmetric electrophilic
alkylation of N-(diphenylmethylene)glycine tert-butylester[498] with 49. The
alkylation reaction was carried out using 20 mol% of O-(9)allyl-N-(9-
anthracenylmethyl)cinchonidinium bromide (50) as a phase transfer catalyst and
afforded the crude Schiff base 51 in 85% yield, which was used without further
purification. The enantiomeric excess of 90% ee of 51 was determined by
derivatisation with N-(2,4-dinitro-5-fluorophenyl)-L-valinamide (modified Marfey’s
reagent) and subsequent HPLC analysis.[499] Deprotection of the Schiff base in TFA
containing ethanedithiol as a scavenger, yielded DANA (41), which was Fmoc-
protected using Fmoc-OSu in water/acetone at pH 8, to furnish Fmoc-DANA-OH (52)
in 96% yield.
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Scheme 2 Synthetic approach to the synthesis of Fmoc-DANA-OH (52).
3.8.3.2 Synthesis of fluorescently labelled AMPMs
Fluorescently labelled peptide analogues of mimetic 16 and mimetic-17 were
prepared recently by a co-worker in our group, permuting the DANA fluorophore
through all positions in the peptide with the exception of the D-Pro-L-Pro template.[500]
In this work, 72 and 77, in which Trp-8 of the scaffolds of mimetics 17 and 19,
respectively is replaced with the fluorophore, were synthesised. The synthesis of
fluorescently labelled analogues was carried out according to the standard protocol for
the synthesis of AMPMs outlined in Section 3.1 and described in detail in Section
5.2. The fluorescent amino acid was incorporated into the peptide chain by manually
coupling 1.5 equivalents of 52 using 1.45 equivalents of HATU as activating reagent
and 3.0 equivalents of DIEA. Crude peptides were purified by RP-HPLC and
determined to be of at least 98% purity by analytical HPLC. ESI mass spectrometric
and analytical HPLC data are summarised in Appendix 2.
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Table 3.12 Antimicrobial activities for the fluorescently labelled analogues of mimetics 16 .and
17, as well as for a fluorescently labelled analogue of mimetic 19. The position of the incorporated
DANA fluorophore is underlined and highlighted in green, and the numbering of amino acid residues is
given for the parent compounds. The fluorescently labelled analogues that retain the characteristic
activity pattern are highlighted.
IDa sequenceb MICc [g/mL]
E. coli P. aeruginosa S. aureus
25922d 27853d PAO1d 25923d 29213d
16 1L2R3L4K5K6R7R8W9K10Y11R12VpP 4 2 2 16 16
53 LRLKKRRWKYRVpP 4 2 4 16 8
54 LRLKKRRWKYRVpP 16 16 32 16 16
55 LRLKKRRWKYRVpP 16 8 8 8 8
56 LRLKKRRWKYRVpP 8 8 16 8 8
57 LRLKKRRWKYRVpP 8 16 16 8 8
58 LRLKKRRWKYRVpP 4 4 8 8 8
59 LRLKKRRWKYRVpP 8 4 8 16 8
60 LRLKKRRWKYRVpP 8 4 8 16 16
61 LRLKKRRWKYRVpP 8 8 8 8 4
62 LRLKKRRWKYRVpP 8 8 8 8 4
63 LRLKKRRWKYRVpP 16 16 32 16 16
64 LRLKKRRWKYRVpP 8 8 16 16 8
17 1R2W3L4K5K6Q7R8W9K10Y11Y12RpP 16 0.25 1 16 > 64
65 RWLKKQRWKYYRpP 8 64 64 32 16
66 RWLKKQRWKYYRpP 4 16 16 64 32
67 RWLKKQRWKYYRpP 8 64 64 16 16
68 RWLKKQRWKYYRpP 4 64 64 32 16
69 RWLKKQRWKYYRpP 4 32 32 32 16
70 RWLKKQRWKYYRpP 4 8 8 8 8
71 RWLKKQRWKYYRpP 8 32 32 32 16
72 RWLKKQRWKYYRpP 8 0.5 0.5 32 16
73 RWLKKQRWKYYRpP 16 32 32 16 16
74 RWLKKQRWKYYRpP 16 32 16 32 16
75 RWLKKQRWKYYRpP 8 16 16 16 8
76 RWLKKQRWKYYRpP 8 64 32 64 32
19 1T2W3L4K5K6R7R8W9K10K11A12KpP 64 0.008 0.015 > 64 > 64
77 TWLKKRRWKKAKpP 64 0.125 0.5 > 64 > 64
a Substance identifier; b p = D-Pro; c minimal inhibitory concentration; d strain or ATCC number.
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3.8.3.3 Biological activities of the fluorescently labelled AMPMs
The biological activities of the synthesised AMPM analogues were evaluated
against our panel of microbial test organisms and the results are summarized in Table
3.12. It can be seen that the series of compounds derived from mimetic-16 was
insensitive to the position into which the fluorescently labelled amino acid was
incorporated. All compounds retained the broad spectrum activity of the parent
mimetic, albeit with a slightly reduced potency. Only compound 53, in which the
Leu-1 was replaced by the fluorophore, fully retained the antimicrobial activity of
mimetic 16, whereas replacement of Arg-2 or Arg-12 in 54 and 63 lead to a larger
decrease in activity than for the rest of the series.
For the series of analogues derived from mimetic-17, on the other hand, only
substitution of Trp-8 by the DANA fluorophore in compound 72 resulted in retention
of the selectivity towards P. aeruginosa, which is characteristic for the second to
fourth generation AMPMs derived from protegrin-1. This might be explicable by the
similar physico-chemical properties of the fluorescent label as compared to
tryptophan, both being amino acids bearing aromatic side chain functionalities of
comparable steric bulk. Analogously, the DANA fluorophore could also be
incorporated into the Trp-8 position of mimetic 19 to yield an analogue with good
activity against P. aeruginosa. Interestingly, the replacement of residues other than
Trp-8 in the scaffold of 17 did not lead to a complete loss of antimicrobial activity. In
fact, a slight improvement of activity against E. coli and S. aureus was observed,
while on the other hand, the activity against P. aeruginosa was reduced to a level
comparable to that observed for E. coli and S. aureus.
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3.8.4 Fluorescent properties of the DANA fluorophore
As a first step in evaluating the fluorescence properties of the labelled model
compounds, NAAA (N-acetyl-aladan amide, 78), an amidated and N-acetylated
derivative of DANA was prepared (Figure 3.55), and the dependence of the
fluorescence spectroscopic characteristics of the fluorophore on the environment was
examined by recording fluorescence emission spectra of 78 in various bulk solvents
(Figure 3.56)
Me2N
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Figure 3.55 N-Acetyl-aladan amide (78); an amidated DANA derivative used for the evaluation
of the spectroscopic properties of the fluorophore.
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Figure 3.56 Fluorescence emission spectra of 78 in various bulk solvents. Water (blue), TFE
(light blue), ethanol (red), DMF (green), Ethyl acetate (black), and diethyl ether (pink).
Apart from cyclohexane and carbon tetrachloride, in which 78 was not
sufficiently soluble, all tested solvent systems caused a more or less pronounced
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increase of fluorescence intensity, concomitant with the typical blue-shift of the
emission maximum. The largest effects were found for ether solvents, whereas
alcoholic solvents resulted in intermediate changes in the fluorescence spectra. The
emission maxima and the relative fluorescence intensities of 78 in over 20 common
solvents are given in Table A5.1 (see Appendix 5).
Additionally, the fluorescence spectra of 78 in the presence or absence of SDS
micelles, as a simple membrane mimicking environment, were recorded and are
shown in Figure 3.57. It was found that 78 showed about a sevenfold enhancement in
fluorescence intensity upon transition to the membrane-mimicking environment, thus
rendering it potentially useful for studying peptide-membrane interactions.
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Figure 3.57 Fluorescence emission spectra of 2 M 78 in the presence (red) and absence (blue) of
25 mM SDS (10 mM Tris; 10 mM NaCl; pH 7.0; ex = 360 nm).
The increase in fluorescence intensity in the presence of SDS is comparable to
the values obtained for 78 in alcoholic solvents (c.f. Figure 3.56). It is interesting to
note in this respect, that TFE which is often used as a membrane-mimicking solvent in
NMR studies, only leads to a very weak increase in DANA fluorescence as compared
to an aqueous solution.
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3.8.4 Applications of fluorescently labelled AMPMs
With a variety of fluorescently labelled analogues in hand, several experiments
were carried out to demonstrate the usefulness of DANA-labelled mimetics as model
compounds for studying mechanisms of action of AMPMs. For example, the
interaction of fluorescently labelled analogues of mimetic-16 with liposomal model
membrane systems has been studied by a fluorescence spectroscopic method, and
furthermore, the practicality of DANA-labelled AMPMs for (confocal) fluorescence
microscopy studies has been investigated.
3.8.4.1 Peptide-bilayer interactions of the mimetic 16 scaffold
As discussed above, the properties of the DANA fluorophore can be used to
study the interaction of labelled AMPMs with model membrane systems. Such
interaction is best described as the partitioning of the peptides into the (model)
membrane. Frequently, the partitioning of peptides into membranes is accompanied
by the formation of secondary structure, and this has also been found to be the case
for mimetic-16 (c.f. Section 3.2). As a result, peptides bound to membranes often
have a much higher structural content than they do in aqueous solution, and this is a
widespread phenomenon encountered with antimicrobial peptides.[501]
The folded peptide must have a lower free energy in the membrane compared
to the unfolded peptide. Because of the fluid nature of membranes, and since the
hydrophobic and electrostatic components that are the major driving forces of most
peptide-bilayer interactions arise from the collective properties of the lipids
comprising the bilayer, the interactions of peptides with membranes should be
considered as interactions with an assembly of lipids (bilayer), rather than as
interaction with the individual lipid molecules of which it is comprised. Thus
chemical equilibria such as P + L PL are inappropriate descriptions of peptide-
bilayer interactions. Biologically relevant bilayers are in highly thermodynamically
disordered states, and the association of peptides with bilayers should therefore be
treated as partitioning between two immiscible fluid phases. The chemical potentials
 of a peptide in the aqueous and in the bilayer phase must be equal at equilibrium.
Hence one can define a mole fraction partition coefficient Kx given by
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Kx 
[P]bilayer /([L] [P]bilayer )
[P]water /([W]  [P]water )
[equation 3.2]
where [P]bilayer and [P]water denote the bulk molar concentrations of peptide in the
bilayer, respectively water, phase and [L] and [W] stand for the molar concentrations
of lipid and water.[502]
3.8.4.2 Determination of membrane partitioning coefficients
Methods for the experimental determination of partition coefficients are based
on either physical separation such as dialysis, or on titration methods such as
fluorescence and CD spectroscopy.[502] In the case of spectroscopic titration methods,
the fraction fp of partitioned molecules is not immediately known. Instead, one
measures a spectroscopic response, such as fluorescence intensity, that is assumed to
be proportional to the fp, and the proportionality constant must be defined by the
maximum signal change at full binding. To be of use for binding measurements,
spectroscopic parameters need to be linear-response functions. An example of a
linear-response function is steady-state fluorescence intensity at a constant
wavelength, as employed in our experiments.
Membrane partitioning coefficients for DANA labelled analogues of mimetic
16 were measured using a POPC/POPG liposomal model system. LUVs of
appropriate phospholipid compositions and a diameter of 100 nm were prepared
according to the extrusion method described in Section 3.5. To obtain the fraction of
partitioned molecules, fp, the increase in fluorescence intensity at 400 nm was
measured and the data were fitted to the following equation:[503]
fp 
Kx[L]
[W]  K x[L]
[equation 3.3]
A representative fluorescence titration curve of 62 is shown in Figure 3.58, and the
partitioning coefficients obtained for the series of analogues derived from mimetic-16
with three different liposomal systems are summarized in Table 3.13.
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Figure 3.58 Fluorescence titration of 64 with increasing amounts of the POPC/POPG (80:20)
liposomal system. The fitting of the fluorescence intensity at 400 nm to equation 3.3 is shown in the
inset.
It can be seen from Table 3.13 that all tested compounds have the ability to
partition into negatively charged model membranes, and that this ability generally
increases with increased negative character of the liposome system. It is noteworthy
that there was no observable change in the fluorescence intensity of DANA-labelled
AMPMs when the purely zwitterionic POPC systems was used in the titration
experiments, thus not allowing for the determination of a partitioning constant for this
system.
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Table 3.13 Membrane partitioning coefficients Kx obtained from fitting the experimental data to
equation 3.3 and free energies G calculated as G = -RT ln(Kx)[502] for the series of DANA labelled
analogues derived from mimetic 16. Measurements were carried out for three different POPC/POPG
liposomal systems.
POPC/POPG (80:20) POPC/POPG (70:30) POPG
Substance Kx [×10-5] G [kJmol-1] Kx [×10-5] G [kJmol-1] Kx [×10-5] G [kJmol-1]
53 4.8 -31.9 7.1 -32.8 155.4 -40.3
54 3.9 -31.3 9.5 -33.5 141.9 -40.1
55 1.8 -29.4 6.4 -32.6 257.0 -41.6
56 7.0 -32.8 16.3 -34.8 34.6 -36.7
57 7.8 -33.0 13.3 -34.4 236.8 -41.4
58 9.1 -33.4 n.d.a n.d. 189.7 -40.8
59 3.4 -31.1 6.8 -32.7 35.9 -36.8
60 5.4 -32.2 4.9 -31.9 131.5 -39.9
61 3.0 -30.6 21.1 -35.5 253.5 -41.5
62 7.5 -33.0 10.4 -33.7 56.8 -37.9
63 7.5 -33.0 15.2 -34.7 113.3 -39.6
64 3.2 -30.9 5.7 -32.3 50.2 -37.6
a n.d. = not determined.
3.8.5 Fluorescence microscopy with DANA labelled AMPMs
To test whether DANA-labelled mimetics could be used as tools in
fluorescence microscopic studies, experiments were carried out on the incorporation
of the labelled mimetics 56 and 72 into HeLa cells via confocal fluorescence
microscopy (Figure 3.59). Compound 56 was chosen as a representative of the series
of analogues derived from 16, and compound 72 was selected since at the time it was
the only DANA-labelled compound that retained the selective activity pattern of
mimetic 17.
Briefly, HeLa cells at a concentration of 6×104 cells/mL were incubated in
Lab-Tek 22×22 mm flat-bottomed chamber slides (Nunc, Roskilde, Denmark), and
incubated overnight at 37 °C. The fluorescently labelled peptides 56 or 72 were then
added to the cell cultures and incubated at 37 °C for 1 to 6 hours. The cells were
subsequently washed three times with PBS, and fixed in methanol-acetone (1:1) at
−20°C for 30 min.
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Additionally, P. aeruginosa PAO1 cells were incubated with mimetic 19
analogue 77 under conditions identical to those employed in the proteomic
experiments towards target identification (Figure 3.60, c.f. Section 4.1). Briefly, P.
aeruginosa PAO1 cells were grown to an OD of 0.2 and corresponding to
approximately 1×108 CFU/mL. Bacterial cells were washed twice in Mueller-Hinton
broth and incubated with 0.3 g/mL of 77.
Figure 3.59 Uptake of fluorescently labelled analogues of AMPMs into HeLa cells. (A) 10 M
of 56, 6h; (B) 1 M of 72, 6h.
Figure 3.60 Fluorescence microscopy image of P. aeruginosa PAO1 cells treated with compound
77. Cells were incubated with 0.3 g/mL of 77 for 60 minutes.
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As can been seen from Figures 3.59 and 3.60, DANA-labelled peptides could
be used in fluorescent microscopy applications, thus validating the potential of site-
specifically fluorescently labelled AMPMs for studying AMP action in vivo. Due to
possible artefacts during the fixation procedure employed during experiments with
HeLa cells, it is not advisable to make statements about uptake mechanisms into these
cell cultures for our AMPMs. However, it can be clearly seen from Figure 3.59 that
there are significant differences in the obtained fluorescence pattern for both
compounds. Compound 72, on one hand, was incorporated more efficiently, since a
tenfold higher concentration of 56 was required to achieve a similar level of
fluorescence intensity under similar experimental conditions, and compound 72 was
also able to translocate into the cell nucleus, as manifested by visualisation of
nucleolic structures. Compound 56, on the other hand, accumulated largely in a
region around the cell nucleus which is typically occupied by the endoplasmatic
reticulum (ER).
3.8.5 Conclusions
The synthesis of fluorescently labelled analogues of mimetics 16 and 17, as
well as of one compound derived from 19 showed that the DANA fluorophore could
be conveniently incorporated site-specifically into the scaffold of AMPMs derived
from protegrin-1 (11). It was found that in mimetic 17, only the aromatic residue Trp-
8 could be replaced by the DANA fluorophore with retention of the selective activity
against P. aeruginosa. The loss of the anti-pseudomonal activity by the other
analogues of 17 emphasises the need for methods capable of site-specific labelling in
this system. Furthermore it corroborates the notion of a mechanism of antimicrobial
action for mimetic 17 and the later generation AMPMs that depends on more than just
the physico-chemical parameters of these molecules, such as hydrophobicity and
amphipathicity.
However, the retention of antimicrobial activity for those analogues that lost
the selectivity towards P. aeruginosa, as well as the insensitivity of mimetic 16
towards the incorporation of the fluorophore, indicates that for both AMPMs a more
unselective, presumably membrane-active, mechanism of action is also operating. In
the case of 16, such a mechanism would account solely for the antimicrobial activity,
whereas for mimetic 17 it can provide an explanation for the observed residual
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antimicrobial activity against E. coli and S. aureus. In the case of 17 and congeners,
this basic, or residual membrane-active mechanism is then supplemented by an
alternative (and stereospecific, c.f. Section 3.4) mechanism of action, which does not
necessarily have to be independent from the membrane-active mechanism. It is
noteworthy that the MIC values obtained for the analogues of 17 are generally two- to
fourfold higher than observed for the series derived from 16, which might point
towards a reduced potency of 17 for (stereo-)unspecific interaction with membrane
systems or other cellular compounds.
The practicality of using DANA-labelled compounds for studying AMPMs by
(confocal) fluorescence microscopy has been validated in this work. Also an assay
has been established that allows for quantification of the interaction of labelled
peptide mimetics with liposomal model membrane systems. In the latter experiments,
which were carried out with analogues of mimetic 16, it has been found that,
paralleling their broad-spectrum antimicrobial activity, all tested analogues showed
comparable energetics for the interaction with the model membranes. Moreover, it
was found that increasing the negative charge of the model membrane system led to
increased partitioning of the peptide mimetics into the bilayer. It is noteworthy that
there was no appreciable partitioning into the purely zwitterionic model membrane
system (i.e. into vesicles composed solely of POPC), which is in agreement with the
results form the dye-leakage experiments of 16 (c.f. Section 3.5), and also with the
low haemolytic activity of this compound. Although partitioning into the liposomal
systems was most favourable for the purely anionic POPG system, substantial
partitioning into the bilayer also occurred for the mixed liposomal systems. This is
somewhat in contrast to the results of the dye-leakage experiments conducted with
mimetics 16 and 17, where it was found that appreciable leakage of encapsulated
calcein only occurred with POPG liposomes. These findings could be interpreted as
indicating that 16 and fluorescently labelled analogues of 16 are able to interact with
(i.e. to partition into) mixed model membrane systems, but are unable to induce
leakage of compounds the size of calcein or larger except from the most negatively
charged model systems.
Finally, the fluorescently labelled compound 77, which is derived from
mimetic 19, retained - analogously to compound 72 - the selective antimicrobial
activity against P. aeruginosa. Due to the increased antimicrobial activity of 77,
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which also parallels the higher activity of 19 compared to 17, this compound might
prove a valuable tool for studying AMPMs via fluorescence methodologies.
4 Approaches towards target identification
With the experiments described in Chapter 3 providing further corroborating
evidence of the prevalence of an alternative mechanism of antimicrobial action for the
AMPMs derived from protegrin-1 (11), several approaches have been employed
towards the elucidation of putative molecular targets for this class of compounds in P.
aeruginosa PAO1. As outlined in Chapter 1, there are two conceptually different
approaches towards antibacterial drug discovery. Target based drug discovery starts
from the identification of a viable (antibacterial) drug target, possibly via a
bioinformatic approach that takes advantage of the increasing availability of genomic
sequence data, and usually relies on high-throughput screening of large compound
libraries with an assay system based on the putatively identified target. Several
problems associated with this approach, such as the often unfavourable uptake
characteristics of the identified drug candidates into bacterial cells were mentioned in
Section 1.1.
The second and more classical approach, which is currently receiving renewed
interest - not least because of the to date disillusioning results of target based drug
discovery programmes - starts from a lead compound that is selected by virtue of its
activity in an in vivo based assay system. That is to say that the identified lead
compound(s) display(s) sufficient activity to elicit a desired phenotypic change in the
assay system; in the case of antibacterial drug discovery the desired phenotypic
change is represented by the inhibition of bacterial growth or by a direct bactericidal
action. The advantage of this second approach with respect to the ultimately
necessary in vivo activity is evident, but it suffers from the fact that the mode of
action, and hence the molecular target(s) of the lead compound(s) emerging from
activity based screens, are generally unknown.
However, identification of the molecular target(s) of potential therapeutic
agents is important in several regards. First of all, an insight into drug-target
interactions on the molecular level enables the design of target based assays, which in
turn allow for more efficient SAR studies, and greatly aid in the efforts of medicinal
chemistry towards modification of the lead structure. With respect to our AMPMs,
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for instance, such knowledge might also allow us to extend the antibacterial spectrum
towards other species. Secondly, knowledge of the lead compounds’ mechanism of
action should aid in the identification or anticipation of possible side-effects on
human cells, and thus open the way to their minimisation. Moreover, once the mode
of action of a potential drug candidate is established, target validation of structurally
modified compounds derived from the lead compound becomes more straightforward.
Finally, even though historically many antibiotics were successfully marketed and
used long before their underlying mechanisms were elucidated, knowledge of an
antimicrobial agent’s mode of action is often regarded nowadays as mandatory for
further development. The remainder of this chapter will thus be concerned with the
problem of identifying putative targets subsequent to the establishment of a desired
biological activity, whereby the discussion will be focused on biochemical/proteomic
methodologies. For an overview on the use of genetic methods applied to the target
identification problem, the reader is referred to the recent review article by Zheng et
al.[504]
Again, there are two conceptually different approaches towards target
identification for compounds resulting from phenotypic activity screening, such as our
AMPMs. The first approach aims for the direct identification of molecular
interactions of the lead compound with the target molecule, and employs methods
such as affinity chromatography, photo-affinity labelling, (chemical) cross-linking,
immune precipitation, display cloning, yeast two hybrid systems, or more recently
protein micro-arrays.[505, 506] The second, complementary approach consists of the
evaluation of mRNA, protein, or metabolite expression profiles obtained from
organisms treated with the lead compound. The indirect nature of this approach
renders the interpretation of its results dependent on the availability of expression
profiles obtained with compounds of known mechanisms, against which the newly
obtained data can be compared.
The process of target identification for a lead compound emerging from
activity based phenotypic screening is often referred to as chemical genetics or
forward chemical genetics, and the relation of this approach to the target identification
problem posed by the AMPMs derived from protegrin-1 is evident. Therefore, in the
following sections, experiments aimed at the identification of targets of the AMPMs
are described, beginning with an indirect method, namely the recording of protein
expression profiles of P. aeruginosa PAO1 in the presence and absence of mimetic
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18. The chapter will then be concluded with the description of two direct biochemical
approaches, based on affinity chromatography and photo-affinity labelling (PAL).
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4.1 Proteomics approach
Since the completion of the first genome of a free-living organism,
Haemophilus influenzae in 1995,[507] the number of fully sequenced genomes is
growing at an ever increasing pace, not least due to the introduction of new
sequencing technologies.[508] With an increasing amount of completely sequenced
genomes at hand (460 as of November 2006**) - especially those of important model
organisms - the elucidation of the functional roles of the newly available gene
products has shifted into the focus of biological research. To emphasize the
conceptual break between the acquisition of sequence data, and the experiments that
are enabled by the availability of this data, the term post-genomic era is often used to
encompass the new experimental methodologies that aim to extract structural and
functional information out of the wealth of sequence information.
It is becoming increasingly clear that biological function is not mediated by a
static genome, but rather by the cells’ complement of proteins, which in turn is
determined through a dynamic interplay of external stimuli, gene regulation and levels
of expressed proteins.[509] The field of functional genomics focuses on such dynamic
aspects as transcription, translation and protein/protein interactions by making use of
large scale experiments (so-called -omics), enabled by the availability of the genomic
sequence data and progress in bioinformatic methodologies. Transcriptomics, for
instance, is concerned with the subset of transcribed genes in a given organism under
specified conditions. This subset, which is also called the transcriptome, dynamically
links the genome of an organism with its proteome and hence with the phenotype of
the cell. Although transcriptomics offers immense potential for understanding
complex biological systems on the molecular level, processes such as posttranslational
modification of the translated proteins can influence their behaviour to a greater
extent than their actual rate of synthesis. Additionally, mRNA profiling generally
does not allow studies on the cellular localisation or on the sequestration of the
protein products, for example by interaction with other macromolecules, or on other
effects such as proteolysis.
Therefore, the expression patterns of proteins are expected to correlate more
closely with cellular processes than the expression patterns of the corresponding
genes, and the direct analysis of the cells’ inventory of proteins is an important and
** http://www.genomesonline.org/gold.cgi
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complementary approach to the analysis of the transcriptome. The field of proteomics
is concerned with such an analysis of the expression, cellular localisation, structure,
biochemical activity, and interaction with other cellular compounds of as many
proteins as possible. Originally, the proteome was defined as the complete cellular
complement of proteins expressed by a given genome.[510] More recently, since it has
become clear that the complement of expressed proteins depends intricately on the
cellular state of the organism, it was suggested that a definition of the proteome
should include the state of the organism, as well as posttranslational modifications and
protein isoforms which arise, for example, by alternative splicing.[509]
4.1.1 Proteomics and antibacterial target identification
The applicability of a proteomic approach to the identification of putative
targets of antimicrobial agents is based on the general utility of the method in
studying the adaptation of micro-organisms to environmental stimuli. That is,
proteomics are widely used to analyse the proteomes of cells grown under specified
growth conditions, and in this respect there are no conceptual differences between the
study of the bacterial response to antibiotic action or to other stress factors, such as
temperature shock or growth under limitation of certain nutrients.
In proteome mapping, 2D-PAGE gels are used to identify and locate as many
proteins of the organism under investigation as possible, and to link this information
with protein function. The latter can be achieved by computational methods and
database searching, for example via identification of orthologous genes from different
organisms with known function; such information is therefore ultimately dependent
on classical biochemical experiments. There still exist limitations as to the amount of
proteins that can be identified by 2D-PAGE analyses, but a variety of advanced
protein maps for several prokaryotic organisms are available.[511-513] However, a
major drawback of protein reference maps is that they do not represent an actual
snapshot of the protein expression pattern of a given organism under specified
experimental conditions, as would be obtained from a single experiment. The latter is
rather referred to as a protein expression profile,[514] and the study of antibiotic action
depends on obtaining such protein expression profiles. Accordingly, the term
stimulon has been introduced to specify proteins whose expression profiles are
affected by a stimulus such as antibiotic action on a phenotypic level.[515]
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Furthermore, proteomic signatures are defined as subsets of proteins that show
differential expression under specified experimental conditions, which can be related
to functions or pathways specific to the stimulus. Proteins or sets of proteins that
constitute a particular proteomic signature can be indicative of a particular
physiological state of the organism under investigation. Since it is possible that more
than one proteomic signature constitute the observable protein expression profile of a
given stimulus, the determination of proteomic signatures has to depend on the
analysis of expression profiles of various related and unrelated stimuli. While it may
take considerable effort to determine reliable proteomic signatures, once available
they can function as invaluable tools for the analysis of expression profiles obtained
with a hitherto unstudied stimulus. It is important to emphasise at this point that
proteomic signatures do not have to be identical for different organisms, even if the
organisms are closely related.
Several proteomic studies have been undertaken with emphasis on the mode
and/or mechanisms of action of antibacterial drugs, in which changes in the protein
expression profiles of antibiotic challenged bacterial organisms were analysed. In an
early set of experiments, van Bogelen et al. correlated the proteomic signatures for
cold and heat shock in E. coli with the protein expression profiles obtained from cells
treated with several antibiotics that impair protein biosynthesis, such as
chloramphenicol, erythromycin, fusidic acid, aminoglycosides, or tetracycline.[516]
Evers et al. examined the protein expression patterns of H. influenza cells treated with
inhibitors of RNA and protein biosynthesis, and found that apart from the
aminoglycosides employed in their experiments, all antibiotic compounds led to an
increased expression rate of ribosomal proteins and of RNA polymerase subunits.[517]
Another study with H. influenza was directed towards the two DNA gyrase inhibitors
ciprofloxacin and novobiocin, where clear differences in the protein expression
profiles induced by these two compounds, that act by different mechanisms, could be
discerned.[518] Furthermore, Singh et al. described the protein expression profiles of S.
aureus treated with several antibiotics that act on bacterial cell wall biosynthesis, and
found that the patterns obtained were different from those displayed by antibiotics
acting via different modes of action.[519] Additionally, inhibitors of peptide
deformylase (PDF) have been studied, in which case the protein expression profiles
were characterised by changes in the pI of the majority of proteins, caused by
retention of the N-formyl-Met terminus.[520, 521] Other recent studies described in
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more detail include the response of P. putida towards tetracycline,[522] and of E. coli
towards silver nanoparticles.[523]
A logical extension to these experiments is the compilation of reference
databases of protein expression profiles for a variety of different antibiotic compounds
whose modes of action are secured, and which in an ideal case can permit the
delineation of proteomic signatures for the antibiotic stimuli. One of the ultimate
goals of such an approach is the prediction or delineation of the mode/mechanism of
action for new antibacterial compounds by comparison with the protein expression
profiles or proteomic signatures contained in the database.
Along these lines, Bandow et al. recently described a database containing the
protein expression profiles of B. subtilis obtained with 30 antimicrobial agents, or
generally cell-damaging compounds, via a dual-channel imaging protocol.[520] The
authors could demonstrate the utility of the database approach by assigning the
mechanism of action to nitrofurantoin as well as to a novel pyridiminone antibiotic,
by comparison of the obtained protein expression profiles to the other profiles within
the reference database. Additionally, they introduced marker proteins that were over-
expressed at least two-fold and which comprised at least 0.05 % of the total protein
synthesised after induction with the (antibiotic) stimulus, to allow for efficient, more
reliable and less biased evaluation of the expression profile data sets. A natural
requirement of the database approach in target identification is the availability of a
sufficient number of proteomic signatures. However, compounds that display
fundamentally new modes of action will not have corresponding proteomic signature
entries in the database, and for such compounds, the analysis of mutants might aid in
target validation and/or identification.
4.1.2 Experimental considerations
The most widely used experimental implementation of comparative proteome
analysis to date is represented by two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE) combined with protein identification by mass spectrometric methods.[524]
The experimental technique of 2D-PAGE, which allows for the analysis of complex
protein mixtures based on separation according to the isoelectric point (pI, first
dimension) and the molecular weight (second dimension) of the analytes, was
developed in 1975 by O’Farrel[525] and by Klose.[526] Although this method was
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already shortly thereafter applied to the study of protein expression profiles of
organisms subjected to differential growth conditions[527] or to exogenous stress
stimuli,[528] it was only after significant advances in the field of protein identification
were made that the technique gained widespread popularity. The advances in the
identification of proteins relied heavily both on progress in mass spectrometric
methods and on the increased availability of DNA sequence data.
In principle, the mass spectrometric identification of protein spots obtained by
2D-PAGE can be achieved by two complementary methods. Firstly, in peptide mass
fingerprinting (PMF), digestion of proteins with a sequence-specific endoprotease,
typically trypsin, is followed by determination of the molecular masses of the
generated protein fragments via MALDI-TOF, and the experimentally obtained
molecular masses are compared with the theoretical molecular masses of protein
fragments obtained from sequence databases. Additionally, and especially in such
cases where PMF does not lead to unambiguous identification, tandem MS methods,
which are used to obtain peptide fragments of the tryptic digests, can be used to
identify the proteins via the obtained fragmentation patterns, again with the input of
theoretically computed fragmentation patterns obtained from sequence databases.
Since both mass spectrometric methods rely heavily on the availability of genomic
sequence data to produce theoretical digestion fragments of proteins and/or theoretical
fragmentation patterns, which can be compared to the experimentally obtained lists of
peak intensities and m/z values, it is evident that the availability of genomic sequence
data is indispensable for proteomic experiments.
Furthermore, technological advances concerning all aspects of gel-based
proteomics, for example, the introduction of immobilised pH gradients (IPG) leading
to improved reproducibility, the introduction of new staining methods, leading to
increased sensitivity, the introduction of narrow pI IPG strips, leading to improved
resolution, and advances in sample preparation and automation, have contributed to
establish 2D-PAGE as the most versatile method for comparative proteomic analyses
today. Last but not least, the introduction of and advances in image analysis software
have greatly facilitated the quantification and analysis of protein spots obtained from
large numbers of 2D gels. Today, 2D-PAGE is routinely applied for large-scale
parallel quantitative profiling of complex protein mixtures, and can routinely separate
2000 individual protein spots or more, in favourable cases even over 5000. For a
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recent comprehensive review on the experimental aspects of 2D-PAGE, the reader is
referred to the review article by Görg et al.[524]
Nevertheless, there are several drawbacks to gel-based proteomics, such as
difficulties in the analysis of proteins with extreme physicochemical properties. For
example, large proteins or protein complexes might not enter the second dimension of
the gel and may be lost from the protein expression profiles. Additionally, the
isoelectric focussing of very acidic or very basic proteins often causes problems, and
extremely hydrophobic proteins, such as membrane proteins, are often lost during
sample preparation due to their lower solubility. Moreover, limitations in the
resolution of 2D-PAGE still exist, and not all protein species of a given sample can be
resolved. Another major problem of proteomic methods in general is the difficulty in
detecting low-abundance proteins; typically such proteins have to be enriched in order
to become detectable.
As alternatives to 2D-PAGE, several non-gel based methods have emerged
recently that show promise in circumventing at least some of the above mentioned
shortcomings. Generally, these methods are based on the combination of LC
separation techniques with mass spectrometric analysis. For instance, in the MudPit
approach, tryptic digests of complex protein samples are separated by cation exchange
and reverse phase HPLC to reduce the sample complexity.[529] Additionally, heavy-
isotope labelling is commonly used for the quantification of the results, and the
labelling is achieved, for example, by stable isotope labelling with amino acids in cell
culture (SILAC), or by the isotope-coded affinity tag technology (ICAT).[530]
Although these alternative approaches seem to offer some advantages over gel based
proteomics for the future, such as higher sensitivity, currently 2D-PAGE is without
doubt the mainstay of comparative proteomics.[524] Finally, it should be mentioned
that a major advantage of gel-based proteomics, as compared to LC-MS/MS
proteomics, consists of the straightforward detection and quantification of post-
translational modifications in the former method.
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4.1.3 Expression profiles of P. aeruginosa PAO1 in the presence
and absence of 18
For the determination of 2D protein expression profiles of P. aeruginosa
PAO1 in the presence and absence of mimetic 18, a protocol involving the
prefractionation of the bacterial proteins, developed by Riedel et al, was
employed.[531-533] The experiments were carried out under guidance of Dr. K. Riedel
in the laboratory of Prof. Dr. L. Eberl at the University of Zurich. Prefractionation
into intracellular, extracellular, and surface proteins serves several purposes. Firstly,
it helps to reduce the complexity of the sample and can thus lead to a higher
resolution in gels of the sub-cellular fractions. Secondly, fractionation can be an
effective method for enriching particular types of proteins, such as hydrophobic
membrane proteins in the membrane-, or surface-bound fractions, and thus often
increases the sensitivity of the method towards the corresponding sub-proteome.
Thirdly, pinning down identified protein spots to a certain sub-cellular location can
provide a first clue as to their functional role. P. aeruginosa strain PAO1 was chosen
for the proteomic experiments, since the genome of this organism has been fully
sequenced, which is a pre-requisite for the identification of the protein spots via
MALDI-TOF or other mass spectrometric methods (vide supra), and 5570 ORFs were
annotated.[534]
Briefly, cultures of P. aeruginosa PAO1 were grown in the presence and
absence of 18 at concentrations that inhibited, without completely suppressing, the
growth of the bacteria. The general growth conditions were identical to those
employed in the kinetic experiments (c.f. Section 3.3), apart from the use of larger
culture volumes (1.2 or 2.4 L). To ensure maximal compatibility with the time-kill
analyses as well as with the incorporation studies, 18 was added to bacterial cultures
of an optical density of OD600 = 0.2. Due to the changes in culture volume and the
need to work at sub-MIC concentrations, the necessary amount of 18 was determined
in preliminary experiments that were identical in all experimental parameters to the
later protein expression profiling experiments.
The effect of the change in culture volume on the required amount of mimetic
18 deserves special discussion. It was elaborated in Section 3.3 that the positive
charge inherent to the majority of AMP(M)s can lead to adsorption onto the surface of
the culture vessel(s), with a concomitant increase in the apparent MIC, and that to
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counteract this effect, 0.01% of BSA is added in the routine MIC protocol. However,
no BSA was added for the recording of the protein expression profiles, the time-kill
analyses and the incorporation studies, in order to exclude any potential side-effects of
BSA on these experiments. Due to the larger culture volumes, 2L or 3L glass flasks
were used for the incubation, and since it was found that the use of glass vessels in
experiments conducted without added BSA leads to an even higher increase of the
apparent MIC values than experienced with polypropylene or polyethylene surfaces,
the optimal concentration of mimetic 18 for obtaining protein expression profiles was
determined to be 0.3 g/mL; a value that is considerably higher than would be
expected from the routine determination of the MIC value of 18.
As mentioned above, PAO1 cells were incubated at concentrations of 18 that
did not completely inhibit the bacterial growth. However, it could be seen that the
well-documented bacteriostatic effect of 18 set in about 30 minutes after addition (i.e.
approximately one generation time under the experimental conditions), with no
appreciable subsequent increase in the OD, which typically reached a final value of
OD600 = 0.35. Cells were harvested after a maximum of 2 hours incubation to ensure
that the control cultures were still in the exponential growth phase.
It is of interest to mention at this point, that the acquisition of sufficient
quantities of surface-bound proteins from the mimetic 18 treated samples proved to be
difficult, and could only be achieved by a large increase in the overall volume of cell
culture used in the experiment. It is also interesting to note that the protocol for
isolation of the surface-bound fraction involves re-suspending in 0.2M glycine buffer,
and that this re-suspension proved to be difficult for mimetic 18 treated cells.
Whereas the cell pellets of the control cultures were of a slightly pink colour and
easily re-suspended, the mimetic 18 treated cells had a black appearance, displayed a
slimy consistency, and were reluctant to re-suspend. While stirring of the control
culture readily yielded a uniform bacterial suspension, the same procedure with the
treated culture afforded a slightly grey suspension containing a large amount of
unsuspended black flakes of cellular material.
2D gels were run with total protein concentrations of 350 g, as determined by
Bradford analysis.[535] For the isoelectric focussing of the intracellular protein
fractions, IPG strips with an immobilised pH gradient 4-7 were used, whereas the
other fractions were run with IPG strips with immobilised pH gradients of 3-10.
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Scanned gel images of the different sub-cellular fractions challenged with 18 or the
control cultures were overlaid for comparison, using the ProteomWeaver™ software
package, to aid in the analysis of results by visual inspection. Protein spots whose
expression was found to be differentially regulated by the addition of 18 were
subjected to in-gel tryptic digestion followed by characterization by MALDI-TOF
peptide mass fingerprinting and tandem MS/MS analysis at the Functional Genomics
Center Zurich (FGCZ).
The excised protein spots are highlighted in Figures 4.1-4.3, and the results of
the protein identification which was carried out employing the GPS-explorer™
software package with the included MASCOT search engine,[536] based on the
obtained mass spectrometric data, are summarised in Tables 4.1-4.3. For the database
searches, the non-redundant NCBI database and the updated P. aeruginosa genome
sequences database of P. aeruginosa PAO1 from the P. aeruginosa Community
Annotation Project were used.[537]
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Figure 4.1 Differentially expressed proteins of the intracellular fraction of P. aeruginosa PAO1.
Top: down-regulated; bottom: up-regulated after induction with mimetic 18.
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Figure 4.2 Differentially expressed proteins of the surface-bound fraction of P. aeruginosa
PAO1. Top: down-regulated; bottom: up-regulated after induction with mimetic 18.
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Figure 4.3 Differentially expressed proteins of the extracellular fraction of P. aeruginosa PAO1.
Top: down-regulated; bottom: up-regulated after induction with mimetic 18.
Table 4.1 Identification of mimetic 18 affected proteins in the intracellular fraction of P. aeruginosa PAO1. Spots A1-A16 were found to be down-regulated after
induction with 18, whereas spots B1-B12 where found up-regulated. Missing spot numbers correspond to unidentified proteins.
Spot noa PA nob Theoretical
pI
Theoretical
Mr
Protein scorec Sequence
coverage [%]d
Protein description
A1 PA1092 5.4 49.2 386 38 flagellin type B
A2 PA1074 5.6 39.9 187 47 branched-chain amino acid transport protein BraC
A3 PA1074 5.6 39.9 104 16 branched-chain amino acid transport protein BraC
A4 PA3190 5.7 45.3 271 32 probable binding protein component of ABC sugar transporter
A6 PA1493 7.8 36.5 228 58 sulfate-binding protein of ABC transporter
A7 PA0300 7 40.7 133 20 polyamine transport protein
A8 PA0301 5.5 40.2 182 31 polyamine transport protein
A9 PA0888 6.4 28.1 460 52 arginine/ornithine binding protein AotJ
A10 PA5153 5.1 27.7 137 26 probable periplasmic binding protein
A12 PA1657 4.8 18.2 78 29 hypothetical protein PA1657
A13 PA2966 4.1 8.7 88 12 acyl carrier protein
A14 PA4922 6.4 16.2 328 40 azurin precursor
A15 PA4067 4.9 25.2 137 21 outer membrane protein OprG precursor
A16 PA0388 6.6 15.4 203 41 hypothetical protein PA0388
B1 PA0482 5.5 78.8 273 35 malate synthase G
B2 PA0482 5.5 78.8 377 50 malate synthase G
B3 PA2300 5.2 53.1 128 18 chitinase
B4 PA2001 6 40.6 453 66 acetyl-CoA acetyltransferase
B5 PA1588 5.8 41.8 586 72 succinyl-CoA synthetase beta chain
Table 4.1 (continued)
B6 PA3686 6 23.2 367 63 adenylate kinase
B7 PA0139 5.9 20.6 419 57 alkyl hydroperoxide reductase subunit C
B8 PA1777 5 37.8 169 27 outer membrane protein OprF precursor
B10 PA0837 4.5 17 66 46 peptidyl-prolyl cis-trans isomerase Sly-D
B11 PA5178 5.5 15.5 249 64 hypothetical protein PA5178
B12 PA1777 5 37.8 173 11 outer membrane protein OprF precursor
a Spot numbers refer to Figure 4.1.
b Data generated from peptide mass maps were compared to the translated open reading frames (ORF) for P. aeruginosa PAO1 (http://v2.pseudomonas.com).
c Probability score of the MASCOT database search based on an implementation of the Mowse algorithm;[538] scores greater than 50 are considered significant (p<0.05).
d Sequence coverage denotes the percentage of the protein sequence for which matching peptide fragments have been identified.
Table 4.2 Identification of mimetic 18 affected proteins in the surface-bound fraction of P. aeruginosa PAO1. Spots C1-C32 were found to be down-regulated after
induction with 18, whereas spots D1-D22 where found up-regulated. Missing spot numbers correspond to unidentified proteins.
Spot noa PA nob theoretical
pI
theoretical
Mr
Protein
scorec
Sequence
coverage [%]
Protein description
C8 PA0958 4.96 48.3 412 53 outer membrane porin protein OprD precursor
C9 PA2760 5.5 46.9 486 47 probable outer membrane protein
C10 PA1288 5.7 45.5 415 53 probable outer membrane protein
C11 PA1288 5.7 45.5 463 53 probable outer membrane protein
C12 PA0291 8.7 49.6 367 56 outer membrane porin OprE precursor
C13 PA0291 8.7 49.6 439 56 outer membrane porin OprE precursor
C14 PA0300 7 40.7 183 25 polyamine transport protein PotF2
C15 PA1777 5 37.8 500 63 outer membrane protein OprF precursor
C16 PA1777 5 37.8 472 70 outer membrane protein OprF precursor
C17 PA5472 5.5 29.3 248 60 hypothetical protein PA5472
C18 PA0888 6.4 28.1 629 78 arginine/ornithine binding protein AotJ
C19 PA4067 4.9 25.2 501 50 outer membrane protein OprG precursor
C20 PA4067 4.9 25.2 456 50 outer membrane protein OprG precursor
C21 PA4067 4.9 25.2 305 33 outer membrane protein OprG precursor
C22 PA1178 9 21.6 296 69 outer membrane protein H1 precursor
C23 PA1178 9 21.6 350 70 outer membrane protein H1 precursor
C24 PA3227 7.9 20.1 410 61 peptidyl-prolyl cis-trans isomerase A PpiA
C25 PA4922 6.4 16.2 202 26 azurin precursor
C26 PA4922 6.4 16.2 266 39 azurin precursor
Table 4.2 (continued)
C27 PA4922 6.4 16.2 334 40 azurin precursor
C28 PA4922 6.4 16.2 284 40 azurin precursor
C29 PA0388 6.6 15.3 318 74 hypothetical protein
C30 PA0409 5.4 13.3 315 83 twitching motility protein PilH
C31 PA0958 5 48.3 372 61 outer membrane porin protein OprD precursor
C32 PA0958 5 48.3 357 42 outer membrane porin protein OprD precursor
D1 PA4385 5 57.1 732 53 GroEL protein
D2 PA4761 4.8 68.5 689 69 DnaK protein
D3 PA4385 5 57.1 345 43 GroEL protein
D4 PA3162 4.8 62 166 38 30S ribosomal protein S1 RpsA
D5 PA4266 5.1 78.1 143 36 elongation factor G FusA1
D6 PA1596 5.1 71.6 363 51 heat shock protein HtpG
D7 PA1092 5.4 49.2 424 55 flagellin type B FliC
D8 PA1094 6.5 49.4 288 49 flagellar capping protein FliD
D9 PA0766 7 50.3 153 30 serine protease MucD precursor
D10 PA1587 6.5 50.4 325 46 lipoamide dehydrogenase-glc
D11 PA1587 6.5 50.4 302 42 lipoamide dehydrogenase-glc
D12 PA0946 4.9 36.8 278 40 hypothetical protein PA0946
D13 PA2951 5 31.4 477 74 electron transfer flavoprotein alpha-subunit EtfA
D15 PA4495 5.7 24.9 392 64 hypothetical protein PA4495
D16 PA1589 5.8 30.6 618 90 succinyl-CoA synthetase alpha chain SucD
D17 PA0329 9.3 11.8 439 76 hypothetical protein PA0329
Table 4.2 (continued)
D18 PA2952 9 26.4 561 76 electron transfer flavoprotein beta-subunit EtfB
D19 PA4386 5.2 10.3 268 65 GroES protein
D20 PA4271 4.7 12.5 191 79 50S ribosomal protein L7 / L12
D21 PA1777 5 37.8 332 36 outer membrane protein OprF precursor
a Spot numbers refer to Figure 4.2.
b Data generated from peptide mass maps were compared to the translated open reading frames (ORF) for P. aeruginosa PAO1 (http://v2.pseudomonas.com).
c Probability score of the MASCOT database search based on an implementation of the Mowse algorithm;[538] scores greater than 50 are considered significant (p<0.05).
d Sequence coverage denotes the percentage of the protein sequence for which matching peptide fragments have been identified.
Table 4.3 Identification of mimetic 18 affected proteins in the extracellular fraction of P. aeruginosa PAO1. Spots E1-E30 were found to be down-regulated after
induction with 18, whereas spots F1-F12 where found up-regulated. Missing spot numbers correspond to unidentified proteins.
Spot noa PA nob Theoretical pI Theoretical Mr Protein Scorec Sequence coverage [%] Protein description
E1 PA3162 4.8 61.9 480 53 30S ribosomal protein S1
E2 PA4266 5.1 78.1 280 43 elongation factor G
E4 PA1596 5.1 71.6 347 53 heat shock protein HtpG
E7 PA0572 6.1 100.6 340 39 hypothetical protein PA0572
E8 PA1094 6.5 49.4 668 81 flagellar capping protein FliD
E9 PA5078 6.5 59.4 206 41 hypothetical protein PA5078
E10 PA4236 6.2 55.6 146 31 catalase
E11 PA1587 6.5 50.4 311 42 lipoamide dehydrogenase-glc
E12 PA4175 6.5 48.6 409 51 probable endoproteinase Arg-C precursor
E13 PA0291 8.7 49.6 272 45 outer membrane porin OprE precursor
E14 PA0852 6.4 42.3 324 61 chitin-binding protein CbpD precursor
E15 PA1094 6.5 49.4 628 70 flagellar capping protein FliD
E16 PA1094 6.5 49.4 752 81 flagellar capping protein FliD
E17 PA5171 5.5 46.8 248 58 arginine deiminase
E18 PA1094 6.5 49.4 686 79 flagellar capping protein FliD
E19 PA0622 5.3 41.4 538 81 probable bacteriophage protein
E20 PA5033 5.4 34.3 561 62 hypothetical protein PA5033
E22 PA4067 4.9 25.2 353 34 outer membrane protein OprG precursor
E23 PA5139 5.7 27.8 363 50 hypothetical protein PA5139
Table 4.3 (continued)
E24 PA0633 4.9 17.6 40 12 hypothetical protein PA0633
E25 PA0623 5.1 17.9 309 81 probable bacteriophage protein
E26 PA3309 5.5 16.5 340 75 hypothetical protein PA3309
E27 PA4067 4.9 25.2 89 34 outer membrane protein OprG precursor
E28 PA3021 7.6 14.5 318 68 hypothetical protein PA3021
E30 PA0807 5.9 28.7 461 70 hypothetical protein PA0807
F1 PA0423 6.1 20.8 444 80 hypothetical protein PA0423
F2 PA0423 6.1 20.8 610 82 hypothetical protein PA0423
F3 PA0320 4.7 12.6 359 66 hypothetical protein PA0320
F5 PA2659 4.9 11.2 145 44 hypothetical protein PA2659
F6 PA4578 5.9 17 174 33 hypothetical protein PA4578
F7 PA0315 6.6 15.5 109 71 hypothetical protein PA0315
F8 PA0833 8.9 24.8 140 40 hypothetical protein PA0833
F9 PA4495 5.8 24.9 226 41 hypothetical protein PA4495
F10 PA4453 9.1 23.7 374 70 hypothetical protein PA4453
F11 PA4273 9.6 24.2 43 31 50S ribosomal protein L1
F12 PA0766 7 50.3 49 7 serine protease MucD precursor
a Spot numbers refer to Figure 4.3.
b Data generated from peptide mass maps were compared to the translated open reading frames (ORF) for P. aeruginosa PAO1 (http://v2.pseudomonas.com).
c Probability score of the MASCOT database search based on an implementation of the Mowse algorithm;[538] scores greater than 50 are considered significant (p<0.05).
d Sequence coverage denotes the percentage of the protein sequence for which matching peptide fragments have been identified.
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4.1.4 Results of the protein expression profiling
In total, 122 protein spots were excised from the 2D-PAGE gels and subjected
to tryptic digestion and mass spectrometric analysis. Out of these, 104 could be
identified by peptide mass fingerprinting (PMF) and MS/MS analyses, with a
MASCOT probability score of at least 66. The probability score of the MASCOT
database search is based on an implementation of the Mowse algorithm;[538] and
scores greater than 50 are considered significant (p<0.05) for the used database(s).
Additionally, the hypothetical protein PA0633, the 50S ribosomal protein L1 and the
serine protease MucD precursor were identified in the extracellular protein fraction
with probability scores of 40, 43 and 49, respectively.
It is noteworthy that several proteins were found to be differentially regulated
in more than one location on the 2D-PAGE gels, thus resulting in the identification of
a total of 66 unique proteins of P. aeruginosa PAO1, that were differentially regulated
by induction with mimetic 18.
To summarise, 14 out of 16 protein spots down-regulated in the intracellular
fraction of P. aeruginosa PAO1 by induction with 18 could be identified, representing
13 unique protein species. Only BraC (PA1074), a branched-chain amino acid
transport protein that binds to leucine, isoleucine, and valine was found in two
different locations on the 2D gels, corresponding to slight variations in the observed
pI values. Out of the 12 up-regulated protein spots in the intracellular fraction, 11
could be identified and were assigned to 9 unique proteins. In the surface-bound
protein fraction of P. aeruginosa PAO1, 32 protein spots were found to be down-
regulated, of which 25 could be identified, corresponding to 14 unique protein
species, whereas from the 21 up-regulated protein spots, 20 protein species,
comprising of 18 unique proteins, were identified. Finally, in the extracellular
fraction, out of the 30 down-regulated protein spots, 25 could be identified,
representing 21 unique proteins and from the total of 12 protein spots up-regulated
after induction with 18, 11 spots were identified, composed of 10 unique proteins.
The identities of these 66 unique protein species are listed in Table 4.4, grouped
according to the sub-cellular fractions from which they were identified.
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Table 4.4 Differential regulation of the 66 unique protein species identified from mimetic-18
challenged P. aeruginosa PAO1. The protein species are listed according to their functional
classification in the COG database and the magnitude of the regulation is indicated by + (up-regulation
in the presence of mimetic 18) and – (down-regulation in the presence of mimetic 18) signs; proteins
identified from more than one location on the 2D gels are separated by /.
Regulation
Protein identity PA noa intra-
cellular
surface extra-
cellular
Amino acid transport and metabolism
Polyamine transport protein PotF2 PA0300 - -
Polyamine transport protein PA0301 -
Arginine/ornithine binding protein AotJ PA0888 --- --
Branched-chain amino acid transport protein BraC PA1074 -/--
Hypothetical ABC-type amino acid transporter PA5139 -
Probable periplasmic binding protein PA5153 -
Arginine deiminase PA5171 --
Carbohydrate transport and metabolism
Chitinase PA2300 ++
Probable binding protein component of ABC sugar
transporter
PA3190 --
Lipid transport and metabolism
Long-chain fatty acid transport protein PA1288 --/--
Acetyl-CoA acetyltransferase PA2001 + +
Acyl carrier protein PA2966 - - -
Energy production and conversion
Malate synthase G PA0482 +/++
Lipoamide dehydrogenase PA1587 +/++ --
Succinyl-CoA synthetase beta chain PA1588 +++
Succinyl-CoA synthetase alpha chain SucD PA1589 +++
Electron transfer flavoprotein -subunit EtfA PA2951 ++
Electron transfer flavoprotein -subunit EtfB PA2952 ++
Azurin precursor PA4922 ---- -/--/--/--
-
Nucleotide transport and metabolism
Adenylate kinase PA3686 ++
Inorganic ion transport and metabolism
Sulfate-binding protein of ABC transporter PA1493 -
Catalase PA4236 -
Periplasmic glucans biosynthesis protein PA5078 -
Secondary metabolites biosynthesis, transport and catabolism
ABC-type transport system involved in resistance to
organic solvents
PA4453 ++
Cellular processes and signaling
Cell motility
Flagellin type B FliC PA1092 -- +
Flagellar capping protein FliD PA1094 + --/--/--/--
Cell wall/membrane biogenesis
Outer membrane porin OprE precursor PA0291 --/-- --
Peptidoglycan-associated (lipo)proteins PA0833 ++
Outer membrane porin protein OprD precursor PA0958 --/--/---
Outer membrane protein H1 precursor PA1178 --/-
Outer membrane protein OprF precursor PA1777 +/++ ++/--/--
Outer membrane protein OprG precursor PA4067 -- -/--/--- -/--
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Table 4.4 (continued)
Posttranslational modification, protein turnover,
Chaperones
Alkyl hydroperoxide reductase subunit C PA0139 + +
Serine protease MucD precursor PA0766 ++ +
Peptidyl-prolyl cis-trans isomerase SlyD PA0837 +
Heat shock protein HtpG PA1596 + --
Peptidyl-prolyl cis-trans isomerase A PpiA PA3227 -
GroEL protein PA4385 +/++
GroES protein PA4386 ++
DnaK protein PA4761 +
Defence mechanisms
Negative regulator of beta-lactamase expression PA0807 -
Signal transduction mechanisms
Twitching motility protein PilH PA0409 -
Translation
30S ribosomal protein S1 RpsA PA3162 + --
Elongation factor G FusA1 PA4266 + -
50S ribosomal protein L7 / L12 PA4271 +++
50S ribosomal protein L1 PA4273 +
General function prediction only
Phage tail sheath protein FI PA0622 -
Phage tail tube protein FII PA0623 -
Function unknown
Hypothetical protein PA0315 ++
Predicted membrane protein PA0320 ++
Uncharacterized protein conserved in bacteria PA0329 +++
Hypothetical protein PA0388 - --
Uncharacterized conserved protein PA0423 ++/++
Hypothetical protein PA0572 -
Hypothetical protein PA0633 -
Uncharacterized protein conserved in bacteria PA0852 --
Predicted periplasmic/secreted protein PA0946 +
Uncharacterized protein conserved in bacteria PA1657 -
Predicted periplasmic/secreted protein PA2659 +++
Probable outer membrane protein PA2760 --
Uncharacterized conserved protein PA3021 -
Hypothetical protein PA3309 --
Probable endoproteinase Arg-C precursor PA4175 -
Hypothetical protein PA4495 ++ +
Hypothetical protein PA4578 ++
Hypothetical protein PA5033 -
Hypothetical protein PA5178 ++
Hypothetical protein PA5472 -
a Data generated from peptide mass maps were compared to the translated open reading frames (ORF)
for P. aeruginosa PAO1 (http://v2.pseudomonas.com).
In order to classify the identified proteins, as well as to allow inference of
possible functional roles, the Conserved Domain Database (CDD),6 the Cluster of
orthologous groups database (COG),7 and the Pseudomonas Genome Database[537]8
6 http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi
7 http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml
8 http://v2.pseudomonas.com/search.jsp
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were searched using the results of the protein identification. The functional
classification of the identified proteins according to the categories of the COG-
database, is included in Table 4.4, and summarised graphically in Figure 4.4.
It can be seen from Table 4.4 and Figure 4.4 that the majority of differentially
regulated proteins for which functional classes could be assigned from the COG
database are involved in central cellular housekeeping functions, such as transport and
metabolism of amino acids (7), energy production and conversion (7), cell
wall/membrane biogenesis (6), and in the posttranslational modification (PTM) of
proteins (7). However, a large proportion of identified protein spots was found to be
either functionally poorly characterised or functionally uncharacterised. More
precisely, for two proteins down-regulated in the extra-cellular fraction after induction
with mimetic 18 (PA0622, PA0623), only general predictions of function as phage tail
sheath or tube proteins could be made. Furthermore, the function of 20 of the
uniquely identified proteins is still unknown. It is noteworthy that almost all proteins
for which no putative function could be assigned were identified either from the
extracellular or the surface-bound protein fraction, whereas only three were found in
the intracellular fraction of P. aeruginosa PAO1.
As already mentioned, several proteins were identified in more than one spot,
but additionally, it was also often the case that a given protein species was found to be
differentially regulated in more than one sub-cellular fraction. For instance, there
were 11 proteins that could be found in two different fractions, and the outer
membrane protein OprG (PA4067) was identified in all three sub-cellular fractions.
The identification of a protein from separate spots on the same 2D gel is readily
explicable by posttranslational modifications (PTM) of the proteins, such as
phosphorylation, glycosylation, acetylation and C-terminal amidation on the one
hand, or by the aggregation of proteins into homo- respectively hetero-multimeric
complexes on the other hand, both being processes which can substantially influence
the pI and/or the molecular mass of the protein species. The utility of gel-based
proteomics for assessing PTMs has been mentioned, and the high proportion of
proteins identified from more than one location on the 2D gels suggests that
posttranslational processing might play an important role in the effects of mimetic 18
on P. aeruginosa PAO1.
Apart from the obvious possibility that the expression of a given protein might
be simultaneously affected by 18 in different sub-cellular fractions, the identification
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of a differentially regulated protein species in more than one sub-cellular fraction may
also be an artefact of the fractionation protocol. Moreover, and of special interest
with respect to AMPs, it is also conceivable that the impairment of membrane
structure and/or integrity could lead to the redistribution of protein species between
different sub-cellular fractions, for example by releasing intracellular or surface-
bound compounds into the surrounding medium. The latter possibilities should be
taken into account when considering proteins that are found in sub-cellular fractions
in which their presence is not expected based on their functional classes or protein
reference maps, if such assignments exist. For example, the 30S ribosomal protein S1
(PA3162) was found to be down-regulated in the extracellular fraction of P.
aeruginosa PAO1 after induction with mimetic 18. It has to be mentioned, however,
that the ribosomal S1 protein, which is involved in non-specific mRNA binding, is
known to be only loosely attached to the 30S subunit.[539]
While the majority of proteins that were found in more than one location on
the 2D gels of a given sub-cellular fraction were characterised by variations in the
observed pI values, there were, in addition, larger deviations from the theoretically
expected molecular masses for several of the outer membrane proteins isolated in this
study. For example, the outer membrane protein OprF precursor (PA1777) was
identified twice as down-regulated in the surface-bound protein fraction of P.
aeruginosa PAO1. Both spots corresponding to PA1777 in the control culture were
located at positions on the gel that correlate well with the theoretical pI and molecular
mass of OprF, being separated only slightly with respect to their pI. However, in the
fraction up-regulated by induction with mimetic 18, PA1777 was identified from a
protein spot corresponding to a much lower molecular weight (~ 20 kDa vs. 37.8 kDa)
and also at slightly lower pI (~ 4.2 vs. 5.0), than would be expected theoretically. It is
worth mentioning that the outer membrane protein OprF precursor (PA1777), or
rather some of its post-translationally modified forms, was the only protein species
identified to be both up- and down-regulated in the same sub-cellular fraction.
Similar behaviour, namely the isolation of protein species from gel locations
corresponding to a significantly lower molecular mass than to be expected
theoretically, was also found for the outer membrane protein OprG (PA4067). OprG,
which was identified as down-regulated simultaneously in all sub-proteomes, was
located at positions on the gels corresponding to the theoretical pI/Mr values (pI = 4.9,
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Mr = 25.2 kDa), but also at positions corresponding to a lower molecular weight (Mr ~
15 kDa or ~ 12 kDa).
Several general trends can be extracted from the expression patterns according
to the assigned functional classes. For instance, all unique protein species identified
to be functionally involved in amino acid transport and metabolism were negatively
affected by induction with mimetic 18 (8 out of 8), and furthermore, almost all
proteins assigned as playing a role in either energy production and conversion (6 out
of 7), or in the post-translational modification of proteins and in protein turnover (9
out of 10) were up-regulated in at least one of the sub-cellular fractions, after
induction with 18.
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Figure 4.4 Functional classification of the identified protein species differentially expressed by
mimetic 18 treated P. aeruginosa PAO1. The functional classes correspond to the nomenclature of the
COG database, and the occurrence in different sub-cellular fractions is indicated by different
colouration of the horizontal bars (blue = intracellular; beige = surface-bound; turquoise =
extracellular).
The largest changes in the proteome expression patterns as assessed by visual
inspection was the down-regulation of the azurin precursor (PA4922) in the
intracellular, as well as in the surface-bound protein fraction of P. aeruginosa PAO1.
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In total, azurin was identified once in the intracellular, and four times in the surface-
bound protein fraction of the P. aeruginosa control culture. It is noteworthy that all
protein spots from which azurin was identified correlate well with the theoretical Mr
and pI value, apart from the spot C25, which shows a decrease in pI of about 1 unit.
Azurin is a blue copper protein (cupredoxin) that has been shown to be able to act as
an electron donor for nitrite reductase (NIR) in a variety of in vitro experiments.[540]
However, it has been demonstrated by the use of strains deficient in azurin,
that this protein is not required for denitrification in P. aeruginosa.[541] Similar
experiments established that azurin plays no obligatory role as electron acceptor for
either aromatic amine dehydrogenase or ethanol dehydrogenase, both activities with
which the protein has been formerly associated.[541] Furthermore, it has been shown
that azurin expression is induced either by transition from the exponential to the
stationary growth phase or by anaerobiosis.[541] Based on the sensitivity of an azu
mutant of P. aeruginosa towards reactive oxygen species (ROS), it has been proposed
that a functional role of azurin might consist of responding to oxidative stress.[541]
Recently, it was found that azurin was up-regulated together with flagellin
(PA1092) and flagellar capping protein (PA1094), in the extracellular protein fraction
of either an rsmY rsmZ double mutant or a gacA mutant of P. aeruginosa, which both
show reduced synthesis of the quorum sensing signalling molecule N-butanoyl-
homoserine lactone.[542] Interestingly, the expression of both flagellin and the
flagellar capping protein was also found to be affected by mimetic-18, although with a
different and more diverse pattern than in the above mentioned study. That is,
whereas flagellin was down-regulated in the intracellular fraction, both proteins were
up-regulated in the surface-bound fraction of P. aeruginosa PAO1. Remarkably, the
most apparent changes in the expression pattern for the flagellar capping protein FliD,
which was found down-regulated in the extracellular fraction, were delineated from
four different protein spots that showed a large spread in pI, as well as in molecular
mass.
Apart from azurin, all other proteins that were identified as being functionally
related to energy production and conversion were found to be up-regulated. In
particular, succinyl-CoA synthetase  and  chains (PA 1588, PA1589), which are
involved in the tricarboxylic acid cycle, together with a lipoamide dehydrogenase
(PA1587) and malate synthase (PA0482) were up-regulated in the intracellular or
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surface-bound protein fraction, respectively. Moreover, electron transfer flavoprotein
subunits A and B (PA2951, PA2952) were found to be up-regulated in the surface-
bound fraction.
The majority of proteins involved in the transport of amino acids,
carbohydrates, lipids or other metabolites were found to be down-regulated after
induction with mimetic 18. In particular, transport proteins found to be down-
regulated included two polyamine transport proteins (PA0300, PA0301), the
arginine/ornithine binding protein AotJ (PA0888),[543] a hypothetical ABC-type sugar
transporters (PA5139), a hypothetical ABC-type amino acid transporter (PA3190), a
sulphate binding protein (PA1493), a branched amino acid binding protein (PA1074),
a long chain fatty acid transport protein (PA1288), and a hypothetical periplasmic
binding protein (PA5153). The only transport system found to be up-regulated was an
ABC-type transport system involved in resistance to organic solvents (PA4453).
Additionally, the expression profiles of outer membrane proteins after
induction with mimetic 18 were also found to be characterised predominantly by
down-regulation. For instance, OprE (PA0291; surface and extracellular fraction) and
the basic amino acid specific OprD (PA0958; surface fraction) were found to be
under-expressed in cell cultures treated with 18. Notably, OprD has been reported to
be involved in the uptake of the antibiotics imipenem and meropenem,[544] and in the
response to oxidative stress, as induced by copper.[545] Other down-regulated proteins
comprise OprH (PA1178; surface fraction) and OprG (PA4067; all fractions), which
belongs to the OmpW outer membrane protein family. On the other hand, OprF
(PA1777) was found to be differentially regulated in the intracellular and the surface-
bound protein fractions (vide supra). OprF is the major outer membrane protein of
Pseudomonas spp. and is thought to play a role during growth in environments
characterised by low osmolality, in adhesion to supports such as roots or exogenous
macromolecules, and in the maintenance of cell shape.[546] Interestingly, it has been
demonstrated recently that P. aeruginosa OprF binds to interferon-, highlighting the
possibility that pathogens might be able to sense alterations in the immune function of
the host.[547] Finally, a hypothetical membrane protein (PA0833),, belonging to the
OmpA family, was also found up-regulated in the extracellular sub-proteome.
The heat shock response is a mechanism elicited in all organisms as a reaction
to an increase in temperature as well as to other exogenous stress factors. The heat
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shock response consists of the enhanced synthesis of heat shock proteins (HSPs), such
as chaperones, chaperonins, proteases which remove misfolded polypeptide chains, or
isomerases which aid in the refolding or reformation of native disulfide bonds.[548]
From the protein expression profiles, it was found that the group I chaperonins,
GroEL and GroES, as well as the chaperone DnaK, the prokaryotic homolog of the
eukaryotic Hsp70, were up-regulated. Additionally, the prokaryotic analogue of
Hsp90, HtpG was found up-regulated in the surface-bound fraction, yet down-
regulated in the extracellular fraction. Furthermore, MucD, an endoprotease
presumed to be involved in the proteolysis of misfolded periplasmic proteins,[549] was
up-regulated in the surface and extracellular fractions. Two peptidyl-prolyl cis-trans
isomerases, SlyD and PipA were found to be affected by 18 in a differential manner,
that is SlyD was up-regulated intra-cellularly and PipA was down-regulated in the
surface-bound fraction. Peptidyl-prolyl cis-trans isomerases catalyse the
interconversion of cis-trans peptide bonds preceding proline residues, and are
involved in protein folding.[550] They play a role in the heat-shock response, but are
also thought to be involved in processes such as cellular signalling (c.f. Section
3.2).[551] Additionally, SlyD has been implicated to be involved in the hydrogenase
pathway of E. coli by aiding the [NiFe] metallo-centre biosynthesis.[552]
Additionally, the expression of several ribosomal proteins was affected by 18,
notably in the surface-bound and/or extracellular fractions. The most prominent
changes with respect to ribosomal proteins were detected for the L7/L12 ribosomal
protein. L7 is the N-terminally acetylated form of L12, and both proteins are often
referred to more generally as L7/L12. Tetramers of L7/L12 make up a flexible
protuberance of bacterial ribosomes, also called the ribosomal stalk,[553] and this
structure is involved in binding translational factors as well as in GTP hydrolysis.[554]
Interestingly, the prokaryotic elongation factor G was also found to be up-regulated
by mimetic-18. Recently, there have been increasing reports of ribosomal proteins
carrying out extra-ribosomal functions,[555, 556] and although such functions have not
been associated with L7/L12, the L12 fold has been related to the RRM fold of RNA
binding proteins,[557] and to the ovomucoid proteinase inhibitor.[558] Additionally, a
3-hydroxysteroid dehydrogenase from Pseudomonas testosteroni has been found to
be homologous to a fusion of the bacterial L10 and L7/L12 genes.[559, 560]
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Finally, four more proteins from different functional classes should be
mentioned which showed large differences in the protein expression profiles after
induction with 18. Chitinase (PA2300), was found up-regulated in the intracellular
fraction, as was acetyl-CoA acetyltransferase (PA2001) and also adenylate kinase
(PA3686), which has been shown to be a virulence factor of P. aeruginosa.[561] Acyl
carrier protein, on the other hand, was found to be down-regulated in the intracellular
fraction of P. aeruginosa.
4.1.5 Conclusions of the protein expression profiling
The analysis of the protein expression patterns of the three sub-fractions of P.
aeruginosa PAO1 after induction with mimetic 18 led to several interesting results
with respect to possible modes of action of our AMPMs. First of all, it should be
mentioned that it was possible to incubate the bacterial cells with a concentration of
18 that did not completely suppress bacterial growth for at least one generation time
under the experimental conditions. This situation is to be contrasted with the
behaviour of gramicidin S, for which Bandow et al. found that after reaching a
threshold concentration, rapid lysis of the bacterial cells occurred, thus complicating
the recording of protein expression profiles.[520]
For our protein expression profiles, it was found that a high proportion of the
proteins that were shown to be affected by induction with 18 were functionally related
to transport and uptake processes of the bacteria, such transport proteins being
involved in the uptake of certain amino acids or a variety of outer membrane proteins,
which are often implicated in the uptake of small hydrophilic molecules.
Additionally, the expression of a variety of so-called heat-shock proteins was found to
be significantly up-regulated in the mimetic 18 treated cells.
With respect to possible modes of action for AMPMs, it is of interest to
compare the protein expression profiles obtained to the results available from other
proteomic and transcriptional analyses. For example, the report by Bandow et al.
documents the induction of class I heat shock proteins (GroE, GroEL, and/or GroES)
in B. subtilis by those inhibitors of protein biosynthesis that affect the fidelity of the
translation process, namely the aminoglycosides gentamicin, streptomycin, and
kanamycin.[520] Since the expression of class I heat shock proteins in these instances
is thought to be induced by the appearance of misfolded proteins, it is conceivable that
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any kind of process that leads to the increased formation of corrupted proteins should
elicit similar responses. Not surprisingly, therefore, class I HSPs were also found to
be induced by puromycin, which causes abortive translation, or diamide (N,N,N',N'-
tetramethylazodicarboxamide), which causes the formation of non-native inter- and
intramolecular disulfide bonds. Similar results of increased expression of HSPs in a
concentration-dependent manner after treatment with aminoglycosides have been
described for E. coli, and based on these findings, HSPs were suggested to be a
proteomic signature for impaired ribosome function.[514]
It is interesting to recall, in this respect, that the flexible ribosome stalk, which
largely consists of L7/L12, is thought to confer proof reading abilities to the bacterial
ribosome and thus to play an important role in the control of translational
accuracy.[562] For instance, it has been shown that mutations of evolutionarily
conserved residues in the C-terminal domain of E. coli L7/L12 lead to increased
nonsense codon read-through in vivo, and to an increased rate of missense errors in
vitro.[563] It is noteworthy that L7/L12 was one of the proteins that showed large
changes in expression, that is, it was found to be strongly up-regulated in the surface-
bound protein fraction after induction with 18. It should also be recalled that the
studies on the incorporation of radio-labelled precursors of macromolecular
biosynthesis showed that the rate of incorporation of labelled leucine was not
primarily reduced by mimetic 18, but this result would not be incompatible with
defective protein biosynthesis.
However, translating overexpression of HSPs into a proteomic signature for
antibiotic action involved in misfolding or defective synthesis of proteins would be
too simplistic. Problems in associating antibiotic action with such a proteomic
signature arise, for example, since HSPs are also reported to be affected by other
factors, such as the physiological state of the bacterial cell or oxidative stress;[564-566]
the results of these studies are, however, sometimes not unambiguous. For instance,
the amount of heat shock proteins DnaK and GroEL was found to be increased in E.
coli growing to a high cell density together with alkyl-hydroperoxide reductase, and
these changes were attributed to an increased level of misfolded proteins and
increased level of oxidative stress caused by the high cell density of the cultures.[566]
Similarly, oxidative stress elicited in Porphyromonas gingivalis cell cultures grown
under hemin limitation, led to increase expression of the heat shock proteins HtpG,
GroEL, DnaK.[567]
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In contrast to this, a different picture arose from the analysis of the protein
expression profiles of S. aureus cells in the stationary or exponential growth
phase.[564] With respect to heat shock proteins, the authors of this study found that
DnaK and the co-chaperones GroE, GroEL, and GroES were all down-regulated, and
attributed this effect to the decreased translational activity in stationary phase cells,
concomitant with a reduced “protein stress”. On the other hand, several proteins to
which roles in the response to oxidative stress have been attributed, such as the above
mentioned alkyl-hydroperoxide reductase, as well as catalyse, superoxide dismutase,
and thioredoxin reductase, were found to be up-regulated.[564] Alkyl hydroperoxide
reductase was also found to be up-regulated in the response of Bacillus subtilis
towards superoxide and peroxide stress,[568] and if one attributes to this protein a
function as marker of oxidative stress, then it is of interest to recall that alkyl
hydroperoxide reductase was found to be up-regulated in the mimetic 18 treated
intracellular protein fraction. Of course, it should be emphasised that most of the
published expression profiles were not obtained with Pseudomonas spp., and
therefore caution should be taken not to draw too close analogies.
The differential regulation of a variety of different proteins involved in
chaperone function and stress response for cells under different growth conditions are
also of interest with respect to the observed down-regulation of azurin in the
intracellular and surface-bound protein fractions after induction with 18. That is,
since the expression of azurin has been associated with stationary phase growth or
anaerobiosis, the absence of the corresponding protein spots/species from mimetic 18
treated cells might arise from higher cell density experienced by the control cultures.
On the other hand, the expression patterns of mimetic 18 treated cells with respect to
the above mentioned HSPs, alkyl hydroperoxide reductase, and the variety of outer
membrane proteins, show no apparent similarity with those obtained from high
density or stationary phase cell cultures. Moreover, the publication by Kay et al. also
demonstrates that increased expression of azurin can occur under conditions that are
not related to high cell density conditions.[542]
Furthermore, interesting conclusions can be drawn from the expression
profiles of the outer-membrane proteins that, notably, made up a large fraction of
mimetic 18 affected proteins, with respect to the resistance of P. aeruginosa towards
antimicrobial agents. For example, the protein expression profiles of sarcosine-
insoluble outer membrane fractions obtained with strains of P. aeruginosa resistant
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towards the antibiotics ampicillin, kanamycin, and tetracycline have been studied. [569]
It was found that in these cases, OprF was up-regulated in all three resistant strains,
whereas OprH was up-regulated in bacteria resistant to the first two antibiotics, and
OprD was over-expressed in a strain resistant to tetracycline. Additionally, the outer
membrane protein OprG was found to be down-regulated in the strains resistant to
kanamycin and tetracycline. It is well established that an increased expression of
OprH is connected to resistance of P. aeruginosa towards aminoglycoside antibiotics,
the cationic peptide antibiotic polymyxin B, or the chelating agent EDTA.[570] In P.
aeruginosa, the PhoP-PhoQ two-component regulatory system responds to
magnesium limited growth conditions by auto-regulating the oprH-phoP-phoQ
operon. OprH is known to be over-expressed when cells are grown under magnesium
limiting conditions,[571] and protein expression profiles of P. aeruginosa, determined
under magnesium limiting growth conditions, showed a high increase in expression of
OprH in the membrane sub-proteome.[572] The PhoP-PhoQ two-component regulatory
system has been implied in resistance to the above mentioned cationic antibiotics, as
well as to antimicrobial peptides under magnesium limiting growth conditions.[573]
Recently, a second two-component regulatory system, PmrA-PmrB has been
associated with the response of P. aeruginosa to growth under magnesium limiting
conditions, and with the regulation of resistance towards cationic antibiotics and
antimicrobial peptides, such as LL37 and indolicidin.[574]
The increased resistance of P. aeruginosa under magnesium limiting growth
conditions is thought to be mediated via induction of a LPS modification system by
the PhoP-PhoQ, and/or the PmrA-PmrB regulatory systems, which leads to the
synthesis of a less negatively charged lipid A moiety.[575] Interestingly, in P.
aeruginosa the induction of the oprH-phoP-phoQ operon by polyamines such as
spermidine,[576] was observed and the pmrA-pmrB operon has been shown to be
activated by cationic antibiotics and antimicrobial peptides,[574] whereby AMPs that
displayed lower MIC values were found to be weaker inducers of the pmrA-pmrB
operon.
However, it has been found from the evaluation of our protein expression
profiles that the regulation of the outer membrane protein OprH was negatively
affected by induction with 18. Moreover, McPhee et al. studied isogenic phoP and
pmrA mutants of P. aeruginosa grown under magnesium limiting conditions via
transcriptional profiling,[577] and it is noteworthy that none of the 36 gene products
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that were reported to be regulated by PmrA could be identified from our protein
expression profiles. Similarly, only two out of 19 gene products could be identified
from the expression profiles that were described to be regulated by PhoP, with an
additional discrepancy being the direction of regulation of OprH. Furthermore, no
differential regulation of either PhoP or PhoQ could be detected in our protein
expression profiles. Therefore, there is no experimental evidence that would point
towards an activation of either the oprH-phoP-phoQ or the pmrA-pmrB operon by 18.
These findings are also of special interest with respect to potential therapeutic
applications of our AMPMs, since they indicate that these molecules might be less
prone to cause resistance towards cationic AMPs or other cationic antibiotics via the
above mentioned mechanisms. It is interesting to note that polyphemusins have been
demonstrated to be, on the one hand, almost unaffected by PmrA-PmrB mediated
resistance, and on the other hand, to show a very low tendency to activate the pmrA-
pmrB operon, when compared to other AMPs such as indolicidin, or to a linear
analogue of polyphemusin.[574] The importance of -hairpin AMPs such as
polyphemusin as starting points for AMPMs was discussed in Section 1.5. Finally, it
should be mentioned that since AMPs of diverse structure and origins are capable of
activating the PhoP-PhoQ regulatory system, presumably by displacing magnesium
cations from an acidic patch on the surface of PhoQ,[578] such a mechanism is unlikely
to account for the stereospecificity of mimetic 18.
To summarise, the protein expression profiles of P. aeruginosa PAO1 induced
with 18 suggest that the AMPM inflicts protein folding stress on P. aeruginosa
cultures. Furthermore, the amount of protein folding stress might be under estimated,
if the presumably higher rate of protein synthesis in the control cultures and/or the
higher expression of heat shock proteins in cultures of higher cell density are
considered. Due to the lack of a reference database of expression profiles from P.
aeruginosa challenged by antibiotic stimuli, it is not possible to make a reliable
prediction of an actual mode of action for mimetic 18 at this stage. Nevertheless, the
expression profiles might prove valuable in rationalising and validating putative
targets of mimetic 18 that may be identified from other, independent methodologies
(c.f. Section 4.2-4.3).
By comparison of the expression profiles seen here to the B. subtilis reference
database of Bandow et al,[520] impairment of ribosome fidelity emerges as a possible
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starting point for further studies. Due to the highly charged nature of 18, the question
of the specificity of a putative AMPM-ribosome interaction is immediately raised, not
least because of the acidic character of L7/L12 (pI = 4.7). However, any complete
mechanistic interpretation of the anti-pseudomonal activity of 18 has to satisfactorily
account for its stereospecificity, and it would also be conceivable that the uptake of
mimetic 18 into P. aeruginosa depends on a stereospecific interaction with cell
wall/membrane components. Such specific uptake could, for example, be mediated
by a variety of outer membrane or transport proteins, and a large proportion of
proteins belonging to both functional classes were shown to be negatively affected in
their expression by 18. An illustrative example that outer membrane proteins are able
to transport polypeptides into bacterial cells is given by the E. coli outer membrane
protein OmpW. OmpW, which is related to OprG in P. aeruginosa, was found to be
involved in the uptake of colicin S4, a group A bacteriocin, into susceptible strains of
E. coli.[579] The often remarkably high selectivities of bacteriocins have been
described in Section 3.3.2, and interestingly, OprG was found in this work to be
down-regulated in all sub-cellular fractions.
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4.2 Direct approaches towards target identification
4.2.1 Affinity chromatography of AMPMs
Affinity chromatography (AC) is a widely used chromatographic separation
technique based on the reversible interaction of a target macromolecule or a target
complex with a specific ligand that has been immobilised on a solid support (affinity
matrix). Most frequently, AC is used for the preparative purification of
macromolecules, and in such applications purification levels of several thousand-fold
are routinely achieved in a single step. Major advantages of AC comprise high
selectivity, high resolution, high recovery, and isolation of the target compound(s) in
concentrated form.
The main requirement for the successful application of AC is the availability
of a ligand specific for the target molecule(s); common examples of frequently used
ligand/target combinations are lectins/polysaccharides, complementary base
sequences/nucleic acids, glutathione/GST fusion proteins, metal ions such as Ni/poly-
His fusion proteins, avidin or streptavidin/biotinylated molecules, and
antibody/antigen (immuno-affinity chromatography).
Additionally, AC is used in proteomic studies to increase sensitivity, either by
removing from a complex protein mixture (classes of) proteins that might interfere
with the 2D-PAGE analysis, or by concentrating (classes of) proteins which are not
abundant enough to be detected.[580] Moreover, AC is an integral part of non-gel
based quantitative proteomic techniques such as ICAT, in which biotinylated isotope
labelled peptide fragments are purified by avidin affinity chromatography before they
are analyzed by mass-spectrometric methods.[581]
4.2.1.1 Affinity chromatography and target identification
Apart from the above mentioned applications in the purification of known
target molecules or classes of target molecules, AC is also a valuable tool for target
identification following phenotypic screening. In this regard, AC seeks to exploit
interactions of lead compounds with putative target molecule(s). Several successful
examples exist of the application of AC techniques to the target identification
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problem. For example, FKBP was discovered by an AC approach to be the molecular
target of FK-506, an important immuno-suppressant.[582] Other examples comprise
the identification of histone deacetylases as targets for the fungal metabolite
trapoxin,[583] or of ATP citrate lyase as a target for the macrolide radicol.[584] The use
of biotinylated analogues of the insect Pro/Arg-rich AMP pyrrhocoricin in the
identification of DnaK as a putative target for this class of AMPs has been described
in detail in Section 2.1.2.1.
However, it should be emphasised that successful examples of molecular
targets identified by AC described in the literature typically operate with a
combination of a high affinity small molecule ligand interacting with at least fairly
abundant target molecules. Before examining the AC experiments with AMPMs
derived from protegrin-1 in detail, it will be illustrative to summarise briefly the
principles of AC, with special emphasis on aspects concerning the use of AC for
target identification.
4.2.1.2 Principles of affinity chromatography
A typical AC experiment consists of three basic steps listed below; a
theoretical chromatogram illustrating these steps is shown in Figure 4.5:
1. equilibration of the affinity matrix.
2. sample application under conditions that favour the binding of the target
molecule(s).
3. elution under conditions that favour the dissociation of the ligand target
complex(es).
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Figure 4.5 Schematic representation of an affinity chromatography experiment.
First of all, the ligand has to be immobilised onto a solid support, in order to
create the affinity matrix. This is generally achieved by coupling the ligand
covalently to the resin, although attachment via exceptionally strong non-covalent
interactions, such as avidin/streptavidin/biotin or antibody/antigen is also possible.
Typical methods for immobilising ligands comprise the use of NHS-activated
supports (via amino groups), CNBr-activated supports (via amino groups), epoxide
functionalised supports (via nucleophiles in general), or the use of amino-
functionalised supports (via carboxylic acids).
Of paramount importance for AC is that the ligand retains its activity after the
immobilisation step. To achieve this, the incorporation of a spacer arm between the
matrix and the ligand is often necessary, especially in such cases where the binding
site is located deep inside the target molecule. The steric repulsion from the affinity
matrix is expected to be more severe for small molecule ligands and might also be a
concern for AMPMs, which are of intermediate size. On the other hand, potential
linkers should not be longer than necessary for optimal activity, since they can also
lead to unspecific binding of macromolecular components, for example, via
hydrophobic interactions.
The potential problem of losing affinity upon immobilisation applies to all
chemical genetics/proteomics approaches in which a tag, a label other than an isotope
label, or other reactive functionality is introduced into the molecule. Indeed, the
problem is more severe for target identification applications, since during purification
196 Chapter 4
of known target molecules, parameters such as the target affinity of the immobilised
ligand can readily be verified.
The elution of bound target molecules from the affinity matrix can be achieved
by both selective and non-selective methods. Commonly, non-specific elution is
achieved by altering the pH, the ionic strength, or the polarity of the buffer system, in
order to weaken ligand/target interactions, which can depend on electrostatic
interactions, hydrophobic interactions, hydrogen bonding or van der Waals forces.
On the other hand, target molecule(s) can be eluted selectively by supplementing the
elution buffer with a competitive ligand. These ligands can disrupt ligand/target
interactions by binding selectively either to the ligand or to the target molecule, thus
leading to displacement of the target molecule from the affinity matrix. Ideally, the
free ligand can be used for competitive elution, if it is available in sufficient
quantities. The use of ligands with very high affinity might necessitate denaturing
elution conditions such as the addition of chaotropic reagents and/or detergents to the
buffer system. For example, streptavidin binds biotinylated molecules with such high
affinity that they are generally eluted by boiling the affinity matrix in SDS buffer
systems. Whereas the use of such harsh conditions can be problematic or impossible
if one is interested in the isolation of a functional compound, the isolation of a native
target molecule is not necessary for target identification by mass spectrometric or
other sequencing methods.
Finally, for target identification by AC it is desirable to include an additional
washing step into the experiment that is as stringent as possible, in order to remove
proteins that might be bound non-specifically to the affinity matrix. However, again it
is not possible to decide a priori how extensive the washing step can be made without
dissociating the ligand/target interactions.
4.2.1.3 AMPMs as ligands for affinity chromatography
In general, peptidic compounds display several potential attachment points for
their capture on solid supports. Whereas the immobilisation of proteins via reactive
side-chains is carried out routinely, and is generally applicable because it does
normally not introduce large structural alterations to the binding site, the same might
not be true for smaller peptides such as the AMPMs. That the introduction of
alternative functionality into AMPMs can severely impair their biological activity has
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been demonstrated amply by the DANA-labelled library of mimetic-17 (c.f. Section
3.8.3.3).
However, the scaffolds of AMPMs in general and the scaffolds of mimetics 18
and 19 in particular offer a large fraction of residues that might be attached to solid
supports. More precisely, both 18 and 19 possess five lysine residues that could be
covalently linked to create an affinity matrix. A first indication of the potential
feasibility of unselective attachment of AMPMs to solid supports derives from an
alanine scan on mimetic 18, carried out in our group by N. Srinivas.[139] Therein, it
was discovered that the anti-pseudomonal activity of the alanine analogues of 18 was
insensitive towards alanine substitution except at the two aromatic positions. Apart
from replacement of Trp-2 and Trp-8, which led to loss of the anti-pseudomonal
activity, all other analogues were comparable in activity to the parent compound and,
in fact, mimetic 19 was discovered during these studies as a new antimicrobial lead
compound.
However, the alanine scan does not take into account steric influences of the
solid support on the MIC values, and therefore a method of immobilisation which
allows for site-specific immobilisation of AMPMs might be desirable. A variety of
approaches exist for selectively immobilising peptidic compounds containing multiple
reactive functionalities. For example, the increased nucleophilicity of hydrazines or
thiols, the use of an orthogonal functionality such as an aldehyde, or the use of strong
non-covalent interactions such as biotin/streptavidin are possible. Methods of
introducing additional functionality into the AMPM framework have been discussed
in Section 3.8.
For the incorporation of a handle into the scaffold of mimetic-19 that allows
for its site-specific immobilisation, again a strategy employing SPPS was used, with
commercially available N--Fmoc-N--(N-biotinyl-3-(2-(2-(3-aminopropyloxy)-
ethoxy)-ethoxy)-propyl)-L-glutamine (Fmoc-Glu(biotinyl-PEG)-OH; 79; Figure 4.6).
79 was chosen to allow for capture of mimetic 19 onto an avidin or streptavidin-
functionalised solid supports, and since biotin represents a versatile functionality that
can be used in a variety of applications (vide infra). Moreover, 79 contains a 15 atom
hydrophilic PEG spacer arm, that is not prone to unspecific hydrophobic interactions
and which also allows for better estimation of steric influences on the anti-
pseudomonal activity of mimetic 19.
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Figure 4.6 Fmoc-Glu(biotinyl-PEG)-OH (79) used for the synthesis of biotinylated analogues of
mimetic 19.
79 was incorporated into the scaffold of mimetic 19 by single replacement of
all residues except Trp-2, Trp-8 and the D-Pro-L-Pro template. The synthesis of the
biotinylated analogues was carried out according to our standard protocol for the
synthesis of AMPMs outlined in Section 3.1 and described in detail in Section 5.2.
The biotin functionality was incorporated into the peptide chain by manually coupling
1.5 equivalents of 79 using 1.45 equivalents of HATU as activating reagent and 3.0
equivalents of DIEA. Crude peptides were purified by RP-HPLC and determined to
be of at least 98% purity by analytical HPLC. ESI mass spectrometric and analytical
HPLC data are summarised in Appendix 2. The biological activities of the
biotinylated analogues of mimetic 19 were determined against our panel of test micro-
organisms and are summarised in Table 4.5. It can be seen, that the scaffold of
mimetic 19 is surprisingly tolerant to the introduction of Glu(biotinyl-PEG)-OH.
Incorporation of biotin functionality replacing residues Thr-1 and Lys-12, which flank
the D-Pro-L-Pro template, leads to analogues (80 and 89) with excellent anti-
pseudomonal activity. More precisely, the activities are of the same order of
magnitude as for 19. Although for some compounds there is a larger decrease in the
biological activity, they all display the same specific activity pattern that is
characteristic of the later generation AMPMs (c.f. Section 3.3).
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Table 4.5 Antimicrobial activities of the biotinylated analogues of mimetic-19. The position of
the incorporated biotin label is underlined and highlighted in red, and the numbering of amino acid
residues is given for the parent compound.
IDa sequenceb MICc [g/mL]
E. coli P. aeruginosa S. aureus
25922d 27853d PAO1d 25923d 29213d
19 1T2W3L4K5K6R7R8W9K10K11A12KpP 64 0.008 0.015 > 64 > 64
80 BWLKKRRWKKAKpP 32 0.06 0.06 > 64 > 64
81 TWBKKRRWKKAKpP > 64 > 64 > 64 > 64 > 64
82 TWLBKRRWKKAKpP 64 0.125 0.5 > 64 > 64
83 TWLKBRRWKKAKpP > 64 16 64 > 64 > 64
84 TWLKKBRWKKAKpP > 64 0.5 1 > 64 > 64
85 TWLKKRBWKKAKpP 64 4 16 > 64 > 64
86 TWLKKRRWBKAKpP > 64 0.25 0.5 > 64 > 64
87 TWLKKRRWKBAKpP 64 0.125 0.5 > 64 > 64
88 TWLKKRRWKKBKpP 64 2 2 > 64 > 64
89 TWLKKRRWKKABpP > 64 0.06 0.125 > 64 > 64
a Substance identifier; b B = Glu(biotinyl-PEG)-OH; c MIC = minimal inhibitory concentration.
This pattern is even discernible for compound 85, which is three orders of
magnitude less active than the parent compound. Only compounds 81 and 83, in
which Leu-3 and Lys-5 were replaced respectively, lose the activity pattern. For
compound 81, this corresponds to a decrease in activity of at least four orders of
magnitude. Finally, the findings that biotin can be incorporated successfully into the
scaffold of mimetic-19, especially by replacement of four out of five lysine residues
with a biotinylated amino acid containing a 15 atom spacer arm, corroborates the
feasibility of unselective coupling of the ligand to the matrix.
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4.2.1.4 Affinity chromatography experiments with P. aeruginosa
PAO1
For AC experiments with P. aeruginosa PAO1, cell cultures were grown
according to the standard incubation conditions described for the protein expression
profiling (c.f. Section 4.1 and Section 3.3). In analogy to the protein expression
profiling, three fractions were prepared for analyses. However, due to the denaturing
conditions of the prefractionation employed for the proteomics experiments, a
different protocol, based on differential centrifugation was used. Briefly, cell cultures
were harvested in the mid-logarithmic growth phase, typically after three hours of
incubation, corresponding to an OD600 of 1.0, and were ruptured either by sonication
or via a French pressure cell. Protease inhibitors were added to prevent proteolytic
breakdown of proteins, and large cell debris was removed by low speed centrifugation
at 5000 g for 10 minutes. The crude cell mixture were further fractionated by
centrifugation at 40000 g for 30 minutes to remove the outer membrane fraction and
smaller cell debris. A final centrifugation step at 100000 g separated the cytoplasmic
membrane and smaller outer membrane fragments from the intracellular fraction. For
experiments with membrane preparations, 1% of the non-ionic detergent Triton-X
100™ was added to the buffer systems as a solubilising agent. Since it was found that
neither the extracellular nor the membrane fractions lead to the isolation of protein
bands on 1D gels, the following discussion will focus on the intracellular fraction of
P. aeruginosa PAO1. In order to minimise denaturing effects that might impair
putative AMPM/target interactions, all operations were carried out on the same day
and at 4°C.
For the preparation of affinity columns, mimetics 19 and ent-18 were coupled
to NHS-activated sepharose HiTrap™ columns (1 mL) according to the
manufacturer’s instructions. Briefly, AMPM ligands were coupled in standard
coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) for 30 minutes at room
temperature, and unreacted NHS on the matrix was deactivated with a buffer
containing 0.5M ethanolamine, 0.5M NaCl, pH 8.3. The coupling efficiencies were
determined by UV spectroscopy and were found to be always ≥ 90%.
In a first set of experiments, 5 mg of mimetic 19 were immobilised onto NHS-
activated sepharose and samples of cell lysate of P. aeruginosa PAO1, corresponding
to 10 mg of protein, as determined by Bradford analysis, were used for the
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experiments. To check for unspecific binding of macromolecules to the solid support,
a control column, capped with ethanolamine, was used. Unbound proteins were
washed out with standard buffer (50 mM phosphate, 100 mM NaCl, pH 7.0), and
bound macromolecules were eluted non-selectively with an elution buffer consisting
of 50 mM ethanolamine, 100 mM NaCl, pH 9.5. A chromatogram of the affinity
purification is depicted in Figure 4.7 and a corresponding 1D-PAGE gel is shown in
Figure 4.8.
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Figure 4.7 Chromatogram of an AC experiment with 5 mg of mimetic-19 immobilised on 1 ml
of NHS-activated Sepharose. Elution buffer (A): 50 mM ethanolamine, 100 mM NaCl, pH 9.5;
binding buffer (B): 50 mM phosphate, 100 mM NaCl, pH 7.0. Conditions: applied protein = 10 mg;
flow = 1 mL/min; blue trace = 226 nm; red trace= 254 nm. The arrows mark changes in the buffer
system. The second elution step checks for the influence of changing the buffer systems on the UV
traces.
It can be seen from this figure that mimetic 19 binds a variety of proteinaceous
species on the affinity matrix (lane B), and that the ethanolamine-capped control
column (lane C) does not non-specifically retain proteinaceous compounds. For the
identification of these proteins and to further increase the resolution, a 2D–PAGE gel
was run with an IPG pI gradient from 3 to 10, and the gel is shown in Figure 4.9.
Protein spots that were subjected to Tryptic digestion and mass spectrometric analysis
(c.f. Section 4.1) are indicated.
A A
B
B
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Figure 4.8 Coomassie-stained 1D PAGE corresponding to the
AC experiment of Figure 4.7. From left to right: (A) molecular
mass standards; (B) elution from the affinity matrix created by
immobilising 5 mg of mimetic 19; (C) elution from an ethanolamine
capped negative control column.
In total, out of 26 protein spots, 21 could be identified, corresponding to 9
different protein species of P. aeruginosa PAO1, and these are summarised in Table
4.6. The identified proteins belong to three different classes. Nine spots
corresponded to GroEL, a bacterial heat shock protein, three spots corresponded to the
-chain of DNA-directed polymerase and finally, 12 protein spots originated from
seven different ribosomal proteins. Most prominent on the 2D gel are spots S23 and
S24, which both correspond to ribosomal protein L7/L12. However, it should be
mentioned (c.f. Table 4.6) that the majority of the identified proteins are negatively
charged and highly abundant in the bacterial cells.
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Figure 4.9 Coomassie stained 2D gel of proteins bound to a mimetic-19 affinity matrix.
Table 4.6 Identification of proteins of the intracellular fraction of P. aeruginosa PAO1 retained on a mimetic-19 affinity column. Missing spot numbers correspond
to unidentified proteins.
a Spot numbers refer to Figure 4.9.
b Data generated from peptide mass maps were compared to the translated open reading frames (ORF) for P. aeruginosa PAO1 (http://v2.pseudomonas.com).
c Probability score of the MASCOT database search based on an implementation of the Mowse algorithm;[538] scores greater than 60 are considered significant (p<0.05).
d Sequence coverage denotes the percentage of the protein sequence for which matching peptide fragments have been identified.
Spot noa PA nob Protein description Theoretical pI Theoretical Mr Protein scorec Sequence coverage [%]
S1 PA4385 GroEL protein 5.0 57.0 462 47
S2 PA4385 GroEL protein 5.0 57.0 333 44
S3 PA4385 GroEL protein 5.0 57.0 412 45
S4 PA4385 GroEL protein 5.0 57.0 211 28
S5 PA4385 GroEL protein 5.0 57.0 701 50
S26 PA4385 GroEL protein 5.0 57.0 219 36
S8 PA4385 GroEL protein 5.0 57.0 701 58
S9 PA4385 GroEL protein 5.0 57.0 341 39
S10 PA4385 GroEL protein 5.0 57.0 244 35
S12 PA4238 DNA-directed RNA polymerase  chain 4.9 36.7 492 57
S13 PA4238 DNA-directed RNA polymerase  chain 4.9 36.7 353 43
S14 PA4238 DNA-directed RNA polymerase  chain 4.9 36.7 413 48
S6 PA3162 30S ribosomal protein S1 4.8 61.9 337 43
S7 PA3162 30S ribosomal protein S1 4.8 61.9 403 47
S17 PA4935 30S ribosomal protein S6 4.9 16.2 168 57
S15 PA4273 50S ribosomal protein L1 9.6 24.0 287 53
S19 PA4932 50S ribosomal protein L9 5.5 15.5 442 63
S20 PA4272 50S ribosomal protein L10 8.9 17.6 154 32
S21 PA4274 50S ribosomal protein L11 9.8 20.0 147 39
S23 PA4271 50S ribosomal protein L7/L12 4.7 12.5 119 65
S24 PA4271 50S ribosomal protein L7/L12 4.7 12.5 124 65
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In order to check the specificity of the retention of the identified protein
species, two different approaches were implemented employing the enantiomer of 18.
In one set of experiments, both 19 and ent-18 were immobilised on NHS-activated
Sepharose columns, and bound molecules were eluted non-selectively from the
affinity matrices with increasing ionic strength, that is with increasing amounts of
NaCl added to the standard buffer. Additionally, the concentration ratio of applied
protein to ligand was increased. This is thought to help in suppressing unspecific
interactions with the immobilised ligand, as well as resulting in higher sensitivity, and
was achieved by decreasing the amount of immobilised ligand from 5 to 1 mg, and by
increasing the amount of applied protein from 10 to 30 mg.
Figure 4.10 shows a chromatogram from an AC experiment with immobilised
mimetic 19 and elution with increasing ionic strength. It can be seen that elution with
buffers containing 0.2M and 0.35M of NaCl led to the release of a significant amount
of macromolecules from the affinity matrix. However, the ratio of UV absorption
between different wavelengths is not as to be expected for a preparation consisting
only of proteinaceous compounds, and thus suggests the presence of nucleic acids.
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Figure 4.10 Affinity chromatography experiment with 1 mg of immobilised mimetic-19 and
elution with AC standard buffer (50 mM phosphate, 100 mM NaCl, pH 7.0) supplemented with
increasing amounts of NaCl. The final concentrations of NaCl in the elution buffer are (A): 0.2M; (B):
0.35M; (C): 0.5M; (D): 1M; (E): 2M.
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Figure 4.11 Silver stained 1D PAGE of an AC experiment using an elution buffer system of
increasing ionic strength to elute macromolecules bound to mimetic-19 and ent-18 affinity matrices.
From left to right: (A) 0.5M NaCl, immobilised ent-18; (B) 0.5M NaCl, immobilised 19; (C) 0.2M
NaCl, immobilised ent-18; (D) 0.2M NaCl, immobilised 19; (E) 0.35M NaCl, immobilised ent-18; (F)
0.35M NaCl, immobilised 19; (G) 2M NaCl, immobilised ent-18; (H) 2M NaCl, immobilised 19.
A corresponding 1D PAGE gel showing fractions eluted with different ionic
strength is shown in Figure 4.11. It can be seen that, as to be expected from the
chromatogram(s), a large number of bands is detected from fractions collected with
elution buffers containing 0.2M, and 0.35M of NaCl. It is noteworthy that these
species are concentrated between molecular masses of around 10 to 30 kDa.
However, it can also be seen that there are no obvious differences between the 1D gel
profiles of mimetic-19 and the unspecific control compound ent-18.
In another set of control experiments, 19 and ent-18 were used to
competitively displace putative target molecules from an affinity matrix composed of
immobilised 19. A silver-stained 1D gel from an experiment with such competitive
elution is shown in Figure 4.12. Similar to elution using increasing ionic strength,
there is a large amount of bands concentrated in a molecular mass region between 10
and 30 kDa. Although the band patterns of the macromolecular fractions eluted with
either 19 or ent-18 added to the binding buffer at concentrations of 1mg/mL show a
similar overall appearance, there seem to be discernible differences in the patterns,
especially at molecular masses between 10 and 15 kDa. In future work, it will be of
interest to analyse these patterns further by 2D-PAGE analysis.
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Figure 4.12 Silver stained 1D PAGE of an AC experiment with immobilised mimetic-19 using
competitive elution with either 19 or ent-18 added to the elution buffer (50 mM phosphate, 100 mM
NaCl, pH 7.0). Elution with 3 mL of ent-18 in elution buffer (D), followed by additional 3 mL of ent-
18 in elution buffer (E), acidic elution with 50 mM acetate, 100 mM NaCl, pH 4 (B), and basic elution
with 50 mM ethanolamine, 100 mM NaCl, pH 9.5 (H). Elution with 3 mL of 19 in elution buffer(E),
followed by additional 3 mL of 19 in elution buffer (F), acidic elution with 50 mM acetate, 100 mM
NaCl, pH 4 (C), and basic elution with 50 mM ethanolamine, 100 mM NaCl, pH 9.5 (I). Lane A
corresponds to the molecular mass standards.
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4.2.2 Photoaffinity Labelling
Another direct approach towards target identification consists of covalently
linking ligands to their target molecule(s), where the ligands are functionalised so as
to allow for the isolation and identification of the newly formed adduct. In chemical
crosslinking, this can be achieved, for example, by using homo- or hetero-bifunctional
linkers, such as EDC and glutardialdehyde, that form bonds with amine or carboxylic
acid functionalities of biological macromolecules.[585] Alternatively, in photoaffinity
labelling (PAL), formation of a covalent bond is achieved by radiative activation of a
photo-reactive moiety creating a highly reactive intermediate species. One advantage
of crosslinking experiments compared to AC, with respect to the target identification
problem is the potential use of the former method for in vivo applications.
The process of designing and using (small) synthetic molecules as chemical
probes to covalently modify and identify target proteins, is termed chemical
proteomics.[586] Activity-based chemical probes react with classes of enzymes by
virtue of the enzymatic reaction mechanism, such as the labelling of cysteine
proteases with chemical probes containing epoxide functionalities that are irreversibly
attached by bond formation between the active-site cysteine residue and the
epoxide.[587] Affinity-based probes, on the other hand, are covalently attached to non-
catalytic residues of the target molecule(s), and hence require selective and strong
binding to their target molecule(s). Moreover, there is also a third class of chemical
probes which are used to covalently modify proteins in an unselective manner. In
quantitative non-gel based proteomics, for instance, the ICAT reagent is attached to
proteins containing thiol functionality via the general alkylating property of the
iodoacetamide moiety of the ICAT reagent.
Typically, a chemical proteomics probe possesses three to four distinct
components. These consist firstly of a reactive group for attaching the probe
molecule to the target compound, secondly a linker to modulate the reactivity and the
specificity of the reactive group, and thirdly a label/tag functionality that allows for
identification and/or purification of the newly formed adduct. The use of affinity-
based probes as in PAL necessitates a fourth element that is responsible for binding to
the target molecule with high affinity, and such elements can also be included in
activity-based probes in order to enhance selective binding. Commonly employed tag
functionalities are biotin and radioactive or fluorescent labels. One advantage of the
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use of biotin tags is the possibility to concentrate biotinylated target molecules from
complex protein mixtures via AC, prior to attempting protein identification.
As mentioned, PAL is a direct method for the identification of potential target
molecules and in favourable cases this can be achieved at different levels. Apart from
the first level of identification, which is concerned with the identity of the target
molecule(s), the fragmentation of covalently labelled proteins can permit mapping of
the binding site or even the delineation of the site of attachment. As such, PAL is a
complementary approach to site directed mutagenesis for the mapping of binding
sites, especially in such instances where NMR or X-ray data is not available.[588]
Once again, it is of major importance that the introduction of extra
functionality into the ligand in order to create the chemical probe molecules does not
impair the biological activity. However, it has been argued that PAL probes which
are up to three orders of magnitude less active than the parent compound can still be
successfully used in PAL experiments, although this obviously necessitates a high
initial activity of the parent compound.[588]
Several examples of the successful application of PAL in target identification
schemes have been reported.[589] For instance, the binding of the oxazolidinone
antibiotic eperezolid to the ribosome was mapped onto the L27 ribosomal protein,
tRNA, ribosome-associated LepA protein, and a conserved base in the peptidyl
transferase centre of 23S RNA by the use of a radio-labelled photo-reactive eperezolid
analogue.[590] Similarly, an analogue of pioglitazone, an anti-diabetic compound, led
to the isolation of a hitherto uncharacterised mitochondrial membrane protein as a
putative target for pioglitazones and related compounds.[589] Moreover, photo-
reactive analogues of the angiotensin AT-4 have been demonstrated to be efficient
tools for the identification of AT4 receptors in various tissues.[591] Finally, Hatanaka
et al. described the use of biotinylated diazirine for the analysis of galactosyl
transferase binding sites,[592] and recently, the binding site of HIV-1 integrase for
coumarin-based inhibitors was identified using photo-reactive analogues.[593]
4.2.2.1 Photo-reactive groups
As mentioned, successful PAL depends on the availability of photo-reactive
groups that can be incorporated into the molecular framework of the ligand without
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loss of its biological activity. Several requirements for such photo-reactive groups to
be useful for PAL experiments in biological systems are summarised below:
1. Excited state with a lifetime shorter than dissociation of the ligand but long
enough to allow for covalent linkage.
2. Unambiguous photochemistry to provide desired photo-adducts.
3. Possibility to react with C-H and X-H (X=N, O) bonds.
4. Stability under ambient conditions.
5. High excitation wavelengths.
The last criterion is not stringent for target identification, in which damage to
proteins caused by UV irradiation is tolerable as long as it does not interfere with the
identification of the target molecule. Three different photo-reactive groups are most
frequently used for PAL, and these are based on benzophenone, azide, and diazirine
functional groups. The photochemical transformations commonly encountered with
these photo-reactive groups are summarised in Figure 4.13. Additionally, the use of
aromatic diazo compounds has been described for PAL.[594]
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Figure 4.13 Photochemistry of photo-reactive groups used for PAL of biological macromolecules
as exemplified with proteins. (A): benzophenone-based probes; (B) aromatic azide-based probes; and
(C): diazirine-based probes.
4.2.2.2 Synthesis of PAL probe molecules
For the synthesis of PAL probes of our AMPMs, two commercially available
N--Fmoc-protected amino acids containing either a benzophenone or an aromatic
azide photo-reactive moiety were chosen (Figure 4.14). Both N--Fmoc-p-azido-L-
Phe-OH (90) and N--Fmoc-p-benzoyl-L-Phe-OH (91) can be conveniently
introduced into the AMPM scaffold during SPPS.
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Figure 4.14 Commercially available building blocks for the SPPS synthesis of photo-reactive
analogues of mimetic-19.
Since it was known from the synthesis of DANA-labelled AMPM analogues
(c.f. Section 3.8), that the incorporation of aromatic amino acids into the scaffold of
mimetic 17 under retention of activity was only possible by replacing an aromatic Trp
residue, the photo-reactive amino acids 90 and 91 were introduced into positions Trp-
2 or Trp-8 of the scaffold of mimetic 19. The synthesis of photo-reactive analogues
was carried out according to the standard protocol for the synthesis of AMPMs
outlined in Section 3.1) and described in detail in Section 5.2, with the only
modification that the unnatural amino acids were coupled manually, using 1.5
equivalents of amino acid, 1.45 equivalents of HATU as activating reagent and 3
equivalents of DIEA. Crude peptides were purified by RP-HPLC and determined to
be of at least 98% purity by analytical HPLC. ESI mass spectrometric and analytical
HPLC data of the photo-reactive analogues of mimetic 19 are summarised in
Appendix 2. The antimicrobial activity of the synthesised photo-reactive AMPMs
against our panel of test organisms are shown in Table 4.7, in which a DANA-
labelled analogue of 19 is included for comparison.
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Table 4.7 Antimicrobial activities of photo-reactive analogues of mimetic-19. Photo-reactive
and biotinylated amino acids are highlighted in blue and red, respectively. Compound 75 is included
for comparison.
IDa sequenceb MICc [g/mL]
E. coli P. aeruginosa S. aureus
25922d 27853d PAO1d 25923d 29213d
19 1T2W3L4K5K6R7R8W9K10K11A12KpP 64 0.008 0.015 > 64 > 64
92 TZLKKRRWKKAKpP > 64 0.06 0.25 > 64 > 64
93 TWLKKRRZKKAKpP 64 ≤ 0.03 0.06 > 64 > 64
94 TOLKKRRWKKAKpP 64 4 8 > 64 64
95 TWLKKRROKKAKpP 64 0.125 0.5 > 64 > 64
96 BZLKKRRWKKAKpP > 64 0.5 1 64 32
97 BWLKKRRZKKAKpP > 64 0.125 0.25 > 64 64
98 TWLKKRRZKKABpP 64 1 4 > 64 > 64
99 BOLKKRRWKKAKpP 16 2 2 > 64 32
100 BWLKKRROKKAKpP 64 0.25 0.5 > 64 > 64
77 TWLKKRRDKKAKpP 64 0.125 0.5 > 64 > 64
a Substance identifier; b B = Glu(biotinyl-PEG), Z = p-azido-Phe, O = p-benzoyl-Phe; D = DANA; c
MIC = minimal inhibitory concentration; d strain or ATCC number.
It can be seen from Table 4.7, that both photo-reactive amino acids could be
introduced into both Trp positions with retention of the selective anti-pseudomonal
activity of the parent compound. Additionally, it is evident that the replacement of
tryptophan with p-azido-Phe-OH (92 and 93) leads to less decrease in the biological
activity than substitution with p-benzoyl-Phe-OH (94 and 95). This finding might be
explicable by the increased steric bulk of the benzophenone moiety; along these lines
the DANA-labelled compound 77 shows almost identical activity compared to 95.
Interestingly, both Trp positions could thus be replaced by either (a) a benzene ring
system, (b) a benzophenone moiety, or (c) the aromatic naphthalene system, albeit
with a loss of activity of about one order of magnitude.
Moreover, substitution in position 2 was generally found to be more
detrimental for the biological activity than in position 8, and this is in agreement with
the results obtained from the introduction of DANA into the scaffold of mimetic-17.
In the latter case replacement of Trp-2 even led to complete loss of the specific
activity pattern (c.f. Section 3.8).
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Finally, in order to obtain probe molecules that could be used in PAL
experiments, bi-functionally modified AMPM analogues, carrying both a photo-
reactive group as well as a biotin label, were synthesised as outlined in the standard
protocol for the synthesis of AMPMs (c.f. Section 3.1) and described in detail in
Section 5.2, with the only modification that the unnatural amino acids were coupled
manually, using 1.5 equivalents of amino acid, 1.45 equivalents of HATU as
activating reagent and 3 equivalents of DIEA. Crude peptides were purified by RP-
HPLC and determined to be of at least 98% purity by analytical HPLC. ESI mass
spectrometric and analytical HPLC data of the photo-reactive analogues of mimetic
19 are summarised in Appendix 2. The antibacterial activities of the PAL probe
molecules were determined against the panel of test organism and are included in
Table 4.3. For the syntheses the probe molecules, Glu(biotinyl-PEG) was
incorporated into position Thr-1, since this was found (c.f. Table 4.3) to yield the
biotinylated analogue of 19 with the best retention of anti-pseudomonal activity. For
Glu(biotinyl-PEG) in position 1, combinations with both photo-reactive groups in
either position 2 or position 8 were synthesised. Additionally, replacement of Trp-8
by p-azido-Phe was tested together with replacement of Lys-11 by the biotinylated
glutamic acid derivative, since this leads to a PAL probe with decreased positive
charge.
Interestingly, the incorporation of the biotin-label into the scaffold of the
photo-reactive analogues of mimetic-19 leads to a higher decrease in anti-
pseudomonal activity for both p-azido-Phe functionalised systems than to be expected
from the results derived from the library of biotinylated analogues (c.f. Section 4.2.1).
Moreover, the combination of a biotin label together with p-benzoyl-Phe led to
practically no further loss of activity, unlike the combination of the biotin label with
the p-azido-Phe photo-reactive group. Nevertheless, the PAL probe with the best
anti-pseudomonal activity was obtained by substitution of Thr-1 with Glu(biotinyl-
PEG) and of Trp-8 with p-azido-Phe (97).
4.2.2.3 PAL with P. aeruginosa PAO1
For the PAL experiments, only membrane and intracellular fractions were
investigated. Moreover, since PAL allows the in vivo labelling of cell cultures, and
since the AC experiments with membrane fractions were inconclusive, special
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emphasis was put here on the membrane fractions. All experiments described herein
are concerned with the biologically most active photo-reactive analogue of mimetic-
19, namely 97. For in vivo PAL, cultures of P. aeruginosa PAO1 were harvested in
their mid logarithmic growth phase when they reached an OD600 of 0.1. Cells were
washed twice in PAL standard buffer (50 mM phosphate, 100 mM NaCl, pH 7.3), and
re-suspended in standard buffer to give a cell density of 5×109 CFU/mL. 10 mL
portions of the cell suspensions were incubated for 30 minutes and at 4°C in Petri
dishes of a diameter of 10 cm together with 97 and subsequently irradiated at a
wavelength of 254 nm and at a distance of 5 cm. After irradiation, the cell
suspensions were fractionated according to the differential centrifugation protocol
described for the AC experiments in (c.f. Section 4.2.1) to obtain the intracellular and
membrane protein fractions. Alternatively, for in vitro PAL, cell cultures were first
fractionated according to the differential centrifugation protocol, and the intracellular
or membrane fractions were re-suspended in standard buffer before the incubation
with PAL probes and the subsequent irradiation. In experiments with competitive
ligands, either mimetic-19 or ent-18 was pre-incubated for 30 minutes with the cell
suspensions before addition of the PAL probe.
In order to concentrate biotinylated molecules, from the cell suspensions were
incubated with streptavidin immobilised on agarose beads. Streptavidin-bound
biotinylated macromolecules were analysed directly by 1D SDS PAGE; the
dissociation of the strong biotin-streptavidin complex was achieved by boiling
streptavidin beads with SDS PAGE sample buffer. Prior to the concentration steps,
PAL samples were dialysed against PAL standard buffer, in order to remove low
molecular weight biotinylated compounds. For the detection of biotinylated
molecules, a modified Western-blot procedure, based on the amplified alkaline
phosphatase Immun-Blot® kit, was used. Briefly, samples from the 1D SDS PAGE
were blotted onto PVDF membranes and blocked with 1% BSA. The detection of the
biotinylated molecules was achieved by treating the protein blot with a complex of
biotinylated alkaline phosphatase/streptavidin (3:1), which possesses one free binding
site for attaching to biotinylated species on the PVDF membrane, and which improves
the sensitivity as one biotinylated molecule on the membrane is linked to three
molecules of alkaline phosphatase. Biotinylated macromolecular bands on the blot
were subsequently visualised by a chromogenic enzymatic reaction with BCIP (5-
216 Chapter 4
bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium) as substrates
and with alkaline phosphatase, yielding a purple/blue precipitate.
Firstly, since one focus has been on the identification of putative targets in the
membrane fractions of P. aeruginosa, several methods for extracting membrane
proteins were studied for their applicability in the PAL experiments. Therefore, P.
aeruginosa PAO1 cells were labelled with 97 in vivo as described above, and several
different protocols for the extraction of membrane proteins were evaluated. Firstly,
three common detergents used to solubilise membrane proteins, namely SDS, Triton-
X 100™, and Triton-X 114™ were tested, as well as a method based on extraction
with TFE and one method based on extraction with a carbonate buffer system. The
extraction protocol employing Triton-X 114™ exploits the low cloud point of the
detergent, which leads to phase separation above 20°C and allows for the convenient
isolation of hydrophobic proteins in the detergent phase.[595] Extraction with Triton-X
114™ and cooling of the detergent fraction below 4°C also furnishes a precipitate that
contains membrane proteins,[596] and which was also analysed in the experiment.
Additionally, the different extraction methods were compared to the direct
solubilisation of membrane proteins with SDS-PAGE sample buffer.
A modified Western-Blot of the 1D-PAGE, comparing the different extraction
methods is shown in Figure 4.15. It can be seen that solubilisation of membrane
proteins with both Triton-X 100™ or with SDS led to the visualisation of the most
bands and was superior to the other extraction methods inasmuch as both were able to
visualise more proteins. TFE extraction furnished lower background but was less
sensitive in the lower molecular weight range. Finally, both carbonate extraction and
analysis of the cold pellet of the Triton-X114™ detergent fraction were
unsatisfactory. Despite the larger background, the direct solubilisation with SDS-
PAGE offered the highest sensitivity for in vivo PAL with membrane fractions.
Additionally, it can be seen that TX-100™ can be used in protocols in which
membrane proteins are to be extracted under retention of their native activity, and for
which the use of non-ionic detergents is highly recommendable.
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Figure 4.15 Solubilisation of biotinylated proteins of the membrane-fraction of P. aeruginosa
PAO1. (A): Triton-X 114™, (B): Triton-X 100™, (C) SDS-PAGE sample buffer, (D): SDS, (E),
carbonate extraction, (F) TFE extraction, (G) Triton-X 114™ cold pellet.
In one set of experiments, the membrane fraction of P. aeruginosa PAO1 was
studied in an in vivo labelling approach with 97 in the presence or absence of 19 or
ent-18. Briefly, 10 mL suspensions of bacterial cells corresponding to 5×109
CFU/mL were irradiated in the presence of 10 g/mL of 97 after pre-incubation with
a fifty-fold excess of either ent-18 or mimetic-19, and the modified Western Blot of
the experiment is shown in Figure 4.16. It can be seen from this figure that there are
no discernible differences between the samples. Additionally, in the case of the
concentrated samples, it becomes apparent that a variety of bands are already present
in the control, which means that they represent endogenously biotinylated species.
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Figure 4.16 In vivo PAL of the membrane fraction of P. aeruginosa PAO1 with 97. (A): control,
(B) co-incubation with 19, (C) incubation with 94 alone, (D) co-incubation with ent-18. Lanes E-H
correspond to lanes A-D and were concentrated four-fold with the use of Ultrafree®-MC centrifugal
filter devices (Millipore, Bedford, US) with a molecular weight cut-off of 5 kDa.
Therefore, a protocol with pre-fractionation into intracellular and membrane
fractions was used which allows for the removal of endogenous biotin and in which
several steps were taken to increase selectivity of a putative ligand/target interaction.
Firstly, the concentration of 97 was reduced to 0.05 g/mL, secondly, the protein
concentration was increased two-fold, and thirdly the ionic strength was increased by
adjusting the standard PAL buffer to a final NaCl concentration of 350 mM.
Furthermore, crude cell lysates were incubated with 0.5 mg/30 mL of RNase A prior
to the pre-fractionation protocol, and both fractions were treated with immobilised
streptavidin, in order to remove endogenous biotin. Moreover, the ratio of 97 to the
competitive inhibitors 19 or ent-18 was decreased to 1:500. For the solubilisation of
PAL membrane fractions after irradiation, 1% of Triton-X 100™ was added to the
buffer system.
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Figure 4.17 PAL experiment with pre-fractionated membrane (A-C) and intracellular (D-F)
fractions of P. aeruginosa PAO1. A and F: control; B and E: co-incubation with 19; C and D:
incubation with 94 alone.
A corresponding modified Western blot is depicted in Figure 4.17, from
which it can be seen that there are no discernible differences between the three
samples in either the intracellular or the membrane fractions, and that endogenous
biotin was still present in all samples. Additionally, it can be seen that there is a
higher background for the membrane fractions which indicates a large background of
labelling.
4.2.3 Conclusions
Several analogues of mimetic-19 have been developed that show potential for
identifying putative target molecules of our AMPMs in P. aeruginosa. SAR data such
as the alanine scan of mimetic 18, the biological activities of the series of biotinylated
analogues of mimetic-19, and input from the fluorescently labelled library of mimetic
17 have been used to guide the synthesis of biotinylated PAL probe molecules.
Moreover, the series of biotinylated analogues of mimetic 19 itself confirmed the
potential of using 19 and derivatives as ligands in AC experiments. It has been found
that the scaffold of 19 was surprisingly tolerant towards the introduction of the
sterically demanding biotinylated PEG linker, inasmuch as only the replacement of
Lys-5 and Leu-3 lead to complete loss of the biological activity.
220 Chapter 4
A complication for both AC and PAL approaches towards target identification
is that lead compounds obtained from phenotypic screening are often only moderately
active in the micromolar range. However, mimetic 19 shows excellent anti-
pseudomonal activity, with an MIC value that corresponds to a concentration of 4 nM.
Moreover, since the most active biotinylated analogues of 19 lose less than one order
of magnitude of anti-pseudomonal activity compared to the parent compound, and
since the specific activity pattern is retained for four out of five analogues where
lysine is replaced by the biotin tag, 19 could be shown to represent an excellent
starting point for an AC approach towards target identification.
Additionally, it could be shown that it is possible to synthesise multi-
functionalised affinity-based photo-reactive probe molecules that retain good activity
against P. aeruginosa. These PAL probes are composed of a biotin tag, a hydrophilic
spacer arm, a photo-reactive moiety and the peptide scaffold which is responsible for
creating target affinity, and which can also function as an additional spacer for
separating the photo-reactive group from the biotin tag.
Furthermore, for both target identification approaches, an almost ideal control
compound exists, namely the enantiomer of mimetic 18 which can, for example, be
used for immobilisation to the affinity support in order to check for non-specific
binding events. Similarly 19 and ent-18 can be assayed for their ability to
competitively displace putative target molecules from the affinity matrix or from the
PAL probe.
The utility of AC with 19 and ent-18 coupled to NHS-activated sepharose and
of PAL with 97 was evaluated for identifying putative targets of the AMPMs in P.
aeruginosa. To summarise, it has to be concluded that so far both approaches seem to
be prone to unspecific interactions with intracellular and membrane compounds of P.
aeruginosa. The problems of unspecific binding might arise, for example, from the
low abundance of a putative target protein or from possible denaturation during the
experiments. This would result in the greatest noticeable effect being non-specific
binding mediated by the considerable positive charge of 19.
Therefore, further work should be carried out to overcome such interactions,
especially since the proven stereospecificity of the anti-pseudomonal action must be
explicable on the molecular level. For PAL, this might necessitate a change to
different photo-reactive groups or the prefractionation of cellular fractions before the
labelling experiment, in order to reduce sample complexity. Moreover, re-evaluation
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of the membrane fractions using alternative detergent systems might allow for
detection of a putative target molecule.
Nevertheless, the experiments towards target identification show that mimetic
19 is a highly versatile scaffold for the introduction of a variety of different
functionalities, and that the functionalised analogues have great potential for
development into successful chemical proteomic probes. Moreover, the obtained
biotinylated analogues of 19 could prove useful for a variety of applications, such as
immuno-fluorescence microscopy,[597] or Far-Western blotting.[598]
Furthermore, the mass spectrometric analysis of proteins retained on an
affinity matrix based on 19 led to the identification of 9 different proteinaceous
species, consisting of seven ribosomal proteins, the bacterial heat shock protein
GroEL, and of the  subunit DNA directed RNA polymerase. Although the control
experiments with ent-18 did not yet allow for the identification of a target molecule, it
is interesting to note that the most apparent spots from the 2D gel correspond to the
ribosomal protein L7/L12 which has also been found to be up-regulated by induction
with mimetic 18 in the protein expression profiling experiments (c.f. Section 4.1).
The role of L7/L12 for the fidelity of bacterial protein synthesis has been mentioned
in Section 4.1. Moreover, the ribosomal proteins L10 and L11 were identified from
the 2D gel, both of which are closely associated with the L12-stalk in vivo. That is,
L12 tetramers/hexamers bind directly to L10 which, in turn, interacts with 23S rRNA.
L11 also binds to 23sRNA in the bacterial ribosome, where it is located at the base of
the L7/L12 stalk.[599]
Recently, L7/L12 has been identified from a pull-down assay employing
immobilised glutathione fusion of a glucan binding protein in membrane fractions of
Streptococcus mutans, and has been suggested to be involved in cell division and
peptidoglycan biosynthesis.[600] Although the majority of identified proteins are
negatively charged and highly abundant in the bacterial cell, L7/L12 was also isolated
from a location of the 2D gel that corresponds to a more neutral pI, and which
presumably represents the N-terminally acetylated isoforms of the protein. Moreover,
both L10 and L11 are positively charged at physiological pH. It is conceivable that
ribosomal sub-structures, possibly together with rRNA, are retained on the affinity
matrix. On the other hand, only a small fraction of ribosomal proteins were actually
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isolated. Therefore, L7/L12 emerges as a promising target for the AMPMs acting
selectively against P. aeruginosa.
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5 Experimental part
5.1 General notes
5.1.1 Chemical synthesis
SOLVENTS AND REAGENTS Ethyl acetate, diethyl ether, DCM, and
cyclohexane were redistilled from K2CO3 or CaCl2. Dry DCM and dry toluene were
obtained by distillation from CaH2. HMPT was purchased from Fluka (Buchs,
Switzerland), dried over CaO for 24 hours and distilled from CaH2 under vacuum.
THF was purchased from Fluka and distilled from benzophenone/Na under nitrogen.
Benzophenone, benzophenone imine, CaH2, iodine, and lithium shots were purchased
from Fluka and used without further purification. Glycine tert-butyl ester and Fmoc-
OSu were purchased from NovaBiochem (EMD Biosciences, San Diego, US).
Lithium HMDS was purchased from Aldrich (Buchs, Switzerland) and used without
further purification. 2-Acetyl-6-methoxynaphthalene was purchased from Lancaster
Synthesis (Alpha Aeser, Karlsruhe, Germany) and used without further purification.
MATERIAL AND INSTRUMENTATION Flash chromatography was carried out on
silica gel 60 (230-400 mesh, 0.04-0.063 mm) from Merck (Darmstadt, Germany) or
CU Chemie Uetikon AG (Uetikon, Switzerland) Thin layer chromatography (TLC)
was performed using Polygram SIL G/UV254 plates from Machery-Nagel (Düren,
Germany) or Silica gel 60 F254 plates from Merck (Darmstadt, Germany). Melting
points (m.p.) were measured on a Kofler apparatus connected to a Nikon YS 100
microscope (Egg, Switzerland). 1H NMR and 13C NMR spectra were measured at 300
MHz on a Bruker ARX-300 or Bruker AV-300 spectrometer (Bruker, Rheinstetten,
Germany) and the chemical shift values are given in ppm relative to the solvent
resonances.[601] The coupling constants J are given in Hz and resonance multiplicity
is described as s for singlet, d for doublet, t for triplet and m for multiplet; br is used
to describe a broad resonance signal. For 13C-NMR spectroscopy, the multiplicities s,
d, t, and q denote C, CH, CH2, respectively CH3, as determined from DEPT-135/90
spectra.[602]
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Infrared spectra were measured with a Perkin-Elmer Spectrum One FT-IR
spectrometer (Perkin-Elmer, Shelton, CT) and  is given in cm-1. The signals and
intensities of the bands are described as br for broad, s for strong, m for medium and
w for weak.
5.2 Peptide synthesis
5.2.1 Synthesis of peptide mimetics
SOLVENTS AND AMINO ACIDS NMP and piperidine were purchased from Acros
Organics (Geel, Belgium) and used without further purification. DMF was purchased
from Acros Organics and redistilled under vacuum from ninhydrin, in order to remove
amine impurities. DIEA was purchased from Acros Organics and redistilled under
vacuum first from ninhydrin and subsequently from KOH. HBTU and HOBt were
purchased from Biosolve (Valkenswaard, Netherlands) and used without further
purification. High purity water was obtained from de-ionised water using an
Elgastat® UHP-UF water purification system (High Wycombe, UK). Amino acids
were purchased from Novabiochem or Bachem (Bubendorf, Switzerland) and 2-
chlorotrityl chloride resin (100-200 mesh) with a loading of 1.2 mmol/g was
purchased from Novabiochem. The following N--Fmoc protected L-amino acids
were used for routine Fmoc-SPPS of peptide mimetics:
Fmoc-Ser(tBu)-OH, Fmoc-Gln(Mtt)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH,
Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH,
Fmoc-Tyr(tBu)-OH, and Fmoc-Thr(tBu)-OH, as well as Fmoc-D-Pro-OH for synthesis
of the D-Pro-L-Pro template. For the synthesis of enantiomeric AMPMs the
corresponding N--Fmoc-protected D-amino acids and Fmoc-L-Pro-OH were used,
with the exception of Fmoc-D-Gln(Trt)-OH.
LOADING OF AMINO ACIDS ON THE RESIN For coupling of the first amino
acid to 2-chlorotrityl chloride resin, a loading of 0.3 to 0.6 mmol amino acid per gram
of resin was typically used. The calculated amount of N--Fmoc-protected amino
acid was dissolved in 10 mL of dry DCM per g of resin, and if necessary, dry DMF
was added dropwise to facilitate dissolution. After swelling of the resin in dry DCM
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for 30 min, the amino acid solution was treated with 4 equivalents of DIEA and
transferred immediately to the resin. The reaction mixture was sealed under nitrogen
and agitated on a S50 wrist arm shaker (CAT, Germany) for 30 to 90 minutes. After
the coupling reaction, the resin was first blocked three times with a solution of
DCM/MeOH/DIEA (17:2:1) and subsequently washed three times with dry DCM,
twice with dry DMF and twice with dry DCM. The resin was dried overnight under
vacuum over KOH. For the determination of the amino acid loading, dry resin
corresponding to approximately 1 µmol of Fmoc functionality was weighed into two
3×10 mm quartz UV cells, and treated with 3 mL of a freshly prepared solution of
20% piperidine in dry DMF. The Fmoc deprotection was left for at least one hour at
room temperature and the cuvettes were agitated occasionally by inversion of the
cuvettes. The UV absorption at 290 nm was measured on a Cary 3 UV-Vis
spectrometer (Varian, Palo Alto, US), with the 20% piperidine solution as blank, and
re-measured after 30 minutes to check for further increase in the UV absorption. The
amino acid loading was then calculated according to the following equation:
   
 sin7.1
290290
remg
blankAsampleAloadingFmoc


 [equation 5.1]
AUTOMATED PEPTIDE SYNTHESIS Peptides were synthesised on an Applied
Biosystems ABI 433A automated peptide synthesiser (Applied Biosystems, Foster City,
CA) coupled to a Perkin-Elmer 785A UV/VIS detector or a Perkin-Elmer Series 200
UV/VIS detector using either the 0.25 mmol or the 0.1 mmol FastMoc® chemistry. In
the FastMoc® chemistry, 1 mmol of an N--Fmoc protected amino acid (i.e. 4
equivalents for a 0.25 mmol scale synthesis) is activated with 0.9 mmol of 0.45M
HBTU/HOBt in DMF (2.0 g) together with 2.1 g of NMP and 1 mL of 2M DIEA in
NMP for 2 minutes. After transfer of the activated amino acid to the resin, coupling is
allowed for either 20 (standard) or 40 minutes (extended coupling) under vortexing.
Deprotection is achieved with 18% piperidine in NMP for three minutes and
subsequently with 20% piperidine in NMP for seven minutes. The progress of the
deprotection reaction is monitored by measuring the UV absorption of N-(9-fluorenyl-
methyl) piperidine at 301 nm. If the UV absorption obtained for the second
deprotection is higher than 3.5% of the preceding value, additional deprotection steps
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of 10 minutes each with 20% piperidine in DMF are carried out until the 3.5%
criterion is met, or up to a maximum of six additional deprotection steps. In case of a
sluggish deprotection profile, the following amino acid is attached with extended
coupling. All intermittent washing steps during the automated SPPS are carried out
with NMP.
MANUAL COUPLING OF AMINO ACIDS Coupling of non-standard amino
acids was carried out manually with 2 equivalents of the N--Fmoc-protected amino
acid activated with 1.9 equivalents of HATU and 4 equivalents of DIEA in 10 mL dry
DMF/g of resin. The coupling reactions were carried out for one hour under vigorous
agitation with a wrist arm shaker, and completion of the coupling reactions was
monitored by Kaiser testing (Fluka Kaiser-testkit, Cat. No 60017).[603]
CLEAVAGE FROM THE RESIN The linear, side-chain protected peptides were
cleaved from the resin by treating them successively 7 times with 10 mL portions of a
0.8% TFA solution in dry DCM for 2 to 4 minutes each. The TFA solutions were
filtered from the resin into a flask containing 14 ml of a solution of 10 % pyridine in
MeOH and the combined filtrates were concentrated on a rotary evaporator to about
5% of the initial volume, treated with 200 mL of water and left to precipitate at 4°C
for at least four hours. The obtained precipitate was filtered off, washed subsequently
three times with water, three times with 5% of NaHCO3, three times with water, three
times with 0.05M NaHSO4, twice with water and dried overnight in a desiccator over
KOH under vacuum.
CYCLISATION AND DEPROTECTION Linear precursors were cyclised under
stirring at room temperature with 1.25 equivalents (with respect to the crude linear
precursor) of HATU, 1.25 equivalents of HOAt and 12.5 equivalents of DIEA in dry
DMF. For the cyclisation reactions, concentrations of crude linear precursor ranging
from 1 to 2.5 mg/mL were used. The progress of the reaction was monitored by
LC/MS and after consumption of the starting material the reaction mixture was
evaporated to dryness under vacuum, yielding a colourless to slightly yellow resin.
The crude cyclised peptides were deprotected in 10 mL of TFA/TIS/water (95:2.5:2.5
v/v/v) under stirring at room temperature for 2 h or until LC/MS analysis showed the
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absence of peaks that could be attributed to partially deprotected side-products. The
deprotection mixture was concentrated to half its original volume, or until a
precipitate formed, and was then partitioned into 50 mL glass centrifuge tubes. Crude
peptides were precipitated with 30 mL/tube of diethyl ether cooled to -20°C in an ice-
bath and centrifuged at 2000 rpm in a desktop centrifuge (Megafuge 1.0R, Heraeus,
Hanau, Germany). The ether layers were decanted, and the precipitates were washed
and centrifuged three times with additional 30 mL portions of diethyl ether. The mass
balance of crude peptide mimetics after air-drying overnight were between 90-120%.
PURIFICATION AND ANALYSIS Crude cyclic peptide mimetics were
purified by RP-HPLC chromatography with linear gradients of acetonitrile in water
(20 to 50%) with added 0.1% of TFA on an ÄKTApurifier 100 system (Amersham
Biosciences) using either a Vydac C18 (Grace Vydac, Hesperia, US) 218TP1022 (10
m, 300 Å, 22×100 mm), a Zorbax eclipse XDB-C18 (Agilent, Santa Clara, US), (7
m, 125 Å, 21.2×250 mm), or an Interchrom UP10WC4/25M (Interchim, Asnières,
France), (10 m, 300 Å, 21.2×250 mm) preparative column with flow rates between
10 and 20 mL/min and with UV detection at 226 nm, 254 nm, and 278 nm. Typical
yields for purified AMPMs were in the range of 30 to 50 %.
Analytical HPLC chromatograms were run with linear gradients of acetonitrile
in water (5 to 100%) with added 0.1% of TFA on an ÄKTA purifier 10 system using
Vydac C18 218TP104 (4.6×250 mm, 10 m, 300 Å), Vydac C18 218TP54 (4.6×250
mm, 5 m, 300 Å), and Zorbax eclipse C18, (4.6×250 mm, 125 Å, 5 m) analytical
columns with a flow rate of 1 mL/min. LC/MS analyses were carried out on an HPLC
system consisting of a Dionex P580 Pump (Sunnyvale, US), a Gilson 215 liquid
handler (Middleton, US), and a Dionex UVD 170S four channel UV detector,
connected to a ThermoFinnigan Quadrupole-ESI mass spectrometer (Thermo Fisher
Scientific, Waltham, US). Columns used were either Vydac 218MS5215 (C18,
2.1×150 mm, 5 m, 300 Å), Vydac 214MS5215 (C4, 2.1×150 mm, 5 m, 300 Å), or
Zorbax SB-C18 (C18, 2.1×150 mm, 3.5 m, 80 Å) and chromatograms were run with
0.1% formic acid replacing TFA as ion pairing reagent.
Mass analyses were carried out by the MS-service of the University of Zurich.
ESI mass spectra were recorded either on a Waters Q-tof Ultima API instrument
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(Milford, US), a Bruker ESQUIRE-LC quadrupole ion trap instrument or a Finnigan
TSQ-700 instrument. Typical measurement error is 0.1%.
Analytical HPLC and mass spectrometric data of AMP(M)s and analogues as
well as of LPS binding mimetics are summarised in Appendix 2.
SYNTHESIS OF PROTEGRIN-1 The synthesis of protegrin-1 (11) was carried out
on the ABI 433A automated peptide synthesiser on a 0.25 mmol scale, using a Rink
amide resin with a substitution of (0.66 mmol/g, Novabiochem) and FastMoc®
chemistry according to the general procedure described above. Fmoc-deprotection of
the resin and coupling of the first amino acid were carried out on the synthesiser. The
linear protegrin-1 precursor was cleaved from the resin in its fully deprotected form
by stirring it overnight with 25 mL of TFA/phenol/thioanisole/EDT (82.5:5:5:2.5).
The resin was filtered off and washed twice with TFA and the combined filtrates were
concentrated under vacuum until a precipitate formed. Precipitation was completed
by addition of ice-cold diethyl ether. The crude material was centrifuged at 2000 rpm
in a desktop centrifuge, washed three times with diethyl ether and dried in a desiccator
in a rough vacuum over KOH. To achieve disulfide bond-formation, the linear
protegrin-1 precursor was dissolved in 0.1 M ammonium bicarbonate at a
concentration of 0.1 mg/mL and stirred at room temperature for 2 days. After
analytical RP-HPLC showed complete consumption of the linear precursor, the
reaction mixture was lyophilized to give crude protegrin-1 (11) as a white solid.
Crude material was purified by RP- HPLC on an XTerra™ C18 (4.6×100 mm, 5 m,
125 Å) preparative column (Waters, Milford, US) in a gradient of 10-60 %
acetonitrile in water +0.1 % TFA over 15 minutes, and checked for the absence of free
thiol functionalities via Ellman testing.[604] ESI [M+H]+ = 1078.5 (calc.:1078.5); ESI
[M+2H]2+ = 719.2 (calc.:719.4)
5.2.2 NMR analysis of peptides
1D and 2D spectra were recorded at 600MHz on a Bruker DRX-600 or Bruker
AV-600 spectrometer, or at 700MHz on a Bruker AV-700 spectrometer Unless stated
otherwise, spectra were recorded at peptide concentrations of 10 mg/ml in H2O/D2O
9:1 with sodium 3-trimethylsilyl(2,2,3,3,-d4)propanoate (TSP) as internal standard.
Water suppression was performed by using the WATERGATE sequence,[605] and
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amino acid spin systems were identified from a TOCSY experiment.[606] NOESY
experiments were used for both the sequence-specific sequentional resonance
assignment and the determination of upper proton-proton distance limits required for
structure calculations.[607] The structure calculation was performed by restrained
molecular dynamics in torsion angle space by applying the SA protocol implemented
in the program DYANA.[317] Restrained energy minimization was performed with the
OPAL software,[608] which utilizes AMBER force-field. RMSD values were
calculated with the program MOLMOL.[609]
NMR studies in the presence of micelles were recorded at a peptide
concentration of 2 mM and at 310 K, pH 5.0, in 300 mM solutions of d38-DPC in 90%
H2O/10% D2O.
5.3 Bacteriological experiments
CULTURE MEDIA For the preparation of all solutions and media, water
was purified using an Elgastat® UHP-UF water purification system. Unless noted
otherwise, all experiments with bacterial cultures were carried out with Difco™
Mueller Hinton broth (Becton Dickinson, Sparks, MD) containing approximately 2.0 g
of beef extract powder, 17.5 g of an acid digest of casein and 1.5 g of starch per
litre.[610] For solid media, Difco™ Mueller Hinton agar containing an additional 17.0
g/L of agarose was used. All media were prepared according to the manufacturer’s
instructions and sterilised by autoclaving with a Model FVA steriliser (Fedegari
Autoclavi, Albuzzano, Italy) for 20 minutes at 121 °C and 1.013×105 Pa.
CULTURE CONDITIONS AND GROWTH CONTROL Unless noted otherwise,
all bacterial cultures were incubated at 37°C in conical flasks and agitated under
orbital shaking at 200 rpm. Overnight bacterial cultures were inoculated with single
colonies from agar plates freshly incubated overnight and used in turn to inoculate
sterile Muller-Hinton broth, typically at a ratio of ~1:100 (v/v). For growth control,
the cell density was estimated photometrically via the turbidity of the bacterial cell
suspensions at 600 nm with a Cary 3 UV/Vis spectrometer (Varian, Palo Alto, CA).
For short-term storage, bacterial strains were stored on Mueller Hinton agar plates at
4°C and were used to inoculate fresh agar plates weekly. For long term storage,
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bacterial cultures were stored in 30% glycerol solution at -80°C. The control
antibiotics polymyxin B sulphate, rifampicin, tobramycin and aztreonam were
purchased from Sigma (Buchs, Switzerland); ciprofloxacin was purchased from
Fluka.
MIC DETERMINATION The determination of the MIC was carried out
according to a standard protocol[611] with the modifications of Steinberg et al. to
account for unspecific adsorption of AMP(M)s onto reaction vessel surfaces,[312] and
with minor modifications as described herein. Lyophylised AMP(M)s and control
antibiotics were dissolved in 0.01% HOAc at a concentration of 1 mg/mL. For the
routine determination of the MIC, colony material from agar plates incubated freshly
overnight was taken with an inoculation loop and transferred into 3 mL of 0.9% NaCl
solution. The turbidity of the bacterial suspension was adjusted to McFarland
standard 0.5, and 100 L of this bacterial suspension was transferred into 10 mL of
Mueller Hinton broth supplemented with 0.02% BSA. In 96 well microtitre plates,
two-fold serial dilutions of the AMP(M)s or of the control antibiotics were prepared in
Mueller Hinton broth. The broth was supplemented with 0.02% BSA and the final
volume of each dilution was 50 L. Finally, 50 L of the bacterial suspension were
used to inoculate the microtitre plates to give a final cell density of approximately
5×105 CFU/mL in a final volume of 100 L. Alternatively, for MIC determinations
corresponding to higher cell density of the inoculum, overnight cultures of bacteria
were diluted ~1:100 into fresh Mueller Hinton broth and incubated for 105 minutes
under standard conditions to yield approximately 2×108 CFU/mL (for P. aeruginosa
PAO1). These bacterial suspensions were then used to inoculate the two-fold serial
dilutions of test compounds, which were prepared in Mueller Hinton broth
supplemented with 0.04% of BSA. The microtitre plates were covered and incubated
overnight at 37°C in an orbital shaker at 200 rpm. The MIC was determined by visual
inspection as the minimum concentration at which no visible growth occurred after 18
to 20 hours of incubation and is expressed in g/mL.
HAEMOLYTIC ACTIVITIES The haemolytic activities of AMP(M)s and
control compounds against human red blood cells (hRBCs) were tested by a
photometric assay as follows. Fresh hRBCs were washed with phosphate buffered
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saline (PBS) and centrifuged three times for 10 minutes at 2’000 g in a desk-top
centrifuge. Test compounds at concentrations of 100 g/mL were incubated with
20% (w/v) of hRBCs at 37°C for one hour and at a final erythrocyte concentration of
0.9×109/mL. The samples were centrifuged at 2’000 g, the supernatant was diluted
twenty-fold in PBS, and the optical density was measured at 540 nm. The values
corresponding to 0% and 100% lysis were determined by incubation of hRBCs with
PBS or 0.1% Triton X-100 in water, respectively. The OD540nm corresponding to
100% lysis typically ranges from 1.6 to 2.0 and the haemolytic activity obtained for
the test compounds is expressed as a percentage relative to the 100% value.
KINETICS OF BACTERIAL KILLING For the recording of killing curves, 50
mL of Mueller Hinton broth, pre-warmed to 37 °C, were inoculated ~1:100 from an
overnight culture of P. aeruginosa PAO1 to give a starting OD600 of approximately
0.05. The cell culture was incubated under standard conditions and after 105 minutes,
after which time the cultures typically reach a cell density of 1×108 CFU/mL, 10 mL
portions were added to sterile 50 mL conical flasks pre-warmed to 37 °C and
containing an appropriate amount of test compound. At desired time intervals before
and after splitting the bacterial culture, 100 L samples were withdrawn and diluted
serially 1:10 in sterile Mueller Hinton broth. 100 L of appropriate dilutions of the
bacterial suspensions were plated in duplicate on Mueller Hinton agar plates by a
spread plate method,[441] and incubated for 20 hours at 37°C. The appropriate dilution
factors were determined by preliminary experiments. Bacterial colonies were counted
by visual inspection and count rates between 30 and 300 were used to calculate the
viable cell count which is expressed as CFU/mL.
POST-ANTIBIOTIC EFFECT For determination of the influence of washing
bacterial cultures free of mimetic 18, 400 mL of a bacterial culture of P. aeruginosa
PAO1 were grown under standard conditions in a 2 L conical flask. After 105
minutes of incubation, corresponding to approximately 1×108 CFU/mL, 50 mL
portions of the bacterial suspensions were withdrawn and transferred into 250 mL
conical flasks. Of these, two cultures were treated with mimetic 18 while one culture
was left as a control. The cultures were incubated under standard conditions for 2
hours before being centrifuged at 5000 g in a Sorvall® GSA rotor (Kendro, Zürich,
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Switzerland). The control culture and one of the cultures treated with mimetic 18,
were washed and re-suspended twice in 50 mL of sterile Mueller Hinton broth, and
finally re-suspended in 50 mL of Mueller-Hinton broth. The other culture induced
with mimetic 18 was used as a positive control, and was treated identically to the
other samples, but without removal of the original medium. Enumeration of the
viable cell count at appropriate time intervals was carried out as described above.
MINIMAL BACTERICIDAL CONCENTRATION For the determination of the
MBC, the experimental setup was essentially identical to the one described for the
MIC determination in 96 well microtitre plates. However, in addition, the viable cell
count for the bacterial cell suspension that was used to inoculate the microtitre plates
and the viable cell count for the serial dilutions of test compounds that showed no
visible growth after 20 hours of incubation at 37°C were determined as described
above and used to calculate the corresponding CFU/mL. The MBC is defined as the
minimum concentration of test compound that yields a reduction of at least 3log10 in
the viable cell count the incubation period.
5.4 Dye-leakage experiments
PREPARATION OF CALCEIN-ENTRAPPED VESICLES In a 25 mL round-
bottomed flask, 10 mg of a mixture of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC, 26) and 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)] (POPG, 27) (Genzyme, Liestal, Switzerland) in the desired ratio were
dissolved in 10 mL of DCM/MeOH (1:1 v/v) and evaporated to dryness on a rotary
evaporator to provide a lipid film on the surface of the round-bottomed flask. The
lipid films were further dried on a lyophiliser for at least 2h, and then hydrated with a
50 mM calcein solution (10 mM Tris, 10 mM NaCl, 0.1 mM EDTA pH 7.4).
Agitation with glass beads was used to facilitate the formation of multilamellar
vesicles. Solutions of the multilamellar vesicles were then subjected to six freeze–
thaw cycles with liquid nitrogen and extruded 13 times through a 100 nm
polycarbonate membrane (Nucleopore, Pleasanton, CA) using an extruder (Lipex
Biomembranes, Canada). The size distribution of the obtained LUVs was confirmed
by dynamic light-scattering with a model 370 particle sizing system (Nicomp, Santa
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Barbara, CA). Calcein-entrapped vesicles were separated from free dye by gel
filtration through a Sephadex G-25 column (1×25 cm) with standard buffer (10 mM
Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4), possessing a comparable osmolarity to
the 50 mM calcein solution, as eluent. The final phospholipid concentration was
determined by phosphorus analysis as described below.
PHOSPHATE DETERMINATION The amount of phosphate was
determined by a Bartlett assay[421] modified as follows: a calibration curve ranging
from 0 to 80 nmol phosphate was prepared from a 1 mM KH2PO4 solution (1 µL = 1
nmol). The standards and the samples were prepared in borosilicate tubes and dried in
a Tecon heat block at 100°C-120°C. Care has to be taken to increase the temperature
slowly to avoid spillage of liquid from the tubes. The dry samples were then treated
with 70 l of a freshly prepared mixture of H2SO4/HClO4 (1:1 v/v) and kept at 230-
250 °C for 15-30 minutes to combust all phosphorous to inorganic phosphates. The
samples were left to cool to room temperature and 1.6 mL of freshly prepared assay
solution (0.835% ascorbic acid/0.2% ammonium molybdate) was added. After
incubation at 45°C for 30 minutes the absorbance of each sample was measured at
820 nm, using an UV spectrometer with the phosphate-free standard solution as blank.
The phosphorous concentration of the sample was then calculated from the calibration
curve.
GENERAL PROCEDURE FOR THE DYE LEAKAGE ASSAY The peptide-
induced leakage of calcein from the LUVs was monitored by measuring the
fluorescence intensity of calcein released into the standard buffer at 20 °C. Dye-
entrapped vesicles were diluted in standard buffer (2 mL) to give a final phospholipid
concentration of 30 M. The release of dye was then initiated by addition of an
aliquot of peptide and the increase of the calcein fluorescence intensity was recorded
for 5 minutes after addition of the test compounds with a Perkin–Elmer LS55
luminescence spectrophotometer (Perkin-Elmer, Shelton, CT) set to an emission
wavelength of em = 519 nm. The excitation wavelength was set in the range of ex =
430–490 nm to obtain a fluorescence signal within the optimal working range of the
photo detector. Slit widths of 4 nm were used throughout. The apparent percentage
of calcein release was calculated according to:
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where Ft is the fluorescence intensity induced by the peptide after 5 minutes of
incubation, and F0 and Fmax denote the fluorescence intensities before addition of the
test compound, and after addition of 0.1% of Triton-X 100™, respectively. Triton-X
100™ was added at the end of each experiment to cause complete disruption of the
liposomes.
5.5 Incorporation experiments
RADIO-LABELLED COMPOUNDS L-[4,5-3H]-leucine with a specific
activity of 37 MBq/mL (1 mCi/mL), [5,6-3H]-uridine with a specific activity of 37
MBq/mL (1 mCi/mL), [methyl-3H]-thymidine with a specific activity of 37 MBq/mL
(1 mCi/mL), [8-3H]-adenine with a specific activity of 37 MBq/mL (1 mCi/mL), and
N-acetyl-D-[1-3H]-glucosamine with a specific activity of 37 MBq/mL (1 mCi/mL)
were purchased from Amersham (GE Healthcare Europe, Otelfingen, Switzerland).
All radiochemicals were supplied as sterilised aqueous solutions containing 2%
ethanol.
GENERAL PROCEDURE FOR CONTINUOUS LABELLING For continuous
labelling of trichloroacetic acid (TCA) insoluble fractions of P. aeruginosa PAO1
with tritiated precursors of macromolecular biosynthesis, 50 mL of bacterial cell
suspension were grown under standard conditions. After 90 minutes of incubation,
corresponding to an OD600 of 0.2, radioactive label was added to the cell culture to
give a final activity of 5 Ci/mL. The cell culture was grown for 15 minutes in the
presence of the radioactive label, after which time 1 mL portions were transferred to
10 mL sealable tubes containing the desired amount of test compound (from 1 mg/mL
stock solution in 0.01% HOAc and 0.01% HOAc for the control sample). At desired
time intervals before and after addition of the test compounds, 50 L samples were
withdrawn and added to 2 mL of ice-cold 10% TCA in 15 mL polypropylene tubes
(Greiner, Frickenhausen, Germany). The samples were left at 0 °C for at least 50
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minutes, warmed to 37 °C for 25 minutes and finally cooled again to 0 °C for at least
10 minutes. The acid insoluble precipitates were filtered through GF/C glass-fibre
filters of 24 mm diameter (Whatman, Brentford, UK). The tubes were washed out
twice with 1 mL of ice-cold 10% TCA and the filters were finally washed with ~5 mL
of ice-cold 10% TCA. Filters were dried overnight in an oven at 40 °C. For
quantification of radioactivity, the dried filters were measured in Econo 20 mL glass
scintillation vials (Packard, Meriden, US) with 10 mL of NOCS 104 scintillation
cocktail for organic solutes (Amersham Biosciences, Sweden) with a Packard 2000
CA scintillation analyser, upgraded to 2200 CA.
GENERAL PROCEDURE FOR PULSE-LABELLING For pulse-labelling of the
TCA-insoluble fraction of P. aeruginosa PAO1, a 50 mL bacterial culture was grown
under standard incubation conditions as described for the killing kinetic experiments.
After 105 minutes of incubation, the bacterial suspension was split by transferring 10
mL portions to sterile 50 mL conical flasks, pre-warmed to 37 °C, and containing an
appropriate amount of test compound from a 1 mg/mL stock solution in 0.01% HOAc.
The test cultures were incubated at 200 rpm and 37 °C, and at the desired time
intervals before and after splitting of the bacterial culture, 0.2 ml of the samples were
withdrawn and added to 0.8 ml of Mueller Hinton broth pre-warmed to 37 °C in 10
mL tubes, containing the appropriate test compound at concentrations identical to the
test concentrations, and with a final specific radioactivity of 1 μCi/mL of the radio-
labelled precursor. To ensure maximum reproducibility, the radio-labelled precursor
was added to a stock solution of Mueller Hinton broth from which the individual 0.8
mL portions containing the appropriate concentration of test compound were
prepared. The 1 mL cultures were pulse-labelled by incubation at 37°C and 200 rpm
for 6 minutes before they were precipitated with 1 mL ice-cold 20% TCA to give a
final concentration of 10% TCA in 2 mL total volume, and the obtained precipitate
was further processed as described above for the continuous labelling experiments.
In the case of pulse-labelling with [8-3H]-adenine (33), NaOH and EDTA
were added immediately after pulse-labelling to give final concentrations of 0.3M and
0.1% (w/v), respectively. The samples were then incubated overnight at 37°C to
hydrolyse RNA. After the overnight incubation, the samples were cooled in an ice-
bath and precipitated with 1 ml of 20% TCA and further processed as described
above.
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5.6 LPS binding
PREPARATION OF DANSYLATED POLYMYXIN B To a solution of 40 mg of
polymyxin B sulfate in 1.2 mL of 0.1 M NaHCO3, a solution of 10 mg of dansyl
chloride in 800 µL of acetone was added dropwise. During addition of the acetone
solution, a white precipitate formed and the reaction mixture was left to stand in the
dark at room temperature for 2h. The resulting yellow suspension was centrifuged at
2’000 rpm for 8 minutes in a desktop centrifuge, and the supernatant solution was
subjected to gel-filtration using a 2.5 x 30 cm column packed with Sephadex G 25 and
equilibrated with 0.1 M sodium chloride. The fluorescent fractions were combined
and extracted with n-butanol and evaporated to dryness to give crude dansyl
polymyxin B as a yellow solid. Crude dansyl polymyxin was purified by RP-HPLC
using a Vydac 218TP1022 C18 preparative column and a gradient of 16-33%
acetonitrile in water containing 0.1% TFA in 35 minutes to give a mixture of five
mono-dansylated products.
For the displacement assays, the concentration of mono-dansylated polymyxin
B in solution was determined with a dinitrophenylation assay as follows: Standard
solutions of 0 µg/mL, 5 µg/mL, 10 µg/mL, 20 µg/mL, 30 µg/mL, 40 µg/mL, and 50
µg/mL polymyxin B were prepared. To 50 µL of standard or test solution, 200 µL of
a 1% (w/v) sodium tetraborate solution in H2O and 25 µL of a 100 mM solution of 1-
fluoro-2,4-dinitrobenzene in ethanol were added, and the samples were left at 37 °C
for one hour. 1 mL portions of 2M HCl were added, and the aqueous phases were
extracted with 1 mL of n-butanol. The absorbance of the organic phase was measured
at 420 nm and the concentration of dansyl-polymyxin was calculated from the
calibration curve obtained with the standard solutions.
GENERAL PROCEDURE FOR THE POLYMYXIN-DISPLACEMENT-ASSAY
Lipopolysaccharides from E. coli (Serotype 0111:B4) and P. aeruginosa
(Serotype 10) were purchased from Sigma. Stock solutions containing 1 mg/mL of
LPS were prepared in 5 mM HEPES buffer, pH 7.0 and stored at -20 °C. Dansyl
polymyxin and bacterial LPS were used to prepare an assay solution containing 3 µg
of both LPS and dansyl polymyxin. 2 mL of the assay solution were transferred to 3
mL fluorescence cuvettes with a pathlength of 1 cm. The fluorescence spectra were
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recorded on a Perkin Elmer LS55 luminescence spectrometer with an excitation
wavelength of ex = 340 nm (slit width 15.0 nm) and an emission wavelength of em =
485 nm (slit width 2.5 nm), equipped with a stirrable cell holder. Assay solutions
were titrated by addition of appropriate amounts of test compounds (from 1 mg/mL
stock solutions) to the stirred assay solution. The I50 and Imax values for the test
compound were calculated from a plot of 1/%inhibition versus 1/concentration as
described in Section 3.7.
5.7 Fluorescently labelled peptides
5.7.1 Synthesis of Fmoc-DANA-OH (52)
2-ACETYL-6-DIMETHYLAMINONAPHTHALENE (ACEDAN, 48)
Me2N
O
A two-necked, round-bottomed flask was charged with 16 mL of HMPT and
dimethylamine was bubbled through the solution until weighing of the flask indicated
the absorption of 2.4 g (53 mmol). To the colourless solution, 353 mg (50 mmol) of
lithium shots were added and the reaction mixture was stirred at room temperature
under argon for 1.5 hours to give a deep red solution. To this, 3.00 g (15 mmol) of 2-
acetyl-6-methoxynaphthalene (47) were added and the reaction mixture was stirred
overnight at room temperature and under argon. The mixture was then cooled in an
ice-bath and poured into a cold mixture of 200 ml water and 200 ml ethyl acetate.
After thorough mixing, the aqueous phase was separated and extracted twice with 100
ml of ethyl acetate. The combined organic phases were dried over Na2SO4 and
evaporated to dryness to give 3.15 g (99 %) of crude acedan (48). Recrystallisation
from ethanol afforded 2.24 g (70 %) of 48 as yellow flakes. M.p. 154-155 °C (from
ethanol, lit.[612]: 153.5-155 °C). IR (KBr): 1663 s (CO). 1H-NMR (300 MHz;
CDCl3): 2.65 (3 H, s, acetyl-CH3), 3.09 (6 H, s, N-(CH3)2), 6.88 (1 H, m, Ar-H), 7.16
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(1 H, dd, J 2.6 and 9.1, Ar-H), 7.62 (1 H, d, J 8.7, Ar-H), 7.78 (1 H, d, J 9.1, Ar-H),
8.26 (1 H, dd, J 1.8 and 8.7, Ar-H), 8.26 (1 H, m, Ar-H). 13C-NMR (75.5 MHz;
CDCl3): 26.3 (q), 40.4 (q), 105.4 (d), 116.2 (d), 124.5 (d), 125.0 (s), 126.1 (d), 130.2
(d), 130.6 (d), 130.8 (s), 137.5 (s), 150.1 (s), 197.5 (s). ESI-MS [M+H]+ = 214.2
(calc.: 214.1).
2-(-IODOACETYL)-6-DIMETHYLAMINONAPHTHALENE (49)
Me2N
O
I
In a 250 ml three-necked, round-bottomed flask equipped with a magnetic
stirrer bar and a reaction thermometer, 2.00 g (9.4 mmol) of 48 were dissolved in 25
mL of dry THF to give a clear, slightly yellow solution. Subsequently, the solution
was cooled in an acetone/dry ice bath to -78 °C. 48 started to precipitate at a
temperature of about -10 °C, giving a white suspension. To this suspension 10.3 mL
of a 1.0M solution of lithium bis(trimethylsilyl)amide in THF, that had been pre-
cooled to 0 °C, were added dropwise via a syringe. The temperature during the
addition was kept below -70 °C, and the reaction mixture was then stirred under argon
for 30 minutes to yield a clear solution. Addition of another 0.5 mL of base and
stirring for 10 minutes resulted in a clear, slightly orange solution of the enolate. To
the enolate, a solution of 2.44 g (9.8 mmol) of iodine in 20 mL of THF that had been
pre-cooled to 0 °C was added dropwise via a syringe, keeping the temperature below -
70 °C. The reaction mixture was then stirred under argon for one hour at -78 °C in
the dark. After quenching with 1 mL of a 1.0 M solution of NaHSO4, the mixture was
allowed to warm to 0 °C and a further 17 mL of the NaHSO4 solution were added.
After addition of 40 mL of water and 300 mL of ethyl acetate, the layers were
separated and the organic phases were washed twice with 50 mL of concentrated
Na2S2O3 solution, once with 50 mL of water and finally with 50 mL of brine. The
resultant orange solution was dried over Na2SO4 and evaporated to dryness to yield
3.15 g (9.3 mmol, 99%) of crude 49 as an orange solid. IR (KBr): 1647 s (CO). 1H-
NMR (300 MHz; CDCl3): 3.11 (6 H, s, N-(CH3)2), 4.42 (1 H, s, CH2I) 6.85 (1 H, d, J
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2.5, Ar-H), 7.15 (1 H, dd, J 2.5 and 9.1, Ar-H), 7.62 (1 H, d, J 8.7, Ar-H), 7.79 (1 H,
d, J 9.1, Ar-H), 7.89 (1 H, dd, J 1.9 and 8.7, Ar-H), 8.35 (1 H, m, Ar-H); 13C-NMR
(75.5 MHz; CDCl3): 0.8 (t), 38.4 (q), 103.3 (d), 114.3 (d), 122.9 (s), 123.1 (d), 124.4
(d), 124.8 (s), 128.9 (d), 129.1 (d), 136.0 (s), 148.5 (s), 190.2 (s). ESI-MS [M+H]+ =
201.3 (calc.: 201.1). ESI-MS [M+H]+ = 340.2 (calc.: 340.0).
PRODAN SCHIFF BASE (51)
Me2N
O
N
OtBuO
PhPh
In a 250 mL three-necked, round-bottomed flask equipped with a magnetic stirrer bar
and a reaction thermometer, 731 mg (2.47 mmol) of N-(diphenylmethylene)glycine
tert-butyl ester[613] and 260 mg (0.50 mmol, 20 mol%) of the phase-transfer catalyst
O-(9)allyl-N-(9-anthracenylmethyl)cinchonidinium bromide (50) were dissolved in 5
mL of dry DCM to give a clear, colourless solution. The solution was cooled to -78
°C in an acetone/dry ice bath under argon and 4.5 g (27 mol) of caesium hydroxide
monohydrate were added portionwise to give a brown suspension. To this
suspension, a solution of 900 mg (2.65 mmol) of 49 in 20 mL of dry DCM, pre-cooled
to -78 °C was added, keeping the temperature below -60 °C. The reaction mixture
was stirred under argon at -78 °C overnight. After HPLC MS analysis showed no
more consumption of 49, even after addition of another 150 mg N-
(diphenylmethylene)glycine tert-butyl ester, the reaction mixture was allowed to
warm to 0 °C and was diluted with 250 mL of diethyl ether and 50 mL of water. The
organic phase was washed three times with 20 mL of water and 20 mL of brine, dried
over Na2SO4 and evaporated to dryness to yield 1.14 g (85 %) of crude PRODAN
Schiff base (51) as an orange solid which was used without further purification. 1H-
NMR (300 MHz; CDCl3): 1.44 (9 H, s, C(CH3)3), 3.09 (6 H, s, N-(CH3)2), 3.58 (1 H,
dd, J 7.2 and 16.7, CH2), 3.75 (1 H, dd, J 5.8 and 16.7, CH2), 4.69 (1 H, dd, J 5.8 and
7.2, CH), 6.85 (1 H, d, J 2.5, Ar-H), 7.14 (1 H, dd, J 2.5 and 9.1, Ar-H), 7.30 (6 H, m,
Ar-H), 7.42 (2 H, m, Ar-H), 7.58 (3 H, m, Ar-H), 7.77 (1 H, d, J 9.1, Ar-H), 7.89 (1 H,
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dd, J 1.8 and 8.7, Ar-H), 8.35 (1 H, m, Ar-H). ESI-MS [M+H]+ = 507.5 (calc.:
507.3).
DANA-OH (41)
Me2N
O
NH2.TFA
OHO
Crude PRODAN Schiff base 51 (720 mg, 1.38 mmol) was dissolved in 10 mL
of TFA containing 250 L of ethanedithiol and was stirred overnight under argon.
The TFA solution was concentrated under vacuum to give a dark green highly viscous
solution that was partitioned into two 50 mL glass centrifuge tubes and precipitated
with ice-cold diethyl ether to afford a yellow-brown solid. The precipitate was
washed, centrifuged at 2000 rpm in a desk-top centrifuge at room temperature, and
washed twice with diethyl ether to afford 379 mg (96 %) of crude 41 as a dark yellow
solid which was used without further purification. For analytical purposes, a small
amount of DANA-OH was purified by reversed phase HPLC. 1H-NMR (300 MHz;
DMSO-d6): 3.07 (6 H, s, N-(CH3)2), 3.67 (2 H, m, CH2), 4.20 (1 H, m, CH), 6.95 (1 H,
d, J 2.2, Ar-H), 7.28 (1 H, dd, J 2.5 and 9.2, Ar-H), 7.67 (1 H, d, J 8.7, Ar-H), 7.81 (1
H, dd, J 1.6 and 8.7, Ar-H), 7.91 (1 H, d, J 9.2, Ar-H), 8.47 (1 H, br, Ar-H). ESI-MS
[M+H]+ = 201.3 (calc.: 201.1). ESI-MS [M+H]+ = 287.1 (calc.: 287.1).
FMOC-DANA-OH (52)
Me2N
O
NH-Fmoc
OHO
Crude 41 (347 mg, 1.2 mmol) was suspended in 20 mL of water and the pH
was adjusted to 8.0 by addition of NaHCO3. A solution of 520 mg (1.54 mmol) of
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Fmoc-OSu in 20 mL of acetone was added and the reaction mixture was stirred for 3
hours at room temperature. Since LC/MS analysis of the reaction mixture showed
complete consumption of 41, the solution was diluted with 400 ml of ethyl acetate and
acidified with 2.0 M HCl to a pH of 2-3. The aqueous phase was extracted three
times with 100 mL of ethyl acetate and the combined organic phases were dried over
NaHCO3 and evaporated to dryness to give 585 mg (96 %) of Fmoc-DANA (52) as a
yellow solid. 1H-NMR (300 MHz; CDCl3): 3.12 (6 H, s, N-(CH3)2), 3.61 (1 H, dd, J 4
and 18.3 CH) 3.92 (1 H, dd, J 4 and 18.3, C-H), 4.20 (1 H, t, J 6.9, C-H), 4.38 (2 H,
m, J 8.7, CH2), 4.83 (1 H, m, C-H), 6.03 (1 H, d, J 8.1 C-H), 6.93 (1 H, br, Ar-H);
7.15-7.39 (5 H, m, Ar-H), 7.57 (2 H, d, J 7.4, Ar-H), 7.64 (1 H, d, J 8.8, Ar-H), 7.71
(2 H, m, Ar-H), 7.79 (1 H, d, J 9.1, Ar-H), 7.89 (1 H, d, J 8.5, Ar-H), 8.32 (1 H, br,
Ar-H). ESI-MS [M+H]+ = 509.3 (calc.: 509.2).
DETERMINATION OF ENANTIOMERIC EXCESS OF DANA-OH (41) For the
determination of the enantiomeric excess of 41 according to Marfey,[614] 2.5 mg (9
mol) of 41 were dissolved in 400 L of DMF/water (1:1) and the pH of the solution
was adjusted to pH 8 by addition of NaHCO3. 3 mg of N-(2,4-Dinitro-5-
fluorophenyl)-L-valinamide[615] (10 mol) were added, and the reaction mixture was
left to stand at 37 °C for one hour. The mixture was then acidified with 40 L of
1.0M HCl and subjected to analytical HPLC and LC/MS analysis. Integration of the
corresponding peaks gave an enantiomeric excess of 90% ee.
FLUORESCENCE MEASUREMENTS WITH NAAA (78) Fluorescence
spectra were recorded on a Perkin Elmer LS 55 luminescence spectrometer, equipped
with a stirrable four-cell holder. Quartz cuvettes with a path length of 1 cm and a
total volume of 3 ml were used throughout and all measurements were carried out at
20 °C. An acetonitrile stock solution of N-acetyl-DANA-NH2 (NAAA, 78) was
prepared with a concentration of 20 M and diluted 1:100 into cuvettes containing 2
ml of the appropriate solvent to give a final concentration of the fluorophore of 200
nM. Fluorescence emission spectra were recorded with an excitation wavelength of
360 nm and excitation/emission slit widths of 5.0 nm. All measurements were carried
out in triplicate.
242 Chapter 5
5.7.2 Fluorescence measurements
FLUORESCENCE MEASUREMENTS WITH AMPMS Fluorescence spectra of
AMPMs in the presence and absence SDS micelles were recorded on a Perkin Elmer
LS 55 luminescence spectrometer, equipped with a stirrable four-cell holder and at 20
°C. Quartz cuvettes with a path length of 1 cm and a total volume of 3 ml were used
throughout. 2 M of the appropriate peptide AMPM were titrated into matched
quartz cuvettes containing 2 mL of 10 mM Tris-buffer (pH 7.0, 10 mM NaCl) either
in the presence or absence of 25 mM SDS. Excitation wavelengths were 295, or 280
nm with a slit width of 5.0 nm.
MEMBRANE PARTITIONING EXPERIMENTS POPC/POPG LUVs were
prepared as described for the calcein-entrapped vesicles using a buffer system without
calcein (10 mM Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4). Fluorescence spectra
were measured on a Perkin Elmer LS 55 luminescence spectrometer, equipped with a
stirrable four-cell exchanger at 20 °C. Quartz cuvettes with a path length of 1 cm and
a total volume of 3 mL were used throughout. The polarization filters in the
excitation and emission pathways were set to vertical (excitation) and horizontal
(emission) and the spectra were recorded with an excitation wavelength of ex = 360
nm with slit widths of 4.0 nm for both excitation and emission. To a solution of the
fluorescently labelled peptide at a final peptide concentration of 1 M, increasing
amounts of the POPC/POPG liposomes system were titrated and mixed by inversion.
Assay solutions were equilibrated for at least 20 minutes before the fluorescence
spectra were recorded. All measurements were carried out in triplicate and all spectra
were corrected for the background emission of the buffer system as well as for the
background emission of liposome solutions alone.
5.8 Protein expression profiling
FRACTIONATION PROTOCOL 600 mL cultures of P. aeruginosa PAO1 were
grown under standard incubation conditions in 2 L conical flasks. After 105 minutes
of incubation, bacterial cultures were induced with either 0.3 g/mL of mimetic 18
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from a 1 mg/mL stock solution in 0.01% HOAc or with a corresponding volume of
0.01% HOAc (control). After three hours of incubation, cells were harvested via
centrifugation at 5000 rpm with a Sorvall® GS-3 rotor for 30 minutes at 4 °C. Cell
pellets were washed twice with 50 mM Tris/HCl, pH 7.5 and centrifuged at 5000 rpm
for 15 minutes.
For the isolation of extracellular proteins, the supernatant of the first
centrifugation was precipitated with 10% w/v TCA at 4°C overnight. The precipitate
was isolated by centrifugation at 5000 rpm in a GS-3 rotor for 1.5 h at 4°C, washed
and centrifuged twice with ethanol, and air-dried.
For the isolation of surface-associated proteins, four grams of the bacterial cell
pellet were re-suspended in 0.2M glycine/HCl, pH 2.2 and the suspension was stirred
at room temperature for 15 minutes. Cells were removed by centrifugation at 5000
rpm with a Sorvall® GSA rotor for 20 minutes at 4 °C and the pH of the supernatant
was adjusted to 7.5 by addition of NaOH. Extracted proteins were treated with
acetone corresponding to three times the original volume and subsequently
precipitated overnight at -20 °C. The obtained precipitate was isolated by
centrifugation at 7000 rpm for 30 minutes at 4 °C, washed and centrifuged first with
70% EtOH and subsequently with 70% acetone, and air-dried overnight.
For the isolation of intracellular proteins, cell pellets were taken up in 20 mL
of 50 mM Tris/HCl, supplemented with protease inhibitors (Calbiochem Protease
Inhibitor Cocktail Set I, EMD Biosciences, San Diego, US), and broken up by
sonicating 5 times for 1 minute with a Branson model 450 tip sonicator (Banbury,
US) at an amplitude of 40%. To prevent heating, samples were cooled in an ice-bath
and pauses of at least two minutes were implemented between the sonication pulse
programs. Cell debris was removed by centrifugation at 12000 rpm with a Sorvall®
SS34 rotor and the supernatant was split into aliquots of 1 ml and stored at -20°C.
PHENOL EXTRACTION Precipitates from the extracellular or surface-
associated fractions were taken up in 50 mM Tris/HCl, pH 7.5 at concentrations of 50
mg/mL. 1 mL aliquots of the different protein fractions were mixed with 1 mL of
phenol under vortexing and heated to 70°C for 10 minutes. The samples were cooled
on ice for 5 minutes and centrifuged at 5000 rpm in an Eppendorf desk-top centrifuge
(Hamburg, Germany) for 10 minutes to result in phase separation. The upper aqueous
layer was discarded and the phenol layer was washed with 1 mL of water and
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centrifuged as described above. After removal of the aqueous layer, 1 mL acetone,
pre-cooled to -20°C was added and proteins were precipitated for 3 to 20 hours at -
20°C. Precipitated proteins were isolated by centrifugation for 20 minutes at 13200
rpm and the supernatant was discarded. The protein pellet was washed with ice-cold
acetone, centrifuged at 13200 rpm, and then air-dried at room temperature.
ISOELECTRIC FOCUSSING For isoelectric focussing, pellets were taken up
in rehydration buffer [8M urea, 2% (w/v) CHAPS, 15 mM DTT, 0.5% (v/v)
immobilised pH-gradient (IPG) buffer pH 3-10 or 4-7]. The IPG buffers consist of
carrier ampholytes formulated for Amersham Immobiline™ DryStrip pH-gradients
(GE Healthcare Bio-Sciences, Uppsala, Sweden). Protein concentrations were
determined by a Bradford assay with 5 L of the protein solution, mixed with 1 mL of
Coomassie Plus protein assay reagent (Pierce, Rockford, IL) and measured at 595 nm
relative to BSA as a standard.
IEF was carried out with immobilised pH gradient (IPG) strips (Amersham)
with an Ettan™ IPGPhor II™ IEF unit (Amersham) and settings according to Table
5.1. For each run, 300 to 350 g of proteins in 450 L of rehydration buffer were
used, which were spread evenly between the electrodes of the ceramic strip-holder
(Amersham). Immobilised IPG strips were laid onto the protein mixture with care not
to entrap air bubbles. IPG strips were covered with mineral oil and with the provided
lids.
Table 5.1 Ettan™ IPGPhor II™ settings for the isoelectric focussing of IPG strips.
Basic parameters
Temperature 20 °C
Maximum current 50 A per IPG strip
Voltage Time
30 V 13 h (rehydration of the gel-matrix and of application of the sample)
200 V 1h 30min
500 V 1h 30min
1000 V 1h 30 min
Gradient 1000 V 8000 V 1h
8000 V 5h
Total time 23.5 h
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SECOND DIMENSION For separation according to the molecular masses, IPG
strips were transferred into sealable tubes in which they were agitated gently on an
orbital shaker together with 10 mL of equilibration buffer A [Appendix 3] for 10 to
15 minutes. After decanting equilibration buffer A, the procedure was repeated with
equilibration buffer B [Appendix 3]. Equilibrated IPG strips were washed briefly in
electrophoresis buffer and applied to the top of the SDS-PAGE gels, where special
care was taken that no air bubbles were trapped between the gel and the IPG strips.
2D PAGE gels were of dimensions of 26×20×0.15 cm and contained 12.5%
polyacrylamide. The gels were cast manually with 12.5% gel solution [Appendix 3]
in an Ettan™ DALTtwelve gel caster (Amersham) according to the manufacturers
instructions, and stored at 4 °C in storage buffer before use [Appendix 3].
At the acidic end of the IPG strips, square filter paper was added which had
been soaked with 15 L of Bio-Rad Precision Plus Protein Standards (Bio-Rad,
Hercules, US). IPG strips were fixed to the surface of the PAGE-gel with 2 mL of 1%
agarose and the gels were run in an Ettan™ DALTtwelve vertical chamber
(Amersham) with electrophoresis with 2D electrophoresis buffer [Appendix 3], and
according to the settings described in Table 5.2.
Table 5.2 Instrument settings for the second dimension electrophoretic separation.
Time Settings of the power source Remarks
45 to 60min 40 mA constant Sample application
4 to 6h 90 to 120W constant Depending on the
number of gels
VISUALISATION AND DOCUMENTATION After the electrophoresis run, gels
were removed from the gel cassettes and the IPG strips and the agarose were
removed. Gels were fixed in fixing solution [Appendix 3] for at least one hour at
room temperature, washed with water, and proteins were visualised by overnight
incubation with colloidal Coomassie Brilliant Blue G-250 staining solution
[Appendix 3], under gentle agitation on an orbital shaker at room temperature.
Stained gels were discoloured by washing with water under gentle agitation for about
24 hours whereby the water was exchanged frequently. Wet gels were scanned
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immediately with an ImageScanner™ (Amersham) at 300 dpi. Gels were stored at 4
°C in sealed plastic bags in aqueous solution supplemented with NaN3 to prevent
microbial growth.
IDENTIFICATION OF PROTEIN SPOTS For the identification of protein spots,
gels were washed with water for 30 minutes to remove NaN3, and protein spots were
picked from the gel by using 1000 L disposable pipette tips, whose diameter had
been cut to match the size of the protein spot, and transferred to 96 well microtitre
plates. Unless noted otherwise, the following operations were carried out with 100
L solutions. Protein spots were destained with 100 mM (NH4)HCO3, pH 8.0/MeOH
(50:50 v/v) for 3 hours at 37 °C, washed twice with water and once with 100 mM
NH4HCO3, pH 8.0. Gel plugs were then shrunk by dehydrating in 80% acetonitrile
for 10 minutes until the gel plugs assumed an opaque appearance. The solvent was
then removed by drying at 50 °C for 30 minutes and the gel plugs were re-hydrated in
10 L of trypsin solution (10 ng/L of trypsin in 5 mM Tris buffer, pH 7.8-8.0) at
room temperature for 15 minutes. After rehydration, the gel plugs were covered with
20 L of 5mM Tris, pH 7.8-8.0 and proteins were digested for 3 to 6 hours at 37 °C.
Protein digests were stored at -20 °C until spotting onto MALDI plates.
MASS SPECTROMETRIC ANALYSIS OF TRYPTIC PROTEIN DIGESTS The
supernatant of the digested protein spots was spotted on MALDI plates coated with
0.25 mL of a 1 mg/mL -cyano-4-hydroxycinnamic acid solution in acetonitrile and
air-dried. Subsequently, 50 L of the sample were added to the MALDI plate and
mixed with 0.5 L of the matrix solution containing 15 mg/mL -cyano-4-
hydroxycinnamic acid in 50% acetonitrile, containing 0.5% TFA). The matrix
solutions were then air-dried for 10 minutes.
MALDI plates were measured at the Functional Genomics Centre Zürich
(FGCZ), using a 4700 Proteomics Analyzer MALDI-TOF/TOF mass spectrometer
(Applied Biosystems, Foster City, CA), allowing for the detection of both intact
peptides and of fragment ions created in the collision cell of the instrument. The mass
spectrometer is equipped with a Nd:YAG-laser working at a frequency of 200 Hz.
Mass spectra were recorded in positive ion reflector mode and the mass spectrometer
was calibrated by a multilevel external calibration with six peptide samples and
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spectra were calibrated internally using the trypsin autolysis fragments corresponding
to 842.509 and 2211.101 Da, resulting in an accuracy of the mass determination of 10
ppm or better.
Proteins were identified from their peptide mass maps using the GPS-explorer
software (Applied Biosystems, Foster City, US) with the integrated MASCOT search
engine (Matrix Science, London, UK). A maximum of one missed enzymatic
cleavage and modification of cysteines by carboxymethylation and of methionines by
partial oxidation were considered during the searches, which were based on the non-
redundant NCBI database and the annotated sequence database of P. aeruginosa
PAO1.[537]
5.9 Affinity chromatography
PREPARATION OF AFFINITY COLUMNS For the preparation of affinity
columns, AMPMs were coupled to NHS-activated sepharose HiTrap™ columns (1
mL, Amersham) according to the manufacturer’s instructions. Briefly, AMPM
ligands were coupled in standard coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH
8.3) for 30 minutes at room temperature, and unreacted NHS on the matrix was
blocked with a buffer containing 0.5M ethanolamine, 0.5M NaCl, pH 8.3. The
coupling efficiencies were determined spectrometrically via the UV absorption of the
ligand at 280 nm and were found to be always ≥ 90%. Columns were equilibrated
with affinity chromatography standard buffer (50 mM potassium phosphate, 100 mM
NaCl, pH 7.0), and stored at 4 °C in standard buffer supplemented with 0.1% NaN3.
FRACTIONATION OF P. AERUGINOSA PAO1 For affinity chromatography
experiments with P. aeruginosa PAO1, cell cultures were harvested in their mid-
logarithmic growth phase, typically at an OD600 of 1.0, via centrifugation at 5000 rpm
for 30 minutes in a Sorvall® GS-3 rotor, and the cell pellets were washed twice in
standard buffer (50 mM potassium phosphate, 100 mM NaCl, pH 7.0)
The cell pellet was taken up in 30 mL of standard buffer and protease
inhibitors were added (Calbiochem Protease Inhibitor Cocktail Set I). Cells were
broken up either by sonicating five times with a tip sonicator as described above, or
by passing the bacterial suspension twice through a French pressure cell (SLM
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Aminco, Urbana, US) cooled to 0 °C. Cell debris was removed by low speed
centrifugation at 5000 g for 10 minutes in an SS34 rotor, and the crude cell mixtures
were further fractionated by centrifugation at 40000 g for 30 minutes in an SS34 rotor.
A final centrifugation step of the supernatant at 100000 g in a Sorvall OTD-Combi
ultracentrifuge (Kendro, Zürich, Switzerland) with the T 865 rotor was carried out to
separate the cytoplasmic membrane and smaller outer membrane fragments from the
soluble intracellular fraction. For experiments with membrane preparations, 1% of
the non-ionic detergent Triton-X 100™ was added to the buffer systems as
solubilising agent. Protein concentrations were determined from the UV absorptions
at 260 and 280 nm, and by Bradford analysis.[535]
AFFINITY CHROMATOGRAPHY Affinity chromatography experiments
with AMPMs coupled to 1 mL of NHS-activated sepharose pre-packed columns were
carried out with a P-1 peristaltic pump (Pharmacia, Uppsala, Sweden) set to flow rate
of 1 mL/min. The outlet of the column was connected to the UV detector of an
AKTA purifier 10 system (Amersham, Uppsala, Sweden) and the UV absorptions at
226 nm, 254 nm and 278 nm were recorded. The eluate was collected in fractions of
3 mL and the fractions were frozen immediately and stored at -20°C until further
analysis.
PAGE ANALYSIS 1D PAGE gels were run either on the Phast™ system
using pre-cast Phast gels (Amersham, Uppsala, Sweden), or according to standard
procedures[616] with manually cast gels of dimensions 18×12×0.1 cm with a stacking
gel of 5% polyacrylamide and with 12% or 15% of polyacrylamide gel solutions
[Appendix 3] in a vertical electrophoresis chamber. Proteins were visualised either
by staining with colloidal Coomassie Brilliant Blue G-250 dye,[617] or by silver
staining.[616] Separation of protein mixtures by 2D-PAGE and mass spectrometric
analysis of excised protein spots was performed as described above for the protein
expression profiling experiments.
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5.10 Photo-affinity labelling
PAL WITH PHOTO-REACTIVE ANALOGUES OF MIMETIC 19 For the PAL
experiments cultures of P. aeruginosa were either labelled in vivo or in vitro. For in
vivo PAL, P. aeruginosa PAO1 cells were harvested in their logarithmic growth phase
and washed twice by re-suspending them in standard PAL buffer and centrifugation at
5’000 rpm for 30 minutes. Cells were re-suspended in PAL standard buffer in
aliquots of either 5 or 10 mL to give an approximate cell density of 5×109 CFU/mL.
Alternatively, for in vitro PAL, bacterial cell suspensions were pre-fractionated
according to the differential centrifugation protocol described for the affinity
chromatography experiments.
Bacterial suspensions, or membrane or intracellular fractions of P. aeruginosa
PAO1 were incubated with 5 or 10 g/mL of the photo-reactive AMPM in Sterilin
Petri dishes of 5 or 10 cm diameter (Bibby Sterilin, Stone, UK) corresponding to 5 or
10 mL of bacterial suspension for 30 minutes at 4 °C in the dark. Prior to that,
labelling mixtures were incubated with 100 or 500-fold excess of competitive ligand
(either mimetic 19 or ent-18) for 30 minutes at 4 °C in the dark. PAL was carried out
for 10 minutes in the Petri dishes with handheld Model UVGL-55 Mineralight™
multiband UV lamps (UVP, Upland, US) at a distance of 5 cm from the light sources
at 4 °C and under agitation on an orbital shaker at 50 rpm.
For in vivo PAL, samples were fractionated according to the protocol
described above and biotinylated species were isolated by incubation with streptavidin
immobilised on agarose (ImmunoPure® Immobilized Streptavidin Gel, Pierce,
Rockford, US). In the case of membrane systems, 1% of Triton-X 100™ was added
to the buffer systems to aid in solubilisation of membrane proteins. For 1D PAGE
analysis, biotinylated species retained on the streptavidin matrix were eluted directly
by boiling with SDS sample buffer for 10 minutes with intermittent vortexing.
BLOTTING 1D PAGE gels were run as described for the affinity
chromatography experiments and transferred immediately to Amersham Hybond™-P
PVDF membranes (Amersham, Uppsala, Sweden) by semi-dry blotting with either a
Multiphor II (Amersham, Uppsala, Sweden) semi-dry transfer chamber for 1 h at 0.8
mA/cm2 or with the PhastTransfer™ semi-dry transfer kit (Pharmacia, Uppsala,
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Sweden) for 30 minutes at 1 mA/cm2 with transfer buffer [Appendix 3]. For the
detection of biotinylated species, a modified Western blot procedure was employed.
Unless noted otherwise, the following operations were carried out under gentle
agitation on an orbital shaker at 50 rpm.
Immediately after transfer, the membrane was blocked with 5% BSA in TBS
buffer [Appendix 3] for at least 2 hours, preferably overnight. The blocking solution
was decanted and the membrane was washed three times with TTBS buffer
[Appendix 3]. One hour before washing the membrane with TTBS buffer, the
alkaline phosphatase/streptavidin complex was formed by incubating biotinylated
alkaline phosphatase with streptavidin in TTBS buffer according to the
manufacturer’s instructions*** for one hour in TBS buffer. The membrane was
incubated with the complex for one to two hours under gentle agitation on an orbital
shaker. The solution was then decanted off, and the membrane was washed with
TTBS buffer four times for 10 minutes. For colour development, the membrane was
covered with the BCIP/NBT reagent (Sigma, Buchs, Switzerland) and incubated for a
maximum of 30 minutes. Colour development was stopped by washing twice 10
minutes in double-distilled water.
*** “Amplified Alkaline Phosphatase Goat Anti-Rabbit Immun-Blot® Assay Kit” instruction manual,
catalogue number 170-6412, Bio-Rad, Hercules, USA
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Appendix 1: Abbreviations
AMP Antimicrobial peptide
AMPM Antimicrobial peptide mimetics
APS Ammonium peroxodisulfate
BCIP 5-Brom-4-chlor-3-indoxylphosphat
BSA Bovine serum albumin
Boc tert-Butyloxycarbonyl
tBu tert-Butyl
calc. Calculated
CFU Colony forming units
CHAPS 3-((3-Cholamidopropyl)dimethylammonio)-1-propanesulfonate
DCM dichloromethane
DEPT Distortionless enhancement by polarization transfer
DIEA N,N-Diisopropylethylamine
DME 1,2-Dimethoxyethane
DMF N,N-Dimethylformamide
DMSO Dimethylsulfoxid
DNA Deoxyribonucleic acid
DPC Dodecylphosphocholine
DQF-COSY Double quantum filtered correlated spectroscopy
DTT Dithiothreitol
EDT Ethanedithiol
em Emission
ESI Electrospray ionisation
ex Excitation
FGCZ Functional Genomic Center Zurich
Fmoc N-9H-Fluoren-2-ylmethoxycarbonyl
Fmoc-OSu N-(9H-Fluoren-2-ylmethoxycarbonyl)succinimide
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HBTU O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
HMPT Hexamethylphosphorous triamide
HOAt 1-Hydroxy-7-azabenzotriazole
HOBt 1-Hydroxybenzotriazole
HPLC High performance liquid chromatography
IPG Immobilised pH gradient
MALDI Matrix-assisted laser desorption/ionisation
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MH broth/agar Mueller-Hinton broth/agar
M.p. Melting point
MS/MS Tandem mass spectroscopy
Mtt Methyltrityl
NBT Nitro-blue tetrazolium chloride
NCBI National Center for Biotechnology Information
NHS N-Hydroxysuccinimide
NOESY Nuclear overhauser enhancement spectroscopy
OD Optical density
PAGE Polyacrylamide gel electrophoresis
Pbf Pentamethyldihydrobenzofuran-5-sulfonyl-
PMF Peptide mass fingerprinting
RP Reversed phase
Rpm Revolutions per minute
R.t. Room temperature
SA Simulated annealing
SDS Sodium dodecylphosphate
SPPS Solid phase peptide synthesis
TBS Tris-buffered saline
TCA Trichloroacetic acid
TEMED N,N,N',N'-Tetramethylethylenediamine
TFA Trifluoroacetic acid
TFE Trifluoroethanol
TIS Triisopropylsilane
TOCSY Totally correlated spectroscopy
Tris Tris-(hydroxymethyl-)aminoethane
Trt Trityl
TSP 3-Trimethylsilylpropionic acid-d4 sodium salt
Appendix 2: Analytical data
Table A2.1 Summary of the HPLC and ESI mass spectrometric analytical data of AMPMs (16-19), LPS binding mimetics (34-36), and labelled AMPM-analogues (70,
75, 77-86, and 89-97).
12
11
10
9
8
7
6
5
4
3
2
1
13
14
identifier positiona columnb conditionsc tR [min]d masse
1 2 3 4 5 6 7 8 9 10 11 12 13 14
16 Leu Arg Leu Lys Lys Arg Arg Trp Lys Tyr Arg Val pro Pro A A 14.7 940.1 (939.6) [M+2H]2+
627.0 (626.7) [M+3H]3+
ent-16 leu arg leu lys lys arg arg trp lys tyr arg val Pro pro A A 14.7 940.1 (939.6) [M+2H]2+
626.9 (626.7) [M+3H]3+
17 Arg Trp Leu Lys Lys Gln Arg Trp Lys Tyr Tyr Arg pro Pro A A 13.4 and
14.0f
994.6 (994.6) [M+2H]2+
663.2 (663.4) [M+3H]3+
ent-17 arg trp leu lys lys gln arg trp lys tyr tyr arg Pro pro A A 13.4 and
14.0f
994.6 (994.6) [M+2H]2+
663.3 (663.4) [M+3H]3+
18 Thr Trp Leu Lys Lys Arg Arg Trp Lys Lys Val Lys pro Pro A A 13.2 917.1 (917.6) [M+2H]2+
611.9 (612.1) [M+3H]3+
ent-18 thr trp leu lys lys arg arg trp lys lys val lys Pro pro A A 13.2 917.6 (917.6) [M+2H]2+
611.9 (612.1) [M+3H]3+
19 Thr Trp Leu Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.1 903.1 (903.6) [M+2H]2+
602.6 (602.7) [M+3H]3+
36 Lys Trp Lys Ala Phe Lys Arg Gln Leu Lys Met Ser pro Pro B B 16.8 1727.3 (1727.0) [M+H]+
864.2 (864.0) [M+2H]2+
37 Arg Trp Lys Val Arg Lys Ser Phe Phe Lys Leu Gln pro Pro B B 19.4 1799.3 (1799.1) [M+H]+
900.4 (900.0) [M+2H]2+
38 Lys Pro Thr Phe Arg Arg Leu Lys Trp Lys Tyr Lys pro Pro B B 16.0 1827.2 (1827.1) [M+H]+
914.3 (914.0) [M+2H]2+
Table A2.1 (continued)
identifier positiona columnb conditionsc tR [min]d masse
1 2 3 4 5 6 7 8 9 10 11 12 13 14
72 Arg Trp Leu Lys Lys Gln Arg Dan Lys Tyr Tyr Arg pro Pro A A 13.7 1035.6 (1035.6) [M+2H]2+
690.7 (690.7) [M+3H]3+
77 Thr Trp Leu Lys Lys Arg Arg Dan Lys Lys Ala Lys pro Pro A A 13.4 1888.3 (1888.2) [M+H]+
944.8 (944.6) [M+2H]2+
80 Biot Trp Leu Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.5 1131.7 (1131.7) [M+2H]2+
754.7 (754.8) [M+3H]3+
81 Thr Trp Biot Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 12.9 1125.7 (1125.7) [M+2H]2+
750.7 (750.8) [M+3H]3+
82 Thr Trp Leu Biot Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.9 1118.1 (1118.2) [M+2H]2+
745.7 (745.8) [M+3H]3+
83 Thr Trp Leu Lys Biot Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.6 1118.1 (1118.2) [M+2H]2+
745.7 (745.8) [M+3H]3+
84 Thr Trp Leu Lys Lys Biot Arg Trp Lys Lys Ala Lys pro Pro A A 13.5 1104.1 (1104.2) [M+2H]2+
736.4 (736.4) [M+3H]3+
85 Thr Trp Leu Lys Lys Arg Biot Trp Lys Lys Ala Lys pro Pro A A 13.5 1104.1 (1104.2) [M+2H]2+
736.4 (736.4) [M+3H]3+
86 Thr Trp Leu Lys Lys Arg Arg Trp Biot Lys Ala Lys pro Pro A A 13.5 1118.1 (1118.2) [M+2H]2+
745.7 (745.8) [M+3H]3+
87 Thr Trp Leu Lys Lys Arg Arg Trp Lys Biot Ala Lys pro Pro A A 13.4 1118.1 (1118.2) [M+2H]2+
745.7 (745.8) [M+3H]3+
88 Thr Trp Leu Lys Lys Arg Arg Trp Lys Lys Biot Lys pro Pro A A 13.1 1146.7 (1146.7) [M+2H]2+
764.6 (764.8) [M+3H]3+
89 Thr Trp Leu Lys Lys Arg Arg Trp Lys Lys Ala Biot pro Pro A A 13.7 1118.2 (1118.2) [M+2H]2+
745.7 (745.8) [M+3H]3+
92 Thr Paz Leu Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.1 1808.3 (1888.1) [M+H]+
93 Thr Trp Leu Lys Lys Arg Arg Paz Lys Lys Ala Lys pro Pro A A 13.0 1808.3 (1888.1) [M+H]+
94 Thr Bpa Leu Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.4 1871.3 (1871.1) [M+H]+
936.2 (936.1) [M+2H]2+
95 Thr Trp Leu Lys Lys Arg Arg Bpa Lys Lys Ala Lys pro Pro A A 13.5 1871.3 (1871.1) [M+H]+
936.2 (936.1) [M+2H]2+
Table A2.1 (continued)
identifier positiona columnb conditionsc tR [min]d masse
1 2 3 4 5 6 7 8 9 10 11 12 13 14
96 Biot Paz Leu Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 13.8 1133.2 (1132.7) [M+2H]2+
97 Biot Trp Leu Lys Lys Arg Arg Paz Lys Lys Ala Lys pro Pro A A 13.6 1132.9 (1132.7) [M+2H]2+
98 Thr Trp Leu Lys Lys Arg Arg Paz Lys Lys Ala Biot pro Pro A A 13.8 1119.3 (1119.2) [M+2H]2+
99 Biot Bpa Leu Lys Lys Arg Arg Trp Lys Lys Ala Lys pro Pro A A 14.1 2327.7 (2327.4) [M+H]+
1164.6 (1164.2) [M+2H]2+
100 Biot Trp Leu Lys Lys Arg Arg Bpa Lys Lys Ala Lys pro Pro A A 13.8 1164.4 (1164.2) [M+2H]2+
776.7 (776.5) [M+3H]3+
a Dan = DANA (39); Biot = Glu(biotinyl-PEG); Paz = p-azido-Phe; Bpa = p-benzoyl-Phe.
b A = Grace Vydac 218TP54 (C18, 4.6×250 mm, 5 m, 300 Ǻ); B = Vydac 218TP54 (C18, 4.6×250 mm, 5 m, 300 Ǻ).
c A = 5% acetonitrile in water, containing 0.1% TFA for 4.2 minutes, followed by a gradient from 5 to 100% acetonitrile in water, containing
0.1% TFA over 25 minutes; B = gradient from 5 to 100% acetonitrile in water, containing 0.1% TFA over 60 minutes
d tR = retention time.
e Observed m/z values measured with positive ion mode ESI; calculated values of the basis peaks are given in parentheses.
f Two peak pattern.
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Appendix 3: Buffers
H2O used for the preparation of buffers was of double distilled quality. Unless
stated otherwise, the concentrations of aqueous solutions of solid compounds are
given as weight-volume percentage (% w/v)
Table A3.1 Buffer systems used for gel electrophoresis, affinity chromatography and
photoaffinity labelling.
system contents amount remarks
1.5M Tris 182 gGel buffer, 4×, pH 8.8
H2O ad 1000 mL
store at 4 °C
6M urea 180 g
30% glycerol 150 g
2% SDS 10 g
4× Gel buffer 16.7 mL
equilibration buffer
(stock)
H2O ad 500 mL
store at 4 °C
DTT 1 gequilibration buffer A
equilibration buffer
(stock)
100 mL
prepare freshly; 10 mL per IPG
strip
iodo acetamide 4 gequilibration buffer B
equilibration buffer
(stock)
100 mL
prepare freshly; 10 mL per IPG
strip
EtOH 800 mL
HOAc 200 mL
fixing solution
H2O ad 2000 mL
prepare freshly; 200 mL per gel
(NH4)2SO4 100 g
H3PO4 20 g
MeOH 250 mL
Coomassie Brilliant
Blue G250
0.625 mg
staining solution
H2O ad 1000 mL
store at r.t. in the dark
Acrylamide monomer
solution
41.7 mL
4× Gel buffer 25.0 mL
10% SDS 1.0 mL
H2O 31.8 mL
10% APS 0.5 mL
12.5% gel solution
TEMED 33 L
for 900 mL (14 gels)
4× Gel buffer 250 mL
10% SDS 10 mL
2D Gel storage buffer
H2O ad 1000 mL
store at 4 °C
25 mM Tris 15.1 g
192 mM Glycine 72.1 g
0.1% SDS 5 g
2D electrophoresis
buffer
H2O ad 5000 mL
prepare freshly
EtOH 800 mL
HOAc 200 mL
Fixing solution
H2O ad 2000 mL
prepare freshly; ca. 200 mL/gel
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Table A3.1 (continued)
(NH4)2SO4 100 g
H3PO4 (85%) 20 g
MeOH 250 mL
Coomassie Brilliant
Blue G-250 (Merck)
0.625 mg
2D staining solution
(colloidal Coomassie)
H2O ad 1000 mL
store at r.t. in the dark
Tris 18.2 g
10% SDS 4 mL
1D Gel buffer, pH 8.8
H2O ad 100 mL
Tris 6.1 g
10% SDS 4 mL
1D Stacking gel buffer,
pH 6.8
H2O ad 100 mL
Acrylamide monomer
solution
16 mL
1D gel buffer 10 mL
H2O 14 mL
APS 250 L
1D gel solution (12%)
TEMED 150 L
for 3 gels
Acrylamide monomer
solution
20 mL
1D gel buffer 10 mL
H2O 10 mL
APS 250 L
1D gel solution (15%)
TEMED 150 L
for 3 gels
Acrylamide monomer
solution
3.4 mL
1D gel buffer 5 mL
H2O 11.6 mL
APS 150 L
1D Stacking gel
solution (12%)
TEMED 15 L
for 3 gels
Glycerol 7.5 mL
-Mercaptoethanol 2.5 mL
SDS 1.2 g
1% Bromophenol blue 200 L
Tris 0.4 g
4× Sample buffer, pH
6.8
H2O ad 50 mL
for manually cast gels
Tris 3.0 g
Glycine 14.4 g
MeOH 200 mL
Transfer buffer, pH 8.3
H2O ad 1000 mL
Tris 24.2 g
NaCl 290 g
10× TBS, pH 7.0
H2O ad 1000 mL
Filter sterilise
10× TBS 100 mLTBS buffer, pH 7.0
H2O ad 1000 mL
prepare freshly
10× TBS 90 mL
Tween® 20 450 L
TTBS buffer, pH 7.0
H2O ad 900 mL
prepare freshly
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Appendix 4: NMR data for 17 and 18
Figure A4.1 Top: 600 MHz 1H-NMR spectrum of 17 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure A4.2 Top: 600 MHz 1H-NMR spectrum of 18 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure A4.3 Top: 600 MHz 1H-NMR spectrum of 17 in a 300 mM solution of DPC-d38 in
H2O/D2O (9:1), pH 5, 300K. Bottom: expansion of the amide NH region.
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Table A4.1 Chemical shift values obtained for 17 relative to the internal TSP standard at 300K
and pH 5 in a 300 mM solution of DPC-d38 in H2O/D2O (9:1).
Residue NH H-C() H-C() Others
Arg1 8.81 3.84 1.63, 1.85 CH2() 1.62, 1.62; CH2() 3.19, 3.19; NH() -a;
NH2() -, -
Trp2 6.80 4.50 3.25, 3.53 H() 7.42; H() 7.33; H() 6.92; H() 6.98;
H() 7.37; NH() 10.88
Leu3 7.00 4.44 1.40, 1.47 CH() 1.18; CH3() 0.64, 0.71
Lys4 8.56 4.26 1.85, 1.95 CH2() 1.49, 1.49; CH2() 1.70, 1.70; CH2() 3.06,
3.06; NH3+() -
Lys5 7.99 4.18 1.69, 1.84 CH2() 1.42, 1.61; CH2() 1.52, 1.52; CH2() 2.96,
2.96; NH3+() -
Gln6 - 3.98 2.08, 2.08 CH2() 2.43, 2.43; NH2() 6.85, 7.48
Arg7 8.18 4.08 1.28, 1.69 CH2() 1.00, 1.00; CH2() 2.77, 2.91; NH() -;
NH2() -, -
Trp8 7.49 5.08 2.97, 3.62 H() 7.16; H() 7.49; H() 6.96; H() 7.06;
H() 7.44; NH() 10.68
Lys9 7.66 3.95 1.65, 1.75 CH2() 1.04, 1.18; CH2() 1.54, 1.54; CH2() 2.87,
2.87; NH3+() -
Tyr10 7.73 4.22 2.60, 2.68 H( 6.69, 6.69; H( 6.75, 6.75
Tyr11 7.74 4.33 2.87, 3.25 H( 7.13, 7.13; H( 6.90, 6.90
Arg12 7.16 3.92 1.64, 1.64 CH2() 1.52, 1.64; CH2() 3.13, 3.13; NH() -;
NH2() -, -
DPro13 - 5.56 1.95, 2.23 CH2() 1.93, 1.93; CH2() 3.49, 3.54
Pro14 - 4.26 0.51, 1.68 CH2() 1.34, 1.54; CH2() 3.37, 3.60
a - = not observed
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Table A4.2 Distance restraints derived from 1H,1H-NOE connectivities for mimetic 17 in 300
mM micellar solution used for SA calculations with the DYANA software packages.
INTRARESIDUAL NOE UPPER-
DISTANCE LIMITS
SEQUENTIAL NOE UPPER-
DISTANCE LIMITS
MEDIUM and LONG RANGE NOE
UPPER-DISTANCE LIMITS
1 ARG+ HN 1 ARG+ HB2 2.86 1 ARG+ HN 2 TRP HN 3.58 1 ARG+ HA 3 LEU HN 4.14
1 ARG+ HN 1 ARG+ HB3 3.30 1 ARG+ HN 14 PRO HA 2.71 1 ARG+ HA 12 ARG+ QD 6.04
1 ARG+ HN 1 ARG+ QD 6.38 1 ARG+ HN 14 PRO HB2 4.91 2 TRP HN 14 PRO HA 4.11
1 ARG+ HA 1 ARG+ HB2 2.68 1 ARG+ HN 14 PRO HB3 4.91 2 TRP HN 14 PRO QB 5.17
1 ARG+ HA 1 ARG+ HB3 3.05 1 ARG+ HN 14 PRO QB 4.52 3 LEU HN 14 PRO QB 6.07
1 ARG+ HA 1 ARG+ QD 6.38 1 ARG+ HB2 2 TRP HN 3.61 3 LEU HA 5 LYS+ HN 3.48
1 ARG+ HB2 1 ARG+ HE 5.50 1 ARG+ HB3 2 TRP HN 3.45 3 LEU HA 8 TRP HE3 5.50
2 TRP HN 2 TRP HB2 3.48 2 TRP HB2 3 LEU HN 4.32 3 LEU QD1 8 TRP HB3 5.78
2 TRP HN 2 TRP HB3 3.58 2 TRP HB3 3 LEU HN 4.35 3 LEU QD1 8 TRP HD1 6.47
2 TRP HA 2 TRP HB2 2.90 2 TRP HE3 3 LEU HA 4.45 3 LEU QD1 8 TRP HE3 6.19
2 TRP HA 2 TRP HD1 4.63 2 TRP HE3 3 LEU HG 5.38 3 LEU QD1 11 TYR QE 8.66
2 TRP HA 2 TRP HE3 5.50 2 TRP HE3 3 LEU QD1 5.35 3 LEU QD1 14 PRO QD 7.42
2 TRP HB2 2 TRP HD1 3.39 2 TRP HE3 3 LEU QD2 6.53 3 LEU QD2 8 TRP HB3 5.41
2 TRP HB2 2 TRP HE3 4.07 2 TRP HZ3 3 LEU HA 5.50 3 LEU QD2 8 TRP HD1 6.53
2 TRP HB3 2 TRP HE3 3.76 2 TRP HZ3 3 LEU QD1 6.09 3 LEU QD2 8 TRP HE3 6.53
3 LEU HN 3 LEU HG 3.79 2 TRP HZ3 3 LEU QD2 6.53 3 LEU QD2 11 TYR HB3 6.28
3 LEU HN 3 LEU QD1 5.57 3 LEU HA 4 LYS+ HN 2.86 3 LEU QD2 11 TYR QD 8.67
3 LEU HN 3 LEU QD2 5.81 3 LEU QD1 4 LYS+ HN 6.50 3 LEU QD2 11 TYR QE 8.66
3 LEU HA 3 LEU QD1 4.26 4 LYS+ HN 5 LYS+ HN 3.70 3 LEU QD2 12 ARG+ HA 5.29
3 LEU HA 3 LEU QD2 5.72 4 LYS+ HA 5 LYS+ HN 3.36 3 LEU QD2 13 DPR HA 6.22
4 LYS+ HN 4 LYS+ HB2 3.58 7 ARG+ HA 8 TRP HN 3.64 3 LEU QD2 14 PRO HD2 6.16
4 LYS+ HN 4 LYS+ HB3 3.58 7 ARG+ HB2 8 TRP HE3 5.10 3 LEU QD2 14 PRO HD3 6.16
4 LYS+ HN 4 LYS+ QG 5.60 7 ARG+ HB3 8 TRP HE3 5.10 3 LEU QD2 14 PRO QD 5.70
5 LYS+ HN 5 LYS+ HB2 3.30 7 ARG+ QB 8 TRP HD1 6.26 5 LYS+ HN 8 TRP HN 4.54
5 LYS+ HN 5 LYS+ HB3 3.30 7 ARG+ QB 8 TRP HE3 4.69 5 LYS+ HB2 8 TRP HD1 4.69
5 LYS+ HN 5 LYS+ HG2 5.07 7 ARG+ QG 8 TRP HD1 6.38 5 LYS+ HB3 8 TRP HD1 4.69
5 LYS+ HN 5 LYS+ HG3 5.07 7 ARG+ QG 8 TRP HE3 6.38 5 LYS+ QB 8 TRP HD1 4.12
5 LYS+ HN 5 LYS+ QG 4.90 8 TRP HN 9 LYS+ HN 3.08 6 GLN HA 8 TRP HN 4.07
5 LYS+ HN 5 LYS+ QD 5.97 8 TRP HA 9 LYS+ HN 3.42 8 TRP HA 11 TYR QD 6.59
5 LYS+ HA 5 LYS+ HB2 2.90 8 TRP HB2 9 LYS+ HN 4.07 8 TRP HA 11 TYR QE 7.63
5 LYS+ HA 5 LYS+ HB3 2.90 8 TRP HB3 9 LYS+ HN 4.42 8 TRP HB3 11 TYR QD 7.58
5 LYS+ HA 5 LYS+ QD 6.38 9 LYS+ HA 10 TYR HN 3.45 8 TRP HE3 11 TYR HB2 5.31
7 ARG+ HN 7 ARG+ HB2 3.98 9 LYS+ QB 10 TYR HN 4.36 8 TRP HE3 11 TYR QD 6.31
7 ARG+ HN 7 ARG+ HB3 3.98 10 TYR HA 11 TYR HN 3.55 9 LYS+ HA 12 ARG+ HN 3.73
8 TRP HN 8 TRP HB2 3.21 10 TYR HB3 11 TYR QD 7.64 9 LYS+ HA 12 ARG+ QD 6.31
8 TRP HN 8 TRP HB3 3.36 10 TYR HB3 11 TYR QE 7.26 12 ARG+ HA 14 PRO HD2 4.48
8 TRP HA 8 TRP HD1 4.50 10 TYR HB2 11 TYR QD 7.64 12 ARG+ HA 14 PRO HD3 4.48
8 TRP HA 8 TRP HE3 4.00 10 TYR HB2 11 TYR QE 7.63 12 ARG+ HA 14 PRO QD 3.96
8 TRP HB2 8 TRP HD1 3.86 11 TYR HN 12 ARG+ HN 3.08
8 TRP HB2 8 TRP HE3 3.89 11 TYR HA 12 ARG+ HN 3.21
9 LYS+ HN 9 LYS+ HB2 3.27 12 ARG+ HN 13 DPR HA 4.48
9 LYS+ HN 9 LYS+ HB3 3.27 12 ARG+ HA 13 DPR HA 2.55
9 LYS+ HN 9 LYS+ HG2 4.79 12 ARG+ QB 13 DPR HA 4.76
9 LYS+ HN 9 LYS+ HG3 4.79 12 ARG+ QG 13 DPR HA 5.54
9 LYS+ HN 9 LYS+ QG 4.46 13 DPR HA 14 PRO HD2 3.11
9 LYS+ HN 9 LYS+ QD 6.38 13 DPR HA 14 PRO HD3 3.11
9 LYS+ HA 9 LYS+ HB2 2.96 13 DPR HB3 14 PRO HD2 4.76
9 LYS+ HA 9 LYS+ HB3 2.96 13 DPR HB3 14 PRO HD3 4.76
9 LYS+ HA 9 LYS+ QD 5.45 13 DPR HB2 14 PRO HD2 4.76
10 TYR HN 10 TYR HB3 3.05 13 DPR HB2 14 PRO HD3 4.76
10 TYR HN 10 TYR HB2 3.11 13 DPR QB 14 PRO QD 3.86
10 TYR HA 10 TYR HB3 3.05
11 TYR HN 11 TYR HB3 3.33
11 TYR HN 11 TYR HB2 2.99
11 TYR HA 11 TYR HB3 2.96
12 ARG+ HN 12 ARG+ QG 4.74
12 ARG+ HN 12 ARG+ QD 6.38
12 ARG+ HA 12 ARG+ QG 3.97
12 ARG+ HA 12 ARG+ QD 5.79
TOTAL = 61 TOTAL = 51 TOTAL = 38
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Figure A4.4 Top: 600 MHz 1H-NMR spectrum of 18 in a 300 mM solution of DPC-d38 in
H2O/D2O (9:1), pH 5, 300K. Bottom: expansion of the amide NH region. For mimetic 18, amide
resonances corresponding to the cis- or the trans-isomer are depicted in black and red, respectively.
The numbering for the cis-isomer is derived from the normal numbering system by the addition of the
value 20.
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Table A4.3 Chemical shift values obtained for the trans-isomer of 18 relative to the internal TSP
standard at 300K and pH 5in a 300 mM solution of DPC-d38 in H2O/D2O (9:1). In cases where no
unambiguous assignment was possible due to spectral overlap, shift ranges are given.
Residue NH CH() CHn() Others
Thr1 8.29 4.20 4.11 CH3() 1.19
Trp2 7.90 4.54 3.23, 3.32 H() 7.33; H() 7.40; H() 7.42; H() 7.04;
H() 7.06; NH() 10.58
Leu3 7.67 4.19 1.43, 1.43 CH() 1.54; CH3() 0.81, 0.85
Lys4 8.07 4.15 1.78, 1.83 CH2() 1.36, 1.36; CH2() 1.60-1.68, 1.60-1.68;
CH2() 2.91-2.97, 2.91-2.97; NH3+() 1.35
Lys5 7.97 4.22 1.68, 1.77 CH2() 1.35, 1.35; CH2() 1.60-1.68, 1.60-1.68;
CH2() 2.91-2.97, 2.91-2.97; NH3+() 1.48
Arg6 8.02 4.06 1.61, 1.67 CH2() 1.48, 1.48; CH2(δ) 3.06, 3.06; NH() -;
NH2() -a, -
Arg7 7.91 4.19 1.59, 1.66 CH2() 1.37, 1.37; CH2() 3.03, 3.03; NH() -;
NH2() -, -
Trp8 7.99 4.71 3.22, 3.30 H() 7.24; H() 7.53; H() 7.42; H() 6.97;
H() 7.06; NH() 10.54
Lys9 8.17 4.23 1.65, 1.67 CH2() 1.34, 1.40; CH2() 1.60-1.68, 1.60-1.68;
CH2() 2.91-2.97, 2.91-2.97; NH3+() -
Lys10 8.11 4.23 1.65, 1.75 CH2() 1.33, 1.38; CH2() 1.60-1.68, 1.60-1.68;
CH2() 2.91-2.97, 2.91-2.97; NH3+() -
Val11 7.83 4.16 2.01 CH3() 0.81
Lys12 8.17 4.62W 1.64, 1.74 CH2() 1.31, 1.34; CH2() 1.60-1.68, 1.60-1.68;
CH2() 2.91-2.97, 2.91-2.97; NH3+() -
pro13 - 4.60W 1.87, 2.19 CH2() 1.97, 2.04; CH2() 3.66, 3.66
Pro14 - 4.37 1.51, 2.01 CH2() 1.77, 1.83; CH2() 3.48, 3.71
a - = not observed
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Table A4.4 Chemical shift values obtained for the cis-isomer of 18 relative to the internal TSP
standard at 300K in a 300 mM solution of DPC-d38 in H2O/D2O (9:1).
Residue NH CH() CHn() Others
Thr1 8.63 4.27 3.80 CH3() 1.30
Trp2 6.83 4.50 3.21, 3.56 H() 7.41; H() 7.30; H() 7.35; H() 6.87;
H() 6.95; NH() 10.93
Leu3 6.88 4.33 1.28, 1.34 CH() 0.99; CH3() 0.52, 0.62
Lys4 8.60 4.30 1.83, 1.91 CH2() 1.45, 1.49; CH2() 1.70, 1.70; CH2() 3.02,
3.02; NH3+() -a
Lys5 8.15 4.22 1.66, 1.75 CH2() 1.31-1.36, 1.31-1.36; CH2() 1.60-1.68,
1.60-1.68; CH2() 2.91-2.97, 2.91-2.97; NH3+() -
Arg6 8.11 4.22 1.65, 1.75 CH2() 1.65-1.75, 1.65-1.75; CH2(δ) -, -; NH() -;
NH2() -, -
Arg7 8.22 4.00 1.28, 1.61 CH2() 0.91, 0.98; CH2() 2.77, 2.83; NH() -;
NH2() -, -
Trp8 7.36 4.84 2.91, 3.49 H() 7.15; H() 7.41; H() 7.43; H() 6.95;
H() 7.04; NH() 10.72
Lys9 7.75 3.98 1.84, 1.90 CH2() 1.42, 1.42; CH2() 1.66, 1.66; CH2() 2.97,
2.97; NH3+() -
Lys10 8.31 4.14 1.79, 1.79 CH2() 1.43, 1.48; CH2() 1.70, 1.70; CH2() 2.91-
2.97, 2.91-2.97; NH3+() -
Val11 7.51 4.28 2.43 CH3() 0.88, 0.98
Lys12 7.19 3.97 1.53, 1.75 CH2() 1.08, 1.31; CH2() -, -; CH2() -, -; NH3+()
-
pro13 - 5.56 1.95, 2.15 CH2() 1.93, 1.93; CH2() 3.52, 3.52
Pro14 - 4.28 0.44, 1.61 CH2() 1.30, 1.60; CH2() 3.37, 3.51
a - = not observed
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Table A4.5 Distance restraints derived from 1H,1H-NOE connectivities for the cis-isomer of
mimetic 18 in 300 mM micellar solution used for SA calculations with the DYANA software packages.
21 THR HN 21 THR HB 3.36 21 THR HN 22 TRP HN 3.61 21 THR HN 34 PRO HA 2.87
21 THR HN 21 THR QG2 4.67 21 THR HA 22 TRP HN 3.58 21 THR HN 34 PRO HB2 5.16
22 TRP HN 22 TRP HB3 3.52 21 THR HA 22 TRP HD1 5.38 21 THR HN 34 PRO HB3 5.16
22 TRP HN 22 TRP HB2 3.45 21 THR HB 22 TRP HN 3.73 21 THR HN 34 PRO QB 4.90
22 TRP HN 22 TRP HD1 3.55 21 THR QG2 22 TRP HN 5.78 21 THR HB 23 LEU HN 4.29
22 TRP HA 22 TRP HB3 2.74 21 THR QG2 22 TRP HD1 5.75 22 TRP HN 34 PRO QB 5.21
22 TRP HA 22 TRP HB2 2.49 22 TRP HA 23 LEU HN 3.64 22 TRP HD1 34 PRO HB2 5.28
22 TRP HA 22 TRP HD1 4.26 22 TRP HB3 23 LEU HN 3.86 22 TRP HD1 34 PRO HB2 5.28
22 TRP HA 22 TRP HE3 4.88 22 TRP HB2 23 LEU HN 4.26 22 TRP HD1 34 PRO QB 4.76
22 TRP HB3 22 TRP HD1 3.76 22 TRP HE3 23 LEU HA 3.95 22 TRP HE1 34 PRO HB2 4.91
22 TRP HB3 22 TRP HE3 3.64 22 TRP HE3 23 LEU HG 4.72 22 TRP HE1 34 PRO HB3 4.91
22 TRP HB2 22 TRP HD1 3.45 22 TRP HE3 23 LEU QD1 5.01 22 TRP HE1 34 PRO QB 4.66
23 LEU HN 23 LEU HB2 3.36 22 TRP HE3 23 LEU QD2 6.53 22 TRP HZ2 34 PRO QB 4.90
23 LEU HN 23 LEU HB3 3.36 23 LEU HN 24 LYS+ HN 4.01 22 TRP HZ2 34 PRO QG 4.76
23 LEU HN 23 LEU QB 3.09 23 LEU HA 24 LYS+ HN 2.93 23 LEU HB2 28 TRP HD1 5.50
23 LEU HN 23 LEU HG 3.55 23 LEU QD1 24 LYS+ HN 6.43 23 LEU HB3 28 TRP HD1 5.50
23 LEU HN 23 LEU QD1 4.51 24 LYS+ HN 25 LYS+ HN 3.89 23 LEU QB 28 TRP HD1 5.28
23 LEU HN 23 LEU QD2 5.32 24 LYS+ HA 25 LYS+ HN 3.48 23 LEU QD1 28 TRP HD1 6.19
24 LYS+ HN 24 LYS+ HB2 3.67 24 LYS+ HB2 25 LYS+ HN 4.17 23 LEU QD1 28 TRP HE3 6.19
24 LYS+ HN 24 LYS+ HB3 3.67 24 LYS+ HB3 25 LYS+ HN 4.17 23 LEU QD1 28 TRP HZ3 5.94
24 LYS+ HN 24 LYS+ QB 3.45 24 LYS+ QB 25 LYS+ HN 3.83 23 LEU QD1 32 LYS+ HA 6.53
24 LYS+ HN 24 LYS+ HG2 5.50 27 ARG+ HA 28 TRP HN 3.30 23 LEU QD2 28 TRP HB3 5.57
24 LYS+ HN 24 LYS+ HG3 5.50 27 ARG+ QG 28 TRP HD1 6.38 23 LEU QD2 28 TRP HD1 6.53
24 LYS+ HA 24 LYS+ HB2 2.93 28 TRP HN 29 LYS+ HN 3.39 23 LEU QD2 28 TRP HE3 6.53
24 LYS+ HA 24 LYS+ HB3 2.93 28 TRP HA 29 LYS+ HN 3.36 23 LEU QD2 32 LYS+ HA 4.95
24 LYS+ HA 24 LYS+ QB 2.56 28 TRP HB3 29 LYS+ HN 4.07 23 LEU QD2 33 DPR HA 6.28
24 LYS+ HA 24 LYS+ QD 3.90 28 TRP HB2 29 LYS+ HN 4.38 23 LEU QD2 34 PRO HD2 5.63
25 LYS+ HN 25 LYS+ HB2 3.64 29 LYS+ HN 30 LYS+ HN 3.83 23 LEU QD2 34 PRO HD3 5.63
25 LYS+ HN 25 LYS+ HB3 3.64 29 LYS+ HA 30 LYS+ HN 3.58 23 LEU QD2 34 PRO QD 5.18
25 LYS+ HN 25 LYS+ QB 3.35 30 LYS+ HN 31 VAL HN 3.36 25 LYS+ QB 28 TRP HD1 4.86
27 ARG+ HA 27 ARG+ HB2 2.68 30 LYS+ HA 31 VAL HN 3.33 28 TRP HA 30 LYS+ HN 4.35
27 ARG+ HA 27 ARG+ HB3 2.68 30 LYS+ QB 31 VAL HN 4.64 28 TRP HB3 31 VAL QG2 4.79
27 ARG+ HA 27 ARG+ QB 2.39 31 VAL HN 32 LYS+ HN 2.96 28 TRP HB2 31 VAL QG2 5.29
27 ARG+ HA 27 ARG+ HG2 4.23 31 VAL HA 32 LYS+ HN 3.14 28 TRP HD1 31 VAL QG2 6.16
27 ARG+ HA 27 ARG+ HG3 4.23 31 VAL HB 32 LYS+ HN 4.11 28 TRP HE3 31 VAL QG1 5.54
27 ARG+ HA 27 ARG+ QG 4.03 31 VAL QG1 32 LYS+ HN 6.53 28 TRP HE3 31 VAL QG2 4.54
28 TRP HN 28 TRP HB3 3.30 31 VAL QG2 32 LYS+ HN 5.88 28 TRP HZ3 31 VAL QG1 5.01
28 TRP HN 28 TRP HB2 3.21 32 LYS+ HA 33 DPR HA 2.49 28 TRP HZ3 31 VAL QG2 6.09
28 TRP HN 28 TRP HD1 4.51 33 DPR HA 34 PRO HD2 3.02 29 LYS+ HA 31 VAL HN 3.79
28 TRP HA 28 TRP HB3 2.99 33 DPR HA 34 PRO HD3 3.02 30 LYS+ HA 32 LYS+ HN 4.32
28 TRP HA 28 TRP HD1 3.92 33 DPR HA 34 PRO QD 2.80 31 VAL HA 33 DPR HA 3.95
28 TRP HA 28 TRP HE3 3.02 33 DPR HB3 34 PRO HD2 5.89 32 LYS+ HA 34 PRO HD2 4.11
28 TRP HB3 28 TRP HE3 3.70 33 DPR HB3 34 PRO HD3 5.89 32 LYS+ HA 34 PRO HD3 4.11
28 TRP HB2 28 TRP HD1 3.70 33 DPR HB2 34 PRO HD2 5.89 32 LYS+ HA 34 PRO QD 3.72
28 TRP HB2 28 TRP HE3 4.01 33 DPR HB2 34 PRO HD3 5.89
29 LYS+ HN 29 LYS+ HB2 3.30 33 DPR QB 34 PRO QD 4.66
29 LYS+ HN 29 LYS+ HB3 3.30
29 LYS+ HN 29 LYS+ QB 3.12
29 LYS+ HN 29 LYS+ QG 5.82
29 LYS+ HA 29 LYS+ HB2 2.80
29 LYS+ HA 29 LYS+ HB3 2.80
29 LYS+ HA 29 LYS+ QB 2.53
30 LYS+ HN 30 LYS+ HG2 5.00
30 LYS+ HN 30 LYS+ HG3 5.00
30 LYS+ HN 30 LYS+ QG 4.41
31 VAL HN 31 VAL HB 3.42
31 VAL HN 31 VAL QG2 4.11
31 VAL HA 31 VAL HB 2.77
32 LYS+ HN 32 LYS+ HB2 3.08
32 LYS+ HN 32 LYS+ HB3 3.08
32 LYS+ HN 32 LYS+ HG2 5.28
32 LYS+ HN 32 LYS+ HG3 5.28
32 LYS+ HA 32 LYS+ HG2 4.01
32 LYS+ HA 32 LYS+ HG3 4.01
32 LYS+ HA 32 LYS+ QG 3.71
TOTAL = 62 TOTAL = 46 TOTAL = 39
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Appendix 5: Fluorescence properties of 78
Table A5.1 Fluorescence maxima and relative fluorescence intensities of NAAA (78) in various
solvent systems.
Solvent Fluorescence maximum [nm] Fluorescence intensity [a.u.]
H2O 523.60 27.69
TFE 520.69 53.87
MeOH 505.07 213.99
Ethanol 497.59 352.60
nBuOH 492.93 413.84
iPrOH 489.12 423.99
NMP 466.26 439.96
DMSO 469.61 489.60
Acetonitrile 471.53 509.60
DMF 467.02 532.03
Acetone 426.81 555.16
Toluene 434.86 636.91
CHCl3 458.43 674.88
EtOAc 452.67 694.57
DME 455.61 712.60
THF 451.70 720.60
DCM 458.37 757.48
Et2O 430.70 777.82
iPr2O 430.37 777.82
Dioxane 438.45 853.46
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Summary
This work was concerned with experiments aimed at elucidating the
underlying mechanism(s) of antimicrobial action of a class of antimicrobial peptide
mimetics (AMPMs), derived from naturally occurring -hairpin antimicrobial
peptides (AMPs). The latter are emerging as interesting antimicrobial agents, due to
their promising activities against important multidrug resistant pathogens and their
exqpected low tendency to generate bacterial (cross-) resistance. However, a major
drawback in terms of therapeutic applicability is their generally high toxicity and/or
high haemolytic activity, which is thought to be intrinsically related to the typical
membrane-active (i.e. detergent-like) mode of action of these peptides.
It has been shown previously in our group that the antibacterial and
haemolytic activities of prototypal -hairpin AMPs could be separated from each
other by suitable structural modifications. This led to the discovery of 16 as a broad
spectrum -hairpin AMPM based on protegrin-1. Furthermore, several rounds of
screening led to later generations of AMPMs with a quite different selectivity as well
as excellent activity towards the opportunistic bacterial pathogen Pseudomonas
aeruginosa (with a minimal inhibitory concentration (MIC) corresponding to 4 nM for
mimetic 19).
It was demonstrated by bacteriological experiments such as the kinetics of
bacterial killing, that the anti-pseudomonal activity of the later generation AMPMs, in
particular of mimetic 18, is characterised by a pronounced bacteriostatic effect during
the first 2 hours following addition, which is in stark contrast to the behaviour
expected for protegrin-like membrane-active AMPs. Additionally, an exceptionally
large post antibiotic effect (PAE) of more than six hours was observed for mimetic 18
with P. aeruginosa PAO1.
The synthesis of the enantiomers of 16, 17 and 18 showed that, in contrast to
mimetic 16, the anti-pseudomonal activity of later generation AMPMs depends on a
stereospecific interaction of the compounds composed predominantly of L-amino
acids with the target organism. Notably, this behaviour is highly unusual in the field
of AMPs, except for Pro/Arg-rich insect AMPs such as pyrrhocoricin or apidaecin.
Moreover, the greatly diminished broad spectrum antibacterial activity of ent-17
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points towards the possibility of a residual membrane-lytic mode of action for the
later generations of AMPMs.
Dye leakage experiments, in which large unilamellar vesicles composed of
various ratios of either zwitterionic or negatively charged phospholipids were
employed as model membrane systems, were carried out to study peptide-membrane
interactions of 16 and 17. It was found that both compounds were only able to
permeabilise highly negatively charged liposomal systems towards the fluorescent dye
calcein. These results are in agreement with the low haemolytic activity of 16 and 17.
However, neither compound was able to permeabilise membrane systems of mixed
zwitterionic/negatively charged character.
In another biophysical approach, the N--Fmoc protected fluorescent amino
acid DANA (41) was synthesized, which can be incorporated into the molecular
framework of peptide mimetics during routine solid phase peptide synthesis.
Membrane partitioning, as well as fluorescence microscopy experiments with DANA-
labelled analogues of 16 and 17 were used to demonstrate the utility of site-
specifically fluorescent labelling in mechanistic studies with peptide mimetics.
Furthermore, it was shown by means of a displacement assay with dansylated
polymyxin B, that binding to bacterial lipopolysaccharides (LPS) is neither
responsible for the stereospecificity of later generation AMPMs nor for their
selectivity towards P. aeruginosa.
To further investigate possible modes of action of the later generation
AMPMs, the incorporation of radioactively labelled precursor molecules into the
trichloroacetic acid insoluble fraction of P. aeruginosa PAO1 was studied. It was
found that mimetic 18 exerted no immediate effect on the incorporation of
radioactively labelled leucine, uridine, or adenine into bacterial macromolecules, thus
suggesting that neither protein, RNA nor DNA biosynthesis are the primary targets for
the class of compounds represented by 18. Additionally, these experiments further
corroborated the notion of an alternative mode of action for the later generation
AMPMs, since for a membrane active mode of action an instantaneous cessation of
macromolecular biosynthetic processes occurs.
With an alternative mode of action firmly established, both direct and indirect
biochemical approaches towards the identification of a putative target of AMPMs in
P. aeruginosa were followed. In an indirect approach, the protein expression profiles
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of P. aeruginosa PAO1 grown in the presence and absence of mimetic 18 were
recorded, using 2D gel electrophoresis coupled with mass spectrometric analysis for
the identification of differentially regulated proteins. During this proteomic analysis,
a total of 66 unique protein species whose regulation was affected by 18 could be
identified, and out of these, a high proportion consisted of membrane or transport
proteins. Additionally, a variety of heat shock proteins was found to be up-regulated
in mimetic 18 challenged cell cultures, thus indicating the imposition of protein
folding stress.
Furthermore, several analogues of mimetic 19 were synthesised that could be
used in direct biochemical approaches towards target identification, such as affinity
chromatography and photoaffinity labelling (PAL). More precisely, it was possible to
incorporate the biotinylated amino acid H-Glu(biotinyl-PEG)-OH (79), as well as the
two photo-reactive amino acids H-p-azido-Phe-OH (90) and H-p-benzoyl-Phe-OH
(91) into the scaffold of mimetic 19 with excellent retention of the anti-pseudomonal
activity. Additionally, several bi-functional PAL probes comprising both biotin and
photo-reactive functionalities were synthesised, again with good retention of the
biological activity of the parent compound.
Finally, affinity chromatography experiments with mimetic 19 immobilised on
NHS-activated Sepharose showed that a variety of ribosomal proteins were retained
on the affinity matrix. In particular several ribosomal proteins such as L7/L12 and
L11, that are associated with the flexible stalk of the bacterial ribosome, were
identified. Notably L7/12, which was also identified during the protein expression
profiling experiments, is thought to be involved in proof-reading functions of the
bacterial ribosome. Therefore, L7/L12 emerges as a promising lead for further
investigations into the antimicrobial mechanism of action of -hairpin AMPMs.
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Zusammenfassung
Diese Arbeit befasst sich mit Experimenten zur Aufklärung des
antimikrobiellen Wirkmechanismus einer Klasse antimikrobieller Peptidmimetika
(AMPM), die auf den -Haarnadel Strukturen natürlich vorkommender
antimikrobiellen Peptiden (AMP) basiert. Letztere Verbindungen werden neuerdings
vermehrt als vielsprechende antimikrobielle Wirkstoffe diskutiert, da sie einerseits
über ein breites Aktivitätsspektrum gegenüber einer Vielzahl wichtiger Pathogene
verfügen, und da ihnen andererseits eine geringe Tendenz zur Verursachung von
Resistenzen zugewiesen wird. Allerdings ist ein möglicher therapeutischer Nutzen
dieser Peptide, bedingt durch ihre hohe Toxizität und/oder hämolytische Aktivität,
welche generell mit dem für diese Verbindungsklasse oftmals typischen
lösungsmittelartigen Wirkmechanismus in Verbindung gebracht wird, sehr stark
eingeschränkt.
In früheren Arbeiten unserer Gruppe gelang es jedoch, durch Einführung
geeigneter struktureller Modifikationen wie dem D-Pro-L-Pro Templat, die
antibakteriellen Eigenschaften prototypischer, natürlich vorkommender -Haarnadel-
Peptide von deren hämolytischen Aktivitäten zu trennen. Ausgehend von dem auf
Protegrin-1 basierenden AMPM 16 führten mehrere Optimierungsschritte zu drei
weiteren Generationen von AMPM, die sowohl eine bemerkenswerte Selektivität als
auch eine ausgezeichnete Aktivität gegenüber dem Gram-negativen,
opportunistischen Pathogen Pseudomonas aeruginosa aufweisen, und mit deren
Vertretern 17, 18 und 19 diese Arbeit sich im Wesentlichen befasste.
Es konnte durch bakteriologische Experimente, wie z. B. der Bestimmung der
Kinetiken des bakteriellen Absterbevorgangs gezeigt werden, dass die anti-
pseudomonale Aktivität von 18 während der ersten zwei Stunden nach der Induktion
der spätereren Generationen von AMPM durch einen ausgeprägt bakteriostatischen
Charakter gekennzeichnet ist. Dieses Ergebniss steht in grundsätzlichem Kontrast zu
dem für membran-aktive AMP zu erwartetenden Verhalten. Darüber hinaus wurde ein
ausgerwöhnlich langer post-antibiotischer Effekt (> 6h) von Mimetikum 18 auf
Kulturen von P. aeruginosa PAO1 beobachtet.
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Die Synthese der Enantiomere von 16, 17 und 18 ergab, dass die anti-
pseudomonale Aktivität der Vertreter späterer Generationen von AMPM, im
Gegensatz zu Mimetikum 16, von der stereospezifischen Wechselwirkung der
hauptsächlich aus L-Animosäuren bestehenden AMPM mit dem Zielorganismus
abhängt. Interessanterweise handelt es sich dabei um ein auf dem Gebiet der AMP -
abgesehen von einigen Vertretern der Klasse Arg/Pro-reicher AMP wie Pyrrhocoricin
oder Apidaecin - ungewöhnliches Verhalten. Ausserdem deutet die beochtete,
wenngleich auch leicht verminderte breitspektrale Aktivität von ent-17 auf eine
mögliche Mitwirkungung eines membranlytischen Wirkmechanismusses zur
antimikrobiellen Aktivität dieser Verbindungen hin.
Um Peptid-Membran Wechselwirkungen von 16 und 17 zu untersuchen,
wurden Farbstoff-Freisetzungsversuche mit grossen unilamellaren Vesikeln,
bestehend aus varienden Verhältnissen zwitterionischer und negativ geladener
Phospholipide, durchgeführt. Dabei zeigte sich, dass beide Verbindungen nur in der
Lage waren die aus ausschliesslich negativ geladenen Phospholipidien gebildeten
Liposomen gegenüber dem Fluoreszensfarbstoff Calcein zu permeabilisieren, was
auch in Übereinstimmung mit ihrer niedrigen hämolytischen Aktivität steht. In einem
anderen biophysikalischen Ansatz wurde die fluoreszierende Aminosäure DANA (41)
sythetisiert, die während der Festphasensynthese in das molekulare Grundgerüst der
Peptidmimetika eingebaut werden kann. Membranepartitionierungs-Experimente und
Fluoreszenzmikroskopie-Experimente mit DANA markierten Vertretern von 16 und
17 wurden durchgeführt, um den Nutzen dieser Verbindungen für mechanistische
Studien mit Peptidmimetika zu verdeutlichen.
Zusätzlich konnte durch Verdrängungs-Experimente mit dansyliertem
Polymyxin B gezeigt werden, dass eine bindende Wechselwirkung mit bakteriellen
Lipopolysacchariden weder für die Stereospezifität noch für die Selektivität
gegenüber P. aeruginosa der späteren Generationen der AMPM verantwortlich ist.
Um Hinweise auf mögliche Wirkmechanismen dieser Verbindungen zu
erhalten, wurde der Einbau radioaktiv markierter Synthesebausteine der
makromolekularen Biosynthese in die in Trichloressigsäure-unlösliche Fraktion von
P. aeruginosa PAO1 untersucht. Es zeigte sich dabei, dass Mimetikum 18 keinen
unmittelbaren Effekt auf den Einbau von radioaktiv markiertem Leucin, Uridin oder
Adenin hatte, was darauf schliessen lässt, dass diese Verbindung keinen primären
Einfluss auf die Protein, RNA oder DNA Biosynthese ausübt. Ausserdem bestätigten
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diese Experimente, dass für Mimetikum 18 ein membran-lytischer Mechanismus, für
den ein sofortiges Aussetzen aller makromolekularen biosynthetischen Prozesse
erwartet wird, auszuschliessen ist.
Des Weiteren wurden sowohl direkte als auch indirekte Ansätze zur
Identifizierung eines möglichen Zielmoleküles in P. aeruginosa verfolgt. In einem
indirekten Ansatz wurden Zellen des sequenzierten Stammes PAO1 in Gegenwart
oder Abwesenheit von Mimetikum 18 angezogen, Expressionsprofile dieser Kulturen
mittels zweidimensionaler Gel-elektrophorese analysiert, und unterschiedlich
regulierte Proteinspezies durch massenspektrometrischer Methoden identifiziert.
Dieser proteomische Ansatz der auch einen Vorfraktionierungsschritt in
intrazelluläre, extrazelluläre und membrangebundene Proteine beinhaltete, führte zur
Identifizierung von 66 einzigartiger Proteinspezies, deren Regulation durch das
Mimetikum beeinflusst wurde. Diese waren durch eine hohe Anzahl an Membran-
und Transportproteinen gekennzeichnet; ausserdem wurde eine Vielzahl von
Hitzeschock-Proteinen positiv durch die Zugabe 18 reguliert, was auf einen Einfluss
dieser Verbindung auf die Proteinfaltung hindeutet.
Abschliessend wurden mehre Analoge des Mimetikums 19 synthetisiert, die in
direkten biochemischen Ansätzen zur Auffindung eines molekularen Zielmoleküls
dieser Verbindungen, wie z.B. Affinitätschromatographie oder
Photoaffinitätsmarkierung Verwendung finden können. Es gelang dabei, einerseits die
biotinylierte Aminosäure 79, sowohl andererseits eine der beiden photoreaktiven
Aminosäuren 90 oder 91 in das Grundgerüst des Mimetikums 19 unter Beibehaltung
der selektiven Aktivität einzubauen. Darüber hinaus wurden mehrere Probenmoleküle
synthetisiert die sowohl Biotin- als auch photoreaktiv-funktionalisiert sind, und
selektive Aktivität gegenüber P. aeruginosa aufweisen.
Affinitäts-chromatographische Experimente mit 19 zeigten, dass eine Vielzahl
von ribosomalen Proteinen an einer mit diesem Mimetikum gebildeten Sepharose-
Affinitätsmatrix zurückgehalten wurden. Einige dieser Proteine werden mit der
flexiblen Stielstruktur des bakteriellen Ribosoms verknüpft oder konstituieren diese
(L7/L12). Interessanterweise wurden letztere Proteinspezies, welche über ihre
Funktion im bakteriellen Ribosom mit Korrekturfähigkeiten bei der Proteinsynthese in
Verbindung gebracht werden, auch bei den Untersuchungen der Expressionsprofile
identifiziert. Daher tritt L7/L12 as eine interessante Ausgangsspezies für
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weiterführende Studien zum Wirkmechanismus der -Haarnadel AMPM in
Erscheinung.
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